"management of multivessel cad in stemi"
"mechanical complications"
"revascularization in acs with cardiogenic shock"
0/3‑hour algorithm (esc)
10‑year ascvd risk
10‑year ascvd risk calculator
10‑year ascvd risk score
10‑year ascvd risk threshold
10‑year follow‑up
10‑year survival rate
12‑lead ecg
12‑lead ecg assessment
12‑lead ecg findings (high/low voltage, conduction abnormalities, repolarization changes)
12‑lead electrocardiogram
12‑lead electrocardiogram (ecg)
12‑lead electrocardiography
12‑month measurement period
18f‑fdg positron emission tomography (pet)
18f‑fluorodeoxyglucose (18fdg)
18f‑fluorodeoxyglucose pet/ct
1½ ventricular repair
1‑year mortality
1‑year mortality rate
1‑year survival
20‑year ascvd risk
22q11.2 deletion (digeorge syndrome)
22q11.2 deletion syndrome
22q11.2 deletion syndrome (digeorge syndrome, velocardiofacial syndrome)
24‑ to 48‑hour monitoring
24‑hour stool α‑1 antitrypsin clearance
24‑hour urinary fractionated metanephrines
2d volumes
2mace score (cardiovascular risk stratification)
2‑d and 3‑d echocardiography
2‑d echocardiographic aortic root dimensions
2‑d echocardiography
2‑vessel disease with proximal left anterior descending artery
2‑year survival
30‑day mortality
30‑day mortality rate
30‑day readmission
30‑day unplanned readmission
30‑year ascvd risk
3d transesophageal echocardiography (tee)
3d volumes
3t trial (loop diuretic resistance)
3‑d ct scanning
3‑d echocardiographic‑guided surgical repair
3‑d imaging of atrial chambers
3‑d magnetic resonance imaging of coronary arteries
3‑d spatial immunophenotyping
3‑d tee (three‑dimensional transesophageal echocardiography)
3‑dimensional
3‑dimensional (3d) imaging data sets
3‑dimensional cardiovascular magnetic resonance (cmr) imaging
3‑dimensional echo imaging
3‑dimensional guidance for transcatheter procedures
3‑dimensional imaging of the neoaorta
3‑dimensional strain (3d strain)
3‑dimensional strain analysis
3‑dimensional tee (3d tee)
3‑dimensional tee (“surgical view”)
3‑generation family history screening
3‑generation family pedigree
3‑vessel disease
3‑year survival free of heart transplant
4d computed tomography (ct) imaging
4th universal definition of myocardial infarction
4‑d flow mri
4‑dimensional imaging (4d)
4‑factor pcc
4‑factor prothrombin complex concentrate (4‑pcc)
4‑factor prothrombin complex concentrate (pcc)
4 as (access to all aspects of care)
5 a’s (ask, advise, assess, assist, arrange)
5a’s (ask, advise, assess, assist, arrange)
5‑year amputation‑free survival
5‑year follow‑up
5‑year risk estimate calculation
5‑year survival
5‑year survival after aortic repair
6mwt (6‑minute walk test)
6‑minute walk distance
6‑minute walk distance (6mwd)
6‑minute walk test
6‑minute walk test (6mwt)
6‑minute walk test (used for target heart‑rate assessment)
6‑minute walk test distance
6‑minute walk test distance (< 300 m or inability to walk 1 block)
7.5 % 10‑year risk threshold (pce ≥ 7.5 %)
99mtc‑pyp scan (technetium‑99m pyrophosphate)
99th percentile upper reference limit
>50 % stenosis











a to z (aggrastat to zocor) study
a to z trial
a2/p2 scallops
aaa (abdominal aortic aneurysm)
aaa growth rate
aaa management and repair strategies.
aaa repair
aaa‑related mortality
aaa‑related rupture
aacvpr
aacvpr (american association of cardiovascular & pulmonary rehabilitation)
aacvpr (american association of cardiovascular and pulmonary rehabilitation)
aad (antiarrhythmic drug)
aaoca (anomalous aortic origin of a coronary artery)
aapa (american academy of physician assistants)
aask trial
aatac (ablation vs amiodarone for treatment of atrial fibrillation in patients with congestive heart failure and an implanted icd/crtd)
aatac multicentre randomized trial
aatac trial
aats (american association for thoracic surgery)
abbott
abbott (cardiovascular devices)
abbott (device manufacturer for heart conditions)
abbott laboratories
abbott vascular** (vascular‑intervention manufacturer)
abbvie (bristol myers squibb)
abc
abc (american board of cardiology)
abc (association of black cardiologists)
abcd (appropriate blood pressure control in diabetes) study
abciximab
abdominal adiposity
abdominal aorta
abdominal aorta aneurysm
abdominal aortic aneurysm
abdominal aortic aneurysm (aaa)
abdominal aortic aneurysm (aaa) screening
abdominal aortic aneurysm repair
abdominal aortic dilation
abdominal aortic replacement
abdominal aortic ultrasound
abdominal aortic ultrasound (us)
abdominal distention
abdominal fat
abdominal pain
aberrant left vertebral artery
aberrant left vertebral artery origin
aberrant subclavian artery
aberrant subclavian artery (asca)
abi (ankle‑brachial index) – vascular health indicator
abi and arterial dus screening interval (1–3 months, 6 months, 12 months, annual)
abiomed
ablation complication
ablation efficacy
ablation failure
ablation group (first‑line)
ablation index–guided ablation
ablation of ectopy‑triggering ganglionated plexuses
ablation outcomes
ablation procedure safety
ablation protocol (ap) complexity
ablation safety
ablation success rate
ablation therapy
ablation versus amiodarone for persistent atrial fibrillation in heart failure
ablation versus drug therapy for atrial fibrillation in heart failure
ablation vs antiarrhythmic drug therapy
ablation vs drug therapy
ablation vs. antiarrhythmic drug comparison
ablation‑related adverse events
abnormal abi (≤ 0.90)
abnormal abi/tbi values
abnormal blood pressure response to exercise
abnormal cardiovascular function
abnormal carotid pulse
abnormal electrocardiogram (ecg)
abnormal lung function in adult chd
abnormal smooth‑muscle reactivity
abnormal trabeculae
abrupt lowering of blood pressure
abscess
abscess (intracardiac or paravalvular)
abscess formation
absolute risk of future ascvd event
absolute risk reduction
absolute risk reduction (e.g., 1.5 %, 0.6 %)
abuse of vulnerable adults
academic research consortium (arc) high‑bleeding‑risk criteria
academy of cardiovascular & pulmonary rehabilitation (aacvpr)
acc
acc (american college of cardiology)
acc expert consensus statement
acc/aha
acc/aha (american college of cardiology / american heart association)
acc/aha (american college of cardiology/american heart association)
acc/aha (american college of cardiology/american heart association) guidelines
acc/aha 2005 guidelines for peripheral arterial disease
acc/aha aortic disease guideline
acc/aha aortic disease guideline (2022)
acc/aha aortic disease guideline 2022
acc/aha aortic disease guidelines
acc/aha appropriate use criteria
acc/aha cardiovascular disease prevention guidelines
acc/aha clinical practice guidelines
acc/aha clinical practice guidelines (for heart disease)
acc/aha guideline
acc/aha guideline (2020 valvular heart disease)
acc/aha guideline (for cardiovascular prevention)
acc/aha guideline for acute coronary syndromes
acc/aha guideline for hypertension
acc/aha guideline for pad management
acc/aha guideline for the management of valvular heart disease
acc/aha guideline for valvular heart disease
acc/aha guideline on acute coronary syndromes
acc/aha guideline on atrial fibrillation
acc/aha guideline on primary prevention of cardiovascular disease
acc/aha guideline on the primary prevention of cardiovascular disease
acc/aha guideline recommendations
acc/aha guidelines
acc/aha guidelines (cardiology)
acc/aha guidelines for aortic disease
acc/aha guidelines for heart failure management
acc/aha guidelines for pad
acc/aha guidelines for primary prevention of cardiovascular disease
acc/aha guidelines for secondary prevention in coronary disease
acc/aha guidelines for valvular disease
acc/aha guidelines for valvular heart disease
acc/aha heart failure guidelines
acc/aha hypertension guideline
acc/aha hypertension guideline (2017)
acc/aha hypertension guidelines
acc/aha joint committee on clinical practice guidelines
acc/aha joint committees (e.g., on heart failure, valvular disease)
acc/aha pad guideline
acc/aha peripheral artery disease guideline
acc/aha peripheral artery disease guidelines
acc/aha peripheral artery disease measure set
acc/aha peripheral artery disease measures
acc/aha peripheral artery disease measures (qm-1)
acc/aha pooled cohort equations
acc/aha primary‑prevention guidelines
acc/aha secondary‑prevention guideline for coronary and atherosclerotic vascular disease
acc/aha stages of hf
acc/aha stages of hf (stages a, b, c, d)
acc/aha** (combined guideline and organization abbreviation)
acc/aha/aacvpr/apma/abc/scai/svm/svn/svs/sir/vess guideline
acc/aha/acc/accp/aspc/nla/pcna guideline
acc/aha/accp/hrs guideline
acc/aha/esc guidelines for atrial fibrillation
acc/aha/hfsa focused updates (2017, 2013, 2010)
acc/aha/hfsa heart failure guideline (2017)
acc/aha/hfsa heart failure guideline (hf)
acc/aha/hrs guideline on bradycardia and conduction delay
acc/aha/nma/pcna hypertension guideline
acc/aha/scai guideline
acc/aha/scai guideline for coronary artery revascularization
acc/aha/scai guidelines for coronary artery revascularization
acc/aha/scai revascularization guidelines
accentuated s2 heart sound
access to care
access to low‑mortality surgical centers
access to skilled practitioners
access to specialized vascular care
access to therapies for valvular dysfunction
accessory atrioventricular connections
accessory muscle bundles
accessory pathway ablation
accessory pathways
accessory pathways (ap)
accessory pathways (concealed and manifest)
accessory pathways (pre‑excitation)
accf (american college of cardiology foundation)
accf/aha
accf/aha guideline
accf/aha guideline (american college of cardiology foundation/american heart association)
accf/aha guideline for the management of heart failure
accf/aha guideline for thoracic aortic disease
accf/aha guidelines
accf/aha guidelines for hypertrophic cardiomyopathy
accf/aha guidelines for thoracic aortic disease
accf/aha peripheral artery disease performance measures
accf/aha/aats thoracic aortic disease guidelines (2010)
accf/aha/aats/acr/asa/sca/scai/sir/sts/svm guidelines for thoracic aortic disease
accf/aha/aats/acr/asa/sca/scai/sir/sts/svm guidelines for thoracic aortic disease.
accf/aha/acr/scai performance measures for pad
accord‑lipid trial (fenofibrate)
accp (american college of chest physicians)
accp (american college of clinical pharmacology)
accp (american college of clinical pharmacy)
accp antithrombotic and thrombolytic therapy for valvular disease
accreditation council for graduate medical education (acgme) training programs
acc / aha (american college of cardiology / american heart association)
ace (angiotensin‑converting enzyme)
ace inhibitor
ace inhibitor (acei)
ace inhibitor (acei) therapy for hfref
ace inhibitor exposure in the first trimester
ace inhibitors
ace inhibitors (acei)
ace inhibitors (angiotensin‑converting enzyme inhibitors)
ace** – angiotensin‑converting enzyme
ace2‑tropic, cardiotropic, vasculotropic, lymphotropic, cardiotoxic (viral tropism mechanisms)
acei – angiotensin‑converting enzyme inhibitor
acei‑arb (angiotensin‑converting‑enzyme inhibitor / angiotensin‑ii receptor blocker)
acetylcholine testing
acetylcholine testing (coronary function testing)
acetylcholine‑activated inward rectifying k⁺ channel (ikach)
ace‑inhibitor class (e.g., captopril, benazepril, enalapril)
ace‑inhibitors
ace‑intolerant indications
acha/acc
achd (adult congenital heart disease)
achd (adult congenital heart disease) cardiologist
achd (adult congenital heart disease) specialists
achd (aneuploidy or congenital heart disease)
achd advocacy organizations
achd anatomic classification ii/iii
achd cardiologist
achd cardiologist (clinical follow‑up)
achd cardiologists and programs
achd cardiology board certification
achd centers
achd clinical class (ap class)
achd consultation
achd guideline
achd guideline (acute congenital heart disease)
achd interventional cardiologist
achd mortality score
achd physiological stages c/d
achd program
achd program / multidisciplinary achd program
achd program / specialized center
achd** – adult congenital heart disease
acmg/amp variant classification
acoustic shadowing from trachea
acoustic shadowing, paravalvular leak detection challenges (tte suboptimal posterior, tee suboptimal anterior)
acpm (american college of preventive medicine)
acquired cardiovascular disease in achd patients
acquired congenital heart disease (achd)
acquired heart disease
acquired von willebrand syndrome
acr (american college of radiology)
acr appropriateness criteria for suspected acute aortic syndrome
acromegaly (cardiac effects)
acromegaly‑associated heart failure
acromegaly‑related hf
acs (acute coronary syndrome)
acs management guideline
acs – acute coronary syndromes
acs** – acute coronary syndrome
acta2
acta2 mutation
acta2 mutation (smooth muscle alpha‑actin)
acta2, prkg1, myh11, mylk, lox (pathogenic gene variants)
acta2‑associated aortopathy
actc1
actc1 (alpha‑actin 1)
actin‑myosin interaction inhibition
action icu risk score
action trial
action‑potential alternans
activated charcoal
activated clotting time (act)
activated partial thromboplastin time (aptt)
activated pcc (activated prothrombin complex concentrate)
activated prothrombin complex (apcc)
activated prothrombin complex concentrate (apcc)
activated prothrombin concentrate
active bleeding on anticoagulant
active bleeding on anticoagulant therapy
active bronchospasm
active malignancy
active systemic infection
activew trial
activin signaling inhibitor (sotatercept)
activin‑signaling inhibitors
activity monitors
activity tracking











acuity trial
acute and chronic heart failure diagnosis guidelines
acute and chronic heart failure in congenital heart disease (acc/aha statement)
acute angle of takeoff
acute angulation of the left coronary artery
acute aortic disease (including debakey i and stanford type a)
acute aortic dissection
acute aortic dissection (aod)
acute aortic dissection diagnostic imaging modalities
acute aortic events
acute aortic intramural hematoma (imh)
acute aortic intramural hematoma versus dissection in the ascending aorta (clinical features)
acute aortic pathology
acute aortic regurgitation
acute aortic regurgitation (ar)
acute aortic rupture
acute aortic syndrome
acute aortic syndrome (aas)
acute aortic syndrome classification (irad system)
acute aortic syndromes
acute aortic syndromes (aas)
acute ar diagnosis criteria (deceleration time, pressure half‑time, holodiastolic flow reversal)
acute atrial fibrillation (acute af)
acute cardiac care
acute cardiovascular events
acute cardioversion
acute catheterization and urgent intervention triage (acuity) trial
acute catheterization and urgent intervention trials (acuit)
acute chest pain
acute congenital heart disease (achd)
acute coronary event
acute coronary event classification (stemi vs. nste‑acs)
acute coronary event complications
acute coronary events
acute coronary intervention
acute coronary syndrome
acute coronary syndrome (acs)
acute coronary syndrome (acs) – implied by “coronary artery disease”
acute coronary syndrome (differential diagnosis)
acute coronary syndrome (including acute mi, unstable angina)
acute coronary syndrome (referenced as “acute sop/cp”)
acute coronary syndrome guideline
acute coronary syndrome guidelines
acute coronary syndrome management
acute coronary syndrome management algorithms
acute coronary syndrome toolkit (aha)
acute coronary syndromes
acute coronary syndromes (acs)
acute coronary syndromes guideline
acute coronary syndromes (acs)
acute covid‑19 cardiovascular syndrome
acute cvd deaths / cvd‑related deaths
acute decompensated heart failure
acute decompensated heart failure (adhf)
acute decompensated heart failure hospitalizations
acute decompensation of chronic heart failure (hf)
acute diagnostic evaluation
acute heart failure
acute heart failure (acute hf)
acute heart failure with preserved vs. reduced ejection fraction
acute hf
acute hypotension
acute illnesses
acute inflammatory milieu
acute kidney injury
acute kidney injury (aki)
acute kidney injury (aki) after coronary procedures
acute kidney injury (as a cardiovascular complication)
acute limb ischemia
acute limb ischemia (a manifestation of systemic arterial occlusion)
acute limb ischemia (ali)
acute lower extremity ischemia
acute lower‑limb ischemia
acute management of cardiogenic shock
acute medical management of aortic dissection
acute mi
acute mi (myocardial infarction)
acute mi / acute myocardial infarction
acute mitral regurgitation
acute myocardial dysfunction without prior hf
acute myocardial infarction
acute myocardial infarction (ami)
acute myocardial infarction (implied within acs context)
acute myocardial infarction (mi)
acute myocardial infarction with heart failure
acute myocardial ischemia
acute myocarditis
acute non‑ischemic myocardial injury
acute outcomes
acute pancreatitis (risk from hypertriglyceridemia)
acute pericarditis
acute phlebotomy (removal of 250–500 ml blood)
acute presentation
acute pulmonary edema
acute pulmonary hypertension
acute rate control
acute renal failure
acute respiratory distress syndrome (ards)
acute reversibility studies during cardiac catheterization
acute severe ar surgical emergency
acute severe symptomatic mr
acute stroke
acute type a aortic dissection
acute type b aortic dissection
acute type a aortic dissection
acute type‑a aortic dissection
acute type a aortic dissection
acute type b aortic dissection
acute versus chronic ischemia
acute vs delayed inadequate laao occlusion
acute vs. chronic valve disease











ad (type a) with distal extent (e.g., a9)
ada (american diabetes association)
adam (aneurysm detection and management) trial
adamts19 gene mutation
adaptive cardiac resynchronization therapy (adaptive crt)
adaptive servo‑ventilation
adaptive servo‑ventilation (avoided in csa)
adaptive trials
added fats
added sugar
added sugar (risk factor for heart disease)
added sugars
addiction therapy
additional surgical or device therapy
adenosine (antiarrhythmic)
adenosine stress myocardial perfusion scintigraphy
adenosine stress perfusion
adenovirus, enteroviruses, parvovirus b19, cmv, ebv, hhv‑6, hcv, hiv, influenza, mers‑cov, sars‑cov, sars‑cov‑2 (viruses implicated in viral myocarditis)
adhere classification (acute decompensated heart failure national registry)
adherence to recommendations
adiposity
adjunctive therapy
adjunctive catheter ablation
adjuvant (adjunctive) revascularization procedures
administration route (iv, oral, continuous infusion)
administrative and accreditation terms
administrative data / claims
administrative data/claims – data source for cardiovascular measurement
adolescence to young adulthood (13‑18 years) chd care
adolescents / young adults
adonis study (american‑australian‑african trial)
adrenergic agonists
adrenergic receptor stimulation
adrenomedullin
adsorb (acute dissection: stent graft or best medical therapy)
adult care hospitals
adult congenital aortic valve interventions
adult congenital cardiac clinic
adult congenital heart association (acha)
adult congenital heart disease
adult congenital heart disease (achd)
adult congenital heart disease (achd) specialist
adult congenital heart disease (achd) specialists
adult congenital heart disease fellowship
adult congenital heart disease management
adult congenital heart disease program
adult congenital heart program
adult hcm management strategies
adult icd decision‑making (cor 1 & 2a)
adult single ventricle clinic
adult with eisenmenger syndrome clinical characteristics
adulthood (18‑80+ years) chd care
adults with congenital heart disease
adults with congenital heart disease (achd)
adult‑onset hypertrophic cardiomyopathy
advance care planning
advance care planning / advance care directives in hf
advanced (stage d) hf
advanced age
advanced age (≥75 y)
advanced cardiac imaging
advanced cardiac therapies
advanced care modalities
advanced congenital cardiac therapies
advanced cvd (as a reference to severe cardiovascular disease)
advanced dementia
advanced echocardiographic imaging
advanced heart failure
advanced heart failure (adv. hf)
advanced heart failure (advanced hf)
advanced heart failure (hf)
advanced heart failure (hf) therapies
advanced heart failure (stage d)
advanced heart failure (stage d)
advanced heart failure interventions
advanced heart failure management
advanced heart failure progression
advanced heart failure therapies
advanced heart failure therapies (considered pre‑conception)
advanced heart failure therapies (intra‑pump or transplant referral)
advanced heart failure with preserved ejection fraction (hfpef) in hcm
advanced heart‑failure and transplant cardiologist
advanced heart‑failure position statements (european society of cardiology, american heart association)
advanced hf
advanced hf (stage d)
advanced hfref
advanced imaging
advanced imaging endpoints
advanced imaging for lv strain and strain‑rate
advanced imaging markers of disease progression
advanced kidney disease (non‑dialysis)
advanced kidney disease in cad context
advanced lipid disorders program
advanced liver fibrosis
advanced nyha class (iii or iv)
advanced practice provider
advanced practice providers
advanced practice providers (e.g., nurse practitioners, physician assistants)
advanced practice providers (in care delivery)
advanced reperfusion strategies (e.g., arrest trial, cares registry)
advanced screening strategies for hf (cost‑effectiveness, risk prediction)
advanced therapies (e.g., surgical, mechanical support)
advanced therapies (e.g., transplant, mechanical circulatory support)
advanced therapies for lvoto
advanced therapies for relief of lvoto
advanced treatments (e.g., lvad, heart transplant)
advancing age
adventitia
adventitial inflammation
adverse aortic events
adverse cardiac events
adverse cardiovascular events
adverse cardiovascular events (hospitalization, mortality)
adverse cardiovascular outcomes
adverse cardiovascular outcomes (stroke, bleeding, mortality)
adverse drug effects
adverse event risk (mortality, hf, stroke, arrhythmia)
adverse events
adverse events (e.g., tendon rupture, increased uric acid, atrial fibrillation)
adverse maternal and fetal outcomes
adverse outcomes
adverse outcomes (stroke, thromboembolism)
advised risk score
advocacy priorities
aerobic exercise
aerobic exercise (moderate‑intensity, vigorous‑intensity)
aerobic exercise safety
aerobic interval training
aerobic training















aeronautical medical certification for heart disease
aetiology of myocarditis
af
af (atrial fibrillation)
af ablation
af burden
af burden (amount of atrial fibrillation)
af burden (frequency/duration of atrial fibrillation episodes)
af burden / af duration
af burden / episode duration (>24 h or >5 min)
af burden metrics
af burden monitoring
af catheter ablation
af detection from atrial lead
af diagnostic accuracy
af duration
af duration thresholds
af episode
af frequency, duration, burden
af initiation triggers
af management
af management guidelines
af monitoring burden estimation
af prognosis in obesity
af progression
af progression prevention
af recurrence
af recurrence (post‑ablation or post‑treatment)
af recurrence prediction
af recurrence predictors after ablation
af risk
af surveillance
af symptoms
af – atrial fibrillation
af** – atrial fibrillation
affirm study
affirm trial (substudy)
affirm‑ahf trial
affordability
aficamten (myosin inhibitor) clinical trials
afl** – atrial flutter
african american population (race‑specific therapy)
afterload
afterload mismatch
afterload reduction
afterload reduction therapy
af‑chf study
af‑chf trial
af‑induced cardiomyopathy
af‑mediated cardiomyopathy
af‑related morbidity
af‑related mortality
af‑related stroke risk prediction
af‑related symptoms
af‑related thromboembolic risk
agatston units (au) – coronary calcium scoring
age
age (advanced patient age)
age (risk factor for complications)
age (≥65 years, ≥75 years)
age (≥70 years, <40 years)
age >60 years
age >75 years
age > 80 years (destination therapy)
age at aortic event
age at repair <6.5 years
age of af onset (<45, <66 years)
age stratification in valve choice (<50, 50–65, >65 years)
age threshold (≥75 years)
age ≥60 years
age ≥65 y, ≥75 y
age ≥ 75 years
age-related longevity and valve selection
age‐related risk categories (≥85 y, 75‑84 y, 65‑74 y, <65 y)
age‑ and lesion‑related comorbidity burden in congenital heart disease
age‑ and sex‑based st‑elevation thresholds
age‑adjusted hf mortality
age‑appropriate risk factors
age‑based recommendations (≤65 yr, 65–80 yr, >80 yr)
age‑dependent valve choice (≤50 y, 50–65 y, >65 y)
age‑related risk (≤18 years, >18 years, mid‑life ≈ 50 years)
age‑related susceptibility to af
age‑specific risk assessment (20–39 yrs, 40–59 yrs, 60–75 yrs, > 75 yrs)
age‑specific risk prediction models
age‑standardized global prevalence rates of af and afl
age 65–74 years
age > 70 years
age ≥ 75 years
age ≥ 75 years
aggressive aortopathy
aggressive blood‑pressure control
aggressive cardiovascular phenotype of aneurysms‑osteoarthritis syndrome
aggressive decongestion
aggressive diuresis leading to lvoto amplification
agranulocytosis
ags (american geriatrics society)
aha
aha (american heart association)
aha (american heart association) non‑traumatic amputation reduction goal
aha get with the guidelines
aha get with the guidelines score
aha mission: lifeline program
aha scientific statement
aha scientific statements
aha/aacc/scai guidelines for coronary artery revascularization
aha/acc (american heart association / american college of cardiology)
aha/acc (combined aha‑acc entity)
aha/acc chronic coronary disease guideline
aha/acc clinical practice guideline
aha/acc guideline for achd
aha/acc guideline for adult congenital heart disease
aha/acc guideline for adults with congenital heart disease
aha/acc guideline for hcm
aha/acc guideline for hypertrophic cardiomyopathy
aha/acc guideline liaison
aha/acc guideline on lower‑extremity pad
aha/acc heart failure guideline
aha/acc joint committee on clinical practice guidelines
aha/acc pad guideline (2016)
aha/acc performance measures for adults with pad
aha/acc secondary‑prevention guidelines for atherosclerotic vascular disease.
aha/acc/aacvpr/aapa/abc/acpm/ada/ags/apha/aspc/nla/pcna guideline on cholesterol
aha/acc/acc/aspc/nla/pcna chronic coronary disease guideline
aha/acc/accp/aspc/nla/pcna (cardiology guideline alliance)
aha/acc/accp/aspc/nla/pcna chronic coronary disease guideline
aha/acc/accp/aspc/nla/pcna chronic coronary disease guideline (2023)
aha/acc/accp/aspc/nla/pcna chronic coronary disease guideline 2023
aha/acc/accp/aspc/nla/pcna guideline
aha/acc/acc‑aha joint guideline methodology
aha/acc/ase/chest/saem/scct/scmr guideline for chest pain evaluation
aha/acc/hfsa 2022 heart failure guideline
aha/acc/hfsa guideline
aha/acc/hfsa guideline (american heart association/american college of cardiology/heart failure society of america)
aha/acc/hfsa guideline for heart failure management
aha/acc/hfsa guidelines
aha/acc/hfsa heart failure guideline
aha/acc/hfsa heart failure guideline (2022)
aha/acc/hfsa heart failure guideline (contextual reference)
aha/acc/hfsa heart failure guideline 2022
aha/acc/hfsa heart‑failure guideline
aha/acc/hfsa heart‑failure guideline statements
aha/acc/hrs
aha/acc/hrs guideline
aha/acc/hrs guideline for atrial fibrillation
aha/acc/hrs guideline for ventricular arrhythmias & prevention of sudden cardiac death
aha/acc/hrs guidelines for atrial fibrillation
aha/acc/multisociety guideline
ahre** – atrial high‑rate episodes








aim‑high trial
air embolism (intraoperative)
air pollution
air pollution – cardiovascular risk factor
air versus oxygen therapy in stemi
airway compression symptoms (e.g., stridor, wheezing)
ai‑guided atrial fibrillation screening
ai‑powered imaging analysis for early pad detection
akinetic rvot length ≥55 mm
al amyloidosis
alagille syndrome
alagille syndrome (jag1) – peripheral or branch pulmonary artery stenosis, coarctation of the aorta, aortic stenosis, septal defects, mid‑aortic narrowing
albiglutide
albumin
albuminuria (≥30 µg albumin/mg creatinine)
albuminuria / renal function as cvd predictors
alcohol (tobacco‑related risk factor)
alcohol abstinence / reduction (≤3 standard drinks per week)
alcohol abstinence/alcohol control
alcohol abuse
alcohol consumption
alcohol consumption (alcohol abstinence, acute alcohol intake)
alcohol consumption (including binge drinking / holiday heart syndrome)
alcohol consumption (light‑to‑moderate)
alcohol consumption (moderate, binge drinking)
alcohol consumption (moderation)
alcohol consumption (≤1 drink/day for women, ≤2 drinks/day for men)
alcohol consumption reduction
alcohol moderation
alcohol reduction
alcohol septal ablation
alcohol septal ablation (asa)
alcohol septal ablation outcomes
alcohol use
alcohol use / alcohol consumption
alcoholic cardiomyopathy
alcohol‑induced cardiac toxicity
alcohol‑related af episodes
aldactone (spironolactone)
aldosterone antagonist (mineralocorticoid receptor blocker)
aldosterone antagonist therapy
aldosterone antagonists
aldosterone antagonists (e.g., spironolactone)
aldosterone antagonists (e.g., spironolactone, eplerenone)
aldosterone antagonists → spironolactone, eplerenone
aldosterone blockade (mineralocorticoid receptor antagonism)
aldosterone blocker
aldosterone pathway blockade
alirocumab
alirocumab (pcsk9 monoclonal antibody)
alkylating agents
alkylating agents (cyclophosphamide, melphalan)
allhat
allhat (antihypertensive and lipid‑lowering treatment to prevent heart attack trial)
alliance for adult research in congenital cardiology (aarcc)
allogeneic hematopoietic cell transplantation
allograft
allograft cryopreservation
allograft tissue exposure
allografts (cryopreserved aorta)
allostatic load
all‑cause 30‑day mortality
all‑cause death
all‑cause hospitalization
all‑cause mortality
all‑cause mortality (in heart failure context)
all‑cause mortality reduction with gdmt
all‑cause readmission
all‑cause rehospitalization
all‑in cluster randomized trial (integrated af management)
alogliptin
alpha‑1 adrenergic blockers
alpha‑fetoprotein
alteplase
alteplase (alteplase)
alteplase (tpa)
altered intracellular signaling in myocardial inflammation
altered ion‑channel expression
alternating bundle‑branch block
alternative exercise modalities (cycling, recumbent stepping, resistance training)
alternative non‑walking exercise (arm ergometry, stationary cycling)
alternatives to vka anticoagulation
alveolar edema
ambient air pollution
ambient particulate matter exposure
ambient temperature exposure
ambrisentan
ambrisentan (endothelin receptor antagonist)
ambrisentan therapy
ambulatory (holter) monitoring
ambulatory blood pressure monitoring
ambulatory blood‑pressure monitoring
ambulatory ecg
ambulatory ecg monitoring (24–48 h)
ambulatory ecg monitoring (holter)
ambulatory electrocardiographic monitoring
ambulatory electrocardiographic monitoring (24‑48 h)
ambulatory electrocardiography
ambulatory electrocardiography (aecg)
ambulatory management
ambulatory monitor
ambulatory monitoring
ambulatory monitoring (for nsvt)
ambulatory rhythm monitoring
ambulatory status
ambulatory telemetry
american association of black cardiologists (abc)
american association of cardiovascular and pulmonary rehabilitation (aacvpr)
american college of cardiology
american college of cardiology (acc)
american college of cardiology (acc) guideline statements on aortic valve disease
american college of cardiology (acc) guidelines
american college of cardiology (acc) – heart failure stages
american college of cardiology (acc) – major cardiovascular body
american college of cardiology / american heart association (acc/aha) class of recommendation
american college of cardiology / american heart association (acc/aha) guidelines
american college of cardiology foundation (organizational reference)
american college of cardiology guideline
american college of cardiology/american heart association (acc/aha) guideline
american college of cardiology/american heart association task force
american college of cardiology/heart association task force on obesity
american college of cardiology/heart association task force on type 2 diabetes prevention
american college of clinical pharmacy
american college of clinical pharmacy (accp)
american college of preventive cardiology (accp)
american college of radiology (acr) imaging guidelines for aortic disease
american diabetes association position statement
american heart association
american heart association (aha)
american heart association (aha) 2022 heart failure guideline
american heart association (aha) guideline statements on aortic valve disease
american heart association (aha) guidelines
american heart association (aha) recommendations
american heart association (aha) statements/guidelines
american heart association (aha) – heart failure stages
american heart association (aha) – major cardiovascular body
american heart association (organizational reference)
american heart association (reference and source of figures)
american heart association / american college of cardiology (aha/acc) cholesterol guideline
american heart association council on clinical cardiology
american heart association council on nutritional, physical activity, and metabolism
american heart association guideline
american heart association guideline on cardiogenic shock
american heart association guidelines
american heart association impact goal
american heart association policy statements
american heart association scientific statement
american heart association scientific statements on physical activity in health care settings
american heart association statements
american heart association task force on practice guidelines
american heart association/acc guidelines on obesity and overweight
american heart association/american college of cardiology/heart failure society of america (aha/acc/hfsa)
american heart journal
american journal of preventive cardiology
american society for preventive cardiology (aspc)
american society of echocardiography (ase)
american society of nuclear cardiology
american society of preventive cardiology (aspc)
amgen
amgen (cardiovascular biologics)
ami toolkit
ami – acute myocardial infarction
amica (atrial fibrillation management in congestive heart failure with ablation)
amica trial
amino‑terminal pro‑bnp (nt‑probnp)
amiodarone
amiodarone (antiarrhythmic drug)
amiodarone (antiarrhythmic)
amiodarone (arrhythmia‑directed therapy)
amiodarone (bradycardia, rv pacing)
amiodarone (intravenous amiodarone)
amiodarone (intravenous)
amiodarone (pre‑operative prophylaxis)
amiodarone (rate‑ and rhythm‑control, prophylaxis)
amiodarone (rate‑control agent)
amiodarone therapy
amiodarone‑associated thyroid dysfunction
amiodarone‑induced hyperthyroidism
amiodarone‑induced hypothyroidism
amiodarone‑induced thyrotoxicosis
amlodipine
amputation
amputation (above‑knee, below‑knee)
amputation (most distal level)
amputation prevention
amputation rates
amputation risk
amputation‑free survival
amssm (american society of sports medicine)
amyl nitrite
amyl nitrite provocation
amyloid cardiomyopathy (al‑cm)
amyloid heart disease
amyloidosis
amyloidosis (cardiac involvement)
amyloidosis (cardiac)
amyloidosis (infiltrative cardiomyopathy)
anaerobic threshold
analgesic therapies in acs
analgesics (morphine, etc.)
anaphylactic reactions to beta‑blockers
anastomotic pseudoaneurysm
anatomic assessment of disease severity
anatomic characteristics
anatomic classification of limb ischemia (glass/wifi)
anatomic complexity (simple–complex i–iii)
anatomic etiology
anatomic lesions
anatomic or ischemic testing
anatomic pattern of disease
anatomic variability
anatomic variants of the heart
anatomical characteristics
anatomical evaluation of disease
anatomical repairs
anatomic‑physiologic classification system
ancillary imaging for achd
ancillary imaging in achd
ancillary imaging variables (e.g., ct‑fractional flow reserve)
anderson‑fabry disease
anderson‑fabry disease (in hypertrophic cardiomyopathy)
anderson–fabry disease
andexanet alfa
andexanet alfa (anti‑xa antidote)
andexanet alfa (factor xa inhibitor reversal agent)
andromeda (anti‑arrhythmic trial with dronedarone)
anemia
anemia (cardiovascular impact)
anemia in acute coronary syndromes
anemia in heart failure
anemia management (folic acid, iron supplementation, periodic transfusion)
anemia management in acs
anemia – frequently present and prognostic in hf
anesthesia (and anesthetic management)
anesthesia (epidural, general)
anesthesia (local vs. general) in aortic surgery
anesthesia collaboration with achd expertise
anesthesia management in achd
anesthesia‑related cardiac risk (qtc prolongation risk)
anesthesiologist with chd expertise
anesthetic management for cardiac surgery in pregnancy
anesthetic pharmacology in achd
anesthetic planning for achd
aneurysm
aneurysm (aortic aneurysm)
aneurysm (left ventricular apical aneurysm)
aneurysm (lv)
aneurysm (related to aortic dissection)
aneurysm cause
aneurysm diameter thresholds (≥5.5 cm in men, ≥5.0 cm in women)
aneurysm growth
aneurysm growth (≥ 0.5 cm / yr)
aneurysm growth / dilation
aneurysm growth rate
aneurysm growth rate (>0.5 cm in 6 months)
aneurysm neck diameter
aneurysm of the thoracic aorta
aneurysm repair
aneurysm rupture
aneurysm sac
aneurysm sac enlargement
aneurysm sac enlargement risk
aneurysm sac thrombosis prevention
aneurysm screening
aneurysm size threshold (≥ 6.0 cm, ≥ 5.5 cm)
aneurysm surveillance
aneurysm syndromes
aneurysm syndromes caused by tgf‑β mutations
aneurysm-related mortality
aneurysm-related reintervention
aneurysm/pseudoaneurysm
aneurysmal aorta
aneurysmal aortic segment
aneurysmal area
aneurysmal degeneration
aneurysmal disease (adjacent visceral aorta, iliac arteries)
aneurysmal disease extension (proximal arch, ascending aorta, descending thoracic aorta)
aneurysmal pulmonary arteries
aneurysmal sac
aneurysmal segment replacement
aneurysmal threshold (≥ 1.5 × reference diameter)
aneurysmectomy (surgical aneurysmectomy)
aneurysms (aorta)
aneurysms (typically asymptomatic)
aneurysms‑osteoarthritis syndrome
aneurysm‑related death
aneurysm‑related events
aneurysm‑related mortality












angina
angina (baseline angina frequency)
angina (ongoing)
angina (refractory angina)
angina (stable / unstable)
angina (stable and unstable)
angina (stable angina)
angina (stable chest pain)
angina (stable, unstable)
angina / angina pectoris
angina / anginal pain
angina / chest pain
angina pectoris
angina pectoris / angina
angina prevalence
angina prevalence and provider evaluation (appear) study
angina quality of life
angina symptoms (dyspnea, arm pain with exertion)
angina under‑recognition
angina unstable
angina, unstable
anginal episodes
anginal symptom burden
anginal symptoms
anginal symptoms / angina
angina‑related quality of life (qol)
angina pectoris
angiodynamics
angioedema
angioedema (ace‑inhibitor‑associated)
angioedema (as a drug‑related adverse effect)
angioedema (contraindication to acei/arni)
angiogenesis
angiogram (plain imaging of aorta)
angiographic assessment
angiographic assessment of aortic valve stenosis severity.
angiographic assessment of stenosis (≥50 %)
angiographic chronic coronary disease (ccd)
angiographic complexity
angiographic criteria/pressure measurements (hemodynamic significance)
angiographic guidance
angiographic patterns in vsr
angiographic progression of disease
angiographic severity
angiographic severity (≥50 %)
angiographic severity assessment
angiography
angiography (contrast‑enhanced)
angiography (coronary)
angiography (invasive imaging)
angiography / vascular imaging
angiography and invasive hemodynamic assessment
angiography grade (1–4)
angiography‑guided pci
angiography‑guided strategy
angiology (clinical specialty)
angioplasty
angioplasty transluminal percutaneous coronary
angioplasty‑first vs. bypass‑first strategy
angiosafe
angiosome
angiosome (direct pulsatile flow)
angiosomes
angiosome‑targeted revascularization
angiotensin (ii) receptor blocker (arb)
angiotensin ii blockade
angiotensin ii receptor blocker losartan
angiotensin ii receptor blockers (arb)
angiotensin ii receptor blockers (arbs)
angiotensin receptor blocker
angiotensin receptor blocker (arb)
angiotensin receptor blocker (arb) therapy
angiotensin receptor blocker (valsartan)
angiotensin receptor blockers (arb)
angiotensin receptor blockers (arbs)
angiotensin receptor blockers (arbs) – candesartan, valsartan
angiotensin receptor blockers (e.g., valsartan, losartan)
angiotensin receptor neprilysin inhibitor (arni)
angiotensin receptor neprilysin inhibitor (arni) – sacubitril‑valsartan
angiotensin receptor neprilysin inhibitors (arni)
angiotensin receptor‑neprilysin inhibitor (arni)
angiotensin receptor‑neprilysin inhibitors
angiotensin receptor‑neprilysin inhibitors (arni)
angiotensin receptor–neprilysin inhibition (arni) in pre‑hf (stage b) and hfref
angiotensin receptor–neprilysin inhibitors (arni)
angiotensin‑and‑neprilysin receptor antagonist (sacubitril/valsartan)
angiotensin‑converting enzyme
angiotensin‑converting enzyme (ace)
angiotensin‑converting enzyme (ace) inhibition
angiotensin‑converting enzyme (ace) inhibitor
angiotensin‑converting enzyme (ace) inhibitors
angiotensin‑converting enzyme inhibition
angiotensin‑converting enzyme inhibitor
angiotensin‑converting enzyme inhibitor (acei)
angiotensin‑converting enzyme inhibitor (acei) – e.g., captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril
angiotensin‑converting enzyme inhibitor (acei) – e.g., ramipril, enalapril, captopril
angiotensin‑converting enzyme inhibitor (ace‑i)
angiotensin‑converting enzyme inhibitors (ace inhibitors)
angiotensin‑converting enzyme inhibitors (acei)
angiotensin‑converting enzyme inhibitors (acei) – e.g., enalapril, captopril
angiotensin‑converting enzyme inhibitors (aceis)
angiotensin‑converting enzyme inhibitors (ace‑i)
angiotensin‑converting‑enzyme inhibitor
angiotensin‑converting‑enzyme inhibitor (acei)
angiotensin‑converting‑enzyme inhibitor (ace‑i)
angiotensin‑converting‑enzyme inhibitor (enalapril)
angiotensin‑converting‑enzyme inhibitors (acei)
angiotensin‑converting‑enzyme inhibitors (acei) → enalapril, lisinopril, cibis‑ii drug
angiotensin‑converting‑enzyme inhibitors (acei, e.g., enalapril, lisinopril)
angiotensin‑ii receptor antagonists and fetal toxicity
angiotensin‑ii receptor blocker (arb)
angiotensin‑ii receptor blocker (arb) – e.g., valsartan, losartan
angiotensin‑ii receptor blockers
angiotensin‑ii receptor blockers (arb)
angiotensin‑ii receptor blockers (arb) therapy
angiotensin‑ii receptor blockers (arbs)
angiotensin‑neprilysin inhibition (arni)
angiotensin‑neprilysin inhibitor (arni)
angiotensin‑neprilysin inhibitors (arni) → sacubitril/valsartan
angiotensin‑neprilysin receptor antagonist (arni)
angiotensin‑receptor antagonist
angiotensin‑receptor blocker (arb)
angiotensin‑receptor blocker (arb) therapy for hfref
angiotensin‑receptor blocker (arb) – e.g., candesartan, losartan, valsartan
angiotensin‑receptor blockers (arb)
angiotensin‑receptor blockers (arbs)
angiotensin‑receptor neprilysin inhibitor (arni)
angiotensin‑receptor neprilysin inhibitor (arni) in achd
angiotensin‑receptor neprilysin inhibitor (arni) therapy
angiotensin‑receptor neprilysin inhibitor (arni) therapy for hfref
angiotensin‑receptor neprilysin inhibitor (arni) – sacubitril‑valsartan
angiotensin‑receptor neprilysin inhibitors (arnis)
angiotensin‑receptor‑neprilysin inhibitor (arn)
angiotensin‑receptor‑neprilysin inhibitor (arni) – e.g., sacubitril/valsartan
angiotensin ii receptor blocker
angiotensin ii receptor blocker (losartan)
angiotensin ii receptor blockers (arbs)
angiotensin ii receptor blockers (arbs, e.g., candesartan)
angiotensin ii‑dependent tgf‑β signaling
animal protein
animal protein (e.g., lamb, beef, pork, chicken)
ankle pulse volume recordings (pvr)
ankle‑brachial index
ankle‑brachial index (abi)
ankle‑brachial index (abi) <0.80
ankle‑brachial index (abi) ≤ 0.90
ankle‑brachial index (abi) < 0.9
ankle‑brachial index (diagnostic test)
ankle‑brachial index assessment
ankle‑brachial index measurement and interpretation
annual biochemical and hematological testing
annual laboratory evaluation
annual risk of stroke
annual risk of stroke/bleeding
annual surveillance imaging
annular abscess
annular dilation
annular dilation (associated with af)
annular hypoplasia
annular‑to‑coronary ostial distance (ct measurement for tavi planning)
annuloplasty
annuloplasty repair
annuloplasty ring
annuloplasty rings
annulus area (ct measurement for tavi planning)
annulus rupture (not reported)
annulus size and shape
annulus washer technique
anomalous aortic origin of a coronary artery
anomalous aortic origin of a coronary artery (aaoca)
anomalous aortic origin of a coronary artery from the opposite sinus
anomalous aortic origin of the coronary artery
anomalous aortic origin of the coronary artery (aaoca)
anomalous coronary artery
anomalous coronary artery arising from the pulmonary artery
anomalous coronary artery origin
anomalous insertion of papillary muscles
anomalous left coronary artery (alca)
anomalous left coronary artery (alca) from the pulmonary artery
anomalous left coronary artery arising from the pulmonary artery (alcapa)
anomalous left coronary artery from the pulmonary artery
anomalous origin of coronary arteries
anomalous origin of the coronary artery from the opposite sinus of valsalva
anomalous papillary muscle
anomalous pulmonary venous connection (partial or total)
anomalous pulmonary venous connections
anomalous pulmonary venous connections (apvc)
anomalous pulmonary venous return
anomalous right coronary artery (arca)
anomalous right coronary artery (arca) from the pulmonary artery
anomalous right coronary artery arising from the pulmonary artery (arcapa)
anomalous right coronary artery from the left sinus of valsalva
antegrade cerebral perfusion
antegrade perfusion
antegrade propagation
antegrade propagation of dissection
antegrade stenting of the descending thoracic aorta
antegrade stenting of the proximal descending thoracic aorta
anterior aortoiliac disease
anterior free wall
anterior mitral leaflet extension
anterior stemi
anterior‑lateral thoracotomy
anterior‑posterior (annular) dilation
antero‑apical infarction
anthracycline cardiotoxicity
anthracyclines
anthracyclines (doxorubicin, epirubicin, idarubicin, mitoxantrone)
anthracycline‑induced cardiomyopathy
anthracycline‑induced cardiotoxicity
anthracycline‑related cardiotoxicity
antianginal medications
antiarrhythmic agents
antiarrhythmic drug dosing in ckd
antiarrhythmic drug follow‑up
antiarrhythmic drug group
antiarrhythmic drug therapy
antiarrhythmic drug therapy (aad)
antiarrhythmic drugs
antiarrhythmic drugs (e.g., amiodarone, cardioversion drugs)
antiarrhythmic drugs (maintenance of sinus rhythm)
antiarrhythmic medical therapy (general)
antiarrhythmic medication
antiarrhythmic therapy
antiarrhythmic therapy (e.g., metoprolol)
antiarrhythmics
antibiotic duration
antibiotic prophylaxis
antibiotic sensitivity data
antibiotic therapy
antibiotics (for lyme carditis)
anticancer therapies with cardiac toxicity (e.g., ibrutinib)
anticoagulant compliance and drug interactions
anticoagulant dosing
anticoagulant dosing (under‑ dosing, over‑ dosing, label‑adherent dosing)
anticoagulant duration (3 months, prolonged)
anticoagulant interruption timing
anticoagulant management in valve patients
anticoagulant prophylaxis
anticoagulant reversal agents
anticoagulant reversal agents effectiveness
anticoagulant safety profile
anticoagulant target inr (2–3, risk above 4)
anticoagulant therapy
anticoagulant therapy (e.g., warfarin)
anticoagulant therapy (e.g., warfarin, doacs)
anticoagulant therapy (warfarin, doacs)
anticoagulant therapy (warfarin, others)
anticoagulant therapy guidance
anticoagulant therapy in heart failure
anticoagulants
anticoagulants (general)
anticoagulants / thromboprophylaxis (enoxaparin, unfractionated heparin, rivaroxaban, cerotaparin)
anticoagulant‑associated intracerebral hemorrhage
anticoagulant‑related intracerebral hemorrhage
anticoagulant‑related intracranial haemorrhage surveillance
anticoagulated patients
anticoagulation
anticoagulation (direct oral anticoagulants [doacs])
anticoagulation (for amyloidosis)
anticoagulation (for vte prophylaxis in cancer)
anticoagulation (general)
anticoagulation (heparin, warfarin, doacs)
anticoagulation (including doacs such as rivaroxaban)
anticoagulation (including doacs)
anticoagulation (noacs) for systemic right ventricle
anticoagulation (oac)
anticoagulation (oacs)
anticoagulation (oral anticoagulation)
anticoagulation (oral)
anticoagulation (post‑cardioversion)
anticoagulation (post‑operative management)
anticoagulation (post‑replacement)
anticoagulation (prophylactic or therapeutic)
anticoagulation (vitamin k antagonists, direct oral anticoagulants)
anticoagulation (vka therapy)
anticoagulation (warfarin)
anticoagulation (warfarin, direct oral anticoagulants)
anticoagulation (warfarin, doac, vitamin k antagonists)
anticoagulation (warfarin, noacs)
anticoagulation (warfarin, non‑vitamin k oral anticoagulants)
anticoagulation / anticoagulant therapy
anticoagulation / anticoagulants
anticoagulation / oral anticoagulation
anticoagulation adjustment
anticoagulation agents
anticoagulation and antiplatelet therapy
anticoagulation and risk factor stratification tools (atria, cha2ds2‑vasc, garfield‑af)
anticoagulation bridging
anticoagulation considerations
anticoagulation contraindication
anticoagulation control (warfarin, non‑vitamin k antagonist oral anticoagulants)
anticoagulation discontinuation guidelines (post‑ablation)
anticoagulation discontinuation/continuation after ablation
anticoagulation dosing adjustment
anticoagulation drug absorption
anticoagulation during pregnancy
anticoagulation during pregnancy (first, second, third trimesters)
anticoagulation for atrial fibrillation
anticoagulation for atrial fibrillation (af)
anticoagulation for atrial fibrillation (af) in valvular heart disease (vhd)
anticoagulation for atrial fibrillation in valve disease
anticoagulation forum
anticoagulation in ckd and af
anticoagulation in class iii obesity
anticoagulation in eisenmenger syndrome
anticoagulation indication criteria
anticoagulation interruption
anticoagulation management during pregnancy
anticoagulation management in mechanical valve pregnancy
anticoagulation management in pregnancy
anticoagulation monitoring
anticoagulation monitoring (inr levels)
anticoagulation monitoring (inr)
anticoagulation monitoring (last dose, inr, etc.)
anticoagulation monitoring accessibility
anticoagulation prescription fills
anticoagulation resumption
anticoagulation resumption window
anticoagulation reversal
anticoagulation reversal agents
anticoagulation risk
anticoagulation risk reduction
anticoagulation risk-benefit assessment in hcm.
anticoagulation strategies
anticoagulation strategy
anticoagulation strategy for mechanical valves
anticoagulation strategy independent of cha₂ds₂‑vasc score
anticoagulation therapy
anticoagulation therapy (in cardiac amyloidosis)
anticoagulation therapy (including doacs)
anticoagulation therapy (including vka and non‑vkas)
anticoagulation therapy (oacs)
anticoagulation therapy (stroke prevention in af)
anticoagulation therapy for atrial fibrillation
anticoagulation threshold
anticoagulation timing after ich (1–2 weeks, 7–8 weeks, 10–39 days)
anticoagulation titration
anticoagulation-naïve management
anticoagulation-naïve patients
anticoagulation‑associated bleeding risk
anticoagulation‑related bleeding
anticoagulation‑related ich
anticoagulation‑sparing strategies











antidepressant effects
antidepressants (e.g., escitalopram)
antiepileptic drugs
antifungal therapy
antigen‑presenting cells (apcs)
antihypertensive agents
antihypertensive drug treatment
antihypertensive drugs (early treatment)
antihypertensive medication
antihypertensive medication burden (≥2 drugs)
antihypertensive medication treatment
antihypertensive medications
antihypertensive medications (beta‑blockers, calcium‑channel blockers, etc.)
antihypertensive medications (≥ 3 classes)
antihypertensive therapy
antihypertensive therapy for aortic injury
antihypertensive treatment
antimetabolites
antimetabolites (clofarabine, cytarabine, 5‑fluorouracil, capecitabine, gemcitabine)
antimicrobial agents
antimicrobial duration
antimicrobial regimens
antimicrobial stewardship
antimicrobial stewardship for prosthetic vascular infections
antimicrobial therapy
antimicrobial therapy (e.g., cloxacillin, gentamicin)
antimicrobial therapy (prolonged iv antibiotics)
antimicrobial therapy duration 48 hrs - 1 week
antimicrobial therapy for aortic infections
antimicrobial therapy for foot infections
antimicrotubule agents
antineoplastic drug interactions
antineutrophil cytoplasmic antibody (anca)
antineutrophil cytoplasmic antibody‑related vasculitis
antineutrophil‑cytoplasmic‑antibody‑related disease
antinuclear antibody (ana)
antioxidant therapy (vitamin c, beta‑carotene, multivitamins)
antioxidants (e.g., ascorbic acid)
antioxidants, polyunsaturated fatty acids (pufa) for atrial fibrillation risk in hf
antiphospholipid antibody syndrome
antiphospholipid syndrome
antiplatelet agents
antiplatelet agents (aspirin, clopidogrel, ticagrelor)
antiplatelet agents (clopidogrel, ticagrelor, etc.)
antiplatelet agents (e.g., aspirin, clopidogrel)
antiplatelet and anticoagulant therapy
antiplatelet and antithrombotic regimens
antiplatelet drugs (e.g., ticagrelor)
antiplatelet efficacy
antiplatelet medications
antiplatelet monotherapy as standard of care for pad.
antiplatelet regimen
antiplatelet response
antiplatelet strategy
antiplatelet therapy
antiplatelet therapy (apt)
antiplatelet therapy (aspirin, clopidogrel, dual antiplatelet therapy)
antiplatelet therapy (dual antiplatelet therapy, dapt)
antiplatelet therapy (e.g., aspirin)
antiplatelet therapy (e.g., aspirin, clopidogrel)
antiplatelet therapy guidelines
antiplatelet therapy in ckd patients
antiplatelet therapy in patients on anticoagulation post‑discharge
antiretroviral therapy (art)
antitachycardia pacing
antitachycardia pacing (atp) algorithms
antithrombin
antithrombin agents
antithrombotic agents
antithrombotic agents (rivaroxaban, rivaroxaban + aspirin)
antithrombotic and thrombolytic therapy
antithrombotic drugs
antithrombotic effects
antithrombotic options
antithrombotic prophylaxis
antithrombotic regimen
antithrombotic regimens
antithrombotic safety in mechanical valves
antithrombotic strategy
antithrombotic therapies
antithrombotic therapy
antithrombotic therapy (antiplatelets/anticoagulants)
antithrombotic therapy (aspirin, anticoagulants)
antithrombotic therapy (including antiplatelet therapy)
antithrombotic therapy (post‑tavi, mechanical valves)
antithrombotic therapy effectiveness
antithrombotic therapy for prosthetic valves
antithrombotic therapy for symptomatic pad (pm‑4)
antithrombotic therapy guideline
antithrombotic therapy guidelines
antithrombotic therapy in native and prosthetic valves.
antithrombotic therapy in valvular heart disease
antithrombotic therapy post‑mi
antithrombotic treatment
antithrombotic/anticoagulant therapy
antithyroid treatment
anti‑anginal drugs
anti‑anginal drugs (e.g., β‑blockers, nitrates, ranolazine, nifedipine)
anti‑anginal therapy
anti‑arrhythmic agents
anti‑arrhythmic agents / therapy
anti‑arrhythmic drug (aad) therapy
anti‑arrhythmic drug classes
anti‑arrhythmic drug follow‑up
anti‑arrhythmic drug safety and risk/benefit analysis
anti‑arrhythmic drug therapy
anti‑arrhythmic drug therapy for rhythm control
anti‑arrhythmic drug versus amiodarone
anti‑arrhythmic drugs
anti‑arrhythmic drugs (aads)
anti‑arrhythmic drugs (e.g., digoxin)
anti‑arrhythmic drugs → amiodarone, dofetilide
anti‑arrhythmic effects
anti‑arrhythmic medication
anti‑arrhythmic therapy (class i/iii agents, amiodarone)
anti‑arteriosclerotic effects
anti‑coagulation therapy
anti‑cyclic citrullinated peptide (anti‑ccp)
anti‑double‑stranded dna (anti‑dsdna)
anti‑factor xa level monitoring
anti‑factor xa activity
anti‑her2 agents
anti‑human leukocyte antigen (anti‑hla) antibodies
anti‑hypertensive drugs (e.g., diuretics, antihypertensives)
anti‑impulse therapy
anti‑impulse therapy (beta‑blockade, antihypertensive therapy)
anti‑inflammatory diet
anti‑inflammatory therapy
anti‑ischemic effects
anti‑platelet/anticoagulant therapy for aortic complications
anti‑rna polymerase iii
anti‑scl‑70
anti‑ssa (ro)
anti‑ssb (la)
anti‑tachycardia pacing (atp)
anti‑xa activity / anti‑xa levels
anti‑xa agents
anti‑xa direct oral anticoagulants
anti‑xa level
anti‑xa levels
anti‑xa monitoring
anxiety
anxiety in achd
anxiety in patients undergoing abdominal aortic aneurysm surgery









aorta dilation
aorta simplified score (aortas)
aorta‑specific survival
aortic abscess
aortic afterload
aortic anastomotic pseudoaneurysm
aortic aneurysm
aortic aneurysm (aa)
aortic aneurysm (aaa)
aortic aneurysm (ascending aortic aneurysm, thoracic aortic aneurysm)
aortic aneurysm (ascending, hemi‑arch, infrarenal)
aortic aneurysm (general)
aortic aneurysm (imaging of the aorta)
aortic aneurysm (implied)
aortic aneurysm (infra‑inguinal, popliteal)
aortic aneurysm (saccular, pseudoaneurysm)
aortic aneurysm (thoracic and abdominal)
aortic aneurysm (thoracic, abdominal, ascending)
aortic aneurysm (thoracic, descending)
aortic aneurysm / thoracic aortic aneurysm
aortic aneurysm and dissection (aas)
aortic aneurysm diameter/size
aortic aneurysm growth
aortic aneurysm growth rate
aortic aneurysm growth surveillance by ultrasound
aortic aneurysm guidelines (acc/aha)
aortic aneurysm natural history
aortic aneurysm pathophysiology
aortic aneurysm prevalence among relatives
aortic aneurysm registry/quality initiative data
aortic aneurysm repair
aortic aneurysm reporting standards (svs/sts)
aortic aneurysm risk assessment
aortic aneurysm rupture
aortic aneurysm rupture / dissection
aortic aneurysm rupture risk
aortic aneurysm sac diameter
aortic aneurysm screening age limits (e.g., <65 yrs with risk factors)
aortic aneurysm screening thresholds (e.g., ≥65 yrs)
aortic aneurysm surgical decision‑making criteria
aortic aneurysm surveillance
aortic aneurysm symptoms (chest pain, fatigue, neck/jaw/back pain)
aortic aneurysm-related mortality studies
aortic aneurysms (general)
aortic angiography
aortic annulus
aortic annulus size
aortic anomalies in turner’s syndrome
aortic aortitis
aortic arch
aortic arch abnormalities
aortic arch anatomy
aortic arch aneurysm
aortic arch anomaly / bovine arch
aortic arch atheroma
aortic arch atherosclerosis (protuberant lesions)
aortic arch branch vessels
aortic arch branch vessels visualization
aortic arch branching variants
aortic arch dilatation
aortic arch dilation
aortic arch disease
aortic arch hypoplasia
aortic arch involvement
aortic arch pathology
aortic arch reconstruction
aortic arch repair
aortic arch repair techniques
aortic arch replacement
aortic arch replacement strategies
aortic arch surgery
aortic arch surveillance
aortic arch variants
aortic arch zones (2–5)
aortic arch/hemiarch replacement (in some surgical centers)
aortic area
aortic area (indexed to height)
aortic area/height ratio
aortic ascending aorta
aortic atheroma
aortic atheromas ≥ 4 mm
aortic atherosclerosis
aortic atherosclerosis / aortic atherosclerotic disease
aortic balloon valvuloplasty
aortic bifurcation
aortic biomechanics
aortic branch vessel involvement
aortic branch vessels
aortic branches
aortic bruits
aortic calcification
aortic center
aortic coarctation
aortic coarctation (coa)
aortic coarctation (native and repaired)
aortic coarctation gradients
aortic complications
aortic contour defects
aortic cross‑clamping
aortic cross‑sectional area
aortic cross‑sectional area / height ratio
aortic cross‑sectional area/height ratio
aortic cross‑sectional area‑to‑height ratio
aortic cusp prolapse
aortic diameter
aortic diameter (> 4.0 cm)
aortic diameter (inner‑edge to inner‑edge, outer‑edge to outer‑edge, sinus‑to‑sinus)
aortic diameter (size)
aortic diameter measurement
aortic diameter predictive value
aortic diameter threshold (5.0 cm, 5.5 cm)
aortic diameter thresholds (4.0 cm, 4.5 cm)
aortic diameter thresholds (4–5 cm)
aortic diameter thresholds (< 4.5 cm, < 5.0 cm, 4.5 cm, 4.2 cm, 4.0 cm)
aortic diameter thresholds (> 6 cm, ≥ 5.5 cm)
aortic diameter thresholds (≥ 4.0 cm, > 4.5 cm, > 5.0 cm)
aortic diameter to bsa ratio (asi)
aortic diameter to height ratio (ahi)
aortic diameter ≥ 4.0 cm (dilated)
aortic diameter ≥ 4.5 cm (considered for concomitant surgery)
aortic diameter ≥ 5.0 – 5.4 cm (indicates higher risk)
aortic diameter ≥ 5.5 cm (surgical recommendation)
aortic diameters
aortic diastolic pressure equilibration
aortic dilatation
aortic dilatation / aortic enlargement
aortic dilatation / aortic root dilation
aortic dilatation / dilation
aortic dilatation progression
aortic dilation
aortic dilation (aortic aneurysm)
aortic dilation (aortic enlargement)
aortic dilation / aneurysm
aortic dilation / aortic aneurysm
aortic dilation / aortic enlargement
aortic dilation / aortopathy
aortic dilation / enlargement
aortic dilation rate
aortic dilation/enlargement
aortic disease
aortic disease (clinical statements & guidelines)
aortic disease (diagnosis & management)
aortic disease (guideline focus)
aortic disease (including aortic dissection and aneurysm)
aortic disease (tad)
aortic disease / thoracic aortic disease (tad)
aortic disease complications during pregnancy (maternal and fetal outcomes)
aortic disease epidemiology
aortic disease guideline
aortic disease guideline (acc/aha)
aortic disease guidelines
aortic disease guidelines (acc/aha, aha statements)
aortic disease guidelines (acc/aha, esc)
aortic disease in pregnancy – risk of dissection, rupture, and mortality
aortic disease management algorithms
aortic disease management guidelines
aortic disease natural history
aortic disease presentation & outcome
aortic disease progression.
aortic disease reporting standards
aortic disease risk assessment
aortic disease risk factors
aortic disease surgical outcomes
aortic disease surveillance after repair (long‑term imaging)
aortic disease surveillance protocols
aortic disease temporal classification
aortic diseases
aortic disorder
aortic dissection
aortic dissection (aas)
aortic dissection (acute type a)
aortic dissection (acute, type a, type b)
aortic dissection (ad)
aortic dissection (chronic/acute)
aortic dissection (contraindication but relevant to cardiac care)
aortic dissection (general)
aortic dissection (tad)
aortic dissection (type a & type b)
aortic dissection (type a)
aortic dissection (type a, type b)
aortic dissection (type b)
aortic dissection (type a & type b)
aortic dissection (type a)
aortic dissection (type a, type b)
aortic dissection (type a, type b, acute)
aortic dissection (type a, type b, debakey iiia/iiib, chronic)
aortic dissection (type b)
aortic dissection detection risk score
aortic dissection detection risk score (add‑rs)
aortic dissection distal to graft
aortic dissection incidence
aortic dissection management strategies
aortic dissection risk
aortic dissection risk assessment
aortic dissection risk factors (family history, rapid growth ≥ 0.3 cm / yr, body size)
aortic dissection thresholds
aortic dissection type a (de bakey type i)
aortic dissection‑related ar
aortic ectasia
aortic elongation
aortic endograft complications
aortic endograft device
aortic endografting
aortic endovascular repair
aortic enlargement (asymptomatic)
aortic enlargement (true or false lumen)
aortic enlargement / dilation
aortic enlargement / growth rate
aortic event
aortic event (dissection, aneurysm >5 cm, surgery)
aortic event rate
aortic event rates
aortic events (e.g., dissection, rupture)
aortic events (mortality, rupture, dilation)
aortic events (rupture, dissection, aneurysm growth)
aortic expansion
aortic geometry
aortic gradient
aortic graft
aortic graft / endostent
aortic graft infection
aortic graft material
aortic grafting
aortic growth rate
aortic growth rate (≈ 0.3 cm/year)
aortic growth rate (≥ 0.5 cm / year)
aortic growth rate ≥ 0.3 cm/year
aortic growth rate.
aortic height index
aortic height index (ahi)
aortic hypoperfusion (ischemia)
aortic imaging
aortic imaging (ct angiography, mri, fdg‑pet, echocardiography)
aortic imaging (mri, ct, transesophageal echocardiography – tee)
aortic imaging standards.
aortic imaging surveillance schedule
aortic imaging techniques
aortic imaging to avoid radiation exposure (mri without gadolinium)
aortic indexing
aortic inflammation
aortic injury
aortic injury (blunt traumatic abdominal aortic injury, baai)
aortic injury classification schemes
aortic injury management guidelines
aortic insufficiency
aortic insufficiency (ai)
aortic insufficiency (regurgitation)
aortic insufficiency / aortic valve disease
aortic intervention
aortic intramural hematoma
aortic intramural hematoma (imh)
aortic intramural hematoma evolution
aortic intramural hematoma management
aortic involvement in giant cell arteritis
aortic involvement in takayasu arteritis
aortic isthmus
aortic isthmus ratio (cmr/ct angiography)
aortic isthmus ratio <0.5–0.7
aortic isthmus rupture
aortic isthmus stenosis
aortic knob disruption
aortic landing zone definitions (zone 0–4)
aortic length
aortic lumen
aortic measurement standards
aortic media
aortic monitoring frequency (surveillance frequency)
aortic monitoring protocol (for girls and women ≥ 15 years)
aortic mural thrombosis
aortic mural thrombus
aortic murmur characteristics (loudness, onset, peak, a2 component)
aortic neck ifu (instructions for use) violations
aortic occlusion
aortic orifice
aortic pathology
aortic pathology evaluation
aortic pathology in connective‑tissue disorders
aortic plaques (atheromas)
aortic pressure
aortic prosthesis
aortic pseudoaneurysm
aortic reconstruction (of affected segment)
aortic regurgitation
aortic regurgitation (aortic insufficiency)
aortic regurgitation (ar)
aortic regurgitation (ar) – moderate or greater, normal lv systolic function
aortic regurgitation / aortic insufficiency
aortic regurgitation / insufficiency
aortic regurgitation associated with bicuspid valve
aortic regurgitation indication
aortic regurgitation severity
aortic reintervention
aortic remodeling
aortic repair
aortic repair (ascending aorta)
aortic repair (endovascular or open)
aortic repair (open surgery, endovascular repair)
aortic repair (surgical & endovascular)
aortic repair (surgical or prophylactic)
aortic repair (surgical, endovascular)
aortic repair / aortic surgery
aortic repair threshold (≥5.0 cm, ≥4.5 cm)
aortic repair timing
aortic repair timing and surgical decision‑making.
aortic replacement
aortic replacement intervention
aortic resection
aortic root
aortic root (sinus segment)
aortic root anatomy
aortic root and ascending aorta
aortic root and ascending aorta surgery
aortic root and ascending aorta surgical criteria.
aortic root and ascending thoracic aorta aneurysms (degenerative)
aortic root and ascending thoracic aorta aneurysms (heritable)
aortic root and ascending thoracic aorta aneurysms (idiopathic)
aortic root aneurysm
aortic root area (a) measurement
aortic root area / cross‑sectional aortic root area
aortic root assessment
aortic root asymmetry
aortic root complications
aortic root diameter
aortic root diameter (>4.5 cm)
aortic root diameter < 5.0 cm (risk threshold)
aortic root diameter threshold
aortic root diameter threshold (≥5.0 cm)
aortic root diameter ≥ 4.0 cm
aortic root diameter ≥ 4.5 cm
aortic root diameter ≥ 5.0 cm
aortic root dilatation
aortic root dilation
aortic root dilation / aortopathy
aortic root dimensions
aortic root distortion
aortic root enlargement
aortic root growth
aortic root growth rate
aortic root growth rate slowing with combination therapy
aortic root imaging
aortic root index (z‑score)
aortic root involvement
aortic root or ascending aorta non‑surgical indications
aortic root or ascending aorta surgical indications
aortic root or ascending aortic area to height ratio (≥ 10 cm²/m)
aortic root pathology
aortic root procedures
aortic root procedures for aneurysmal disease
aortic root reconstruction
aortic root reconstruction techniques (reimplantation, david procedure)
aortic root remodeling
aortic root repair
aortic root repair (valve‑sparing)
aortic root repair techniques
aortic root replacement
aortic root replacement (including vsrr)
aortic root replacement for children
aortic root replacement indications (rapid growth, family history, pregnancy, severe valve regurgitation, patient preference)
aortic root replacement surgery
aortic root replacement surgical criteria
aortic root size and shape
aortic root surgery
aortic root surgery / replacement / reimplantation
aortic root/ascending aorta aneurysms
aortic rupture
aortic rupture (free or contained)
aortic rupture (risk factor)
aortic rupture incidence (>5% through 8 years)
aortic rupture risk
aortic sac
aortic sac thrombosis
aortic sarcoma
aortic sclerosis (velocity <2.0 m/s)
aortic sinus dilation
aortic sinuses
aortic sinuses (sinuses of valsalva)
aortic sinuses dilation
aortic size
aortic size at dissection or repair
aortic size index
aortic size index (asi)
aortic size index (asi) – indexed aortic diameter (cm / m²)
aortic size index (cm / m²)
aortic size index thresholds (asi > 2.0 cm/m², asi ≥ 2.5 cm/m²)
aortic size measurement
aortic size measurement thresholds
aortic size monitoring
aortic size surveillance intervals
aortic size threshold (e.g., ≥5.5 cm, ≥5 cm)
aortic stenosis
aortic stenosis (as)
aortic stenosis (as) – moderate or greater, severe
aortic stenosis (calcific)
aortic stenosis (implicitly via aortic coarctation)
aortic stenosis (including supravalvular aortic stenosis and congenital aortic valve stenosis)
aortic stenosis in heterozygous/homozygous familial hypercholesterolemia
aortic stiffness
aortic stiffness index (asi)
aortic stump oversewing
aortic surface index (asi)
aortic surgery
aortic surgery (open or endovascular)
aortic surgery (prophylactic, urgent, endovascular)
aortic surgery / repair
aortic surgery threshold (≥ 5.0 cm, ≥ 4.5 cm)
aortic surgery timing
aortic surgical criteria (risk of aortic dissection)
aortic surgical intervention
aortic surgical repair
aortic surveillance
aortic surveillance (monitoring)
aortic surveillance imaging
aortic surveillance imaging (tri‑monthly during pregnancy)
aortic tear (entry tear)
aortic thromboembolism
aortic thrombosis
aortic thrombus
aortic thrombus (mural and primary)
aortic tortuosity
aortic translocation
aortic transvalvular velocity / gradient
aortic true/false lumen tear mechanics
aortic tumor
aortic type b dissection
aortic valve
aortic valve (av)
aortic valve (av) replacement (savr)
aortic valve (bicommissural)
aortic valve (intervention)
aortic valve abnormality
aortic valve anatomy
aortic valve annulus
aortic valve area
aortic valve area (ava)
aortic valve area index (avai)
aortic valve area indexed (avai)
aortic valve calcification
aortic valve calcium score
aortic valve calcium score (ct)
aortic valve calcium volume (ct imaging)
aortic valve complications (e.g., restenosis, prosthetic valve dysfunction)
aortic valve cusp prolapse
aortic valve disease
aortic valve disease (including ascending aortic aneurysm)
aortic valve disease (overall)
aortic valve disease (stenosis, insufficiency)
aortic valve disease / aortic valve replacement
aortic valve disease (arterial valve, aortic stenosis, aortic regurgitation)
aortic valve dysfunction
aortic valve endocarditis
aortic valve event rates
aortic valve function
aortic valve function assessment
aortic valve function monitoring
aortic valve gradients
aortic valve hemodynamics
aortic valve hemodynamics (flow velocity, gradient)
aortic valve hemodynamics (vmax, δp)
aortic valve imaging intervals
aortic valve insufficiency
aortic valve intervention
aortic valve intervention (avr)
aortic valve intervention age considerations
aortic valve interventions
aortic valve involvement
aortic valve leaflet adhesion
aortic valve leaflet tethering / prolapse
aortic valve leaflets
aortic valve lesions
aortic valve molecular genetics
aortic valve palliation
aortic valve pathology
aortic valve pathology (diffuse variant, elastin deficiency)
aortic valve procedure
aortic valve procedures
aortic valve prosthetic choice (mechanical, bioprosthetic)
aortic valve regurgitation
aortic valve regurgitation (avr)
aortic valve regurgitation / dysfunction
aortic valve reimplantation
aortic valve repair
aortic valve repair and replacement
aortic valve repair/replacement
aortic valve replacement
aortic valve replacement (avr)
aortic valve replacement (savr)
aortic valve replacement (savr) with concomitant septal myectomy
aortic valve replacement (surgical avr)
aortic valve replacement criteria
aortic valve replacement outcomes in congenital versus native valve disease
aortic valve root remodeling
aortic valve sclerosis
aortic valve stenosis
aortic valve stenosis (as)
aortic valve stenosis (avs)
aortic valve stenosis progression metrics (velocity, gradient, area changes)
aortic valve surgery
aortic valve surgery (repair, replacement)
aortic valve surgery / aortic valve replacement (avr, savr)
aortic valve surgical durability in young patients
aortic valve surgical indications and timing
aortic valve surgical planning
aortic valve‑related reoperation
aortic valve–sparing operations
aortic valve–sparing root replacement
aortic velocity
aortic velocity (m s⁻¹)
aortic vmax <4 m/s or 2.0–2.9 m/s
aortic vmax ≥4 m/s or ≥5 m/s
aortic volume
aortic volume as disease indicator
aortic wall
aortic wall (medial layer)
aortic wall abnormalities
aortic wall biomechanics
aortic wall changes (inflammation, thickening)
aortic wall disruption
aortic wall false lumen and secondary dilatation
aortic wall integrity
aortic wall remodeling
aortic wall stress
aortic wall thickening
aortic zones of injury (zone 2, zone 3, zone 4)
aortic-related adverse events
aortic-related death
aortic‑pulmonary collaterals (aortopulmonary collaterals)
aortic‑pulmonary transposition
aortic‑related adverse events
aortic‑related complications
aortic‑related death
aortic‑related events
aortic‑related events (rupture or dissection)
aortic‑related mortality
aortic‑related outcomes
aortic diameter > 4 cm
aortic dissection
aortitis









aortobifemoral bypass
aortocaval fistula
aortocavitary fistula
aortoenteric fistula
aortography
aortoiliac arterial disease
aortoiliac arterial segment
aortoiliac disease
aortoiliac occlusive disease
aortoiliac pad
aortoiliac segment
aortoiliac, femoropopliteal, infrapopliteal vessel segments
aortoiliac‑femoral occlusive disease
aortopathic conditions
aortopathy
aortopathy (≥ 5 cm diameter or connective‑tissue disorder)
aortopathy associated with bicuspid aortic valve
aortopathy management during pregnancy
aortopulmonary arteriovenous shunt
aortopulmonary collateral flow
aortopulmonary collaterals
aortopulmonary fistula
aortopulmonary shunt
aortopulmonary shunt closure
aorto‑aortic tube grafting
aorto‑enteric fistula
aorto‑iliac arterial intervention
aorto‑iliac arterial intervention (appropriate use)
aorto‑iliac disease
aorto‑iliac lesions
aorto‑iliac occlusive disease (precluding transfemoral approach)
ap (anatomic and physiological)
ap classification (e.g., class ia, ic–d, iib–d, iiia–d, iic–d, iia–d)
ap** – accessory pathway
apex‑ami trial (mechanical complications after percutaneous coronary intervention)
apha (american pharmacists association)
apical aneurysm
apical aneurysm (lv apical aneurysm)
apical aneurysm after mi
apical hypertrophic cardiomyopathy
apical hypertrophy
apical myectomy
apical outpouching
apical point of maximal impulse
apical site pacing
apical sparing of lv longitudinal strain
apically displaced papillary muscles
apixaban
apixaban for the reduction of thrombo‑embolism in patients with device‑detected subclinical atrial fibrillation (artesia)
apma
apma (american physical medicine & rehabilitation)
apma (american podiatric medical association)
apma (american pulmonary & medical association)
apnea‑hypopnea syndrome
apolipoprotein a‑1
apolipoprotein b
apolipoprotein b (apob)
apolipoprotein b
apolipoprotein b (apob)
appropriate use criteria (auc) for cardiac imaging and revascularization
appropriate use criteria (for vascular diagnostics)
appropriate use criteria for echocardiography
appropriate use criteria for multimodality imaging (acc/aha)
appropriate use criteria for multimodality imaging in congenital heart disease
apt** – antiplatelet therapy
aptt (activated partial thromboplastin time)
apvc (anomalous pulmonary venous connection)
ar (aortic regurgitation abbreviation)
ar (aortic regurgitation)
ara–neprilysin inhibitor (arni)
arb (angiotensin receptor blocker)
arb (angiotensin‑ii receptor blocker)
arb (angiotensin‑receptor blocker)
arb agents (angiotensin ii receptor blockers)
arb class (e.g., losartan, valsartan)
arb – angiotensin receptor blocker
arb** – angiotensin receptor blocker
arbs (angiotensin‑ii receptor blockers)
arch aneurysm
arch repair
arch replacement (total arch, extended arch, partial arch)
arc‑hf (a randomised trial to assess catheter ablation versus rate control in the management of persistent atrial fibrillation in chronic heart failure)
area under the curve (auc)
argatroban
aric (atherosclerosis risk in communities)
aric risk score (atherosclerosis risk in communities)
aric study
aric study (atherosclerosis risk in communities)
aristotle trial
aristotle trial (apixaban efficacy)
arm ergometry
arm‑ergometer exercise
arni (angiotensin receptor‑neprilysin inhibitor)
arni (angiotensin‑receptor‑neprilysin inhibitor)
arrest trial
arrhythmia
arrhythmia (atrial & ventricular)
arrhythmia (atrial or ventricular tachyarrhythmias)
arrhythmia (atrial, ventricular)
arrhythmia (general)
arrhythmia (including complete heart block)
arrhythmia (including sustained or high‑burden tachyarrhythmia)
arrhythmia (post‑operative, post‑cardioversion)
arrhythmia (ventricular tachyarrhythmia, icd shock)
arrhythmia / ventricular arrhythmia
arrhythmia burden
arrhythmia burden, atrial arrhythmia, atrial switch operation
arrhythmia detection
arrhythmia genes
arrhythmia incidence
arrhythmia management
arrhythmia management in adult chd
arrhythmia management in adult congenital heart disease
arrhythmia management in heart failure
arrhythmia monitoring
arrhythmia progression
arrhythmia recurrence
arrhythmia strategies
arrhythmia substrate identification – conduction isthmuses, qrs morphology
arrhythmia suppression trials (e.g., catch, cash, affirm)
arrhythmia surgery
arrhythmia surgery (e.g., maze procedures)
arrhythmia syndrome genes
arrhythmia treatment
arrhythmias
arrhythmias (atrial and ventricular)
arrhythmias (atrial fibrillation, ventricular arrhythmias)
arrhythmias (atrial, ventricular)
arrhythmias (general)
arrhythmias (including bradyarrhythmias)
arrhythmias (including premature ventricular complexes)
arrhythmias (torsades, vt/vf)
arrhythmias during exercise testing
arrhythmias during pregnancy
arrhythmias in adults after rastelli surgery
arrhythmias in pregnancy
arrhythmias post‑fontan
arrhythmia‑free outcome
arrhythmia‑induced cardiomyopathy
arrhythmia‑related symptoms
arrhythmic complications
arrhythmic death
arrhythmic events
arrhythmic events (life‑threatening arrhythmias)
arrhythmic phenotypes (genetic basis)
arrhythmic risk
arrhythmic risk scores in systemic right ventricle
arrhythmic risk stratification
arrhythmogenic cardiomyopathy
arrhythmogenic cardiomyopathy (acm)
arrhythmogenic right ventricular cardiomyopathy (arvc)
arrhythmogenic right ventricular dysplasia/cardiomyopathy
arrhythmogenic right ventricular dysplasia/cardiomyopathy (arvd/c)
arrhythmogenic right‑ventricular cardiomyopathy (arvc)
arrhythmogenic substrate
arrowhead pharmaceuticals (cardiovascular therapeutics)
arterial aneurysm
arterial embolism
arterial intermittent pneumatic compression devices
arterial lactate (≥2.5 mmol/l)
arterial line
arterial line (vascular access)
arterial load
arterial occlusion
arterial occlusive diseases
arterial phase imaging
arterial revascularization
arterial stenosis
arterial stiffness
arterial switch operation
arterial switch operation (d‑tga)
arterial switch operation (jatene procedure)
arterial thromboembolism
arterial thrombosis
arterial tortuosity
arteriopathy clinic
arteriovenous fistula‑related hf
arteriovenous malformations
arteriovenous pressure gradient

















artificial intelligence
artificial intelligence (ai)
artificial intelligence (ai) for af management
artificial intelligence (risk prediction)
artificial intelligence and machine learning in cardiology
artificial intelligence‑based perfusion mapping
artificial intelligence–ecg (ai‑ecg)
artificially sweetened beverages
arvc (arrhythmogenic right ventricular cardiomyopathy)
as (aortic stenosis)
asa (american society of anesthesiologists)
asap study
asap‑too trial
ascending aorta
ascending aorta aneurysm
ascending aorta dilation
ascending aorta dimensions
ascending aorta procedures
ascending aorta repair
ascending aorta repair / replacement
ascending aorta replacement
ascending aortic
ascending aortic aneurysm
ascending aortic aneurysm (aaa)
ascending aortic aneurysm (taa)
ascending aortic aneurysm outcomes
ascending aortic aneurysm surgery
ascending aortic calcification (porcelain aorta)
ascending aortic cannulation
ascending aortic complications
ascending aortic diameter
ascending aortic dilation
ascending aortic replacement
ascending aortic root replacement surgery
ascending thoracic aorta
ascending thoracic aortic aneurysm
ascending thoracic aortic graft
ascites
ascorbic acid (vitamin c) supplementation
ascvd (atherosclerotic cardiovascular disease)
ascvd (atherosclerotic cardiovascular disease) event rates
ascvd (atherothrombotic cardiovascular disease)
ascvd event risk
ascvd events
ascvd risk
ascvd risk calculator
ascvd risk calculators / risk factors (high‑risk clinical factors)
ascvd risk estimate
ascvd risk factors
ascvd risk prediction models
ascvd – atherosclerotic cardiovascular disease
asd (atrial septal defect)
asd closure
ash (american society of hematology)
asi (aortic size index)
asi (aortic size index) – ratio of aortic diameter to body surface area
asian and pacific islander populations
asnc (american society of nuclear cardiology)
aspc (american society for preventive cardiology)
aspc (american society of parenteral and enteral nutrition)
aspc (american society of preventive cardiology)
aspci (society for cardiovascular angiography and interventions)
aspiration thrombectomy
aspiration thrombectomy (thrombus aspiration)
aspirin
aspirin (acetylsalicylic acid)
aspirin (antiplatelet therapy)
aspirin (antiplatelet)
aspirin (asa)
aspirin (for primary prevention)
aspirin (low dose)
aspirin (low‑dose)
aspirin (low‑dose, 81 mg, 75‑100 mg)
aspirin 75‑100 mg daily
aspirin 81 mg daily
aspirin contraindication (increased bleeding risk)
aspirin desensitization (for hypersensitivity)
aspirin discontinuation (1–4 weeks post‑acs)
aspirin discontinuation strategy
aspirin dosing: low-dose (81 mg) and high-dose (325 mg)
aspirin for asymptomatic atherosclerosis (aaa) trial
aspirin hypersensitivity
aspirin loading dose (162–325 mg)
aspirin maintenance dose (75–100 mg/day)
aspirin monotherapy
aspirin sensitivity/desensitization
aspirin therapy
aspirin therapy for pericarditis
aspirin use
aspirin use (for cardiovascular prevention)
aspirin use (pre‑hospital/within 7 days)
aspirin use for primary prevention
aspirin use in transplant patients
aspirin‑induced hemorrhage
assent‑3 trial
assessment of cardiovascular risk
assessment of chest pain for coronary artery disease (cad)
assessment of ischemic myocardium in af patients
assisted delivery
assisted reproductive technology
assisted reproductive technology (art) and cardiac risk
association of black cardiologists
association of black cardiologists (abc)
association of podiatric medical association (apma)
astrazeneca
astrazeneca pharmaceuticals
asymptomatic adult cardiac risk assessment
asymptomatic adult with dcrv
asymptomatic af detection (monitoring)
asymptomatic aortic regurgitation
asymptomatic aortic stenosis
asymptomatic as
asymptomatic atrial fibrillation
asymptomatic cardiomyopathy (ef < 50 %)
asymptomatic heart failure
asymptomatic lv diastolic dysfunction
asymptomatic lv dysfunction
asymptomatic lv systolic dysfunction
asymptomatic mitral regurgitation
asymptomatic pad
asymptomatic pad screening
asymptomatic patients
asymptomatic patients (with severe or moderate ar)
asymptomatic patients.
asymptomatic pau
asymptomatic peripheral artery disease
asymptomatic presentation
asymptomatic severe aortic regurgitation
asymptomatic severe ar
asymptomatic severe ar with normal lv systolic function
asymptomatic severe as
asymptomatic valvular heart disease
asymptomatic vhd patient
asymptomatic vs symptomatic vascular ring/pa sling
asymptomatic/subclinical af (scaf)
asystole
at** – atrial tachycardia
atenolol
atherectomy
atherectomy coronary
atherogenic lipoproteins
atheroma
atherosclerosis
atherosclerosis & vascular calcification (in ckd)
atherosclerosis (atherosclerotic disease)
atherosclerosis (mentioned in context of cardiovascular pathology)
atherosclerosis (peripheral arteries)
atherosclerosis (underlying pathology)
atherosclerosis (vascular disease)
atherosclerosis / atherosclerotic cardiovascular disease
atherosclerosis / atherosclerotic events
atherosclerosis / atherosclerotic risk factors
atherosclerosis / plaque
atherosclerosis of lower extremities
atherosclerosis progression
atherosclerosis risk (aric study)
atherosclerosis risk (associated with turner syndrome)
atherosclerosis risk factors
atherosclerosis risk in communities (aric) study
atherosclerosis risk reduction
atherosclerotic aortic disease
atherosclerotic arterial disease
atherosclerotic burden
atherosclerotic cardiovascular disease
atherosclerotic cardiovascular disease (ascvd)
atherosclerotic cardiovascular disease (broader context)
atherosclerotic cardiovascular disease (cvd)
atherosclerotic cardiovascular disease (implicit in chronic coronary disease)
atherosclerotic cardiovascular disease / coronary artery disease
atherosclerotic cardiovascular disease prevention
atherosclerotic cardiovascular disease risk score
atherosclerotic cardiovascular event
atherosclerotic cardiovascular risk
atherosclerotic disease
atherosclerotic disease elsewhere
atherosclerotic disease of the aorta
atherosclerotic disease risk
atherosclerotic heart disease
atherosclerotic lesion
atherosclerotic occlusive disease
atherosclerotic occlusive disease of the lower extremities (asymptomatic disease and claudication)
atherosclerotic pathways
atherosclerotic plaque
atherosclerotic plaque burden
atherosclerotic plaque instability
atherosclerotic plaque volume
atherosclerotic risk
atherosclerotic taa
atherosclerotic vascular disease
atherothrombosis
atherothrombotic cardiovascular disease (ascvd)
atherothrombotic events
athersys
ather et al. (non‑cardiac comorbidities)
athlete
athlete population
athletes (competitive athletes)
athlete’s heart
athlete’s heart differential diagnosis
athletic activity restrictions
atlas study (low vs high dose lisinopril)
atorvastatin
atorvastatin (10‑20 mg)
atorvastatin (10 mg, 20 mg, 40 mg, 80 mg)
atorvastatin (40‑80 mg)
atorvastatin (40–80 mg)
atorvastatin (≥ 40 mg)
atria score
atria stroke‑risk score
atrial annular dilation
atrial arrhythmia
atrial arrhythmia (including atrial flutter)
atrial arrhythmia (post‑closure arrhythmias)
atrial arrhythmia burden
atrial arrhythmia recurrence
atrial arrhythmias
atrial arrhythmias (28.9% prevalence)
atrial arrhythmias (atrial flutter, atrial fibrillation)
atrial arrhythmias (e.g., atrial fibrillation)
atrial arrhythmias (recurrent atrial arrhythmias)
atrial arrhythmias / atrial arrhythmogenesis
atrial arrhythmia‑related drugs (noting arrhythmia suppression trials)
atrial cardiomyopathy
atrial contraction
atrial dilatation / atrial remodeling
atrial dilation
atrial dysfunction
atrial ectopic beats
atrial ectopy
atrial electromechanical delay
atrial electrophysiology
atrial electrophysiology abnormalities
atrial enlargement
atrial fatty infiltration (adipose)













atrial fenestration
atrial fibrillation
atrial fibrillation (af)
atrial fibrillation (af) (risk factor for tr progression)
atrial fibrillation (af) / new‑onset af
atrial fibrillation (af) / paroxysmal af
atrial fibrillation (af) in vhd
atrial fibrillation (af) management
atrial fibrillation (af) – early‑onset, “lone” af
atrial fibrillation (afib)
atrial fibrillation (athletes)
atrial fibrillation (non‑valvular)
atrial fibrillation (obesity)
atrial fibrillation (post‑operative af)
atrial fibrillation (subclinical, device‑detected, silent episodes)
atrial fibrillation ablation
atrial fibrillation ablation on uninterrupted oral anticoagulation
atrial fibrillation and atrial flutter in congenital heart disease
atrial fibrillation and mortality
atrial fibrillation and quality of life
atrial fibrillation and stroke risk
atrial fibrillation and ventricular fibrosis
atrial fibrillation and weight management
atrial fibrillation as a comorbidity in hf
atrial fibrillation burden
atrial fibrillation burden (inspiratory, rapid atrial pacing, atrial pacing models)
atrial fibrillation classification (stages of disease progression)
atrial fibrillation clinical outcomes
atrial fibrillation economic evaluation
atrial fibrillation follow‑up investigation (affirm)
atrial fibrillation follow‑up investigation of rhythm management (affirm) study
atrial fibrillation in adult congenital heart disease
atrial fibrillation in heart failure patients
atrial fibrillation in patients with implanted devices
atrial fibrillation in patients with permanent pacemakers
atrial fibrillation in patients ≤30 years
atrial fibrillation in pediatric and young adult populations
atrial fibrillation in valvular heart disease
atrial fibrillation incidence in major cancer subtypes
atrial fibrillation management
atrial fibrillation management guidelines (aha/acc/hrs)
atrial fibrillation management strategies
atrial fibrillation mortality risk in cancer patients
atrial fibrillation prevention
atrial fibrillation progression
atrial fibrillation progression risk factors
atrial fibrillation recurrence
atrial fibrillation therapy outcomes
atrial fibrillation treatment strategy
atrial fibrillation treatment trial (aftr) – (e.g., ablate and pace trial)
atrial fibrillation, new‑onset
atrial fibrillation, persistent
atrial fibrillation/flutter
atrial fibrillation‑associated thromboembolism
atrial fibrosis (interstitial)
atrial flutter
atrial flutter (afl)
atrial flutter (afl) – typical & atypical
atrial functional mitral regurgitation
atrial high‑rate episode (ahre)
atrial high‑rate episodes
atrial high‑rate episodes (ahres)
atrial high‑rate episodes (device‑detected)
atrial interstitial collagen
atrial isomerism
atrial kick
atrial lead
atrial maze procedure (modified maze)
atrial myocyte hypertrophy
atrial myopathy
atrial overdrive pacing
atrial pacemaker lead
atrial pacing
atrial pacing algorithms
atrial partial pulmonary venous connection (apvc)
atrial rate control
atrial refractory period
atrial remodeling
atrial remodeling (electrical and structural)
atrial remodeling (structural & functional)
atrial rhythm‑control strategy
atrial scar
atrial scarring
atrial septal defect
atrial septal defect (asd)
atrial septal defect (asd) closure
atrial septal defect (asd)/patent foramen ovale (pfo)
atrial septal defects (asd)
atrial septal dilation
atrial size
atrial structural abnormalities
atrial stunning
atrial substrate
atrial switch
atrial switch (senning/mustard procedures)
atrial switch (surgically induced)
atrial switch operation
atrial switch operation (mustard, senning)
atrial switch operation (senning/mustard)
atrial switch repair
atrial sympathetic and parasympathetic hyperinnervation
atrial tachyarrhythmia
atrial tachyarrhythmias
atrial tachycardia
atrial tachycardia (at)
atrial thrombi
atrial tissue refractory period
atrial‑fibrillation‑related cardiomyopathy
atrial‑ventricular arrhythmias (refractory)
atrial‑ventricular congenital heart disease (achd)
atrial‑ventricular valve dysfunction
atrial–ventricular conduction system
atrial fibrillation
atrial flutter
atria risk score
atriclip device
atricure
atrioesophageal fistula
atriopulmonary fontan
atriotomy scars
atrioventricular
atrioventricular (av) block
atrioventricular (av) complex pathology
atrioventricular (av) conduction
atrioventricular (av) nodal block
atrioventricular (av) nodal blockers
atrioventricular (av) node ablation (avna)
atrioventricular (av) septal defect (avsd)
atrioventricular block
atrioventricular block (high‑grade)
atrioventricular canal
atrioventricular canal defect (avsd) – partial and complete
atrioventricular conduction
atrioventricular conduction abnormalities
atrioventricular conduction block
atrioventricular dyssynchrony
atrioventricular heart block
atrioventricular junction ablation
atrioventricular junction ablation and pacing therapy
atrioventricular junctional radiofrequency ablation
atrioventricular nodal ablation
atrioventricular nodal ablation (avna)
atrioventricular nodal blockers
atrioventricular nodal blocking agent
atrioventricular node
atrioventricular node ablation
atrioventricular node ablation (avna)
atrioventricular node displacement
atrioventricular septal defect (avsd)
atrioventricular septal defect (partial or complete)
atrioventricular synchrony
atrioventricular valve dysfunction
atrioventricular valve failure
atrioventricular valve function
atrioventricular valve regurgitation
atrioventricular valve replacement
atrioventricular valve surgery (e.g., systemic av valve repair)
atrio‑ventricular junction ablation
atrio‑ventricular septal defect (avsd)
atri‑esophageal fistula
attest trial
attr-cm (transthyretin amyloid cardiomyopathy)
attrv (variant transthyretin amyloidosis)
attrwt (wild‑type transthyretin amyloidosis)
attr‑cm (transthyretin amyloid cardiomyopathy)
attr‑cm (transthyretin cardiac amyloidosis)
attr v (variant attr)
attr wt (wild‑type attr)
atypical afl / non‑cavotricuspid isthmus–dependent macroreentrant at
atypical atrial arrhythmias
augustus
augustus trial (antithrombotic therapy after acs/pci in af)
auscultatory findings
autoantibodies:
autogenous vein
autogenous vein bypass graft (avbg)
autogenous vein bypass graft surgery
autogenous vein conduit
autogenous vein graft
autogenous vein graft (e.g., great saphenous vein)
autograft aortic root replacement
autografts (femoral vein)
autoimmune / autoinflammatory conditions
autoimmune causes (e.g., rheumatologic disease)
autoimmune conditions associated with myocarditis
autoimmune myocarditis
autoimmunity (in the context of cardiovascular disease)
autologous vein graft
automated algorithm detection of af
automated algorithms for af detection
autonomic denervation
autonomic disorders
autonomic dysfunction
autonomic dysfunction in amyloidosis
autonomic modulation
autonomic nerve sprouting
autonomic nervous system (ans)
autonomic nervous system (ans) dysfunction
autonomic nervous system (ans) dysregulation
autonomic neuropathy
autosomal dominant inheritance
autosomal dominant transmission of taa
av block
av block (atrioventricular block)
av junction ablation
av nodal ablation
av nodal ablation / left ventricular‑based cardiac stimulation
av nodal ablation strategies
av nodal blocker
av synchrony
avascular aneurysm
averroes trial
avid (antiarrhythmics versus implantable defibrillators trial)
avna** – atrioventricular nodal ablation
avoid (air versus oxygen in stemi) trial
avoidance of invasive procedures in fragile vasculature.
avr (aortic valve replacement)
avsd (atrioventricular septal defect)
av‑nodal blocking agents
awareness of pad
axial imaging
axial versus double‑oblique measurement
axillary artery cannulation
axillary cannulation
axillofemoral bypass
azathioprine
azathioprine (dmard)
azygos vein (off‑loading pathway)
azygous continuation of inferior vena cava
a‑heft (african‑american heart failure trial)












b braun medical
b vitamins and omega‑3 fatty acids (cardiovascular effects)
b-type natriuretic peptide (bnp)
b-type natriuretic peptide (bnp) / natriuretic peptides
b-type natriuretic peptide (bnp) testing
back pain
bacteremia
bacterial aortitis
bacterial endocarditis
bacterial sepsis (cardiovascular impact)
baffle leak
baffle leak (intratrial)
baffle leak / baffle obstruction
baffle leak closure
baffle leaks
baffle obstruction
baffle stenosis
baffle‑leak intervention (e.g., closure procedures)
balloon angioplasty
balloon angioplasty (pulmonary)
balloon aortic valvuloplasty
balloon aortic valvuloplasty (bav)
balloon aortoplasty
balloon catheter
balloon dilatation for severe aortic stenosis
balloon dilatation of the aortic valve
balloon dilation
balloon mitral commissurotomy
balloon mitral valvotomy (bmv)
balloon mitral valvuloplasty
balloon occlusion of the aorta
balloon occlusion test
balloon test occlusion
balloon valvuloplasty
balloon valvuloplasty (pulmonary)
balloon valvuloplasty / balloon dilation of the aortic valve
balloon‑expandable percutaneous valves
balloon‑expandable prostheses
balloon‑expandable pulmonary valve
balloon‑expandable valve
balloon‑expandable valve (e.g., sapien 3)
balloon‑expanded stent
balloon angioplasty
ball‑in‑cage valve
bare metal stent
bare‑metal femoropopliteal stent
bare‑metal stent (bms)
bare‑metal stents
bari 2d trial results
bariatric procedure
bariatric procedure / bariatric surgery
bariatric surgery
bariatric surgery (gastric bypass, sleeve gastrectomy, adjustable gastric banding)
bariatric surgery pharmacokinetics of rivaroxaban
barium swallow testing
barlow’s valve
baroreceptor stimulation
baroreceptor stimulation (carotid artery)
baroreflex activation therapy (bat)
barriers to care & access to specialty services
barriers to care (geographic distance, insurance coverage, socioeconomic challenges)
barriers to care (insurance, distance, socioeconomic factors)
barriers to physical activity in hcm patients
basal anterior septum
basal septal hypertrophy
baseline aortic imaging
baseline coronary imaging
baseline management strategy (invasive or non‑invasive)
baseline mri/ct for aorta and branches
baseline tee (before oral therapy)
baseline transthoracic echocardiography (tte)
basilic vein
basil‑2 (trial)
basil‑2 trial
basil‑2 trial (bypass versus angioplasty for severe ischaemia of the leg)
basket trials
bav (bicuspid aortic valve)
bav aortopathy
bayer
bayer healthcare pharmaceuticals** (cardiovascular drug manufacturer)
bbmeta‑hf (beta‑blockers meta‑analysis)
bcl2‑like protein 12 (bcl2l12)
beautiful trial (ivabradine in cad with lv dysfunction)
beckman coulter
behavior modification
behavior therapy
behavioral change techniques
behavioral coaching (in‑person or virtual)
behavioral counseling
behavioral interventions for tobacco cessation
behavioral risk factor surveillance system (brfss) data on coronary disease prevalence
behavioral risk factors
behavioral support for smoking cessation
behaviours / exposures
behçet disease
behçet’s disease
bempedoic acid
bempedoic acid (atp citrate lyase inhibitor)
bempedoic acid (atp‑citrate lyase inhibitor)
bempedoic acid + ezetimibe combination therapy
bempezoic acid
benchmarking across centers
benchmarking to performance measures
bendopnea
benefit assessment
benefit‑risk assessment
bentall procedure
benzphetamine
berlin heart excor
best (beta‑blocker evaluation of survival trial)
best‑cli (trial)
best‑cli trial
best‑cli trial (best-cli)
beta blocker
beta blocker therapy
beta blockers
beta blockers (in aortic dissection)
beta blockers (including cardioselective agents)
beta blockers (non‑vasodilating)
beta blockers (β‑blockers)
betami
beta‑2 agonists
beta‑adrenergic blockade
beta‑adrenergic blockade (beta‑blockers)
beta‑adrenergic blockade in pregnancy with valvular disease
beta‑adrenergic blocker therapy
beta‑adrenergic blocking agents
beta‑blockade after myocardial infarction
beta‑blocker
beta‑blocker (e.g., metoprolol, metoprolol succinate)
beta‑blocker (β‑blocker)
beta‑blocker / β‑adrenergic antagonist (metoprolol, atenolol, isoproterenol)
beta‑blocker medications
beta‑blocker therapy
beta‑blocker therapy (optimal doses, uptitration)
beta‑blocker therapy as adjunct to arb
beta‑blocker therapy during pregnancy and postpartum
beta‑blocker therapy for hfref
beta‑blocker – e.g., bisoprolol, carvedilol, metoprolol succinate (cr/xl)
beta‑blocker – e.g., carvedilol, other β‑adrenergic antagonists
beta‑blockers
beta‑blockers (av‑nodal blocker)
beta‑blockers (celiprolol, vasodilatory beta‑blockers)
beta‑blockers (e.g., carvedilol, metoprolol)
beta‑blockers (e.g., labetalol)
beta‑blockers (e.g., metoprolol, bisoprolol, labetalol, pindolol, propranolol, atenolol)
beta‑blockers (e.g., metoprolol, carvedilol)
beta‑blockers (e.g., propranolol, metoprolol)
beta‑blockers (e.g., propranolol, nadolol)
beta‑blockers (implicit in acs management)
beta‑blockers (intravenous)
beta‑blockers (metoprolol, other)
beta‑blockers (pre‑operative prophylaxis)
beta‑blockers (rate‑control agents)
beta‑blockers (β‑blockers)
beta‑blockers and antiplatelet agents in scad
beta‑carotene supplementation
beta‑myosin heavy chain 7 (myh7)
bgn
biatrial remodeling
bicarbonate
bicuspid aortic valve
bicuspid aortic valve (bav)
bicuspid aortic valve (bav) disease
bicuspid aortic valve disease
bicuspid valve phenotype
bicuspid valve‑associated aneurysm
bicuspid vs tricuspid aortic valve outcomes
bicuspidoid aortic valve phenotyping
bicuspid aortic valve
bicycle exercise testing
bidirectional cavopulmonary shunt (glenn shunt)
bidirectional shunt
bidirectional shunting
bidirectional superior cavopulmonary (glenn) anastomosis
bidirectional superior cavopulmonary (glenn) shunt
bifid uvula
bifurcated grafting
bifurcation lesion
bifurcation lesion management
bilateral antegrade cerebral perfusion
bilateral aortic injury (baai)
bilateral cerebral perfusion
bilateral/bioprosthetic valve replacement
bile acid sequestrants
bileaflet (anterior‑and‑posterior) prolapse/replacement
bileaflet mechanical aortic valve replacement (avr)
biliary excretion
biliary excretion (liver metabolism of amiodarone)
binge drinking













bioavailability
bioavailability / pharmacokinetics / pharmacodynamics of diuretics
biochemical cardiac biomarkers
biochemical screening
bioimage study (personalized statin allocation)
bioimpedance
biologic disease‑modifying antirheumatic drugs
biologic prosthetic valve
biological prosthesis
biological valve
biological valved conduit
biological‑targeted therapy for takayasu arteritis
biologics / immune‑modulating therapies
biomarker analysis
biomarker assay (nt‑probnp)
biomarker domain
biomarker testing
biomarker utilization in acs
biomarkers
biomarkers (e.g., bnp)
biomarkers (e.g., desmosine, proteomics)
biomarkers (e.g., hs‑crp)
biomarkers (e.g., nt‑probnp, other natriuretic peptides)
biomarkers (e.g., n‑terminal pro‑hormone of b‑type natriuretic peptide, nt‑probnp)
biomarkers (filling pressures, myocardial damage)
biomarkers (in the context of lv function)
biomarkers (troponin, high‑sensitivity troponin)
biomarkers for af and stroke prediction
biomarkers for aortic risk stratification
biomarkers for heart failure (bnp, nt‑probnp)
biomarkers for risk stratification in heart disease
biomarkers in asymptomatic aortic valve disease
biomarkers in hf therapy optimization
biomarkers of cardiac damage
biomarkers of cardiac injury, inflammation, and cardiac strain
biomarkers of cardiac strain
biomarkers: natriuretic peptide (np)
biomarker‑guided therapy
biomechanical modeling of stent‑graft deployment in type b aortic dissection.
biomechanical wall stress in the aorta
biomechanics of the aorta
bioprosthesis
bioprosthesis (bioprosthetic valve prosthesis)
bioprosthetic (biological) valve replacement
bioprosthetic (tissue) valves
bioprosthetic aortic valve
bioprosthetic aortic valve durability
bioprosthetic aortic valve replacement
bioprosthetic aortic valve replacement (bioprosthetic avr)
bioprosthetic heart valves
bioprosthetic leaflet degeneration
bioprosthetic mitral valve
bioprosthetic mitral valve replacement
bioprosthetic prostheses
bioprosthetic pulmonary valves
bioprosthetic surgical aortic valve replacement
bioprosthetic surgical or transcatheter aortic valve
bioprosthetic surgical valve
bioprosthetic tavi
bioprosthetic valve
bioprosthetic valve (bioprosthesis)
bioprosthetic valve (prosthetic)
bioprosthetic valve (surgical & transcatheter)
bioprosthetic valve (≥ 3 months post‑implantation)
bioprosthetic valve degeneration
bioprosthetic valve degeneration (leaflet calcification, non‑coaptation, tear, perforation)
bioprosthetic valve durability
bioprosthetic valve dysfunction
bioprosthetic valve prosthesis
bioprosthetic valve regurgitation (paravalvular)
bioprosthetic valve replacement
bioprosthetic valve replacement or repair
bioprosthetic valve stenosis
bioprosthetic valve thrombosis
bioprosthetic valve thrombosis prevention (aspirin, warfarin, low‑dose warfarin)
bioprosthetic valves
bioresorbable polymer‑coated stent
biosense webster
biosense webster (device manufacturer for cardiac rhythm management)
biotronik
biovasc trial
bio‑absorbable stent implantation
biphasic cardioversion
biphasic energy (≥200 j)
biphasic waveform
birth prevalence of congenital heart defects
bisoprolol
bisoprolol (cibis‑ii)
bivalirudin
biventricular (bi‑v) pacing
biventricular circulation
biventricular condition
biventricular defibrillators (crt‑d)
biventricular dysfunction
biventricular function
biventricular global function index
biventricular global‑function index
biventricular interaction
biventricular outflow tract reconstruction
biventricular pacing
biventricular pacing (bivp)
biventricular pacing (cardiac resynchronization therapy)
biventricular pacing (cardiac resynchronization therapy, crt)
biventricular pacing / biventricular pacemaker
biventricular repair
biventricular surgical strategy
biventricular versus right‑ventricular pacing (block‑hf)
bivp** – biventricular pacing
bi‑directional cavo‑pulmonary shunt
black patient hf incidence, hospitalization, mortality rates
black race
black/african‑american populations
blalock‑taussig‑thomas shunt
bleeding
bleeding (anticoagulant‑related bleeding)
bleeding (in anticoagulation)
bleeding (including non‑cabg major bleeding and life‑threatening bleeds)
bleeding (major bleeding)
bleeding (major, moderate, severe)
bleeding (minor & major)
bleeding / hemorrhage (including uncontrolled bleeding, life‑threatening bleeding)
bleeding academic research consortium (barc)
bleeding complications
bleeding contraindications
bleeding events
bleeding events per year
bleeding history or predisposition
bleeding outcome metrics (per 100 patient‑years)
bleeding risk
bleeding risk (associated with anticoagulation)
bleeding risk (in context of glycoprotein inhibitors)
bleeding risk (including gastrointestinal bleeding)
bleeding risk (intracranial, gastrointestinal)
bleeding risk (low, high)
bleeding risk (major bleeding)
bleeding risk (major bleeding, increased risk of bleeding)
bleeding risk (minor and gastrointestinal bleeding)
bleeding risk (moderate‑to‑severe)
bleeding risk (↓ factor ii, v, vii, ix, x, ↓ von willebrand factor)
bleeding risk / bleeding complications
bleeding risk / clinically relevant bleeding
bleeding risk assessment
bleeding risk assessment (medication or procedural)
bleeding risk assessment scores
bleeding risk factors
bleeding risk from dual antiplatelet therapy (dapt)
bleeding risk in hf patients
bleeding risk management
bleeding risk management in acs
bleeding risk reduction
bleeding risk score (e.g., has‑bled)
bleeding risk vs. ischemic event risk
bleeding‑risk assessment
bleeding‑risk scores (e.g., has‑bled, hemorr2hages, atria)
blind‑ending cardiac chambers
blood cholesterol
blood cholesterol / dyslipidemia
blood cholesterol / lipid levels
blood cholesterol management
blood clot
blood culture
blood culture (diagnostic standard for ie)
blood culture (positive, persistently positive, single positive, etc.)
blood culture negativity
blood cultures
blood distribution efficiency
blood flow (absence in imh)
blood flow outside the graft (persistent endoleak)
blood glucose / hba1c
blood pressure
blood pressure (bp)
blood pressure (bp) / hypertension
blood pressure (bp) control / bp lowering
blood pressure (bp) management
blood pressure (bp) – systolic (sbp) and diastolic (dbp)
blood pressure (bp) — systolic (sbp) and diastolic (dbp)
blood pressure (bp, systolic bp, sbp)
blood pressure (high, systolic, diastolic)
blood pressure (hypertension)
blood pressure (systolic & diastolic)
blood pressure (systolic and optimal)
blood pressure control
blood pressure control / management
blood pressure control in heart disease
blood pressure control standards (acc/aha)
blood pressure cuff
blood pressure differential
blood pressure gradients between cuffs (leg to ankle)
blood pressure homeostasis
blood pressure lowering
blood pressure lowering drugs
blood pressure management
blood pressure management (hypertension)
blood pressure management (renin–angiotensin–aldosterone system inhibitors, beta‑blockers)
blood pressure management / target bp for pad (pm‑1)
blood pressure measurement (upper vs lower extremities)
blood pressure medications
blood pressure monitoring
blood pressure reduction
blood pressure response during exercise
blood pressure response to exercise
blood pressure target
blood pressure targets in established hf and hypertension
blood pressure targets/management in hf
blood pressure – bp
blood pressure/hypertension (risk factor for hf)
blood transfusion
blood transfusion guidelines (aabb, cochrane review)
blood viscosity
blood volume











bloody pleural effusion
blood‐pressure related vascular mortality
blood‑flow metrics (global and regional myocardial blood flow, perfusion reserve)
blood‑pressure (bp) control
blood‑pressure (bp) management
blood‑pressure (bp) targets
blood‑pressure control
blood‑pressure control, including intensive sbp <120 mm hg
blood‑pressure lowering drugs (β‑blockers, ace inhibitors, calcium antagonists, diuretics)
blood‑pressure management
blood‑pressure management (hypertension)
blood‑pressure management in diabetes
blood‑pressure reduction
blood‑pressure trajectories
blood‑pressure variation
blood‑pressure‑lowering therapy
blood‑pressure‑lowering treatment
blowing (major/minor) bleeding
blue‑toe syndrome
bluhm cardiovascular institute
blunt abdominal aortic injury
blunt abdominal aortic injury (baai)
blunt chest trauma
blunt thoracic aortic injury (bttai)
blunt traumatic abdominal aortic injury
blunt traumatic abdominal aortic injury (baai)
blunt traumatic aortic injury
blunt traumatic aortic injury (btai)
blunt traumatic thoracic aortic injury
blunt traumatic thoracic aortic injury (bttai)
bmi <21 kg/m² (risk factor for thyrotoxicosis)
bmi‑adjusted hazard ratios (hr) for af
bnp
bnp (brain natriuretic peptide)
bnp (b‑type natriuretic peptide)
bnp level >300 pg/ml
board certification (american board of internal medicine, american board of pediatrics)
body composition
body mass index
body mass index (bmi)
body mass index (bmi) as a risk factor
body size
body size / body habitus
body size misperception
body surface area
body surface area (bsa)
body surface area (indexing aortic dimensions)
body surface area–adjusted z‑score
body surface area–adjusted z‑score for lv wall thickness
body temperature regulation
body weight
body weight (low‑weight vs high‑weight)
body weight / dose relationship
body weight threshold (<60 kg)
bodyport
body‑mass‑index effects on transplant outcomes
body‑size normalization of aortic dimensions
body‑size perception
body‑size–adjusted normal limits
boehringer ingelheim
bone scintigraphy
bone scintigraphy (for amyloidosis)
borderline abi (0.91–0.99)
borderline risk (5 %–<7.5 %)
borg scale (breathlessness rating)
borg scale of perceived exertion
bosentan
bosentan (endothelin receptor antagonist)
bosentan therapy
boston scientific
boston scientific** (heart‑device manufacturer)
bovine arch
bovine arch (common innominate and left carotid artery)
bowel ischemia
bowel ischemia (mesenteric ischemia)
bp control / bp goal (<130/<80 mm hg)
bp lowering
bp measurement (home, office, electronic)
bp target (<130/80 mmhg)
bp targets (<130/<80 mm hg, 120‑129/<80 mm hg)
bp targets (≤130 mm hg systolic, ≤80 mm hg diastolic)
bp thresholds for treatment
bpd (type b) with proximal/distal extent (e.g., b39)
bp‑lowering medication
bp‑lowering medications
bradyarrhythmia
bradyarrhythmias
bradycardia
bradycardia / rate control
bradycardia pacing
bradykinin
brady‑tachycardia
braf inhibitor (vemurafenib)
braf‑inhibitor‑related cardiotoxicity
brain abscess
brain arteriovenous malformation
brain infarction / brain stem infarctions
brain natriuretic peptide (bnp)
brain‑natriuretic peptide (bnp)















branch artery aneurysm
branch artery dilation / narrowing
branch artery occlusion
branch artery stenosis
branch endovascular therapy
branch pa stenosis
branch pulmonary artery (pa) stenosis
branch pulmonary artery reintervention
branch pulmonary artery size and flow
branch pulmonary artery stenosis
branch stenting
branch vessel anatomy of the aorta
branch vessel aneurysm/aneurysmal disease
branch vessel ostia
branch vessel perfusion
branch vessel stenosis
branch vessels of the aorta
branched endovascular aortic repair
branched graft
branched stent graft
branch pulmonary artery stenosis
breastfeeding in heart failure
breastfeeding‑safe medications (acei, beta‑blockers, diuretics)
bridge procedure
bridge therapy
bridge to cure
bridge to decision
bridge to recovery
bridge to surgery
bridge to transplant
bridge to transplantation
bridge trial
bridge‑to‑decision strategies
bridge‑to‑decision strategy
bridge‑to‑transplant (btt)
bridge‑to‑transplant strategy
bridging anticoagulation
bridging anticoagulation therapy
bridging therapy
brisk physical activity
brockenbrough‑braunwald‑morrow sign
bromocriptine
bromocriptine therapy
brompton risk score
bronchial artery erosion
brugada syndrome
bruise‑control trial
bruton tyrosine kinase inhibitors (btk inhibitors)
bsa (body surface area) indexed parameters
bucindolol
built environment
bumetanide
buprenorphine treatment
bupropion
bupropion (nicotine replacement)
bupropion (nicotinic antagonist)
bupropion (treatment)
bupropion therapy
buttock claudication
bu­cindolol
bypass
bypass (vascular bypass)
bypass angioplasty revascularization investigation 2 diabetes (bari 2d)
bypass conduit (radial artery, ulnar artery, distal radial artery)
bypass graft
bypass graft (coronary artery bypass graft, cabg)
bypass graft failure
bypass graft occlusion
bypass graft patency
bypass graft surgery
bypass grafting
bypass grafting (open bypass surgery)
bypass grafting / open bypass surgery
bypass grafting / vascular surgery
bypass grafting with internal mammary arteries
bypass grafts
bypass surgery
bypass surgery (cabg)
bypass time
bypass versus angioplasty (basil) trial
b‑blocker (beta blocker)
b‑natriuretic peptide (bnp)
b‑type natriuretic peptide
b‑type natriuretic peptide (bnp / nt‑probnp)
b‑type natriuretic peptide (bnp)
b‑type natriuretic peptide (bnp) ≥127 ng/l











c2hest risk score
c2hest score
c2hest score (coronary artery disease, hypertension, elderly, systolic hf, etc.)
ca<sup>2+</sup>/calmodulin‑dependent protein kinase ii (camkii)
cabana (catheter ablation vs antiarrhythmic drug therapy for atrial fibrillation)
cabana trial
cabg (coronary artery bypass graft)
cabg (coronary artery bypass grafting)
cabg patch trial, stich, revived‑bcis2, esh, narrow‑crt, lesser‑earth, spare, companion, etc. (study identifiers)
cabg – coronary artery bypass grafting
cabg** – coronary artery bypass graft surgery
cac measurement
cac score
cachexia
cad (coronary artery disease)
cad – coronary artery disease
cad** – coronary artery disease
cadaveric graft
cadaveric vein graft
caesar (comparison of surveillance vs. aortic endografting for small aneurysm repair)
caffeine abstention / triggers
caffeine consumption
caffeine consumption (coffee, energy drinks)
caffeine consumption (including excessive intake and energy drinks)
caffeine intake
cahp score (cardiac arrest hospital prognosis)
calcific aortic stenosis
calcific aortic stenosis (as)
calcific aortic valve disease
calcific aortic valve stenosis
calcific as of a trileaflet valve
calcific disease
calcific mitral stenosis
calcific mitral stenosis (calcific ms)
calcific valvar stenosis
calcific valve deposits
calcific valve disease
calcification
calcification extent
calcification of aortic wall
calcification of the aorta
calcification of the cor membrane
calcified aortic valve stenosis
calcified plaque burden
calcineurin inhibitor
calcineurin inhibitor elimination (e.g., cyclosporine, tacrolimus)
calciphylaxis
calcium
calcium (ca²⁺) handling abnormalities
calcium channel blocker
calcium channel blocker (ccb)
calcium channel blocker interaction
calcium channel blockers
calcium channel blockers (amlodipine, verapamil, diltiazem)
calcium channel blockers (arterial dilators)
calcium channel blockers (ccbs)
calcium channel blockers (dihydropyridine, nondihydropyridine)
calcium channel blockers (harmful in marfan syndrome)
calcium channel blockers (mentioned in context of anti‑ischemic therapy)
calcium current
calcium deposition (paravalvular calcification)
calcium handling / ca²⁺ release and leak
calcium mishandling
calcium overload
calcium score
calcium sensitization
calcium sign (intimal calcium separation >5 mm)
calcium signaling
calcium signalling pathways
calcium supplementation (≥ 500 mg/d elemental calcium)
calcium upregulation therapy
calcium/vitamin d supplementation
calcium‑calmodulin ii (camkii) activation
calcium‑channel blockade (non‑dihydropyridine)
calcium‑channel blocker (ccb)
calcium‑channel blockers
calcium‑channel blockers (ccbs)
calcium‑channel blockers (e.g., verapamil, diltiazem)
calcium‑channel blockers → amlodipine
calibrated risk scores
camelot trial
camera mri (catheter ablation versus medical rate control in atrial fibrillation and systolic dysfunction-an mri‑guided multi‑centre randomised controlled trial)
camera‑mri study
camkii signaling
camkii‑mediated hyperphosphorylation of ryanodine receptor 2
camtaf (catheter ablation versus medical treatment of af in heart failure)
camtaf trial
canadian cardiovascular society dyslipidaemia guidelines
canadian cardiovascular society guidelines on atrial fibrillation
canagliflozin
canagliflozin (invokana)
cancer chemotherapy (platinum‑based agents)
cancer risk associated with cardiac imaging
cancer risks associated with alcohol
cancer therapeutics associated with increased af risk (e.g., anthracyclines, antimetabolites, alkylating agents, immunomodulators, tyrosine‑kinase inhibitors, vegf inhibitors, braf inhibitors, car t‑cell therapy, monoclonal antibodies)
cancer therapies associated with af
cancer therapy‑related cardiomyopathy
cancer‑associated atrial fibrillation
cancer‑associated cardiovascular risk
cancer‑therapy cardiotoxicity
cancer‑therapy‑related cardiomyopathy
cancer‑therapy–related cardiotoxicity
candesartan
candesartan (angiotensin‑ii receptor blocker)
candesartan (anthro‑study charm)
candesartan (arb)
candidate selection for drug/device therapy
cangrelor
cangrelor (intravenous p2y12 antagonist)
cannabis use
cannulation strategies
canonical wnt–β‑catenin signaling
canvas program (canagliflozin)
canvas trial
capital ami study
caprie trial (clopidogrel versus aspirin in patients at risk of ischemic events)
captopril
captopril (ace inhibitor)
car t‑cell therapies (tisagenlecleucel, axicabtagene ciloleucel)
carbamazepine
carbon dioxide output
carcinoid heart disease
carcinoid syndrome
cardiac
cardiac (brand of products implied)
cardiac (related to heart)
cardiac / heart
cardiac ablation
cardiac adverse effects
cardiac allograft vasculopathy
cardiac allograft vasculopathy (cav)
cardiac allograft vasculopathy progression
cardiac allograft vasculopathy‑related events
cardiac amyloidosis
cardiac amyloidosis (amyloid heart disease)
cardiac amyloidosis / transthyretin amyloid cardiomyopathy
cardiac amyloidosis management
cardiac anesthesia
cardiac anesthesia & icu support
cardiac anesthesia support
cardiac anesthesiologist
cardiac anticoagulation
cardiac arrest
cardiac arrest (documented)
cardiac arrest (during transport or self‑transport)
cardiac arrest (post‑cpr, comatose)
cardiac arrest (sudden cardiac arrest, sca)
cardiac arrest resuscitation guidelines
cardiac arrest study hamburg (cash)
cardiac arrhythmia
cardiac arrhythmia risk factors in cancer
cardiac arrhythmia suppression trial (cast)
cardiac arrhythmia suppression trial (cats)
cardiac arrhythmias
cardiac auscultation
cardiac autonomic afferent dysregulation
cardiac autonomic function
cardiac biomarkers
cardiac biomarkers of stretch or injury
cardiac biomarkers → nt‑probnp, bnp
cardiac bio‑markers
cardiac blood flow velocity
cardiac cachexia
cardiac care
cardiac cath labs (cardiac catheterization)
cardiac catheter ablation
cardiac catheter ablation for atrial fibrillation with heart failure
cardiac catheter intervention safety
cardiac catheterization
cardiac catheterization (coa peak‑to‑peak gradient)
cardiac catheterization (direct pressure measurement, left atrial pressure)
cardiac catheterization (invasive evaluation)
cardiac catheterization (pressure measurement)
cardiac catheterization / angiocardiography
cardiac catheterization / coronary angiography
cardiac catheterization angiography
cardiac catheterization center
cardiac catheterization interventionalist
cardiac catheterization laboratory
cardiac catheterization laboratory management of out‑of‑hospital cardiac arrest
cardiac catheterization laboratory procedure
cardiac catheterization laboratory use in acs
cardiac catheterization procedure
cardiac catheterization team
cardiac catheterization with angiography
cardiac catheter‑based procedures
cardiac causes of thromboembolic disease (e.g., left atrial thrombus, valvular vegetations, intracardiac shunts)
cardiac chamber quantification
cardiac chamber quantification guidelines
cardiac chamber size and function
cardiac clinical education / training
cardiac complications
cardiac complications (10‑30 % rate in undiagnosed severe as)
cardiac complications (associated with baai)
cardiac complications (e.g., increased cardiac events, 30‑day mortality)
cardiac complications (myocardial injury, arrhythmias, ischemia, failure, death)
cardiac complications (post‑operative cardiac events)
cardiac computed tomography
cardiac computed tomography (cardiac ct)
cardiac computed tomography (cct)
cardiac computed tomography (ct)
cardiac computed tomography (ct) angiography
cardiac computed tomography angiography (ct angiography)
cardiac computed tomography angiography (cta)
cardiac computed tomography equipment
cardiac conduction
cardiac conduction delay
cardiac conduction system
cardiac contractility
cardiac contractility modulation
cardiac contractility modulation (ccm)
cardiac criteria
cardiac critical care
cardiac cross‑clamp time
cardiac ct
cardiac ct (ct cardiac)
cardiac ct angiography
cardiac ct coronary angiography (cta)
cardiac ct imaging
cardiac damage
cardiac death
cardiac death (cardiovascular death)
cardiac device endocarditis
cardiac device implantation
cardiac devices (implantable devices)
cardiac devices / implantable devices
cardiac diagnostic pathway (cdp)
cardiac diagnostics
cardiac disease
cardiac disease in pregnancy
cardiac drugs (pharmacological treatment regimens)
cardiac dysfunction
cardiac dysfunction (clinical & subclinical)
cardiac dysfunction (post‑exercise)
cardiac electronic device implantation
cardiac electrophysiology
cardiac electrophysiology evaluation (ambulatory rhythm monitoring)
cardiac electrophysiology fellowship
cardiac electrophysiology procedure
cardiac electrophysiology procedures
cardiac embolization mechanisms
cardiac enlargement, pulmonary venous congestion, gallop rhythm
cardiac evaluation in acute limb ischemia management
cardiac evaluation in asymptomatic af
cardiac evaluation of native versus prosthetic valves
cardiac events
cardiac events (coronary events)
cardiac events (mortality, heart‑failure hospitalization)
cardiac exercise
cardiac exercise physiologist
cardiac failure
cardiac failure/heart failure
cardiac fibrosis
cardiac fluoroscopy (adjunct imaging modality)
cardiac free‑wall rupture
cardiac function
cardiac function (ejection fraction, systolic function)
cardiac function assessment
cardiac function baseline assessment
cardiac function metrics (ef, stroke volume, etc.)
cardiac function monitoring
cardiac functional assessment
cardiac genetics
cardiac genetics and mutation carriers
cardiac genotype
cardiac glycosides
cardiac hemodynamics
cardiac hemodynamics (exercise hemodynamics)
cardiac hospitalization
cardiac hospitalizations & readmissions
cardiac hypertrophy
cardiac icu
cardiac imaging
cardiac imaging (ct, ct/pet)
cardiac imaging (ct, mri, echocardiography)
cardiac imaging (diagnostic and serial assessment)
cardiac imaging (echocardiography)
cardiac imaging (echocardiography, mri, ct angiography)
cardiac imaging (echocardiography, mri, ct, etc.)
cardiac imaging (for maximal lv thickness, wall thickness, ef, lge)
cardiac imaging (implied)
cardiac imaging (including transesophageal echocardiography)
cardiac imaging (mdct, echocardiography, 2‑d echocardiography)
cardiac imaging (serial imaging for hcm)
cardiac imaging (trans‑thoracic echocardiography, 2‑d doppler, speckle tracking, cmr, ct)
cardiac imaging committee (american heart association)
cardiac imaging findings (e.g., oscillating mass, abscess, valve dehiscence)
cardiac imaging for monitoring af burden
cardiac imaging guideline
cardiac imaging guidelines
cardiac imaging in structural heart disease
cardiac imaging markers for cardiomyopathy
cardiac imaging metrics: left ventricular end‑systolic dimension (lvesd)
cardiac imaging modalities
cardiac imaging modalities (invasive vs. non‑invasive)
cardiac imaging modalities (mri, ct, pet)
cardiac imaging parameters
cardiac imaging technology
cardiac imaging with planar technetium‑99m pyrophosphate (tc‑99m‑pyp)
cardiac implantable electronic devices
cardiac implantable electronic devices (cied)
cardiac index
cardiac infiltration (myocardial)
cardiac inflammation
cardiac injury
cardiac instrumentation
cardiac intensive care unit (cicu)
cardiac intensive care unit (cicu) outcomes
cardiac intensivist
cardiac intervention
cardiac intervention (e.g., myectomy, icd placement)
cardiac intervention (e.g., surgery, catheterization)
cardiac interventions
cardiac interventions & surgical repairs
cardiac involvement in al amyloidosis
cardiac ischemia
cardiac ischemia diagnosis and management guidelines
cardiac magnetic resonance
cardiac magnetic resonance (cmr)
cardiac magnetic resonance (cmr) angiography
cardiac magnetic resonance (cmr) imaging
cardiac magnetic resonance (cmr) perfusion imaging
cardiac magnetic resonance (mri)
cardiac magnetic resonance contrast
cardiac magnetic resonance imaging
cardiac magnetic resonance imaging (cmr)
cardiac magnetic resonance imaging (cmr) / mri
cardiac magnetic resonance imaging (mri)
cardiac magnetic resonance imaging (mri) for lvot evaluation
cardiac magnetic resonance imaging equipment
cardiac magnetic resonance in acute heart failure
cardiac magnetic resonance in chronic heart failure
cardiac maladaptive structural changes
cardiac management decisions
cardiac management strategies
cardiac medication during pregnancy (ropac data)
cardiac monitoring
cardiac monitoring (baseline, longitudinal)
cardiac monitoring (intermittent/continuous)
cardiac monitoring via echocardiography
cardiac morbidity
cardiac morbidity during pregnancy
cardiac morphology
cardiac mortality
cardiac mortality (cardiovascular death)
cardiac mortality / short‑ and long‑term cardiac survival
cardiac mortality assessment
cardiac mri
cardiac mri (cmr)
cardiac mri myocardial mapping
cardiac mri predictors of adverse outcomes















cardiac murmur
cardiac myosin (s2 region, alpha‑myosin)
cardiac myosin inhibitor
cardiac myosin inhibitors
cardiac myosin inhibitors (e.g., mavacamten)
cardiac nomenclature (international pediatric and congenital cardiac code)
cardiac operative risk
cardiac outcomes
cardiac outcomes (adult survivors of supravalvar aortic stenosis)
cardiac outcomes in diabetes (type 2)
cardiac output
cardiac output augmentation
cardiac output demands
cardiac output measurement
cardiac output monitoring
cardiac output reserve
cardiac pacemaker
cardiac pacing
cardiac pacing (including lv pacing, crt, conduction‑system pacing)
cardiac pacing (physiological pacing, crt, conduction‑system pacing)
cardiac pacing after av nodal ablation
cardiac perforation
cardiac performance
cardiac perfusion / myocardial oxygen delivery
cardiac pharmacokinetics (loading vs. maintenance doses)
cardiac phenotypic spectrum
cardiac phoenix
cardiac power output (cpo)
cardiac prevention
cardiac procedural outcomes / surgical outcomes
cardiac procedures
cardiac quality of life (qol)
cardiac radiation exposure
cardiac rate control
cardiac refractoriness
cardiac rehab program
cardiac rehabilitation
cardiac rehabilitation (center‑based, home‑based, virtual)
cardiac rehabilitation (cr)
cardiac rehabilitation (cr) – center‑based and home‑based
cardiac rehabilitation (cr) – home‐based vs facility‐based
cardiac rehabilitation (exercise training, education)
cardiac rehabilitation (exercise‑based)
cardiac rehabilitation (hfpef, hfmref)
cardiac rehabilitation (including cardio‑oncology rehabilitation)
cardiac rehabilitation (in‑person & home‑based programs)
cardiac rehabilitation (post‑aortic surgery)
cardiac rehabilitation after mi or angina
cardiac rehabilitation after scad
cardiac rehabilitation and prevention
cardiac rehabilitation attendance / completion / access
cardiac rehabilitation in congenital heart disease
cardiac rehabilitation programs
cardiac rejection
cardiac remodeling
cardiac remodeling (associated with ischemia)
cardiac repolarization abnormalities
cardiac resuscitation
cardiac resuscitation (cpr)
cardiac resynchronisation therapy (crt)
cardiac resynchronisation therapy (crt‑d)
cardiac resynchronization therapy
cardiac resynchronization therapy (crt)
cardiac resynchronization therapy (crt) device
cardiac resynchronization therapy (crt) implantation for hfref
cardiac resynchronization therapy (crts)
cardiac reverse remodeling
cardiac re‑entry circuits
cardiac rhythm
cardiac rhythm abnormalities
cardiac rhythm control
cardiac rhythm conversion time (30–90 min vs 8–12 h)
cardiac rhythm devices with atrial leads
cardiac rhythm disorder
cardiac rhythm disorder registries (e.g., recordaf, camera mri, chinese atrial fibrillation registry)
cardiac rhythm disorders
cardiac rhythm management device
cardiac rhythm management devices with atrial lead (pacemakers, defibrillators)
cardiac rhythm monitoring
cardiac rhythm monitoring (e.g., holter, event recorder)
cardiac rhythm monitoring recommendations
cardiac rhythm restoration
cardiac rhythm‑related causes (tachycardia, premature ventricular contractions)
cardiac risk assessment
cardiac risk index (vascular quality initiative)
cardiac risk score
cardiac risk stratification
cardiac risk stratification for hcm patients
cardiac risk stratification in pregnancy (ap classifications ib–d, iia–d, iiia–d)
cardiac safety
cardiac safety assessment
cardiac safety monitoring in cancer therapy
cardiac sarcoidosis
cardiac sarcomere genes
cardiac screening (genetic testing, imaging)
cardiac shock care centers
cardiac stress imaging
cardiac stress laboratory
cardiac stress testing
cardiac structural abnormalities
cardiac structural assessment
cardiac structure
cardiac structure and function
cardiac surgeon
cardiac surgeons
cardiac surgery
cardiac surgery (achd expertise)
cardiac surgery (e.g., cabg, valve replacement, aortic aneurysm repair)
cardiac surgery (heart valve surgery, cardiopulmonary bypass)
cardiac surgery (including cabg, pci, coronary angiography)
cardiac surgery (open‑heart, valve replacement, coronary bypass)
cardiac surgery (post‑operative arrhythmia conversion)
cardiac surgery (repair, stenting, transcatheter intervention)
cardiac surgery / cardiac operative procedures
cardiac surgery / cardiothoracic surgery
cardiac surgery decision‐making
cardiac surgery education
cardiac surgery for d‑transposition of the great arteries.
cardiac surgery–related postoperative arrhythmias
cardiac surgical care
cardiac surgical expertise
cardiac surgical outcomes in d‑transposition of the great arteries
cardiac surgical outcomes.
cardiac surgical patients with atrial fibrillation
cardiac surgical procedures
cardiac surveillance
cardiac sympathetic activity
cardiac symptoms
cardiac tamponade
cardiac tamponade (implied within hf context)
cardiac therapies
cardiac therapy adherence.
cardiac thromboembolism
cardiac thromboembolism (cardiovascular cause of thromboembolism)
cardiac thrombus
cardiac tissue destruction
cardiac tolerance/long‑term cardiac tolerance
cardiac toxicity
cardiac transplant
cardiac transplant bridge (mechanical assist device)
cardiac transplant in muscular dystrophy patients
cardiac transplant outcomes
cardiac transplant with valve regurgitation caused by an abnormal valve
cardiac transplantation
cardiac transplantation criteria (fontan circulation)
cardiac transplantation evaluation
cardiac transplantation in adult congenital heart disease (achd)
cardiac transplantation in patients with amyloidosis
cardiac troponin
cardiac troponin (cardiac biomarkers of injury)
cardiac troponin (ctn)
cardiac troponin (ctn) assay
cardiac troponin i (tnni3)
cardiac troponin normalization
cardiac troponin t (ctnt)
cardiac ultrasound
cardiac valve abnormality
cardiac valve complications
cardiac valve disease (tricuspid valve dysplasia, mitral‑like valve anomalies)
cardiac valve dysfunction
cardiac valve implantation
cardiac valve replacement/repair (mechanical prosthesis, bioprosthesis)
cardiac valve surgery (tricuspid valve surgery, valve replacement)
cardiac valves
cardiac valvular pathology
cardiac viral infiltrate (viral‑positive / viral‑negative)
cardiac volume
cardiac volumes
cardiac-related pulmonary symptoms (e.g., dyspnea, pulmonary edema)
cardiaca
cardiac‑electrophysiology guidelines for pediatric and congenital heart disease
cardiac‑gated ct
cardiac‑gated ct angiography
cardiac‑implanted electronic devices (cied)
cardiac‑inherited disease (family history approach)
cardiac‑specific effects of substances
cardiac catheterization
cardiac ct
cardiocardiomyopathy relapse
cardioembolic cause (e.g., af, stenosis, thrombus)
cardioembolic events
cardioembolic risk
cardioembolic source
cardioembolic stroke
cardiogenetics
cardiogenic limb emboli
cardiogenic risk in primary prevention of cardiovascular disease
cardiogenic risk stratification in myocarditis
cardiogenic shock
cardiogenic shock (implied by hemodynamic instability)
cardiogenic shock (shock)
cardiogenic shock classification systems
cardiogenic shock diagnostic criteria
cardiogenic shock guideline
cardiogenic shock management
cardiogenic shock protocols / shock protocols
cardioimmunology
cardiologic / cardiology
cardiologist
cardiologist (achd cardiologist)
cardiologist (aortic specialist)
cardiologist / achd cardiologist
cardiologist / cardiologists
cardiologist expert in heart failure
cardiologist follow‑up (achd cardiologist)
cardiologist, aortic specialist, aortic surgeon, maternal‑fetal medicine specialist.
cardiologists
cardiologists (including valve disease specialists)
cardiology
cardiology (congenital)
cardiology (expertise in heart failure management)
cardiology (implied from “cardiovascular”)
cardiology / cardiac
cardiology / cardiovascular (clinical disciplines)
cardiology / cardiovascular health
cardiology department
cardiology editorial work / guidelines
cardiology fellowship program
cardiology guideline terminology
cardiology guidelines
cardiology practice
cardiology specialist role
cardiomegaly
cardiomems device
cardiomems implantable pa pressure sensor
cardiomems implantable pulmonary‑artery pressure sensor
cardiomems implantation and monitoring
cardiometabolic disease
cardiometabolic disease (as a risk factor)
cardiometabolic health
cardiometabolic profile
cardiometabolic risk
cardiometabolic risk factors
cardiometabolic stress testing (treadmill, semi‑supine bicycle)
cardiomyopathies
cardiomyopathies (e.g., peripartum cardiomyopathy, attr cardiomyopathy)
cardiomyopathy
cardiomyopathy (af‑induced, arrhythmia‑induced)
cardiomyopathy (anthracycline‑induced, trastuzumab‑induced, doxorubicin‑related)
cardiomyopathy (general term)
cardiomyopathy (general)
cardiomyopathy (including cancer‑therapy–related cardiomyopathy)
cardiomyopathy (including dilated and familial forms)
cardiomyopathy (ischemic origin)
cardiomyopathy / cardiomyopathies
cardiomyopathy and preeclampsia
cardiomyopathy etiology
cardiomyopathy genes
cardiomyopathy in pregnancy
cardiomyopathy program
cardiomyopathy surveillance
cardiomyopathy unresponsive to standard medical therapy (>3 months)
cardiomyopathy, idiopathic dilated
cardiomyopathy-related genes
cardioprotection
cardioprotective effects (light‑to‑moderate alcohol)
cardioprotective exercise
cardioprotective management strategies
cardiopulmonary arrest
cardiopulmonary assessment
cardiopulmonary bypass
cardiopulmonary bypass in pregnancy
cardiopulmonary bypass time
cardiopulmonary capacity
cardiopulmonary comorbidities
cardiopulmonary complications
cardiopulmonary exercise stress testing
cardiopulmonary exercise stress testing (cpet)
cardiopulmonary exercise test
cardiopulmonary exercise test (cpet)
cardiopulmonary exercise testing
cardiopulmonary exercise testing (cpet)
cardiopulmonary exercise testing (cpet) – functional capacity, exercise tolerance
cardiopulmonary exercise testing (ventilatory efficiency, aerobic capacity)
cardiopulmonary exercise testing / treadmill testing
cardiopulmonary exercise treadmill testing
cardiopulmonary impact
cardiopulmonary magnetic resonance
cardiopulmonary rehabilitation
cardiopulmonary responses
cardiopulmonary resuscitation (cpr)
cardiopulmonary risk assessment
cardiopulmonary status optimization
cardiora

















cardiorenal syndrome
cardiorespiratory fitness
cardiorespiratory training
cardiorheumatology (cardiac involvement in systemic rheumatic disease)
cardioselective beta‑blockers
cardiothoracic (ct)
cardiothoracic imaging
cardiothoracic magnetic resonance imaging (cmr)
cardiothoracic surgeon
cardiothoracic surgery
cardiothoracic surgery (as treatment option)
cardiothoracic surgery (general scope)
cardiotoxic anticancer therapies
cardiotoxicity
cardiotoxicity (e.g., chemotherapy, cancer treatment)
cardiotoxicity risk stratification
cardiovascular
cardiovascular & metabolic sciences
cardiovascular & pulmonary rehabilitation
cardiovascular & risk reduction center
cardiovascular (as an endpoint or cause)
cardiovascular (as in cardiovascular disease, cardiovascular surgery)
cardiovascular (clinical) guidelines (acc/aha)
cardiovascular (cv)
cardiovascular (cvd) mortality
cardiovascular (implied in multiple references)
cardiovascular / vascular function
cardiovascular abnormalities
cardiovascular ageing
cardiovascular and aortic care standards
cardiovascular and cardiac events
cardiovascular and limb events
cardiovascular and limb outcomes
cardiovascular and limb risk reduction efforts
cardiovascular and metabolic sciences
cardiovascular and pulmonary diseases (combined term)
cardiovascular and pulmonary rehabilitation
cardiovascular and pulmonary rehabilitation (aacvpr)
cardiovascular anesthesiologist
cardiovascular anesthesiologists
cardiovascular angiography
cardiovascular angiography and interventions
cardiovascular angiography and interventions (scai)
cardiovascular angioplasty
cardiovascular biomarkers
cardiovascular burden
cardiovascular care
cardiovascular care (clinical context)
cardiovascular catheterisation (procedural and complication nomenclature)
cardiovascular clinic
cardiovascular clinical trials
cardiovascular collapse
cardiovascular community
cardiovascular complications
cardiovascular complications (in interventional cardiology)
cardiovascular complications (stroke, intracranial hemorrhage, embolic events)
cardiovascular complications in pregnancy
cardiovascular complications of cancer therapy
cardiovascular complications of pregnancy
cardiovascular complications of vasculitis
cardiovascular computed tomography
cardiovascular considerations in hiv infection
cardiovascular considerations in pregnancy
cardiovascular death
cardiovascular death, cardiovascular mortality
cardiovascular deaths
cardiovascular device
cardiovascular device manufacturers
cardiovascular devices
cardiovascular diagnostic tests (e.g., cmr before device implantation)
cardiovascular disease
cardiovascular disease (and primary prevention)
cardiovascular disease (broader context)
cardiovascular disease (cvd)
cardiovascular disease (cvd) / cardiovascular complications
cardiovascular disease (cvd) / cardiovascular risk
cardiovascular disease (cvd) events
cardiovascular disease (cvd) in general
cardiovascular disease (general term encompassing pad)
cardiovascular disease (general term)
cardiovascular disease (general)
cardiovascular disease (in clinical statements and guidelines)
cardiovascular disease / cardio‑vascular outcomes
cardiovascular disease / heart disease
cardiovascular disease and comorbid conditions
cardiovascular disease and stroke statistics
cardiovascular disease burden
cardiovascular disease during pregnancy
cardiovascular disease fellowship program
cardiovascular disease in specific populations (hispanic, african american, asian, south asian, american indian)
cardiovascular disease management
cardiovascular disease management programs
cardiovascular disease outcomes
cardiovascular disease outcomes in the jackson heart study
cardiovascular disease prevention
cardiovascular disease prevention guidelines
cardiovascular disease prevention guidelines (acc/aha, european guidelines)
cardiovascular disease prevention policies
cardiovascular disease prevention strategies
cardiovascular disease prevention strategies (e.g., lifestyle, pharmacologic)
cardiovascular disease risk calculators
cardiovascular disease risk factors
cardiovascular disease risk reduction
cardiovascular disease risk statistics
cardiovascular disease terminology
cardiovascular diseases
cardiovascular diseases (cvd)
cardiovascular diseases during pregnancy
cardiovascular division
cardiovascular drugs
cardiovascular drug‑drug interaction recommendations (statins)
cardiovascular effects
cardiovascular effects of cocaine
cardiovascular effects of electronic nicotine‑delivery
cardiovascular effects of marijuana
cardiovascular effects of opioid use
cardiovascular effects of second‑hand smoke
cardiovascular endothelial nitric oxide pathway (includes guanylate cyclase, cgmp)
cardiovascular endpoints
cardiovascular epidemiology
cardiovascular epidemiology in diverse populations
cardiovascular event
cardiovascular event prevention
cardiovascular event prevention therapy
cardiovascular event reduction
cardiovascular event risk
cardiovascular event risk assessment
cardiovascular events
cardiovascular events (acute cvd events)
cardiovascular events (cv events)
cardiovascular events (cve)
cardiovascular events (e.g., arrhythmias, heart failure episodes, mi)
cardiovascular events (e.g., death, stroke, mi)
cardiovascular events (e.g., mi, stroke, peripheral artery disease)
cardiovascular events (e.g., myocardial infarction, stroke)
cardiovascular events (e.g., stroke, myocardial infarction, coronary artery disease, cardiovascular mortality)
cardiovascular events (fatal and non‑fatal, hospitalizations)
cardiovascular events (future ascvd–related events)
cardiovascular events (myocardial infarction, stroke)
cardiovascular events (stroke, death, mi, stent thrombosis)
cardiovascular events / cardiovascular risk
cardiovascular events prevention (therapeutic focus)
cardiovascular events reduction percentages (15 %, 19 %, etc.)
cardiovascular exercise capacity
cardiovascular fellowship
cardiovascular fellowship program
cardiovascular fitness
cardiovascular functional class (e.g., nyha)
cardiovascular genetics
cardiovascular genetics consensus recommendations
cardiovascular genetics programs
cardiovascular genetics specialist
cardiovascular health
cardiovascular health (life’s essential 8)
cardiovascular health disparities
cardiovascular health equity
cardiovascular health interventions
cardiovascular health management
cardiovascular health outcomes in astronauts (astrocharm)
cardiovascular health promotion
cardiovascular health promotion series
cardiovascular health risk discussion
cardiovascular health study
cardiovascular health study variables
cardiovascular hospital admission
cardiovascular hospitalization
cardiovascular hospitalization (related to af)
cardiovascular hospitalizations
cardiovascular imaging
cardiovascular imaging / cardiovascular magnetic resonance
cardiovascular imaging guidelines (american society of echocardiography, european association of cardiovascular imaging, etc.)
cardiovascular imaging modalities
cardiovascular imaging modalities (tte, ct, mri)
cardiovascular imaging registry (eurocmr)
cardiovascular imaging specialists
cardiovascular implantable electronic device (cied)
cardiovascular implantable electronic device infection
cardiovascular institute
cardiovascular institute / prevention program
cardiovascular intervention
cardiovascular interventional
cardiovascular interventional fellows
cardiovascular interventions
cardiovascular magnetic resonance
cardiovascular magnetic resonance (cmr)
cardiovascular magnetic resonance (cmr) imaging
cardiovascular magnetic resonance (cmr) imaging terms (e.g., dyssynchrony, remodeling, cone reconstruction feasibility)
cardiovascular magnetic resonance (cmr) studies
cardiovascular magnetic resonance (jcmr reference)
cardiovascular magnetic resonance (mri)
cardiovascular magnetic resonance imaging
cardiovascular magnetic resonance imaging (cmr)
cardiovascular magnetic resonance imaging (mri)
cardiovascular magnetic resonance techniques
cardiovascular malformations/complications in turner’s syndrome
cardiovascular management
cardiovascular medication safety (pregnancy, lactation)
cardiovascular medications
cardiovascular medicine
cardiovascular monitoring
cardiovascular morbidity
cardiovascular morbidity & mortality
cardiovascular morbidity and mortality
cardiovascular morbidity and mortality in aneurysm patients
cardiovascular morbidity and mortality outcomes at 30 days, 3‑year follow‑up
cardiovascular morbidity and mortality statistics
cardiovascular mortality
cardiovascular mortality (cardiovascular death)
cardiovascular mortality (cvd death)
cardiovascular mortality / death
cardiovascular mortality / deaths
cardiovascular mortality and vascular mortality risk with blood pressure changes.
cardiovascular mortality/deaths
cardiovascular nurses
cardiovascular operations
cardiovascular or cvd
cardiovascular outcome (mace, ckd progression, decline in abi)
cardiovascular outcome metrics (stroke, mortality, complications)
cardiovascular outcome studies (e.g., cass, stich, revived, acc/aha trials)
cardiovascular outcomes
cardiovascular outcomes & limb‑related events
cardiovascular outcomes (all‑cause mortality, composite endpoints)
cardiovascular outcomes (e.g., major adverse cardiovascular events)
cardiovascular outcomes (myocardial infarction, stroke, heart failure)
cardiovascular outcomes / cardiovascular morbidity / mortality
cardiovascular outcomes and coronary events
cardiovascular outcomes in achd
cardiovascular outcomes in diabetes
cardiovascular outcomes in heart failure populations
cardiovascular outcomes in peripheral disease
cardiovascular outcomes research
cardiovascular outcomes trial
cardiovascular performance metrics
cardiovascular pharmacotherapy
cardiovascular phenotype
cardiovascular phenotyping
cardiovascular policy (e.g., smoke‑free workplace policies)
cardiovascular prevention
cardiovascular prevention (primary & secondary)
cardiovascular prevention guideline (acc/aha, esc)
cardiovascular prevention measures
cardiovascular procedures (general)
cardiovascular quality and outcomes research
cardiovascular rehabilitation
cardiovascular rehabilitation (acvpr, aha)
cardiovascular research
cardiovascular research group
cardiovascular research institution
cardiovascular research network
cardiovascular risk
cardiovascular risk (high or very high)
cardiovascular risk (high, very high, moderate)
cardiovascular risk (high‑risk, very high‑risk)
cardiovascular risk (post‑mi)
cardiovascular risk / cardiovascular events
cardiovascular risk algorithm
cardiovascular risk amplifiers (e.g., older age, sex, comorbidities)
cardiovascular risk assessment
cardiovascular risk estimation
cardiovascular risk factor
cardiovascular risk factor management
cardiovascular risk factor modification
cardiovascular risk factor treatment
cardiovascular risk factors
cardiovascular risk factors (additional to cha₂ds₂‑vasc)
cardiovascular risk factors (blood pressure, lipids, body mass index, inflammation, thrombosis)
cardiovascular risk factors (e.g., diabetes, smoking)
cardiovascular risk factors (e.g., smoking, alcohol, secondhand smoke)
cardiovascular risk factors (for aortic aneurysm expansion)
cardiovascular risk factors (hyperlipidemia, hypertension, diabetes, etc.)
cardiovascular risk factors (hypertension, diabetes)
cardiovascular risk factors (hypertension, diabetes, dyslipidemia)
cardiovascular risk factors (hypertension, dyslipidemia, smoking, etc.)
cardiovascular risk factors implied by “ischemia” and “revascularization”
cardiovascular risk in e‑cigarette users
cardiovascular risk in smokers
cardiovascular risk management
cardiovascular risk management in autoimmune disorders (rheumatoid arthritis, psoriasis, etc.)
cardiovascular risk markers
cardiovascular risk prediction / risk assessment
cardiovascular risk prediction in aortopathy
cardiovascular risk profile
cardiovascular risk reduction
cardiovascular risk reduction therapies
cardiovascular risk score
cardiovascular risk scores (e.g., framingham, acc/aha)
cardiovascular risk scores (framingham, charge‑af)
cardiovascular risk stratification
cardiovascular risk stratification in multi‑ethnic cohorts.
cardiovascular risk with second‑hand smoke exposure
cardiovascular risk/vascular risk
cardiovascular risks of pregnancy
cardiovascular safety
cardiovascular safety and risk assessment
cardiovascular safety of nicotine replacement in patients with cad
cardiovascular screening
cardiovascular screening guidelines
cardiovascular service line
cardiovascular services
cardiovascular specialist
cardiovascular specialists
cardiovascular status
cardiovascular stroke
cardiovascular surgery
cardiovascular surgical specialties
cardiovascular surgical team
cardiovascular surveillance
cardiovascular system
cardiovascular systems
cardiovascular systems (company name)
cardiovascular team‑based care
cardiovascular therapies
cardiovascular therapies (pharmacologic agents, device therapies)
cardiovascular therapy
cardiovascular toxicity
cardiovascular toxicity (due to cancer therapy)
cardiovascular** (as a general domain)
cardiovascular‑glycemic management (e.g., glp‑1 and sglt2 agents)
cardiovascular‑related hospitalization
cardiovascular magnetic resonance (cmr) imaging
cardiovascular — cardiology, cardiovascular research, cardiovascular innovations foundation
cardioversion
cardioversion (direct‑current and pharmacologic)
cardioversion (electrical cardioversion)
cardioversion (electrical)
cardioversion (electrical, pharmacologic, direct‑current)
cardioversion (for new or recurrent af)
cardioversion (pharmacologic and electrical)
cardioversion (pharmacologic or electrical)
cardioversion (pharmacologic)
cardioversion and rhythm‑control strategies
cardioversion energy delivery
cardioversion for atrial arrhythmias
cardioversion safety guidelines (duration <48 h)
cardioversion‑bmi trial
cardioversion‑induced left atrial stunning
cardioverter/ablation for af
cardioverter‑defibrillator therapy
cardio‑conversion (electrical cardioversion)
cardio‑embolic stroke
cardio‑gic shock

















cardio‑obstetric care team
cardio‑obstetrics
cardio‑obstetrics (team‑based cardio‑obstetrics model of care)
cardio‑obstetrics care
cardio‑obstetrics program
cardio‑obstetrics team
cardio‑obstetrics team / multidisciplinary cardio‑obstetrics
cardio‑oncological chemotherapy agents (anthracyclines, trastuzumab)
cardio‑oncology
cardio‑oncology (anticoagulation considerations)
cardio‑oncology (cancer therapy‑related cardiac disease)
cardio‑oncology (cardiovascular effects of cancer therapies)
cardio‑oncology (practice of cardiovascular risk stratification in oncology)
cardio‑oncology / cardio‑oncological prevention
cardio‑oncology arrhythmias
cardio‑oncology considerations
cardio‑oncology drug interactions
cardio‑protective diet
cardio‑pulmonary exercise testing
cardio‑pulmonary exercise testing (cpet)
cardio‑renal benefit
cardio‑renal considerations (egfr, ckd stage)
cardio‑respiratory fitness
cardio‑respirology exercise diagnostics
cardio‑thoracic surgery considerations in hcm
cardio‑vacular events
cardio‑vascular
cardio‑vascular disease
cardio‑vascular disease and comorbid conditions
cardio‑vascular disease burden
cardio‑vascular disease epidemiology
cardio‑vascular disease prevention strategies
cardio‑vascular disease risk scores (e.g., framingham)
cardio‑vascular event
cardio‑vascular exercise guidelines
cardio‑vascular guideline
cardio‑vascular innovations foundation
cardio‑vascular meta‑analysis
cardio‑vascular mortality
cardio‑vascular outcome
cardio‑vascular outcomes
cardio‑vascular outcomes in acei/arb trials
cardio‑vascular outcomes in beta‑blocker trials
cardio‑vascular outcomes in calcium channel blocker trials
cardio‑vascular outcomes in diabetes studies
cardio‑vascular outcomes in thiazolidinedione trials
cardio‑vascular rehabilitation
cardio‑vascular risk stratification
cardio‑vascular surgery indications
cardio‑vascular trial
cardi‑olipin igg/igm
care coordination
care setting (inpatient, outpatient)
caregiver support
caregiver support / caregiver stress
care‑hf trial
carnitine
carotid artery disease
carotid atherosclerosis
carotid disease
carotid pathology
carotid revascularization
carpal tunnel syndrome
carpentier‑edwards pericardial bioprosthesis
carpreg ii (cardiac disease in pregnancy study)
carpreg ii risk prediction model / predictors
carpreg ii risk score
carpreg ii score
carpreg 2 score
carress trial
carvedilol
carvedilol (beta‑blocker)
carvedilol (copernicus)
carvedilol in stemi with pci
cascade evaluation
cascade genetic testing
cascade genetic testing / screening
cascade genetic testing for family members
cascade screening
cascade testing
cascade testing of at‑risk relatives
case conferences
case management
case management (case manager, nurse coordinator)
case volume (annual center volume)
case volume (center and surgeon)
cash (cardiac arrest study hamburg)
caspar trial
cast (cardiac arrhythmia suppression trial)
castle‑af (catheter ablation versus standard conventional therapy in patients with left ventricular dysfunction and atrial fibrillation)
castle‑af trial
cast‑ii
catecholamine spillover
cath lab preactivation
catheter ablation
catheter ablation (af ablation)
catheter ablation (af rhythm‑control therapy)
catheter ablation (af)
catheter ablation (atrial arrhythmias)
catheter ablation (cti‑dependent/cti‑ablation)
catheter ablation (electrical cardioversion, ablation)
catheter ablation (electrophysiologic testing)
catheter ablation (for af)
catheter ablation (including 3‑d imaging, mapping, robotic magnetic navigation)
catheter ablation (including left atrial ablation)
catheter ablation (radiofrequency, cryoballoon, surgical)
catheter ablation (ventricular tachycardia)
catheter ablation / cardiac surgery for af
catheter ablation for af
catheter ablation for atrial fibrillation
catheter ablation for atrial fibrillation in asymptomatic patients
catheter ablation for atrial fibrillation in heart failure
catheter ablation for atrial fibrillation in symptomatic patients
catheter ablation in achd
catheter ablation of accessory pathways
catheter ablation of atrial flutter
catheter ablation of ventricular arrhythmia
catheter ablation of ventricular fibrillation
catheter ablation of ventricular tachycardia
catheter ablation success rate
catheter ablation versus anti‑arrhythmic drug therapy
catheter ablation versus rate control
catheter ablation vs. medical therapy comparison
catheter ablation – vt substrate ablation, cryoablation
catheter ablation‑vs‑medical‑therapy trials (e.g., marquo, mercury)
catheter angiography
catheter cardiovascular intervention
catheter insertion and removal
catheter thrombosis
catheterization
catheterization (exercise/at rest)
catheterization in adults with fontan circulation
catheterization in congenital heart disease
catheterization laboratory activation
catheterization laboratory management for cardiac arrest
catheterization laboratory management of comatose patients
catheterization laboratory recommendations
catheter‑based ablation
catheter‑based ablation (including cryoenergy or radiofrequency)
catheter‑based ablation of atrial fibrillation
catheter‑based calculation
catheter‑based cardiac procedures
catheter‑based intervention
catheter‑based intervention (bridge to surgery)
catheter‑based interventions
catheter‑based interventions for baffle repair
catheter‑based interventions for residual lesions
catheter‑based limb angioplasty
catheter‑based mechanical thrombectomy
catheter‑based revascularization
catheter‑based therapies
catheter‑based therapies for isolated tr
catheter‑based therapy
catheter‑based thrombolysis
catheter‑based treatment
catheter‑derived imaging
catheter‑directed endograft techniques
catheter‑directed thrombolysis
catheter‑directed thrombolysis efficacy vs. open surgery
catheter‑guided therapy
catheter‑guided thrombolysis
catheter ablation
cathworks
causative factors of aortic aneurysm
cavopulmonary shunt
cavotricuspid isthmus (cti)
cavotricuspid isthmus ablation
cavotricuspid isthmus–dependent afl (cti‑dependent afl)
cavo‑tricuspid isthmus (cti) ablation
ca²⁺ leak mechanisms
ccd (chronic coronary disease)
ccd – chronic coronary disease
ccd** – chronic coronary disease
cctga (congenitally corrected transposition of the great arteries)
cd4⁺ t cells
cd69 (exhaustion marker)
cdc (centers for disease control and prevention)
cdp – clinical decision pathway
cds‑af tool
celecoxib














celiac artery
celiac artery coverage
celiac, superior mesenteric, and renal artery involvement in aortic aneurysm
cell/gene therapies
center for heart disease prevention
centerline measurement technique
centers for medicare & medicaid services (cms)
center‑based cr programs
central adiposity
central and anterior jets
central aortic cannulation
central cannulation (aortic arch cannulation)
central jet (≥50% right atrial)
central jet mr
central nervous system (cns) event
central obesity
central obesity (waist circumference, waist‑hip ratio)
central sleep apnea
central sleep apnea (csa)
central venous access (in catheter ablation context)
central venous catheter access
central venous oxygen saturation (svo₂ < 55 %)
central venous pressure
central venous pressure (cvp)
central venous pressure prediction
cephalic vein
cephalosporins
cerebral abscess
cerebral abscesses
cerebral amyloid angiopathy
cerebral aneurysm
cerebral embolic events
cerebral embolism
cerebral hemorrhage
cerebral infarction
cerebral ischemia
cerebral ischemia (stroke, neurologic deficits)
cerebral malperfusion
cerebral perfusion
cerebral perfusion (antegrade or retrograde)
cerebral perfusion (antegrade, selective antegrade, retrograde)
cerebral perfusion techniques
cerebral protection strategy
cerebral thromboembolism
cerebrospinal fluid drainage
cerebrospinal fluid drainage (csfd)
cerebrospinal fluid pressure management
cerebrovascular
cerebrovascular accident (cva)
cerebrovascular accident (stroke)
cerebrovascular accidents (cva)
cerebrovascular complications
cerebrovascular disease
cerebrovascular disorders
cerebrovascular events
cerebrovascular events (stroke)
cerebrovascular events (stroke, silent infarcts)
cerebrovascular events in vhd
cervical artery abnormalities (fibromuscular dysplasia, dissection, aneurysm, tortuosity)
cesarean delivery (for aortic disease risk)
cesarean delivery (in aortic disease)
cesarean delivery (in context of aortic dissection)
cesarean delivery (in high‑risk aortic cases)
cesarean delivery (in the context of cardiac risk)
cesarean delivery (in vascular ehlers‑danlos syndrome)
cesarean delivery (when used in management of aortic dissection during pregnancy)
cesarean section
cesarean section (reserved for obstetric or emergency cardiac indications)
cessation counseling
cha2ds2‑vasc score
chads2
chads2 score
chads2‑vasc score
chads‑2/vasc score (cha₂ds₂‑vasc)
chads‑vasc score in ttr amyloidosis
chads₂ score
chads₂ risk score
chagas cardiomyopathy
chagas disease
chagas disease (cardiac form)
chagas’ disease
chamber dilation
chamber dimension assessment
chamber enlargement
chamber function
chamber geometry
chamber quantification
chamber size
chamber size / thickness
chamber volumes
champion trial
champ‑hf registry
champ‑hf study
charcot foot deformity – a severe complication of pad with cardiovascular implications
charge‑af risk model
charge‑af risk prediction model
charge‑af risk score
charge‑af score
charisma (clopidogrel for high atherothrombotic risk and ischemic stabilization, management and avoidance)
charisma trial
charm risk score (candesartan in heart failure‑assessed reduction in mortality and morbidity)
charm‑overall program (candesartan in chf)
charm‑preserved
charm‑preserved trial
cha₂ds₂-vasc score
cha₂ds₂‑vasc
cha₂ds₂‑vasc risk score
cha₂ds₂‑vasc score
cha₂ds₂‑vasc score (and its risk categories)
cha₂ds₂‑vasc score (stroke‑risk assessment in af)
cha₂ds₂‑vasc ≥2
cha₂ds₂‑vasc risk score
chd (congenital heart disease)
chd (coronary heart disease)
chelation therapy
chelation therapy (edta‑based, edta‑chelating agents)
chemotherapeutic‑induced prothrombotic viral states
chemotherapy cardiotoxicity
chemotherapy‑associated cardiotoxicity
chemotherapy‑induced arrhythmias
chemotherapy‑related cardiac monitoring
chemotherapy‑related cardiotoxicity
chest guideline for pulmonary arterial hypertension
chest guideline on pulmonary arterial hypertension
chest pain
chest pain (cardiac origin)
chest pain (diagnostic evaluation)
chest pain (symptom)
chest pain / angina
chest pain / chest discomfort (ap)
chest pain centers
chest pain evaluation
chest pain evaluation guidelines
chest pain evaluation guidelines (aha/acc/ase/chest/saem/scct/scmr)
chest radiation damage
chest radiation therapy
chest radiography
chest tube output
chest x‑ray
chest x‑ray (cardiac size, pulmonary congestion)
chest x‑rays
chf (congestive heart failure)
chf / chd
chf or chd
chiesi usa
childhood / pediatric heart disease
childhood bmi
children’s heart foundation
child‑pugh classification (a, b, c)
child‑pugh classification (a, b, c)
child‑pugh score (liver function)
child‑pugh score/class (a, b, c)
chimeric antigen receptor (car‑t) cell therapy
cholesterol
cholesterol (dietary & blood)
cholesterol (hypercholesterolemia)
cholesterol / dyslipidemia
cholesterol clinical practice guidelines
cholesterol endpoints
cholesterol guideline (e.g., 2023 aha/acc/accp/aspc/nla/pcna chronic coronary disease guideline)
cholesterol lowering
cholesterol management
cholesterol management / blood‑cholesterol guideline
cholesterol treatment
cholesterol treatment trialists (ctt) meta‑analysis
cholesterol treatment trialists’ collaboration
cholesterol‑lowering interventions
cholesterol‑lowering medications
cholesterol‑lowering therapy
chordal connections
chordal rupture
chordal‑sparing mitral valve replacement
chromosomal abnormalities
chromosome 22q11 deletion in truncus arteriosus patients.
chronic angina
chronic anticoagulation
chronic aortic dissection
chronic aortic regurgitation
chronic aortic regurgitation (ar)
chronic atrial fibrillation
chronic colchicine (low‑dose colchicine)
chronic colchicine therapy
chronic congestive heart failure
chronic coronary disease
chronic coronary disease (ccd)
chronic coronary disease (ccsd)
chronic coronary disease / coronary artery disease (cad)
chronic coronary disease guideline
chronic coronary disease guidelines
chronic coronary disease management
chronic coronary disease; coronary heart disease; cardiovascular disease; myocardial infarction; heart failure; atherosclerosis; coronary artery disease; coronary stenosis; cardiovascular outcomes; major adverse cardiovascular events; metabolic syndrome; obesity; central obesity; waist circumference; body mass index; type 2 diabetes; metabolic surgery; bariatric surgery; liposuction; cardiac rehabilitation; exercise‑based rehabilitation; high‑intensity interval training; cardiac allograft vasculopathy; atrial fibrillation; coronary calcium score; coronary angiography; cardiac ct; cardiovascular risk factors; cardiovascular mortality; cardiovascular morbidity; coronary lesion; coronary disease management; cardiac exercise capacity; cardiovascular exercise tolerance; cardiovascular risk assessment; cardiovascular disease prevention; coronary heart disease prevention.
chronic coronary syndrome
chronic coronary syndrome (ccs)
chronic coronary syndromes
chronic coronary syndromes (ccs)
chronic cyanosis
chronic disease management
chronic disease risk behaviors
chronic diseases (multiple chronic disease screening)
chronic embolism risk
chronic heart failure
chronic heart failure (chf)
chronic heart failure (congestive heart failure)
chronic heart failure (hf)
chronic heart failure symptoms
chronic heart‑failure treatment guidelines
chronic hypertension
chronic hypoxemia
chronic infection of pacemaker leads
chronic inflammatory cardiomyopathy
chronic inflammatory conditions
chronic inflammatory disease
chronic kidney disease
chronic kidney disease (ckd)
chronic kidney disease (ckd) / egfr 15‑59 ml/min/ 2
chronic kidney disease (ckd) / kidney failure
chronic kidney disease (ckd) / renal insufficiency
chronic kidney disease (ckd) with egfr 15–59 ml/min/1.73 m²
chronic kidney disease (ckd) – a major cardiovascular comorbidity
chronic kidney disease (ckd) – closely linked comorbidity impacting hf management
chronic kidney disease (ckd) – systemic condition with cardiovascular impact
chronic kidney disease (ckd, implied comorbidity)
chronic limb-threatening ischemia (clti)
chronic limb‑threatening ischemia
chronic limb‑threatening ischemia (clti)
chronic limb‑threatening ischemia (clti) / critical limb ischemia (cli)
chronic limb‑threatening ischemia (clti) management
chronic limb‑threatening ischemia (clti, indicating severe systemic atherosclerosis)
chronic limb‑threatening ischemia guidelines
chronic limb‑threatening ischemia – clti
chronic lung disease
chronic management after spontaneous coronary artery dissection (scad)
chronic mitral regurgitation
chronic myocardial infarction (mi)
chronic myocarditis
chronic obstructive pulmonary disease (copd)
chronic occlusion
chronic primary mitral regurgitation
chronic primary mitral regurgitation (mr)
chronic primary mr
chronic primary mr (valvular heart disease)
chronic pulmonary regurgitation
chronic right‑ventricular (rv) pacing
chronic secondary mitral regurgitation
chronic secondary mr
chronic severe aortic regurgitation (ar)
chronic severe secondary mitral regurgitation (mr)
chronic severe secondary mr
chronic stable angina
chronic stable angina pectoris
chronic stable coronary disease
chronic stable ischemic heart disease guideline citations
chronic symptomatic heart failure
chronic symptomatic pad
chronic symptomatic peripheral artery disease
chronic tachycardia
chronic total occlusion (cto)
chronic type b aortic dissection
chronic coronary disease
chronic anticoagulation
chronotropic incompetence
















cibis iii
cibis‑ii (cardiac insufficiency bisoprolol study)
cicu – cardiac intensive care unit
cids (canadian implantable defibrillator studies)
cigarette smoking
cilostazol
cine gradient echo bright blood sequence
cine magnetic resonance
cine nuclear magnetic resonance (cmri)
cine‑computed tomography (cine‑ct)
cinhl complete
circ pulm health outcomes (journal)
circulating biomarkers
circulating blood markers
circulation
circulation (cardiology journal)
circulation (journal reference)
circulation (journal title, cardiology focus)
circulation (journal)
circulation (peer‑reviewed cardiovascular journal)
circulation biomarkers (e.g., natriuretic peptides)
circulation journal
circulation journals** (cardiology journal)
circulation: cardiovascular interventions
circulation: cardiovascular quality and outcomes
circulatory arrest
cirrhosis
ckd stage 3
ckd stage 4
ck‑mb (creatine kinase mb)
clamp‑on technique
clarithromycin
clarity‑timi 28 trial
class 1/2a/2b recommendations
class ic antiarrhythmic drugs
class ic antiarrhythmic medications
class iii antiarrhythmic drugs
class iii obesity (bmi ≥ 40 kg/m²)
class of recommendation
class of recommendation (clinical guideline classification)
class of recommendation (clinical guideline)
class of recommendation (cor)
class of recommendation (for guideline tiers)
class of recommendation and level of evidence (clinical strategies, interventions, treatments, or diagnostic testing)
classical myocarditis features
classification and stages of tr
classification of cardiogenic shock
class ia antiarrhythmic – procainamide
class ic antiarrhythmics – flecainide, propafenone
class iii antiarrhythmics – dofetilide, dronedarone, sotalol, ibutilide
class 1 recommendations (strong)
class 2 recommendations (moderate)
class 3 recommendations (no benefit)
class i (strong) recommendations
class i antiarrhythmic drugs
class i clinical recommendation
class i indication
class i recommendation
class i recommendation (class 1)
class ia anti‑arrhythmics (e.g., quinidine)
class ib anti‑arrhythmics (e.g., mexiletine)
class ic antiarrhythmic drugs
class ic anti‑arrhythmic agents
class ic anti‑arrhythmics (e.g., encainide, flecainide)
class iia recommendation
class iii antiarrhythmic drugs
class iii anti‑arrhythmics (e.g., dronedarone, sotalol)
class iii obesity (bmi ≥ 40 kg/m²)
claudication
claudication (exertional leg symptoms)
claudication (intermittent claudication)
claudication (leg pain on walking)
clear wisdom trial
clear outcomes trial
cleft in a2/p2 scallops
cleft mitral valve
cleft palate
cleveland clinic – cardiac care
cleveland heart lab
clevidipine
climate‑change‑related cardiovascular impact
clingen (clinical genome resource)
clinical af
clinical and procedural domains
clinical and procedural success rates
clinical arrhythmias
clinical assessment / risk assessment
clinical assessment and prognostic indicators (congestion, weight loss, diuretic dose, icd shocks)
clinical assessment for pad
clinical atherosclerosis (i.e., cad, cerebrovascular disease)
clinical atherosclerotic cardiovascular disease (ascvd)
clinical atherosclerotic cardiovascular disease (cvd)
clinical benefit
clinical benefit (or lack thereof)
clinical benefit / clinical stability
clinical benefit / dose‑response relationship in heart failure therapies
clinical benefit of long‑term beta‑blocker therapy post‑discharge
clinical benefits and risks (fatigue, depression, drug–drug interactions)
clinical cardiac electrophysiology
clinical care pathways
clinical characteristics
clinical characteristics (including baseline pulmonary artery pressure)
clinical characteristics and management of chagas cardiomyopathy
clinical characteristics and outcomes in pregnancy‑associated heart failure.
clinical conditions / syndromes
clinical congestion
clinical course of hypertrophic cardiomyopathy
clinical data standards
clinical data standards (for peripheral atherosclerotic disease)
clinical decision pathway (cdp)
clinical decision pathways for anticoagulation
clinical decision rules
clinical decision support for pad care
clinical decision support in cardiomyopathy
clinical decision support systems (cdss)
clinical decision support tools
clinical decision tools (e.g., clinical risk calculators, calculators embedded in electronic health records)
clinical decision‑making
clinical decision‑making & shared decision‑making processes in cardiac care
clinical decision‑making in valve disease
clinical decision‑making regarding anticoagulation
clinical decision‑support systems (cds)
clinical decompensation
clinical deterioration
clinical deterioration (after abrupt ace inhibition withdrawal)
clinical deterioration (after abrupt acei withdrawal)
clinical device trial data
clinical diagnosis
clinical diagnosis and imaging protocols
clinical diagnosis of hcm
clinical disease relapse
clinical documentation of nyha class
clinical effectiveness
clinical eligibility criteria
clinical endpoints: death, reinfarction, stroke, ischemic events, bleeding.
clinical estimation of symptoms
clinical evaluation
clinical evaluation (pulse, foot assessment)
clinical evaluation and symptom assessment
clinical evaluation for worsening ap class
clinical evaluation of cardiac patients
clinical evaluation of cardiac symptoms
clinical evaluation of occupational risk
clinical evaluation of risk factors (figures 1, 3; table 8)
clinical events (cardiac death, mi, etc.)
clinical events (including aortic surgery, aortic dissection)
clinical events (non‑fatal mi, unstable angina, urgent revascularization)
clinical evidence from clot‑af and x‑tra studies
clinical evidence modifiers
clinical evidence of autonomic dysfunction due to af
clinical evidence of congestion
clinical evidence of end‑organ ischemia
clinical evidence of fluid retention
clinical exercise physiologist
clinical exercise physiologists
clinical features
clinical features and outcomes of pregnancy‑related aortic dissection
clinical features and outcomes, population‑based study
clinical follow‑up (annual, pregnancy)
clinical follow‑up (annual, telehealth, in‑person)
clinical follow‑up plan and testing
clinical follow‑up schedule
clinical frailty scale
clinical genetics
clinical guideline
clinical guideline (2024 hypertrophic cardiomyopathy guideline)
clinical guideline (acc/aha)
clinical guideline (aha/acc)
clinical guideline / statement
clinical guideline classification (e.g., b‑nr, b‑r, c‑eo, c‑ld)
clinical guideline for achd
clinical guideline recommendations (b‑nr, c‑ld)
clinical guideline recommendations (e.g., 2025 acs guideline, 2021 acc/aha/scai guideline for coronary artery revascularization)
clinical guideline statement
clinical guideline statements
clinical guideline statements (acc/aha, 2020)
clinical guideline terminology (acc/aha/hrs, hrs/ehra/ecas)
clinical guidelines
clinical guidelines (2022 acc/aha aortic disease guideline)
clinical guidelines (2023 af guideline, esc heart failure registry)
clinical guidelines (2025 acute coronary syndromes guideline)
clinical guidelines (acc/aha)
clinical guidelines (acc/aha) on valvular heart disease
clinical guidelines (acc/aha, esc)
clinical guidelines (acc/aha, esc, aha/acc)
clinical guidelines (aha/acc/hfsa heart failure guideline, acc/aha hypertension guideline)
clinical guidelines (aha/acc/hfsa)
clinical guidelines (aha/acc/hfsa, dutch practice guideline)
clinical guidelines (e.g., acc/aha, aha/acc/ace)
clinical guidelines (heart failure)
clinical guidelines and systematic reviews for af management.
clinical guidelines for af management
clinical guidelines for af management in the presence of bleeding risk
clinical guidelines for atrial fibrillation
clinical guidelines for chronic coronary disease (aha/acc/accp/aspc/nla/pcna)
clinical guidelines for hcm
clinical guidelines for hcm management
clinical guidelines for heart disease
clinical guidelines for heart failure (aha/acc/hfsa)
clinical guidelines for infective endocarditis
clinical guidelines on cardiovascular disease
clinical guidelines on pad care
clinical guideline‑directed management
clinical guideline‑recommended therapy (gdmt)
clinical hcm onset
clinical heart failure in pa‑ivs
clinical history and physical examination
clinical implementation
clinical judgment
clinical laboratory and imaging surveillance of valvular disease
clinical management guidelines for adult congenital heart disease
clinical management of antithrombotic therapy in valve disease
clinical management of heart failure (hf)
clinical management of pericarditis (aspirin dose, colchicine dosing)
clinical management of stable coronary artery disease (cad)
clinical measures (qm‑4)
clinical or echocardiographic evidence of residual valvular heart disease.
clinical outcome
clinical outcome after septal myectomy
clinical outcome after surgical myectomy
clinical outcome and long‑term survival
clinical outcome and phenotypic expression in lamp2 cardiomyopathy
clinical outcome assessment (e.g., relative risk, odds ratio, confidence interval)
clinical outcome in hypertrophic cardiomyopathy patients
clinical outcome of exercise capacity post‑septal myectomy
clinical outcomes
clinical outcomes & morbidity‑mortality predictors
clinical outcomes & registry data (e.g., critisch, spinach, basil, basil‑2)
clinical outcomes (all‑cause death, all‑cause mortality)
clinical outcomes (death, renal outcomes, rehospitalization)
clinical outcomes (hf)
clinical outcomes (hospitalisation, survival)
clinical outcomes (major adverse cardiovascular events – mace)
clinical outcomes (morbidity/mortality)
clinical outcomes (mortality, hospitalization)
clinical outcomes (mortality, morbidity, quality of life)
clinical outcomes (quality of life, symptom improvement)
clinical outcomes (short‑term, long‑term survival)
clinical outcomes (survival, infarct size, reperfusion success)
clinical outcomes after cardiac surgery
clinical outcomes after myocardial infarction
clinical outcomes and prognostic markers
clinical outcomes and survival metrics in achd
clinical outcomes for srt and surgical myectomy
clinical outcomes in acs
clinical outcomes in cardiac patients
clinical outcomes in elderly populations
clinical outcomes measurement
clinical outcomes of atrial fibrillation
clinical outcomes of functional status
clinical outcomes of pulmonary arterial hypertension in congenital heart disease.
clinical outcomes related to valvular disease management
clinical outcomes studies
clinical outcomes: mortality, morbidity, qol, exercise tolerance
clinical parameters: coronary syndromes, arrhythmia/syncope, chest pain, dyspnea
clinical performance and quality measures for patients with peripheral artery disease
clinical performance measures
clinical performance measures for cardiovascular care
clinical phenotype
clinical phenotype classification in heart failure
clinical phenotype in hypertrophic cardiomyopathy
clinical phenotypes
clinical phenotyping of cardiomyopathy
clinical policy and guidelines (cardiovascular)
clinical practice guideline (aha/acc, acc/aha, esc/ers)
clinical practice guideline for hypertension
clinical practice guideline implementation
clinical practice guidelines
clinical practice guidelines (acc, aha, etc.)
clinical practice guidelines (acc/aha task force)
clinical practice guidelines (acc/aha)
clinical practice guidelines (acc/aha, aha/acc/jacc)
clinical practice guidelines (acc/aha, esc, ehra, eacts)
clinical practice guidelines (acc/aha/accp/aspc/nla/pcna)
clinical practice guidelines (aha/acc, scai, svs, etc.)
clinical practice guidelines (aha/acc/accp/aspc/nla/pcna)
clinical practice guidelines (aha/acc/hfsa)
clinical practice guidelines (joint committee)
clinical practice guidelines for coronary disease
clinical practice guidelines for management of pulmonary valve disease
clinical practice monitoring of health disparities
clinical practice settings
clinical predictors of genetic testing outcomes
clinical presentation (young age, teenage–30 yr)
clinical presentation of endocarditis
clinical presentation of prosthetic valve dysfunction
clinical recommendation
clinical registry outcomes.
clinical remission
clinical risk assessment for anticoagulation
clinical risk factors
clinical risk factors (age, comorbid conditions)
clinical risk factors (male sex, age, height, weight, traditional cardiovascular risk factors)
clinical risk prediction
clinical risk prediction models
clinical risk profiling (cha₂ds₂‑vasc, etc.)
clinical risk scores
clinical risk stratification
clinical risk stratification in congenital heart disease
clinical screening
clinical screening / surveillance
clinical screening for hypertrophic cardiomyopathy in first‑degree relatives
clinical screening intervals (1–2 years)
clinical screening paradigms
clinical screening strategies
clinical sequelae of left atrial hypertension
clinical signs and symptoms of heart failure
clinical signs of congestion
clinical stability
clinical stability and comorbidities
clinical staging of hypertrophic cardiomyopathy
clinical statement
clinical statement / guideline recommendation
clinical statements
clinical statements & guidelines
clinical statements & guidelines (2022)
clinical statements & scientific statements (american heart association)
clinical statements (guidelines)
clinical statements / scientific statements
clinical statements and guidelines (acc/aha)
clinical statements and guidelines (aha/acc/hfsa 2022 hf guideline)
clinical statements and guidelines (for heart disease)
clinical statements and guidelines related to cardiovascular disease
clinical statements and recommendations
clinical statements on ascvd outcomes
clinical statements/ guidelines for valvular management
clinical status
clinical strategies
clinical strategies and interventions for cardiac disease
clinical studies supporting rhythm control (e.g., races, east‑afnet 4)
clinical success rate
clinical surveillance
clinical surveillance programs
clinical surveillance protocol
clinical suspicion of acs
clinical suspicion of pad
clinical testing in children and adolescents
clinical trial
clinical trial (aristotle)
clinical trial (engage af‑timi 48)
clinical trial (general)
clinical trial (re-ly)
clinical trial (rocket af)
clinical trial / randomized controlled trial (rct)
clinical trial and registry acronyms
clinical trial design for hcm therapeutics
clinical trial endpoints (mortality, morbidity, revascularization)
clinical trial enroller
clinical trial enrolment in cardiac research
clinical trial evidence
clinical trial evidence (e.g., embrace, crystal‑af, find‑af, per‑diem, assert)
clinical trial evidence for medical therapies
clinical trial meta‑analysis of rhythm vs. rate control
clinical trial outcomes
clinical trial outcomes for aneurysm management (e.g., losartan trials)
clinical trial representation and inclusivity
clinical trial: plato
clinical trial: triton‑timi 38
clinical trial: triton‑timi 38, plato, and other rcts mentioned
clinical trials
clinical trials & studies:
clinical trials (e.g., af‑chf, race ii, af‑crt)
clinical trials (e.g., smac af, aric study)
clinical trials (e.g., tact, tact2)
clinical trials (rct)
clinical trials (rct, meta‑analysis)
clinical trials / guidelines:
clinical trials / randomized controlled trials
clinical trials / randomized controlled trials (rcts) – e.g., solvd, valiant, optimaal, paradise‑mi
clinical trials / studies
clinical trials / studies:
clinical trials and research studies in heart failure
clinical trials of pah‑directed therapy in eisenmenger syndrome
clinical trials related to heart failure
clinical trials, meta‑analyses, network meta‑analysis (study designs)
clinical trials: aristotle, engage af‑timi 48, re‑ly, aristotle, engage af‑timi 48, etc.
clinical trials: canvas, credence, empa‑reg outcome, euclid, strong heart study
clinical trials: gissi‑3, isis‑4, isis‑2, antithrombotic trialists collaboration, plato, wiviott sd (prasugrel trial), sabatine ms (clopidogrel addition), yusuf s (clopidogrel + aspirin), chen zm (clopidogrel + aspirin), etc.
clinical utility of genetic sequencing (e.g., fh genes)
clinical validity of genetic tests
clinical yield
clinical, anatomical, or technical reasons (affecting access choice)
clinically actionable variants
clinically evident af
clinically relevant risk factors for af management
clinical‑relevant arrhythmias
clinical decompensation
clinicopathologic criteria (lieberman criteria)
clockwise afl
clockwise rotation of the left coronary ostium
clonidine
clopidogrel
clopidogrel (p2y12 inhibitor)
clopidogrel (p2y12 inhibitor, prodrug)
clopidogrel 75 mg daily
clopidogrel monotherapy
clopidogrel resistance
clopidogrel response variability
clopidogrel therapy
closed commissurotomy
closed mitral commissurotomy (cc)
clostridium difficile colitis
closure contraindicated (high‑risk closure)
clotting / thrombosis
clotting mechanisms
clotting or thrombosis of peripheral arteries (implied by pad discussion)
clubbing
cm (cardiomyopathy)
cmr (cardiac magnetic resonance imaging)
cmr (cardiac magnetic resonance)
cmr (cardiovascular magnetic resonance)
cmr assessment
cmr imaging
cmr imaging (cardiac magnetic resonance imaging)
cmr mapping
cmr risk stratification
cmr – cardiac magnetic resonance
cmr‑measured regurgitant fraction
coa (coarctation of the aorta)
coa peak‑to‑peak gradient >20 mm hg
coa pressure gradient
coach study
coach trial
coact trial
coagulase‑negative staphylococci endocarditis
coagulation cascade
coagulation cascade activation
coagulation monitoring (inr)
coagulopathy
coagulopathy / anticoagulation management
coagulopathy / thrombocytopenia
coagulopathy risk
coapt trial
coapt trial outcomes
coaptation length
coarctation of the aorta
coarctation of the aorta (aortic coarctation)
coarctation of the aorta (coa)
coarctation of the aorta
cocaine
cocaine abuse
cocaine use
cocaine‑associated cardiomyopathy
cocaine‑associated myocardial infarction
cochrane library
coenzyme q₁₀
coenzyme q10
cognitive / psychiatric impairment
cognitive disorders
cognitive function
cognitive function / neurocognitive impairment / neurocognitive dysfunction
cognitive impairment
cohort studies
cohort study
colchicine
colchicine (anti‑arrhythmic therapy)
colchicine (anti‑inflammatory)
colchicine (prophylaxis)
colchicine therapy
colchicine therapy (colchicine)
colchicine therapy for pericarditis
colchicine use post‑mi (ongoing trials)
colchicine–cardiovascular medication drug‑drug interactions
colcot trial
cold blood vs. cold crystalloid perfusion
cold extremities / livedo reticularis
collaborative care / team‑based care
collaborative partnerships (health‑care systems & community organizations)
collagen deposition
collateral arteries
collateral circulation
collateral circulation management
collateral formation
collateral vessels
collecting duct
color doppler imaging
color flow doppler
color jet area
combination diuretic therapy
combination of clopidogrel and aspirin
combination therapy (isosorbide dinitrate + hydralazine)
combined epicardial‑endocardial ablation
combined estrogen‑and‑progestin hormone regimens
combined heart‑liver transplantation
combined heart–liver transplantation
combined heart–liver transplantation in the failing fontan
combined transaortic & transapical approach
combined vaccination (ppv + influenza)
comet
commander‑hf (rivaroxaban) trial
commercial driving (occupational consideration)
commercial insurance coverage of exercise therapy
commissural area ratio
commissural calcification
commissural calcium score
commissural calcium score / calcification
commissural fusion
commissural morphology
commissurotomy
commit trial
commit trial (clopidogrel and metoprolol in myocardial infarction)
committee member
common atrioventricular valve
common femoral artery
common femoral artery (access site for cardiac‑related endovascular procedures)
common femoral artery disease
common femoral endarterectomy
common risk factors for aaa
community health workers
community health workers in cardiovascular screening
community risk models
community‑based exercise
community‑based exercise therapy
community‑based screening for pad
comorbid cardiac conditions
comorbidities
comorbidities (e.g., chronic inflammatory conditions, autoimmune disease, hiv infection, socioeconomic disadvantage)
comorbidities (e.g., smoking, diabetes)
comorbidities influencing cardiac outcomes
comorbidities, frailty, patient preferences, and values.
companion trial
comparative effectiveness studies of revascularization strategies.
compartment pressures
compartment syndrome
compartment syndrome (acute extremity)
compartment syndrome (associated with ischemic injury)
compass (anticoagulation strategies) trial
compass study (cardiovascular outcomes for people using anticoagulation strategies)











compass trial
compass trial (cardiovascular outcomes for people using anticoagulation strategies)
compass trial (cardiovascular outcomes)
competing cardiovascular risk factors
competing health outcomes (e.g., exercise capacity vs. pah progression)
competitive athlete eligibility/disqualification criteria
competitive athlete participation
competitive athletics (as a clinical consideration)
competitive athletics / sports participation
competitive sport participation recommendations (chd)
competitive sports
competitive sports and extreme isometric exercise (to be avoided)
competitive sports participation
competitive sports participation guidelines for athletes with cardiovascular abnormalities
competitive sports prohibition
competitive sports restriction
complete av septal defect
complete avsd (complete atrioventricular canal)
complete heart block
complete heart block risk (perimembranous vsd)
complete removal of cardiac electronic device
complete revascularization
complete revascularization (cr)
complex cad (including left‑main, 3‑vessel, diffuse disease)
complex congenital anatomy and physiology
complex congenital heart defects
complex congenital heart disease
complex congenital lesions
complex coronary lesion
complex fractionated electrograms (cfees)
complex lesions
complex revascularization
complex three‑vessel disease
complicated aortic dissection
complicated intramural hematoma
complicated myocarditis
complication rates
complication risk with vsd repair
complications
complications (e.g., aneurysm, dissection, ulcer)
complications (e.g., syncope, ventricular tachycardia, death)
complications (stroke, exsanguination, embolization)
complications after catheter ablation
complications of aortic disease (malperfusion, rupture)
complications of aortic operations (bleeding, thromboembolism, reintervention)
complications of percutaneous transluminal angioplasty
complications of pulmonary artery interventions (adverse events, procedural characteristics)
composite bypass conduit
composite cardiovascular events
composite cardiovascular outcomes (death, stroke, hospitalization)
composite clinical outcome (cardiac death, stroke, hf hospitalization, acs)
composite endpoint
composite endpoint (cardiovascular death or hf hospitalization)
composite endpoint (death, mi, hospitalization)
composite endpoint (hf hospitalization or cardiovascular death)
composite endpoint of cardiovascular death or heart‑failure hospitalization
composite endpoint: death or rehospitalization
composite endpoints (e.g., cardiovascular death or hf hospitalization)
composite evar failure
composite graft replacement
composite hf endpoint
composite of death and hospitalization
composite of mace
composite of mortality and cardiovascular hospitalizations
composite primary endpoint (cardiovascular death, stroke, hf hospitalization)
composite primary endpoint (death, mi, stroke)
composite primary endpoints (death, reinfarction, stroke, hf)
composite primary outcome (stroke, systemic embolism, mi, unstable angina, death)
composite valved graft conduit
composite valve‑graft replacement
composite vein bypass
composite vs. conventional vein conduit
compound and double mutations
comprehensive af care
comprehensive af care in hfpef
comprehensive ascvd prevention
comprehensive cardiac evaluation (annual reassessment)
comprehensive cardiac history
comprehensive cardiology clinic
comprehensive cardiovascular care
comprehensive care
comprehensive hcm center
comprehensive hcm centers
comprehensive heart valve center
comprehensive imaging approach
comprehensive transfer of care
comprehensive tte (transthoracic echocardiography)
comprehensive valve center
comprehensive valve center (cvc)
comprehensive valve center (recommended site for advanced interventions)
compression stockings (support stockings)
computed tomographic angiography
computed tomographic angiography (cta)
computed tomography
computed tomography (ct)
computed tomography (ct) angiography
computed tomography (ct) angiography (cta)
computed tomography (ct) cardiac imaging
computed tomography (ct) imaging
computed tomography (ct) of the aorta
computed tomography (ct) of the thoracic aorta
computed tomography (ct) scan
computed tomography (ct) scans
computed tomography (ct) – gold standard for follow‑up
computed tomography angiography
computed tomography angiography (cta)
computed tomography angiography (cta) of the brain
computed tomography coronary angiography (ccta)
computed tomography coronary angiography (ctca)
computed tomography scanning
computed‑tomeography (cta)
concentric hypertrophy
conception and pregnancy in aortic disease
concomitant af with valvular disease
concomitant aortic surgery
concomitant cardiac abnormalities (systolic, diastolic, valvular)
concomitant hypertension
concomitant prophylactic aortic repair
concomitant septal myectomy with avr
concomitant surgical procedures (e.g., maze procedure for af)
concomitant tricuspid valve repair or replacement with mitral surgery
concomitant valve disease
concurrent cardiac conditions
conduction abnormalities
conduction abnormalities (associated with various syndromes)
conduction block
conduction delay
conduction delays
conduction disease (early onset)
conduction pathways (left‑to‑right atrial)
conduction system disease
conduction system injury
conduction system modulation
conduction system pacing
conduction velocity
conduction velocity slowdown
conduction‑system pacing
conduit
conduit artery dysfunction
conduit calcification
conduit dysfunction
conduit dysfunction evaluation
conduit fracture imaging
conduit insufficiency / calcification
conduit intervention
conduit placement (general)
conduit regurgitation
conduit replacement
conduit stenosis
conduit stent implantation
cone operation (cone reconstruction)
cone procedure (tricuspid valve repair)
confidence interval
confidence interval (ci)
confirmatory diagnostic evaluation
conformable stent graft
congenital abnormalities
congenital abnormalities of the aortic arch
congenital anomalies of the submitral valve apparatus
congenital aortic abnormalities
congenital aortic anomaly
congenital aortic arch abnormalities
congenital aortic stenosis
congenital aortic valve disease
congenital aortic valve diseases
congenital aortic valve stenosis
congenital cardiac conditions
congenital cardiac defects
congenital cardiac surgeon
congenital cardiothoracic surgery
congenital cardiovascular malformations
congenital corrected transposition of the great arteries (cctga)
congenital deafness
congenital disease (e.g., ebstein’s anomaly, levo‑transposition of the great arteries)
congenital heart defect
congenital heart defect / disease
congenital heart defects
congenital heart disease
congenital heart disease (achd)
congenital heart disease (adult congenital)
congenital heart disease (adult)
congenital heart disease (advanced therapies)
congenital heart disease (chd)
congenital heart disease (chd) / achd
congenital heart disease (chd) surgeons / congenital heart surgeons
congenital heart disease (chd) – adult population
congenital heart disease (implicit in arrhythmia research)
congenital heart disease (with residual flow disturbances)
congenital heart disease / adult congenital heart disease (achd)
congenital heart disease advocacy organizations
congenital heart disease diagnosis specifics (name, anatomy, physiology)
congenital heart disease in turner’s syndrome
congenital heart disease management guidelines (acc/aha, aha/acc, etc.)
congenital heart disease surgery
congenital heart public health consortium
congenital heart surgeon
congenital heart surgeon expertise
congenital heart surgery
congenital heart surgery fellowship
congenital left ventricular outflow tract (lvot) obstruction
congenital mitral stenosis
congenital mitral stenosis (including shone complex)
congenital mitral stenosis (parachute mitral valve)
congenital mitral valve disease
congenital or acquired vhd
congenital shunt lesions
congenital valve anomaly / congenital abnormality
congenital valve disease (distinct from acquired valvular disease)
congenital valve dysplasia
congenitally corrected tga (cctga, levo‑tga)
congenitally corrected transposition of the great arteries (cctga)
congenital mitral stenosis
congestion
congestion (clinical congestion, congestion on physical exam)
congestion (in‑hospital and residual)
congestion / decongestion
congestion / residual congestion
congestion / volume overload
congestion assessment
congestive heart failure
congestive heart failure (chf)
congestive heart failure (chf) (any severity)
congestive heart failure (hf)
congestive heart failure / heart failure
congestive heart failure / left‑ventricular dysfunction
congestive heart failure outcomes
congestive hepatopathy
congestive symptoms
connective tissue disease
connective tissue disease (cause of ph)
connective tissue disease‑related hf
connective tissue disorder
connective tissue disorder (ctd)
connective tissue disorders
connective tissue disorders (marfan, loeys‑dietz, etc.)
connective‑tissue disorders (e.g., systemic sclerosis, systemic lupus)
connexin (gap junction protein)
connexin40 (cx40)
connexin43 (cx43)
conotruncal abnormalities
conotruncal anomalies
conotruncal defects
consensus guidelines
consensus statements on bav aortopathy
consensus statements on cardiogenic shock classification (scai)
consensus updates on cardiogenic shock stages (scai)
conservative approach (treatment strategy)
conservative management
conservative strategy
constrictive left ventricular hypertrophy
constrictive pericarditis
constrictive/constricted symptoms (symptoms of congestion)
consultative services with cardiovascular subspecialties
consultative services with other medical and surgical subspecialties
consumer‑accessible electrocardiographic devices
contained rupture










contemporary management strategies
continuity equation
continuous anticoagulation.
continuous ecg monitoring
continuous electrocardiographic monitoring
continuous infusion vs. bolus diuretic administration
continuous intravenous inotropic therapy
continuous loop‑recording ecg monitors
continuous patient education
continuous positive airway pressure
continuous positive airway pressure (cpap)
continuous positive airway pressure (cpap) therapy
continuous positive airway pressure (cpap) – for sleep apnea related to hf
continuous real‑time monitoring of disease progression
continuous rhythm assessment
continuous rhythm monitoring (implantable cardiac monitor)
continuous st‑segment monitoring
continuous ufh infusion for low‑dose warfarin replacement
continuous warfarin therapy
continuous wave doppler (limb assessment)
continuous wearable monitors
continuous‑flow device
continuous‑flow lvad
continuous‑flow ventricular assist device
continuous‑wave doppler
continuous‑wave doppler intensity
continuous‑wave doppler technique
continuous‑wave doppler ultrasound
continuous‑wave doppler waveform
contraception
contraception and reproductive planning in women with cardiovascular disease
contraceptive agents (in achd)
contractile reserve
contractility
contractility impairment
contraindication: high‑dose diuretics
contraindication: positive inotropes
contraindication: pure vasodilators
contraindications and drug–drug interactions in cardiac therapy
contraindications in cardiovascular therapy
contraindications to exercise (severe, life‑threatening, unstable conditions)
contrast allergy
contrast angiography
contrast media
contrast-enhanced mr angiography
contrast‑associated acute kidney injury (ca-aki)
contrast‑enhanced cardiac magnetic resonance (cmr) imaging
contrast‑enhanced cardiac magnetic resonance imaging (cmr) – signal intensity, ventricular volume
contrast‑enhanced cardiovascular magnetic resonance
contrast‑enhanced cmr
contrast‑enhanced coronary ct angiography
contrast‑enhanced imaging
contrast‑enhanced mr imaging
contrast‑enhanced ultrasound (ceus)
contrast‑induced acute kidney injury (aki)
contrast‑induced acute kidney injury (ci-aki)
contrast‑induced nephropathy
contrast‑induced nephropathy (cin) – peri‑procedural renal injury related to cardiac procedures
contrast‑induced nephropathy risk score (mehran score)
conventional catheter ablation.
conventional pacing
conventional synthetic disease‑modifying antirheumatic drugs (csdmards)
conventional treatment
conventional troponin
convergent classification of heart failure (ejection fraction categories, clinical presentation)
conversion of af to sinus rhythm
conversion to sinus rhythm
cook medical (vascular and cardiovascular products)
cooperative north scandinavian enalapril (consensus) study
copd (chronic obstructive pulmonary disease) – as a comorbidity affecting atrial fibrillation
copernicus (captopril in patients with left ventricular dysfunction)
copy‑number variant / de novo mutation
cor pulmonale
cor triatriatum
cor triatriatum membrane
cor triatriatum membrane regrowth
cor triatriatum sinister
cor triatriatum sinister / sinistrum
cordis / cardinal health
cormica trial (coronary microvascular angina trial)
corn oil placebo
corneal microdeposits
corona risk score (controlled rosuvastatin multinational trial in heart failure)
coronary
coronary / peripheral revascularization
coronary anatomy
coronary anatomy contribution to risk stratification
coronary anatomy precluding pci/cabg
coronary anatomy status
coronary and atherosclerotic vascular disease
coronary and other atherosclerotic vascular disease
coronary angiogram
coronary angiographic guidance
coronary angiography
coronary angiography (ct or invasive)
coronary angiography (invasive)
coronary angiography (used to evaluate anomalies)
coronary angiography / coronary catheterization
coronary angioplasty
coronary angioplasty (percutaneous coronary angioplasty)
coronary anomalies
coronary aortic valve geometry
coronary arterial intervention outcomes
coronary arterial lesion assessment
coronary arterial revascularization strategies
coronary arteries
coronary arteriography
coronary arteriopathy
coronary artery
coronary artery abnormalities (diffuse stenosis, obstruction)
coronary artery anatomy
coronary artery anatomy (specifically coronary pattern post‑arterial switch)
coronary artery anatomy post‑arterial switch
coronary artery aneurysm
coronary artery anomalies
coronary artery anomalies / coronary artery abnormalities
coronary artery anomaly (e.g., anomalous lad from rca)
coronary artery assessment
coronary artery bypass
coronary artery bypass (implied by angioplasty context)
coronary artery bypass graft (cabg)
coronary artery bypass graft (cabg) indication
coronary artery bypass graft (cabg) patch trial (contrast with icd benefit)
coronary artery bypass graft (cabg) surgery
coronary artery bypass graft surgery
coronary artery bypass graft surgery (cabg)
coronary artery bypass grafting
coronary artery bypass grafting (cabg)
coronary artery bypass grafting (cabg) / coronary artery bypass graft (cabg)
coronary artery bypass grafting (cabg) surgery
coronary artery bypass grafting (cabg) vs pci decision
coronary artery bypass grafting (cabg) with ablation
coronary artery bypass grafting (cabg) – context for rapid af after surgery
coronary artery bypass grafting mortality in cardiogenic shock
coronary artery bypass surgery
coronary artery bypass surgery outcomes
coronary artery calcium (cac)
coronary artery calcium (cac) scanning
coronary artery calcium (cac) score
coronary artery calcium (cac) score / measurement
coronary artery calcium (cac) scoring
coronary artery calcium (cac) testing
coronary artery calcium and clinical decision making.
coronary artery calcium and lifestyle preventive therapies
coronary artery calcium and longevity
coronary artery calcium and statin allocation
coronary artery calcium and statin therapy initiation
coronary artery calcium and treatment decisions
coronary artery calcium as a determinant of future cardiovascular events
coronary artery calcium imaging
coronary artery calcium improvement of risk assessment
coronary artery calcium in african american individuals
coronary artery calcium in asian americans
coronary artery calcium in different ethnicities
coronary artery calcium measurement
coronary artery calcium prevalence and prognostic implications
coronary artery calcium reclassification
coronary artery calcium score
coronary artery calcium score in agatston units (au)
coronary artery calcium score interpretation
coronary artery calcium score thresholds (0, 1‑99, ≥100)
coronary artery calcium testing guidance
coronary artery calcium versus age in older adults
coronary artery calcium zero (cac=0) as negative risk marker
coronary artery complications
coronary artery compression
coronary artery diameter
coronary artery diameter stenosis severity
coronary artery diastolic filling
coronary artery dilation
coronary artery disease
coronary artery disease (cad)
coronary artery disease (cad) / chronic coronary disease
coronary artery disease (cad) equivalent
coronary artery disease (cad) for congenital heart disease patients
coronary artery disease (cad) in heart failure
coronary artery disease (cad) in vhd patients
coronary artery disease (cad) – concurrent with vhd
coronary artery disease (implicit in cardiovascular context)
coronary artery disease (implicit in myocardial infarction context)
coronary artery disease (implicitly related)
coronary artery disease (implied context)
coronary artery disease (implied in gdmt)
coronary artery disease (implied)
coronary artery disease (inferred from dual antiplatelet therapy context)
coronary artery disease (obstructive disease in congenital anomalies)
coronary artery disease (prior mi, angina, pci, cabg)
coronary artery disease (referenced in broader context)
coronary artery disease (sometimes used interchangeably with chd)
coronary artery disease (stable & acute)
coronary artery disease / atherosclerotic vascular disease
coronary artery disease / coronary heart disease
coronary artery disease / epicardial coronary disease
coronary artery disease / ischemic heart disease
coronary artery disease equivalent
coronary artery disease in patients with diabetes
coronary artery disease management
coronary artery disease management guidelines
coronary artery disease management in advanced kidney disease
coronary artery disease management in hfpef
coronary artery disease progression
coronary artery disease risk modifiers
coronary artery disease risk stratification
coronary artery disease screening in atrial fibrillation patients
coronary artery disease with atrial fibrillation
coronary artery disease (cad)
coronary artery dissection
coronary artery dissection recurrence prevention.
coronary artery ectasia
coronary artery evaluation in ie
coronary artery fistula
coronary artery graft failure
coronary artery interposition graft
coronary artery intervention
coronary artery intervention outcomes
coronary artery intervention trials and meta‑analyses
coronary artery involvement by dissection
coronary artery obstruction
coronary artery obstruction (specific to aortic viv)
coronary artery obstruction surveillance post‑arterial switch
coronary artery occlusion
coronary artery ostia
coronary artery plaque
coronary artery plaque burden
coronary artery protection strategy
coronary artery proximity
coronary artery reimplantation
coronary artery reimplantation (correction of anomalous origin)
coronary artery reintervention
coronary artery relationship to heart structures (anatomical assessment)
coronary artery revascularization
coronary artery revascularization (clinical guideline context)
coronary artery revascularization (e.g., percutaneous coronary intervention [pci], coronary artery bypass grafting)
coronary artery revascularization in ischemic cardiomyopathy
coronary artery spasm
coronary artery stenoses
coronary artery stenosis
coronary artery stenosis (ostial)
coronary artery systolic pressure exposure
coronary artery thrombosis
coronary artery tortuosity
coronary atherosclerosis
coronary burden high‑risk plaque
coronary bypass graft (cabg)
coronary bypass graft surgery (cabg)
coronary bypass grafting
coronary calcification in ckd
coronary calcification in low‑risk women
coronary calcium computed tomography (ct)
coronary calcium score (on ct)
coronary calcium score / coronary calcification
coronary calcium scoring in asymptomatic individuals
coronary care unit
coronary circulation
coronary circulation (implied by cardiac rhythm management studies)
coronary complications
coronary compression testing
coronary computed tomographic angiography (ccta)
coronary computed tomography angiography (ccta)
coronary computed tomography angiography (cta)
coronary computed tomography angiography (ctca)
coronary computed‑tomography (ct) angiography
coronary ct
coronary ct angiography
coronary ct angiography (ccta)
coronary ct angiography contraindications (active angina, documented ischemia, prior cad)
coronary ct angiography‑derived ffr (ct‑ffr)
coronary cta (computed tomography angiography)
coronary disease
coronary disease (general)
coronary disease management
coronary disease secondary prevention
coronary disease, ostial compression, ischemia
coronary dissections
coronary embolism
coronary endothelial function
coronary event
coronary events
coronary events (e.g., mi, unstable angina, revascularization)
coronary events (mi, stroke)
coronary events / coronary artery disease
coronary fistula
coronary fistula closure (surgical or catheter‑based)
coronary fistulas
coronary flow reserve (cfr)
coronary graft occlusion
coronary heart disease
coronary heart disease (chd)
coronary heart disease (chd) / coronary artery disease (cad)
coronary heart disease (implied by ascvd context)
coronary hemodynamics
coronary imaging follow‑up
coronary imaging in vhd
coronary intervention
coronary intervention (including transradial pci)
coronary intervention strategy
coronary intervention vs. bypass grafting outcomes
coronary intervention without revascularization
coronary interventions (percutaneous coronary intervention)
coronary ischemia
coronary ischemia / suspected coronary disease
coronary magnetic resonance imaging (cmr)
coronary malperfusion
coronary microcirculation (in the context of coronary pathophysiology)
coronary microvascular disease
coronary microvascular dysfunction
coronary microvascular dysfunction (cmd)
coronary microvascular endothelial inflammation
coronary microvascular resistance
coronary microvascular resistance indices
coronary obstruction
coronary ostial height
coronary ostial stenosis
coronary patency
coronary pathology
coronary perfusion deficit
coronary perfusion impairment
coronary physiology assessment (e.g., fractional flow reserve)
coronary physiology testing
coronary plaque
coronary plaque assessment
coronary plaque burden
coronary plaque formation / coronary plaque stabilization
coronary plaque phenotype
coronary plaque rupture
coronary reimplantation
coronary reimplantation (surgical technique)
coronary reintervention
coronary reperfusion
coronary reperfusion / revascularization
coronary revascularization
coronary revascularization (pci/cabg)
coronary revascularization (percutaneous coronary intervention, pci)
coronary revascularization / coronary artery bypass grafting
coronary revascularization outcomes (e.g., survival advantage, quality‑of‑life, angina relief)
coronary revascularization procedures
coronary risk factors
coronary risk modification
coronary risk scores
coronary risk stratification.
coronary risk‑factor management
coronary sinus occlusion
coronary sinusoids
coronary slow flow phenomenon
coronary steal phenomenon
coronary stenosis
coronary stenosis (≥50 %)
coronary stent
coronary stent implantation
coronary stenting
coronary stenting (drug‑eluting stent, bare‑metal stent)
coronary syndrome
coronary syndromes
coronary thrombosis
coronary thrombosis / stent thrombosis
coronary thrombus
coronary thrombus resolution
coronary unroofing
coronary unroofing (surgery)
coronary vasculopathy
coronary vasodilator capacity
coronary vasomotor dysfunction
coronary vasorelaxation
coronary vasospasm
coronary vasospasm treatment
coronary vessel anomalies
coronary angiography
coronary artery bypass grafting (cabg)
coronary artery bypass graft survival
coronary artery bypass surgery (cabg)
coronary artery disease (cad)
coronary artery disease management
coronary artery disease treatment trials (ischemia, courage, stich, fame, etc.)
coronary disease adverse events (ami, death, survival)
coronary disease clinical outcomes
coronary disease complex stenoses
coronary disease cost‑effectiveness
coronary disease diabetes mellitus impact
coronary disease evidence‑based guidelines (acc/aha/acc, etc.)
coronary disease invasive vs. conservative strategy
coronary disease meta‑analysis
coronary disease multivessel disease
coronary disease percutaneous vs. surgical outcomes
coronary disease quality‑of‑life outcomes
coronary disease revascularization decision making
coronary disease stable patients
coronary artery disease evaluation
coronar​ry artery calcium (cac)
coronatory artery calcium as a prognostic tool
coronavirus disease‑2019 (covid‑19)
coronavirus disease 2019 (covid‑19)
coro​nary artery bypass grafting (bypass)
coro​nary events
corrected coa gradient >20 mm hg
correlation of risk (cor)
corrigan minehan heart center
corticosteroids (steroids)
cor tiatriatum sinister








cost
cost and value considerations
cost and value considerations in cardiovascular therapy
cost and value of prevention
cost estimates
cost of care
cost of treating icd patients
cost/value methodology (in cardiovascular guideline development)
cost‑effective medical management strategies.
cost‑effective screening of relatives
cost‑effectiveness
cost‑effectiveness (cost‑per‑qaly, <$50,000/qaly)
cost‑effectiveness (qalys, incremental cost‑effectiveness ratio)
cost‑effectiveness / cost‑efficiency
cost‑effectiveness / cost‑saving of lipid‑lowering therapy
cost‑effectiveness / incremental cost‑effectiveness ratio (icer)
cost‑effectiveness / value assessment (high/intermediate)
cost‑effectiveness / value in cardiovascular care
cost‑effectiveness analysis
cost‑effectiveness analysis (of aneurysm screening)
cost‑effectiveness evaluation
cost‑effectiveness in cardiovascular care
cost‑effectiveness modeling
cost‑effectiveness of af treatment
cost‑effectiveness of aortic interventions
cost‑effectiveness of aortic screening
cost‑effectiveness of aortic treatment
cost‑effectiveness of cardiac devices
cost‑effectiveness of collaborative care in cardiology
cost‑effectiveness of mcs strategies
cost‑related medication non‑adherence
cost‑saving approaches (mail order pharmacy, patient assistance programs)
cost‑utility
cost‑value analysis
cost‑value analysis of cardiac drugs and devices
cost‑value considerations
cost–value considerations
cough (acei side effect)
counseling and management of aortic disease in pregnancy and postpartum
counterclockwise afl
counterclockwise and clockwise reentrant directions
courage trial
covadis diagnostic criteria (coronary vasomotion disorders international study group)
coverage not extending to t8
covered stent exclusion
covered stents
covid‑19 / sars‑cov‑2 infection
covid‑19 cardiovascular comorbidities / outcomes
covid‑19 myocarditis / vaccine‑related myocarditis
covid‑19 related cardiac involvement
covid‑19 vaccination
covid‑19 vaccination (as a preventive measure for cardiovascular risk)
covid‑19 vaccination (sars‑cov‑2)
covid‑19‑associated cardiotoxicity
covid‑19‑related myocardial injury
covid‑19–associated thrombosis
cox maze procedure
coxibs
cox‑2 inhibitors
cox‑2 selective inhibitors
co‑surgeon model (achd + acquired disease)
cpet (cardiopulmonary exercise testing)
cr – cardiac rehabilitation
craniosynostosis
crawford classification of taaa
crcl (creatinine clearance)
creatine kinase elevation
creatine kinase mb (ck‑mb)
creatine kinase mm (ck‑mm)
creatine kinase‑myocardial band (ck‑mb)
creatinine
creatinine clearance
creatinine clearance (crcl)
creatinine clearance (crcl) (relevant to drug dosing in cardiovascular therapy)
critical care / acute medical illness or surgery
critical care stages: diagnosis, palliative interventions, transfer to achd, lifelong achd care, reinterventions
critical diagnostic distinction (transvalvular vs. paravalvular)
critical illness
critical illness (in the context of af)
critical leg ischemia prevention (clips) trial
critical limb ischemia
critical limb ischemia (cli)
critical limb ischemia (cli) perfusion assessment
critical limb ischemia (cli/clti)
critical limb ischemia (clti)
critical limb ischemia (clti/cli)
critical limb ischemia / critical limb threatening ischemia (clti)
critical limb ischemia management guidelines
critical limb threatening ischemia (clti)
critical limb-threatening ischemia (clti)
critical limb‑threatening ischemia (clti)
critical time metrics: fmc‑to‑first‑device ≤90 min
critical‑care atrial fibrillation
critical‑care cardiology
crossover rate in trials
cross‑clamp time
cross‑clamp times
cross‑clamp use
cross‑sectional aortic area to height ratio
cross‑sectional area to height ratio
cross‑sectional imaging
cross‑sectional imaging (e.g., ct/mri)
cross‑sectional imaging (for distant pulmonary venous connections)
cross‑sectional imaging of aortic arch and pulmonary arteries
crt (cardiac resynchronization therapy)
crt cost‑effectiveness
crt‑d (crt with defibrillation)
crt‑d (crt with defibrillator)
crt‑defibrillator
crt‑p (crt pacemaker)
crt‑p (crt with pacemaker)
cryoablation
cryoballoon ablation
cryoballoon ablation feasibility in achd
cryoballoon ablation of afl
cryoballoon pulmonary vein isolation (pvi)
cryopreserved allografts
cryopreserved aortoiliac allograft
cryopreserved arterial allograft
cryptogenic stroke
cs – cardiac sarcoidosis
ct (computed tomography)
ct (computed tomography) angiography
ct angiography
ct angiography (cta)
ct aortic valve calcium scoring
ct imaging
ct imaging (4‑d ct)
ct or angiographic imaging for cad exclusion.
ct scan
ct, mri, and echocardiographic imaging of the aorta
ctaf trial (canadian trial of atrial fibrillation)
cti (cave‑to‑tricuspid isthmus) ablation
cti‑dependent atrial flutter
ctn – cardiac troponin
culprit artery only revascularization
culprit lesion
culprit lesion only pci vs. multivessel pci
culprit lesion pci / culprit‑only pci
culprit vessel
culprit‑only pci
culprit‑shock trial
cultural humility
culture‑negative endocarditis
cumulative radiation exposure
cumulative survival rates
cure trial (clopidogrel in unstable angina to prevent recurrent events)
current atherosclerosis reports
current cardiology reports
current evidence and future directions in myocarditis and inflammatory cardiomyopathy
current procedural terminology (cpt) codes (used in cardiovascular coding)
current smoking
current tobacco smoking
customized footwear (pressure‑offloading)
customized grafts
cutaneous stigmata
cvd (cardiovascular disease)
cvd death
cvd events
cvd – cardiovascular disease
cvd‑real study
cvrx
cvrx (cardiovascular research/therapy company)
cyanide toxicity
cyanosis
cyanosis (atrial‑level right‑to‑left shunting)
cyanosis (blue/purple discoloration, ≥ 5 g/dl desaturated hb)
cyanosis (cyanotic achd)
cyanosis at rest or with exercise
cyanosis management
cyanosis‑associated exercise response
cyanotic cardiac defect
cyanotic congenital heart disease
cyanotic heart disease
cyanotic lesions
cyclophosphamide
cyclo‑oxygenase (cox) inhibitors
cyclo‑oxygenase‑2 inhibitors
cyp1a2
cyp2c19
cyp2c19 metabolism (clopidogrel activation)
cyp2c19 polymorphisms
cyp2c9
cyp2c9, cyp2d6, cyp3a (drug metabolism pathways relevant to cardiac drugs)
cyp2d6 metabolism
cyp3a4
cyp3a4 inducers (rifampin, phenytoin, phenobarbital, carbamazepine, st. john’s wort)
cyp3a4 inhibitors (ketoconazole, itraconazole, ritonavir)
cyp3a5
cystatin c
cystic adventitial disease
cytochrome p450 enzyme system (metabolism of clopidogrel)
cytochrome p450 polymorphisms
cytokinetics
c‑index (discrimination)
c‑reactive protein
c‑reactive protein (crp)
c‑reactive protein (crp) as a risk marker
c‑v wave (systolic positive wave)















dabigatran
dabigatran (direct thrombin inhibitor)
dabigatran etexilate
dabigatran vs warfarin trials (re‑align, engage, etc.)
dacron grafts
daiichi sankyo
dairy products
damage to the sinoatrial node
danblock
danger‑shock trial
danish (defibrillator implantation in patients with non‑ischemic systolic heart failure)
danish verapamil infarction trial (davit ii)
danon cardiomyopathy
danon disease
dapagliflozin
dapagliflozin therapy (heart failure)
dapagliflozin.
dapa‑hf (dapagliflozin)
dapa‑hf trial
dapa‑hf trial (dapagliflozin and prevention of adverse outcomes in heart failure)
dapt duration after cabg
dapt duration in the first 12 months post‑discharge
dapt risk score
dapt strategy guidelines (section 11.1)
dapt – dual antiplatelet therapy
darbepoetin α
dash (dietary approaches to stop hypertension) diet
dash (dietary approaches to stop hypertension) diet / dash eating plan
dash diet
dash diet (dietary approaches to stop hypertension)
dash dietary pattern (dietary approaches to stop hypertension)
dat (dual antithrombotic therapy)
data collection and sharing in stemi care
data‑driven quality improvement.
david procedure
daytime sleepiness
dcm (dilated cardiomyopathy)
dcrv (abbreviation)
dcrv (double‑chambered right ventricle)
de novo coronary lesions
deactivation of icd
death
death (all‑cause or cardiovascular)
death / sudden cardiac arrest
debakey classification
debakey classification (system)
debakey classification of aortic dissections
debranching
decision aid
decision aids
decision aids (e.g., pci choice)
decision aids for aneurysm treatment
decision aids for prosthetic valve selection
decision aids for shared decision‑making
decision algorithms for physicians and heart valve teams
decision criteria for valve replacement in symptomatic patients
decision support aids
decision support framework
decision‑making algorithm
decision‑making in valvular heart disease (shared decision‑making)
declare‑timi 58 trial
declining hepatic function
declining renal function
decompensated aortic stenosis (emergency treatment)
decompensated heart failure
decompensated heart failure (adhf)
decompensated heart failure (hf)
decompensation (hf decompensation)
deconditioning
decongestion strategy
decopi (desobstruction coronaire en post‑infarctus)
decreased exercise tolerance
deep hypothermic circulatory arrest
deep vein thrombosis (dvt)
deep venous arterialization
defer study
defibrillation
defibrillation (dual‑defibrillator use)
defibrillation / icd shock
defibrillation threshold
defibrillation threshold / testing
defibrillator
defibrillator for primary prevention of sudden death
defibrillator implantation
defibrillator in acute myocardial infarction trial (dinamit)
defibrillator shocks
defibrillators
definite myocarditis
defint (defibrillators in non‑ischemic cardiomyopathy treatment evaluation)
degenerative aneurysm
degenerative leaflet prolapse
degenerative mitral disease
degenerative mitral regurgitation
degenerative mitral stenosis
degenerative mitral‑valve disease
degenerative taaa
delayed afterdepolarization
delayed afterdepolarizations (dads)
delayed contrast‑enhanced imaging protocol
delayed coronary angiography
delayed enhancement mri
delayed hyperenhancement
delayed invasive strategy
delayed surgery (post‑ami)
delayed surgery for vsr with mechanical circulatory support
delayed‑enhancement magnetic resonance
deliver (dapagliflozin trial)
deliveries in a setting with cardiothoracic surgery available
delivery management in aortopathy
delivery of care
delivery planning in anticoagulated patients
delta hs‑ctn (change in troponin)
demand‑induced mi (type 2)
dementia
dementia (af‑related)
dementia multi infarct
dense continuous‑wave signal (triangular shape)
dental examination (infection source)
dental extraction
dental procedures (gingival manipulation, periapical manipulation, mucosal perforation)
dental-related bacteremia (antibiotic prophylaxis)

















depression
depression (as a cardiovascular comorbidity)
depression (as a cardiovascular risk factor)
depression (as a risk amplifier)
depression (as a risk factor for poor self‑care)
depression (as a risk factor)
depression (co‑morbid psychological factors)
depression (icd‑9/icd codes)
depression (impacting hf prognosis)
depression / depressive symptoms
depression and heart failure outcomes
depression in achd
depression in cardiac patients
depression in heart failure
depression, anxiety, and stress as cardiovascular risk factors
depression/anxiety in aortic patients
dermatologic toxicity (skin)
des (drug‑eluting stents)
desaturation with exercise
descending aorta
descending aorta aneurysm
descending aorta dilation
descending aortic aneurysm
descending aortic replacement
descending thoracic aorta
descending thoracic aorta aneurysm
descending thoracic aortic aneurysm
descending thoracic aortic aneurysm (taa)
desmoplakin (dsp)
desmoplakin (dsp) variants
desmoplakin cardiomyopathy
desmoplakin gene truncating variant
desmoplakin mutation
desmosomal genes
desmosomal protein mutations (e.g., pkp2, dsg2)
destination therapy
destination therapy (dt)
destination therapy strategy
destructive penetrating lesions
detection
determinants of myocardial infarction onset study
deto2x‑ami (efficacy and outcome study of supplemental oxygen treatment in mi) trial
development of independent skills (appointments, prescriptions, provider contact, insurance maintenance)
device
device (as used in cardiac therapy)
device bridging to transplant
device classification (cardiac devices)
device closure (pda closure)
device closure (transcatheter)
device erosion
device extraction
device implantation (cardiac/ep)
device indications
device infection
device lead implantation
device lead‑related tricuspid valve dysfunction
device management (pacemakers, defibrillators, etc.)
device migration, graft kink, graft migration
device placement
device selection considerations (icd, crt‑d, pacemaker)
device selection in aorto‑iliac arterial interventions
device surgery
device therapies (e.g., pacemakers, icd, crt)
device therapy
device therapy (e.g., pacemaker, implantable cardioverter‑defibrillator)
device therapy (permanent device)
devices (cardiovascular devices)
devices (medical devices)
device‑based cardiac therapy (e.g., pacemaker, icd)
device‑based therapy of cardiac rhythm abnormalities
device‑detected af
device‑detected arrhythmia duration
device‑detected atrial arrhythmia
device‑detected atrial fibrillation
device‑detected atrial fibrillation (device‑detected scaf)
device‑detected atrial high‑rate episodes
device‑detected atrial high‑rate episodes (ahre)
device‑detected subclinical atrial fibrillation
device‑related complications
device‑related endocarditis
device‑related thrombosis
device‑related thrombosis (e.g., watchman, lariat, plaao devices)
device‑related thrombus
dextrotransposition of the great arteries (d‑tga)
dextro‑tga after atrial switch (mustard/senning) operation
dextro‑tga after rastelli operation
dextro‑transposition of the great arteries (dtga)
dextro‑transposition of the great arteries (d‑tga)
dextro‑transposition of the great arteries (tga) after arterial switch operation
de‑escalation of dapt
de‑escalation strategy (switching p2y12 inhibitors)
de‑escalation strategy (switching to clopidogrel)
de‑xtro‑transposition of the great arteries (d‑tga)










diabetes
diabetes (as a cardiovascular risk factor)
diabetes (as a cardiovascular risk‑modifier)
diabetes (as a pad comorbidity)
diabetes (comorbidity)
diabetes (in the context of cardiac care)
diabetes (type 1 and type 2)
diabetes (type 2)
diabetes / diabetes mellitus
diabetes care
diabetes care (as a cardiovascular risk modifier)
diabetes in heart failure
diabetes management
diabetes management (as a key cardiovascular risk factor)
diabetes management (in pad)
diabetes management (sglt‑2 inhibitors, glp‑1 receptor agonists)
diabetes management (type 2 diabetes)
diabetes management in pad (pm‑3)
diabetes management – standards of care
diabetes medication
diabetes mellitus
diabetes mellitus (as a cad risk factor)
diabetes mellitus (as a cardiovascular risk factor)
diabetes mellitus (as a comorbid condition in heart disease)
diabetes mellitus (as a modifier of pad severity)
diabetes mellitus (as a risk factor)
diabetes mellitus (as comorbidity)
diabetes mellitus (cardiovascular risk)
diabetes mellitus (dm, specifically type 2 dm – t2dm)
diabetes mellitus (fpg ≥7.0 mmol/l or on hypoglycemic agents/insulin)
diabetes mellitus (general)
diabetes mellitus (in the context of coronary disease)
diabetes mellitus (risk factor for hf)
diabetes mellitus (risk factor)
diabetes mellitus (type 2)
diabetes mellitus (type 1 & type 2)
diabetes mellitus (type 1 and type 2)
diabetes mellitus (type 1 and 2)
diabetes mellitus / blood glucose
diabetes mellitus type 2 and cardiovascular risk
diabetes mellitus type 2 and its interaction with hf
diabetes mellitus type 2
diabetes mellitus type 2
diabetes mellitus type 2 (as a cardiovascular risk factor)
diabetes mellitus type 2 (in relation to coronary disease)
diabetes mellitus type 2 (t2dm)
diabetes mellitus with coronary involvement
diabetes mellitus—impact on ischemia prognosis
diabetes type 2 – prevention of cardiovascular disease
diabetes with poor glycemic control – a key modifiable risk factor for cardiovascular disease
diabetes‑associated neuropathy
diabetes‑related ascvd risk
diabetes‑related cad management (bari‑2d, type‑2 diabetes interventions)
diabetes‑related cardiovascular prevention
diabetes‑related cardiovascular risk
diabetes‑related vascular disease
diabetes‑specific risk enhancers:
diabetic coronary artery disease
diabetic foot ulcer
diabetic foot ulcer (dfu)
diabetic foot ulcers
diabetic neuropathy
diabetic neuropathy (implied comorbidity)
diabetic retinopathy
diagnosis
diagnosis / detection of pad
diagnosis and management
diagnosis and management guidelines (for af)
diagnosis and management of atrial fibrillation
diagnosis and management of chest pain
diagnosis and management of stable ischemic heart disease
diagnosis of heart failure
diagnostic / risk assessment terms
diagnostic accuracy
diagnostic accuracy (95% for sac diameter, 100% for type i/iii endoleaks)
diagnostic accuracy (>90%)
diagnostic accuracy of ambulatory devices
diagnostic accuracy of bnp assays
diagnostic accuracy of handheld ecgs
diagnostic accuracy of smart gadgets/wearables
diagnostic accuracy studies
diagnostic algorithm for hf
diagnostic algorithm for hf classification
diagnostic algorithm for hf classification according to lvef
diagnostic and interventional heart catheterization
diagnostic and treatment strategies for specific dilated cardiomyopathies
diagnostic approaches for coronary disease
diagnostic biomarkers for heart failure
diagnostic challenges
diagnostic clarification
diagnostic criteria
diagnostic criteria for endocarditis
diagnostic criteria for infective endocarditis
diagnostic evaluation
diagnostic hemodynamic cardiac catheterization
diagnostic imaging
diagnostic imaging adjuncts (ct, pet/ct)
diagnostic imaging for coronary and cerebral circulation in coarctation
diagnostic imaging for pad
diagnostic imaging of the aorta
diagnostic imaging: transthoracic echocardiography (tte)
diagnostic indices:
diagnostic laboratory tests
diagnostic monitoring (electrophysiologist’s evaluation, ambulatory rhythm monitoring)
diagnostic performance of troponin assays
diagnostic predictive models (e.g., hcm‑af score)
diagnostic radiologist
diagnostic sensitivity (>90%)
diagnostic specificity
diagnostic specificity (60–90%)
diagnostic testing
diagnostic testing & follow‑up
diagnostic testing (cardiology)
diagnostic testing (e.g., echocardiography, cardiac catheterization)
diagnostic testing (imaging, functional testing)
diagnostic testing (repeat echocardiogram, staged pci)
diagnostic testing for cardiovascular disease
diagnostic testing for hcm
diagnostic testing for heart disease
diagnostic testing for pad
diagnostic testing: changing signs or symptoms
diagnostic thresholds for hs‑ctn
diagnostic transthoracic echocardiography (tte)
diagnostic work‑up for cryptogenic stroke
diameter of aorta (cm)
diameter threshold for intervention (≤ 5.0 cm)
diamond trial
diamond‑forrester probability model (coronary artery disease assessment)
diaphragm
diastolic (preserved‑ejection) heart failure
diastolic (preserved‑ejection‑fraction) heart failure
diastolic abnormalities
diastolic blood pressure
diastolic blood pressure (dbp)
diastolic bp (dbp)
diastolic compliance
diastolic dysfunction
diastolic dysfunction / diastolic heart failure
diastolic dysfunction / impairment
diastolic dysfunction, asymptomatic
diastolic filling interval
diastolic filling period
diastolic forward flow in abdominal aorta
diastolic function
diastolic heart failure
diastolic heart failure (hfpef)
diastolic left‑ventricular (lv) filling time
diastolic parameters
diastolic pressure half‑time
diastolic tail in descending aorta
diclofenac
diet
diet (as a cardiovascular risk factor)
diet / diet therapy (healthy diet)
diet / diet therapy / dietary supplements
diet and dietary supplementation
diet modifications (low‑sodium, heart‑healthy)
diet quality (nutrient composition, fiber)
diet/healthy diet
dietary advice / restrictions
dietary carbohydrate
dietary cholesterol
dietary factors
dietary fat
dietary fat intake (total, saturated, trans)
dietary fats
dietary fiber
dietary fiber intake
dietary habits
dietary pattern for heart health (e.g., mediterranean diet)
dietary patterns
dietary potassium intake
dietary potassium supplementation
dietary restrictions
dietary sodium
dietary sodium (risk factor for heart disease)
dietary sodium and potassium intake/excretion
dietary sodium content
dietary sodium reduction
dietary sodium reduction trials (e.g., 2001 n engl j med study)
dietary sodium restriction
dietary supplement use and cardiovascular risk
dietary supplementation
diethylpropion
dietitians
diffuse aortic root and ascending aortic dilation
diffuse atherosclerotic lesions
diffuse lesions
diffuse myocardial fibrosis
diffuse st‑segment elevation
diffuse thickening (aortitis)
diffusing capacity for carbon monoxide
diflunisal (repurposed)
dig trial (digitalis investigation group)
digital arteries
digital care transformation in cardiovascular health
digital health
digital health interventions (for transition of care)
digital health monitoring
digital health platforms
digital health solutions
digital health tools
digitalis
digitalis (digoxin) – renal clearance and toxicity at >1.2 ng/ml
digitalis therapy (digoxin)
digoxin
digoxin (antiarrhythmic)
digoxin (cardiac glycoside)
digoxin (low dose initiation, serum concentration monitoring)
digoxin (rate‑control agent)
digoxin toxicity
dihomo‑γ‑linolenic acid (dha)
dihydropyridine calcium channel blockers
dihydropyridine calcium channel blockers (ccbs)
dihydropyridine ccb (e.g., amlodipine, nifedipine)
dilated cardiomyopathy
dilated cardiomyopathy (dcm)
dilated cardiomyopathy (implied in hf context)
dilated cardiomyopathy (in genetic context)
dilated cardiomyopathy genes
dilated main pulmonary artery (pa)
dilated or dysfunctional cardiac chambers
dilated phase of hypertrophic cardiomyopathy
dilated pulmonary arteries (pas)
dilated right atrium (ra)
dilated right ventricle (rv)
dilated‑phase hypertrophic cardiomyopathy
diltiazem
diltiazem (av‑nodal blocker)
diltiazem (intravenous)
diltiazem (nondihydropyridine calcium channel blocker)
diltiazem (nondihydropyridine calcium‑channel blocker)
diltiazem post‑infarction therapy
diltiazem therapy
diltiazem, calcium‑channel blocker
dipeptidyl peptidase‑4 (dpp‑4) inhibitors (saxagliptin, alogliptin)
direct aortic cannulation
direct aortic cannulation (tee‑guided seldinger)
direct current cardioversion
direct current cardioversion / electrical cardioversion
direct factor xa inhibitors
direct oral anticoagulant (doac)
direct oral anticoagulant pharmacodynamics
direct oral anticoagulant pharmacokinetics
direct oral anticoagulants
direct oral anticoagulants (dabigatran, rivaroxaban, apixaban, edoxaban)
direct oral anticoagulants (doac)
direct oral anticoagulants (doacs)
direct oral anticoagulants (doacs) – apixaban, dabigatran, edoxaban, rivaroxaban
direct oral anticoagulants (doacs) – apixaban, dabigatran, rivaroxaban, edoxaban
direct oral anticoagulants (doacs) – e.g., rivaroxaban
direct oral anticoagulants (doacs) – noted as “non‑vitamin k oral anticoagulation”
direct oral anticoagulants (doacs):
direct oral anticoagulants (noacs)
direct pah therapy
direct renin inhibitors
direct thrombin inhibitor
direct thrombin inhibitor (dabigatran)
direct thrombin inhibitors
direct vs. indirect angiosomal revascularization
direct‑acting oral anticoagulants (doac)
direct‑acting oral anticoagulants (doacs)
direct‑current ablation
direct‑current cardioversion (dccv)
discharge education
discharge medications
discharge planning
discharge risk scoring models (elan‑hf, escape)
discrete lesions
discrete subaortic stenosis
disease / pathophysiology terms
disease burden
disease continuum in af
disease mechanisms
disease penetrance
disease progression
disease progression therapy
disease staging (stage a; stage b; stage c; stage d)
disease‑management programs
disease‑modifying anti‑rheumatic drug
disease‑modifying anti‑rheumatic drugs (dmards)
disease‑modifying therapies for attr – ttr silencers (inotersen, patisiran)
disease‑modifying therapies – ttr disruptors (doxycycline, tauroursodeoxycholic acid [tudca], epigallocatechin‑3‑galate [egcg])
disease‑modifying therapies – ttr stabilizers (diflunisal, tafamidis)
disease‑related morbidity and mortality in adults
disease‑specific risk scores
disodium edta (chelation therapy)



















disopyramide
disopyramide therapy
disparities (in care, outcomes, access)
disparities in care
dispersion of repolarization
disproportionate functional mitral regurgitation
dissected intima septum
dissecting aneurysm
dissection
dissection at a small aortic diameter
dissection flap
dissection flap (definition)
disseminated cortical superficial siderosis
distal aorta
distal aortic arch repair
distal aortic enlargement / reoperation
distal aortic extension
distal ascending aorta
distal branch perfusion
distal convoluting tubule
distal embolization
distal flow reversals
distal main pulmonary artery (pa)
distal subclavian artery
distance between left coronary ostium and neopulmonary artery
distance to care / travel distance
distance to clinic
distention
distribution curve of aortic size
diuretic
diuretic dose escalation
diuretic escalation (> 160 mg/day furosemide equivalent)
diuretic escalation (hf therapy)
diuretic medications
diuretic optimization
diuretic resistance
diuretic strategies (decongestion strategy)
diuretic synergism
diuretic therapy
diuretic therapy and sodium‑resorption suppression
diuretic therapy monitoring
diuretic treatment
diuretic use
diuretics
diuretics (e.g., furosemide)
diuretics (furosemide, metolazone)
diuretics (furosemide, ultrafiltration, aquapheresis)
diuretics (loop diuretics)
diuretics (titration)
diuretics (titration, adjustment)
diuretics and decongestion strategies
diuretic‑refractory congestion
dizziness
dkcrush‑iii study
dkcrush‑v trial
doac (direct oral anticoagulant)
doac – direct oral anticoagulant
dobutamine
dobutamine challenge (dobutamine stress test)
dobutamine challenge / dobutamine echocardiography
dobutamine echocardiography
dobutamine infusion
dobutamine infusion (chronic dobutamine)
dobutamine infusion (low‑flow states)
dobutamine stress doppler hemodynamics
dobutamine stress echocardiography
dobutamine stress echocardiography (dse)
dobutamine stress echocardiography (se)
dobutamine stress testing
docosahexaenoic acid (dha)
dofetilide
dofetilide (antiarrhythmic)
dofetilide therapy
dominant left vertebral artery
donor allocation policy
donor heart allocation
donor heart allocation system (2018 revision)
donor‑recipient size match
door‑in–door‑out time
door‑to‑balloon time
dopamine
dopaminergic receptor stimulation
dopamine‑agonist therapy
doppler assessment
doppler beam alignment/velocity jet
doppler color flow mapping
doppler device
doppler echocardiography
doppler echocardiography (rest, exercise, upright)
doppler echocardiography (surgical timing)
doppler echocardiography (velocity, gradient measurement)
doppler echocardiography assessment
doppler echocardiography measurements
doppler flow velocity
doppler hemodynamics
doppler imaging
doppler mean gradient >20 mm hg
doppler spectral signal characteristics
doppler ultrasonography (continuous‑wave doppler)
doppler ultrasound
doppler velocity and gradient across the right ventricular outflow tract
doppler velocity data
doppler waveforms
doppler waveforms (continuous‑wave doppler)
doppler waveforms (lower extremity arterial)
doppler‑based valve area
doppler‑catheter correlation
dormant conduction
dorsalis pedis pulse
dosage and medication interactions
dose adjustment
dose trial
dose trial (diuretic optimization strategies evaluation)
dose‑adjusted anticoagulation
dose‑adjusted lmwh
dose‑adjusted lmwh dosing
dose‑adjusted ufh
dose‑adjusted warfarin
dose‑response
dose‑response relationship (high‑quality carbohydrate intake)
dose‑response relationship (saturated fat reduction)
dose‑response relationship to ascvd events and death.
dose‑response to low‑dose dopamine / nesiritide
double density appearance within the aorta
double valve replacement (avr + mitral valve replacement)
double‑chamber right ventricle
double‑chambered right ventricle
double‑chambered right ventricle (dcrv)
double‑chambered right ventricle (dcrv)
double‑orifice mitral valve
double‑outlet right ventricle (dorv)
double‑outlet ventricle
double‑switch operation
down syndrome
down syndrome (trisomy 21)
downsized annuloplasty repair
downstream long‑term consequences of af
doxazosin
doxycycline plus ursodeoxycholic acid (tau)
dpp‑4 inhibitors (saxagliptin, alogliptin, sitagliptin, linagliptin) – hf risk
dressler’s syndrome
dronedarone
dronedarone (antiarrhythmic)
dronedarone (anti‑arrhythmic)
dronedarone therapy in severe heart failure
drug
drug (as used in cardiac therapy)
drug classification (cardiac therapy)
drug interactions
drug interactions (e.g., with amiodarone, digoxin, warfarin, statins)
drug interactions (p‑glycoprotein, cyp3a4 inducers/inhibitors)
drug interactions with opiates and oral p2y12 inhibitors
drug peak trough levels after bariatric surgery
drug potency (clopidogrel vs prasugrel vs ticagrelor)
drug therapy
drug therapy (for arrhythmia)
drug treatment regimens
drug/alcohol concomitancy
drug‑coated balloon angioplasty
drug‑coated balloons (dcb)
drug‑drug interaction
drug‑drug interactions affecting cardiac rhythm (e.g., with warfarin, digoxin, statins, anti‑arrhythmics)
drug‑drug interactions affecting statin use
drug‑drug interactions between cancer therapies and anticoagulants
drug‑drug interactions with cardiovascular therapies
drug‑drug interactions with doacs
drug‑eluting stent
drug‑eluting stent (des)
drug‑eluting stents
drug‑eluting stents (des)
drug‑eluting stents (e.g., everolimus‑eluting)
drug‑eluting stents (implicit in pci)
drug‑induced arrhythmias
drug‑induced heart failure
drug‑induced lung toxicity
drug‑induced torsades de pointes
drug‑induced tr
drug‑prescription antiplatelet therapy (dapt)
drug‑tolerability
drug‑use associated endocarditis (dua)
drug‑use‑associated endocarditis
drug–drug interaction
drug–drug interactions
dual antiplatelet therapy
dual antiplatelet therapy (aspirin + clopidogrel)
dual antiplatelet therapy (dapt)
dual antiplatelet therapy (dapt) duration after pci
dual antiplatelet therapy (dapt) – aspirin + p2y12 inhibitor
dual antiplatelet therapy discontinuation (p2y12 inhibitor discontinuation)
dual antiplatelet therapy duration
dual antiplatelet therapy during hospitalization (oral p2y12 inhibitors)
dual antiplatelet therapy in acs
dual antiplatelet therapy in coronary artery disease
dual antiplatelet therapy in the first 12 months post‑discharge
dual antiplatelet therapy (dapt)
dual antithrombotic therapy
dual antithrombotic therapy (dat)
dual antithrombotic therapy (oac + p2y12 inhibitor)
dual pah therapy
dual sglt2i/sglt1i therapy in hf
dual therapy (oac plus apt)
dual up‑front pah therapy
dual‑acting inhibitor of angiotensin ii receptor and neprilysin
dual‑antiplatelet therapy
dual‑antiplatelet therapy (dapt)
dual‑antiplatelet therapy (e.g., aspirin + clopidogrel)
dual‑chamber icd
dual‑chamber pacing
dual‑chamber pacing system
dual‑coil icd lead
dual‑coil icd leads
dual‑energy x‑ray absorptiometry (dxa)
dual‑organ transplantation (heart‑kidney, heart‑liver)
dual‑site ventricular pacing
ductal anatomy
ductus arteriosus (including patent ductus arteriosus)
ductus closure tolerability
duke clinical research institute (dcri)
duke criteria
duke heart center
duke treadmill score
duke treadmill score (dts)
dulaglutide
duplex ultrasound
duplex ultrasound (vascular laboratory)
duplex ultrasound (with or without contrast) – specific for endoleaks, limited for stent migration/fracture
duplex ultrasound surveillance
duplex ultrasound surveillance (dus)





















durability
durability beyond 5–6 years
durability of repair/replacement
durable left ventricular assist device (lvad)
durable lvad
durable lvad or transplant pathways
durable mcs
durable mcs (lv or biventricular support)
durable mcs / destination therapy
durable mechanical circulatory support (mcs)
durable prosthetic valves (tavi & surgical)
duration of af/ahre (≤5 min, ≥24 h, intermediate)
duration of dual antiplatelet therapy (3 , 6 , 12 , 24 months)
duration of symptoms (acute vs chronic)
dusp13
dynamic intraventricular obstruction
dynamic lv obstruction
dynamic lvot gradient at rest or provocation
dynamic lvot obstruction (lvoto)
dynamic lvoto
dynamic lvoto detection and quantification
dynamic obstruction
dynamic resistance exercise
dynamic st‑segment changes
dyskinesia (mentioned in context of sodium zirconium cyclosilicate)
dyskinetic area
dyslipidemia
dyslipidemia (triglycerides, ldl‑c, hdl‑c)
dyslipidemia / high‑cholesterol / lipid management
dyslipidemia / hyperlipidemia
dyslipidemia / hyperlipidemia / hypertriglyceridemia / blood cholesterol
dyslipidemia management
dyslipidemia – overall cholesterol/lipid disorders
dysmorphic features
dysphagia
dysphagia (esophageal compression)
dysphagia aortica
dysphnea (dyspnea)
dysplastic pulmonary valve cusps
dyspnea
dyspnea (symptom)
dyspnea (tracheal compression, heart failure)
dyspnea / exertional dyspnea
dyspnea / shortness of breath
dyspnea on exertion
dyspnea paroxysmal
d‑dimer
d‑dimer (threshold <500 ng/ml)
d‑sotalol
d‑tga (dextro‑transposition of the great arteries)
d‑transposition of the great arteries (d‑tga)











e/e′ ratio
e/e′ ratio (diastolic function parameter)
early (<1 year) vs late (>1 year) aspirin initiation
early (<2 years) vs late (>2 years) statin initiation
early advance notification to pci‑capable hospital
early age of disease onset
early aggressive invasive intervention for af (early‑af)
early aldosterone blockade
early and late survival after valve replacement
early anticoagulation strategies (short‑term, long‑term)
early aortic valve replacement
early change to oral antibiotic therapy for stable ie
early childhood (0‑12 years) chd care
early childhood cognitive and sensory impairments (associated with phenocopies)
early clinical course
early corrective surgery
early death reduction
early detection of cardiomyopathy
early detection of subclinical myocardial injury
early developmental outcome in single‑ventricle reconstruction
early discharge after pci/angioplasty
early discharge strategy
early eplerenone therapy
early follow‑up (within 7 days of discharge)
early follow‑up and lipid testing
early graft infection (≤3 months)
early initiation of oral beta‑blocker therapy
early intervention
early invasive strategy
early invasive vs. conservative strategy
early markers of myocardial dysfunction
early menopause
early menopause (before age 55 in men, before age 65 in women)
early onset sporadic tad
early postoperative atrial fibrillation
early postoperative complications
early post‑discharge follow‑up
early post‑mi period
early predictors of poor outcome after cardiac arrest (e.g., neurological recovery)
early presenters (≤3 hours after symptom onset)
early repair strategy
early reperfusion strategy
early repolarization pattern
early revascularization
early rhythm control
early rhythm‑control
early rhythm‑control strategies
early rhythm‑control therapy in atrial fibrillation
early satiety
early surgery
early surgery (during initial hospital course)
early surgery for severe aortic stenosis
early surgical intervention
early surgical intervention (nyha ii)
early surgical intervention / valve surgery
early surgical intervention post‑mi
early thrombosis
early thrombotic events
early transfer to specialized center
early versus delayed coronary angiography
early versus staged pci in cardiogenic shock
early vhd
early‑acs trial (early glycoprotein iib/iiia inhibition in non‑st‑elevation acs)
early‑age percutaneous balloon dilatation
early‑onset stroke
early‑stage hcm biomarkers
east‑afnet 4 trial
east‑afnet 4 study
east‑afnet 4 trial
ebstein anomaly
ebstein’s anomaly
eccentric hypertrophy
ecg (12‑lead electrocardiogram)
ecg (electrocardiogram)
ecg algorithm (r'' wave in v1 & terminal qrs vector in avf)
ecg conduction and repolarization abnormalities
ecg findings (pr‑segment depression, concave st elevation, dynamic t‑wave changes)
ecg interpretation criteria (st‑depression, st‑elevation, t‑wave changes)
ecg lead placement for posterior ischemia
ecg monitoring
ecg serial monitoring for nondiagnostic stemi
ecg – electrocardiogram
ecg‑gated acquisition
echo (echocardiography)
echo 3d tee (transesophageal echocardiography)
echocardiogram (normal vs abnormal)
echocardiogram (transthoracic echo)
echocardiogram (tte)
echocardiogram / transthoracic echocardiogram
echocardiogram adequacy
echocardiogram positive for ie
echocardiographer (valve disease expertise)
echocardiographic assessment
echocardiographic assessment (2‑d, 3‑d, doppler)
echocardiographic assessment (echo)
echocardiographic assessment of obstruction severity
echocardiographic assessment of valve stenosis
echocardiographic definitions
echocardiographic detection of vegetation size
echocardiographic diastolic parameters
echocardiographic doppler assessment
echocardiographic evaluation
echocardiographic features
echocardiographic features of pulmonary regurgitation
echocardiographic imaging
echocardiographic imaging (tte)
echocardiographic indices of rv dysfunction
echocardiographic inter‑observer concordance
echocardiographic left atrial diameter
echocardiographic measures (velocity, pressure gradients)
echocardiographic monitoring
echocardiographic parameters: left atrial diameter, lv outflow tract (lvot) gradient
echocardiographic predictors (non‑rheumatic af, lv mass, atrial size)
echocardiographic predictors of outcome
echocardiographic prognostic implications
echocardiographic quantification of valve disease
echocardiographic quantitative assessment
echocardiographic screening
echocardiographic screening in first‑degree relatives
echocardiographic sensitivity
echocardiographic specificity
echocardiographic strain imaging
echocardiographic strain imaging (tte strain)
echocardiography
echocardiography (2‑d & 3‑d)
echocardiography (2‑d and doppler)
echocardiography (2‑d echo)
echocardiography (2‑d, 3‑d, doppler)
echocardiography (2‑d, 3‑d, m‑mode, strain imaging, doppler)
echocardiography (2‑d, 3‑d, transesophageal)
echocardiography (as primary evaluation tool)
echocardiography (cardiac structure & function assessment)
echocardiography (echo)
echocardiography (for lv assessment)
echocardiography (including 3‑d, transesophageal, and imaging for ventricular strain)
echocardiography (including assessment of pulmonary and tricuspid valves, rvot, etc.)
echocardiography (including doppler)
echocardiography (including quantitative doppler)
echocardiography (including transesophageal)
echocardiography (including trans‑esophageal and stress doppler)
echocardiography (screening modality)
echocardiography (serial maternal and fetal imaging)
echocardiography (tee / tte, transthoracic / transesophageal)
echocardiography (transthoracic / transesophageal)
echocardiography (transthoracic and electrocardiogram)
echocardiography (transthoracic echocardiography, tte)
echocardiography (transthoracic)
echocardiography (transthoracic, doppler)
echocardiography (transthoracic, transesophageal)
echocardiography (transthoracic, transesophageal, agitated saline test)
echocardiography (transthoracic, transesophageal, m‑mode, speckle‑tracking)
echocardiography (tte, tee)
echocardiography (tte, tee, 3‑d tee, real‑time 3‑d tee)
echocardiography / doppler imaging
echocardiography / echocardiogram (echo)
echocardiography / exercise echocardiogram
echocardiography and doppler ultrasound in valve assessment
echocardiography – diastolic dysfunction
echocardiography – transthoracic doppler mean gradient
echocardiography‑guided srt
echo‑based assessment of valve function
ecls‑shock trial
ecmo‑cs randomized clinical trial
ecmo‑cs trial
economic analysis of heart failure treatments
economic evaluation of pci vs. medical therapy
economic stability / financial strain
economic value
economic value (intermediate)
economic value indicators: cost per qaly, incremental cost‑effectiveness ratio (icer)
economic value of cardiomems
economic value of cardiovascular therapies (cost per qaly)
economic value of therapy
ectopia lentis (clinical sign of marfan)
ectopic atrial beats
ed bypass to catheterization laboratory
edacs (emergency department assessment of chest pain score)
edema cardiac
edema control
edema despite diuretics
edge disease / edge dissection
edoxaban
educational interventions and training opportunities
educational interventions for providers/patients
educational status
edward life‑sciences
edwards lifesciences
edwards lifesciences (heart valve technology)
edwards lifesciences** (heart‑valve manufacturer)
ef (ejection fraction)
ef < 50 %
effect risk score (enhanced feedback for effective cardiac treatment)
effective orifice area
effective refractory period (erp)
effective regurgitant area (ero)
effective regurgitant orifice (ero)
effective regurgitant orifice (ero) (cm²)
effective regurgitant orifice (ero) (≥0.40 cm²)
effective regurgitant orifice (ero) area
effective regurgitant orifice area (ero)
effective regurgitant orifice area (eroa)
efficacy and safety of anticoagulation strategies
efficacy and safety of low‑dose colchicine after myocardial infarction
efficacy data
efficacy of antiarrhythmic drugs in achd
efficacy of rhythm‑control medications
efficacy studies
ef ≤ 40 %
egfr (estimated glomerular filtration rate)
egfr < 15 ml/min/1.73 m² (estimated glomerular filtration rate)
eggs
ehealth interventions for anxiety in aortic aneurysm surgery
ehlers‑danlos syndrome
ehlers‑danlos syndrome (vascular type)
ehlers–danlos syndrome (vascular type)
ehr (electronic health record)
eicosapentaenoic acid (epa)
eisenmenger physiology
eisenmenger physiology / eisenmenger syndrome
eisenmenger physiology / syndrome
eisenmenger syndrome
ejection fraction
ejection fraction (ef / lvef)
ejection fraction (ef)
ejection fraction (ef) / left ventricular ejection fraction (lvef)
ejection fraction (ef) assessment
ejection fraction (lvef)
ejection fraction (right‑ventricular, left‑ventricular)
ejection fraction assessment
ejection fraction improvement
ejection fraction measurement
ejection fraction recovery
elastic lamellae
elastic recoil
elastin arteriopathy
elastin fragmentation
elastin-specific autoimmunity
elder abuse
elderly
elderly (age ≥ 75 years) – risk factor in atria
elderly (≥ 75 years)
elderly age (≥ 65 years)
elderly status
elective aortic root replacement
elective ascending aortic replacement
elective cabg
elective non‑cardiac surgery
elective repair
elective surgery
elective thoracic aortic repair



















electocardiogram
electrical cardioversion
electrical complications of acs
electrical direct‑current cardioversion
electrical dyssynchrony
electrical fractionation
electrical instability
electrical posterior box isolation
electrical remodeling
electroanatomic mapping
electroanatomical mapping
electrocardiogram
electrocardiogram (ecg)
electrocardiogram (ecg) / electrocardiographic changes (st‑segment elevation)
electrocardiogram (ecg) / holter monitoring
electrocardiogram (ecg) follow‑up
electrocardiogram (ecg) interpretation
electrocardiogram (ecg) monitoring
electrocardiogram (ecg) – qrs duration, fragmentation, isthmus conduction
electrocardiogram monitoring
electrocardiogram qrs voltage
electrocardiogram‑gated coronary ct angiography
electrocardiographic (ecg) abnormalities
electrocardiographic (ecg) changes
electrocardiographic (ecg) monitoring
electrocardiographic abnormalities (ecg/ekg)
electrocardiographic abnormalities (irregular r‑r intervals, absent p waves, fibrillatory waves)
electrocardiographic biomarkers
electrocardiographic changes of ischemia or infarction
electrocardiographic features
electrocardiographic identification
electrocardiographic interpretation for suspected acs
electrocardiographic left ventricular hypertrophy
electrocardiographic monitoring
electrocardiographic monitoring (continuous ecg)
electrocardiographic monitoring (ecg)
electrocardiographic tracing interpretation
electrocardiographic tracings
electrocardiographic tracings / ecg
electrocardiographic‑gated cardiac ct
electrocardiographic‑gated imaging
electrocardiographic‑guided anticoagulation
electrocardiographic‑synchronized ct techniques
electrocardiography
electrocardiography (ecg)
electrocardiography (implied by diagnostic context)
electrocardiography / electrocardiogram (ecg)
electrode vector
electrode vector orientation – anterior‑posterior / anterior‑lateral
electrogenic action of the sodium‑calcium exchanger
electrolyte abnormalities
electrolyte balance
electrolyte management (hyper‑/hypokalemia) in hf
electrolyte monitoring
electrolyte monitoring in af patients
electrolyte monitoring in diuretic therapy
electrolytes monitoring
electromechanical atrial function
electronic cigarette effects
electronic cigarettes
electronic cigarettes (e‑cigarettes)
electronic cigarettes / e‑cigarettes / vape / vaping (ends)
electronic cigarettes / vaping
electronic clinical decision support systems
electronic consults
electronic health record (ehr)
electronic health record (ehr) – data source for cardiovascular assessment
electronic health records (ehr)
electronic health records and databases for monitoring care continuity
electronic medical record integration for risk scoring
electronic medical records (emr)
electronic nicotine delivery systems (ends)
electronic nicotine delivery systems (ends) – cardiovascular risk
electronic nicotine delivery systems (e‑cigarettes)
electronic point‑of‑care reminders (for gdmt)
electron‑beam computed tomography
electrophysiologic interventions
electrophysiologic procedures in achd
electrophysiologic remodeling
electrophysiologic studies (eps)
electrophysiologic study
electrophysiologic testing
electrophysiological (ep) study
electrophysiological ablation
electrophysiological abnormalities (electrical remodeling)
electrophysiological and structural remodeling of the atria
electrophysiological determinants of conversion efficacy
electrophysiological inducibility testing (burst pacing, adenosine challenge)
electrophysiological procedures
electrophysiological remodeling
electrophysiological study
electrophysiological study (eps)
electrophysiological study
electrophysiologist
electrophysiology
electrophysiology (arrhythmia, device implantation, ep study)
electrophysiology (catheter ablation, radiofrequency)
electrophysiology (ep) procedures
electrophysiology ablation
electrophysiology evaluation
electrophysiology in achd
electrophysiology interventions
electrophysiology procedures
electrophysiology study
electrophysiology study (eps) – programmed ventricular stimulation
electrophysiology study / invasive electrophysiology
electro‑cardiographic (implied) imaging of cardiac structures
electro‑cardiographic abnormalities (high‑grade atrioventricular block)
electro‑gram frequency analysis
electro‑mechanical dissociation
electro‑physiologic considerations in congenital heart disease
elephant trunk
elephant trunk procedure
elevated ascvd risk
elevated blood pressure
elevated blood pressure / high blood pressure
elevated b‑type natriuretic peptide (bnp)
elevated cardiovascular biomarkers
elevated erythrocyte sedimentation rate (esr) >50 mm/h
elevated filling pressures
elevated glucose
elevated gradient
elevated heart rate
elevated high‑sensitivity c‑reactive protein (hs‑crp)
elevated jugular venous pressure
elevated jugular venous pressure (jvp)
elevated lifetime ascvd risk
elevated liver‑function tests (adverse effect of ezetimibe)
elevated natriuretic peptide levels
elevated natriuretic peptides (bnp/nt‑probnp)
elevated pre‑therapy troponin (≥14 ng/l or >0.07 ng/ml)
elevated right heart pressure
elevated transaminases
elevated triglyceride levels
elevated triglycerides
elevated white‑blood‑cell count
elevated‑risk non‑cardiac surgery
eli lilly
elite (evaluation of losartan in the elderly) study
elite athletes / extreme exercise
eln gene (elastin) – elastin arteriopathy
elongated anterior mitral leaflet
elongated mitral valve leaflets
elsevier (clinical research)
embase
emboli
embolic complications of aortic plaques
embolic event
embolic events
embolic events (recurrent emboli)
embolic events (systemic emboli, stroke)
embolic potential
embolic risk
embolic stroke of undetermined source
embolisation
embolism
embolism prevention
embolization
embolization of thrombi
embolus
emerge trial
emergency action plans for sudden cardiac arrest in sport.
emergency aortic repair capability
emergency cardiovascular care
emergency central aortic repair
emergency coronary angiography
emergency department (ed)
emergency department (ed) management of chest pain
emergency department (ed) triage for acs
emergency department / acute care setting
emergency department decision‑making in hf
emergency department length of stay
emergency department visits
emergency department visits for anticoagulant‑related bleeding
emergency invasive strategy (<2 hours from admission)
emergency medical services
emergency medical services (ems)
emergency medical services (ems) personnel (paramedics)
emergency medical services (ems) transport
emergency revascularization
emergency revascularization strategy
emergency surgery
emerging lipid‑lowering therapies
emory heart and vascular center
empagliflozin
empagliflozin (emperor‑preserved trial)
empagliflozin (sglt2 inhibitor)
empa‑cardio (context of sglt2i trials)
empa‑reg outcome trial
emperor‑preserved
emperor‑preserved (empagliflozin trial)
emperor‑preserved study
emperor‑reduced
emperor‑reduced trial
emperor‑reduced trial (empagliflozin outcomes trial in patients with chronic heart failure with reduced ejection fraction)
ems transport for suspected acs
enalapril
enalapril (ace inhibitor)
enalapril (acei)
enalapril (ace‑inhibitor)
encainide
encephalopathy
end points: mortality, mace (major adverse cardiovascular events)
end-organ malperfusion
end-to-end anastomosis
endarterectomy
endarterectomy (common femoral)
endarteritis
endocardial ablation
endocardial cushion defect
endocardial cushion tissue
endocardial healing
endocardial imaging
endocardial involvement
endocardial leads
endocardial voltage mapping (evm)
endocarditis
endocarditis classification
endocarditis diagnosis
endocarditis guidelines (acc/aha, esc)
endocarditis mortality
endocarditis prophylaxis
endocarditis prophylaxis (antibiotic prophylaxis)
endocarditis risk evaluation
endocarditis risk in prosthetic valves (transcatheter or surgical)
endocarditis.
endocarditis‑related ar
endoconduit creation
endocrine therapy
endocrine toxicity (thyroid)
endocrine/metabolic conditions (diabetes, obesity, acromegaly, pheochromocytoma)
endocrinologist
endograft
endograft (branched/fenestrated)
endograft (endovascular repair)
endograft failure
endograft migration
endograft migration, fracture, or new non‑contiguous aneurysms
endograft sizing
endograft stenosis
endografting / endovascular repair
endoleak
endoleak (early and late)
endoleak (incl. type i, type ib)
endoleak (type i, type iii, any endoleak)
endoleak (type iia, type iii)
endoleak (type i / type ia)
endoleak (type i, type ii, type iii)
endoleak (type ia)
endoleak type ia (proximal attachment site)
endoleak type ib (distal attachment site)
endoleak type ii (backfilling through branch vessels)
endoleak type iii (graft defect or component misalignment)
endoleak type iv (leakage through graft wall porosity)
endoleak type v (endotension)
endoleaks
endoleaks (type i‑v)
endoluminal aortic aneurysm repair
endoluminal revascularization
endomyocardial biopsies
endomyocardial biopsy
endomyocardial biopsy (emb)
endomyocardial biopsy (risk)
endomyocardial voltage mapping (evm)
endoscopic procedures
endotension
endothelial disruption
endothelial dysfunction
endothelial dysfunction (implied by pad and atherosclerosis)
endothelial function
endothelial function tests
endothelial injury
endothelialization
endothelin receptor antagonist
endothelin receptor antagonist therapy
endothelin receptor antagonists
endothelin system
endothelin‑receptor antagonists
endothelin‑receptor antagonists (eras)















endovascular
endovascular (endovascular repair)
endovascular abdominal aortic aneurysm repair
endovascular abdominal aortic aneurysm repair (evar)
endovascular access
endovascular aneurysm repair
endovascular aneurysm repair (evar)
endovascular aneurysm repair (evar) vs. open repair
endovascular aneurysm repair (tevar)
endovascular aneurysm repair complications
endovascular aneurysm repair follow‑up
endovascular aortic aneurysm repair
endovascular aortic repair
endovascular aortic repair (evar)
endovascular aortic repair (revar / evar)
endovascular aortic repair (stent‑graft)
endovascular aortic repair (thoracic stent‑graft)
endovascular aortic repair for type b dissection with thoracoabdominal aneurysms
endovascular approach
endovascular balloon occlusion
endovascular balloon occlusion (reboa)
endovascular device repair
endovascular devices: balloon angioplasty, drug-coated balloon angioplasty, atherectomy
endovascular disease progression
endovascular era outcomes
endovascular experience
endovascular expertise
endovascular femoropopliteal intervention
endovascular fenestration
endovascular fenestration / stenting
endovascular fenestration / stenting first strategy
endovascular infection
endovascular infections
endovascular injury
endovascular intervention
endovascular intervention (angioplasty, stenting)
endovascular intervention / endovascular repair
endovascular intervention for aortic disease
endovascular intervention in symptomatic peripheral arterial disease
endovascular intervention timing
endovascular limb revascularization
endovascular management
endovascular management of aortic aneurysm
endovascular management of malperfusion syndromes in aortic dissection.
endovascular outcomes
endovascular procedure
endovascular procedures
endovascular repair
endovascular repair (evar)
endovascular repair (evar, tevar)
endovascular repair (including stent grafting)
endovascular repair (stent graft, endovascular treatment)
endovascular repair (tevar)
endovascular repair (thoracic/endovascular aortic repair)
endovascular repair / tevar (thoracic endovascular aortic repair)
endovascular repair complications (access‑site, embolic events)
endovascular repair of aaa
endovascular repair of complex aortic aneurysms
endovascular repair vs. open repair
endovascular revascularisation
endovascular revascularization
endovascular revascularization procedures
endovascular specialist
endovascular specialist competencies for clti care
endovascular stent graft
endovascular stent grafting
endovascular stent grafts
endovascular stenting
endovascular stenting of coa
endovascular stent‑graft complications
endovascular stent‑graft delivery system
endovascular stent‑graft repair
endovascular stent‑grafting
endovascular surgery
endovascular techniques
endovascular techniques (e.g., vessel stenosis treatment)
endovascular techniques (general)
endovascular techniques:
endovascular technology
endovascular therapies (general)
endovascular therapy
endovascular therapy (endovascular revascularization)
endovascular therapy (for type b dissection)
endovascular therapy for pad
endovascular therapy for penetrating ulcers
endovascular thoracic aortic repair (tevar)
endovascular thromboembolectomy
endovascular treatment
endovascular treatment (et)
endovascular treatment of common femoral artery stenosis
endovascular treatment of ruptured aorto‑iliac aneurysms
endovascular versus open repair outcomes
endovascular versus surgical management
endowed chair in cardiology
endo‑tronic (endovascular)
endo‑vascular therapy
endurance exercise
end‑diastolic pressure
end‑hole pigtail catheter
end‑of‑life care
end‑organ damage (hepatic failure, renal failure)
end‑organ damage (liver and kidney)
end‑organ damage criteria
end‑organ damage, cardiac
end‑organ damage/dysfunction (e.g., renal, hepatic)
end‑organ dysfunction
end‑organ dysfunction (right‑ventricular systolic dysfunction, left‑ventricular systolic dysfunction)
end‑organ dysfunction due to low cardiac output
end‑organ hypoperfusion
end‑organ injury
end‑organ ischemia
end‑organ malperfusion
end‑organ malperfusion (e.g., renal, cerebral)
end‑organ performance
end‑organ perfusion
end‑organ perfusion / end‑organ dysfunction
end‑stage cancer
end‑stage heart disease
end‑stage heart failure
end‑stage hypertrophic cardiomyopathy
end‑stage kidney disease (eskd / dialysis dependence)
end‑stage kidney disease (eskd)
end‑stage kidney disease (eskd) – an extreme ckd stage linked to vascular disease
end‑stage renal disease (esrd / eskd)
end‑stage renal disease (esrd)
end‑stage renal function (egfr < 25 ml/min/1.73 m²)
end‑systolic dimension (esd)
end‑systolic volume index (esvi)
end‑to‑end anastomosis
engage af‑timi 48 trial
enhanced external counterpulsation (eecp)
enlarged left atrial volume (≥73 ml) or diameter (≥4.7 cm)
enoxaparin
enoxaparin (low‑molecular‑weight heparin)
enrichd trial
enterococcal infection
enterococcus faecalis (e. faecalis) endocarditis
entrust‑af pci
entry tear location (lesser curvature)
entry tear size (> 10 mm)
entry tear zones (zone 0, zone 1, etc.)
environmental exposures (air pollution, pm₂.₅, noise, heat‑waves)
environmental factors influencing cardiomyopathy
environmental noise
environmental risk factors for aortic aneurysm
enzyme replacement therapy
enzyme replacement therapy (agalsidase β)
enzyme‑inducing antiseizure medications
eosinophil count
eosinophilic myocarditis
eosinophils
ep research foundation
epa/dha plasma levels
epicardial ablation
epicardial adiposity
epicardial apical site pacing
epicardial cad assessment
epicardial coronary arteries
epicardial coronary artery compression
epicardial coronary artery disease
epicardial coronary artery disease (cad)
epicardial coronary artery spasm
epicardial coronary diameter reduction
epicardial coronary obstruction
epicardial fat
epicardial icd system
epicardial laa clipping
epicardial leads
epicardial left atrial appendage clipping
epicardial pacemaker leads
epicardial vessel
epidemiological studies (virani, heidenreich, dunlay, etc.)
epidemiology
epidemiology of aneurysms
epidemiology of hf, hfref, and hfpef
epidemiology of hypertrophic cardiomyopathy
epidemiology of moderate to severe vhd
epidural/spinal (neuraxial) anesthesia
epinephrine
epistaxis
epithelial keratopathy
eplerenone
eplerenone in mild patients hospitalization and survival study in heart failure (emphasis‑hf)
eplerenone post‑acute myocardial infarction heart failure efficacy and survival study (ephesus)
eplerenone post‑acute myocardial infarction heart failure evaluation study (ephesus)
epoprostenol therapy
eptifibatide
equitable care and training opportunities
equity, disparities, and cost‑effective long‑term management in rural settings
era of reperfusion therapy (fibrinolysis‑only, pharmaco‑invasive, ppci)
erato trial
erectile dysfunction
erectile dysfunction (as a pad risk marker)
erectile dysfunction (in cardiovascular patients)
erectile dysfunction as a cardiovascular predictor
erectile function (international index of erectile function)
erk1/2 (extracellular signal‑regulated kinases 1/2)
ertugliflozin
erythrocyte sedimentation rate (esr)
erythrocytosis
erythromycin
erythropoiesis‑stimulating therapy (darbepoetin alfa, erythropoietin)
erythropoietin
erythropoietin‑stimulating agents (contraindicated in hf)
erythropoietin‑stimulating agents (esa)
esc
esc (european society of cardiology)
esc aortic disease guideline
esc aortic disease guideline (2014)
esc aortic diseases guidelines
esc guideline for aortic disease 2014
esc guideline for aortic diseases
esc guideline for atrial fibrillation
esc guideline for hcm
esc guideline on atrial fibrillation
esc guidelines
esc guidelines (european society of cardiology)
esc guidelines for achd management
esc guidelines for aortic disease
esc guidelines for atrial fibrillation
esc guidelines for cardiovascular disease during pregnancy
esc guidelines for cardiovascular disease in pregnancy
esc guidelines for cardiovascular diseases in pregnancy
esc heart failure guidelines (for heart transplant recipients)
esc heart failure outcomes reporting
esc registry of pregnancy and cardiac disease
esc working group on valvular heart disease
esc “board” (bromocriptine, oral hf therapy, anticoagulation, vaso‑relaxing agents, diuretics)
esc, acc, aha, aats/acc/ase/scai/sts guidelines and consensus documents
esc/eac guidelines for congenital heart disease
esc/eacts guidelines
esc/eacts guidelines for valvular disease
esc/eacts guidelines on valvular heart disease
esc/ers guideline for pulmonary hypertension
escape (evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness) risk model
escape risk model (evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness)
escape risk model / discharge score
escape trial
escape trial (clinical assessment of hemodynamics)
esciptacs (escitalopram in depressive patients with acute coronary artery syndrome) study
esophageal atrial fistula
esophageal compression
esophageal compression symptoms (e.g., dysphagia)
esophageal lesion
esophageal varices
esp‑cad trial
estimated 5‑year scd risk
estimated 5‑year sudden death risk
estimated glomerular filtration rate (egfr)
estimated glomerular filtration rate (egfr) <60 ml/min/1.73 m²
estimated glomerular filtration rate (egfr) < 60 ml/min/1.73 m²
estimated pulmonary pressure
estimated pulmonary pressures
estrogen‑containing contraceptive agents
estrogen‑containing contraceptive agents (contraindicated in achd)
estrogen‑containing oral contraceptives (thromboembolic risk)
estrogen‑only hormone regimens
esvs (european society for vascular surgery)
ethanol abuse
ethnic disparities
ethnic disparities (non‑white patients)
ethnic disparities in aortic disease management
ethnically and racially diverse population
etoricoxib
euclid trial
euclid trial (examining ticagrelor in pad)
euclid trial (examining use of ticagrelor in peripheral artery disease)
euclid trial (peripheral artery disease)
euglycemic ketoacidosis
eular (european alliance of associations for rheumatology) guidelines
eular (european league against rheumatism)
euridis study (european trial in atrial fibrillation)
euroaspire iv survey
europa trial
european association for cardio‑thoracic surgery (eacts)
european association of preventive cardiology (position paper)
european heart journal – acute cardiovascular care
european heart journal–acute cardiovascular care
european heart rhythm association (ehra)
european journal of heart failure
european observational research programme (eurobservational)
european society for vascular surgery (esvs)
european society for vascular surgery (esvs) thoracic aortic disease guidelines
european society of cardiology (esc) guideline
european society of cardiology (esc) guidelines on aortic disease
european society of cardiology (esc) heart‑failure definition
european society of cardiology (esc/eas) guidelines
european society of cardiology / european respiratory society guidelines for pulmonary hypertension
european society of cardiology cardiovascular‑disease‑prevention guidelines
european society of cardiology diagnostic algorithm
european society of cardiology guidelines
euroqol (eq‑5d‑5l)
euroscore ii risk calculator
eurostar registry
euthyroid state
euvolemia
eu‑fp7 media study group (diastolic stress tests)
evaluation and diagnosis of chest pain (clinical guideline)
evaluation of out‑of‑hospital cardiac arrest patients in the catheterization laboratory
evaluation of short‑ and long‑term outcomes in complex valve disease.
evaluation of surgical and interventional risk
evaluation, diagnosis, and risk stratification
event monitor
event recording (for palpitations/light‑headedness)
event? or outcome? or episode?
event‑free survival
event‑free survival percentages for severe as
everest trial
everest trial (congestion in heart failure)
everolimus‑eluting stents
every 1–2 years (pediatric, genotype‑positive)
every 2–3 years (all other children/adolescents)
every 3–5 years (adults)










evidence
evidence gaps & future directions
evidence gaps and future directions (e.g., refining diagnosis, new therapies, risk stratification, arrhythmia management, genetic architecture)
evidence gaps and future research directions
evidence gaps in hf management
evidence grade (cor, loe)
evidence grade / recommendation level
evidence level (c‑ld, b‑nr)
evidence levels (e.g., b‑nr, c‑eo)
evidence review committee
evidence table / guideline recommendations
evidence table / level of evidence (loe)
evidence‑based care
evidence‑based guideline
evidence‑based guideline implementation
evidence‑based guideline recommendations for heart disease
evidence‑based guideline terminology (e.g., “recommended”, “reasonable”)
evidence‑based guidelines
evidence‑based interventions
evidence‑based management of hcm
evidence‑based medical therapy
evidence‑based medicine
evidence‑based medicine benchmarks
evidence‑based methodologies
evidence‑based methodology
evidence‑based pharmacotherapy
evidence‑based recommendation
evidence‑based recommendations
evidence‑based risk–benefit ratio for set in pad
evidence‑based therapies
evidence‑based therapy
evm – endocardial voltage mapping
evolocumab
evolocumab (pcsk9 monoclonal antibody)
evopacs trial
ewolution trial
exacerbation of hfref
examine (alogliptin outcomes)
excel trial
excessive alcohol intake
excessive bleeding
excessive dyspnea
excretion path (renal, hepatic, biliary)
exenatide
exercise
exercise & physical activity (modifiable risk factor)
exercise (aerobic & resistance)
exercise (physical activity)
exercise / physical activity
exercise / physical activity (cardiovascular health)
exercise abi testing
exercise adherence and adherence strategies
exercise and functional capacity testing (6‑minute walk, cpet)
exercise capacity
exercise capacity (functional status)
exercise capacity (pre‑operative)
exercise capacity / aerobic capacity / exercise tolerance
exercise capacity / exercise intolerance
exercise capacity / exercise testing
exercise capacity / exercise time
exercise capacity / functional capacity testing
exercise capacity after heart transplantation
exercise capacity assessment
exercise capacity decline
exercise capacity guidelines for congenital heart disease athletes
exercise capacity improvement
exercise capacity metrics (e.g., vo₂ max)
exercise capacity preservation
exercise capacity reduction
exercise capacity – objective and subjective limits
exercise counseling / rehabilitation
exercise doppler echocardiography
exercise duration / exercise tolerance
exercise ecg
exercise echocardiography
exercise guidance for patients with heart disease
exercise guidelines (≥150 min/week moderate or ≥75 min/week vigorous)
exercise hemodynamics
exercise intensity
exercise intensity (low‑, moderate‑, high‑intensity)
exercise intensity (met values)
exercise intolerance
exercise intolerance (chronotropic incompetence)
exercise intolerance / exercise tolerance
exercise intolerance attributable to pr or other causes
exercise limitation (for hypertrophic cardiomyopathy)
exercise limitation / intolerance
exercise limitations
exercise performance
exercise performance (anaerobic threshold)
exercise performance / tolerance
exercise prescription
exercise prescription alterations
exercise prescription for pad
exercise prescription parameters (treadmill walking parameters, 6mwt)
exercise program
exercise programs for patients with pad
exercise recommendation / physical activity
exercise rehabilitation / exercise therapy / exercise training (cardiovascular rehab)
exercise restriction in desmosomal cardiomyopathy
exercise session duration (30‑45 min per 60‑min session)
exercise session frequency (≥3 sessions per week)
exercise stress echocardiography
exercise stress test (est)
exercise stress testing
exercise stress testing (echocardiographic evaluation)
exercise stress testing (treadmill, bicycle)
exercise stress testing / exercise tte
exercise test (exercise‑testing)
exercise test (graded exercise test / gxt)
exercise test abnormalities
exercise testing
exercise testing (6‑minute walk)
exercise testing (acute phase & follow‑up)
exercise testing (cardiovascular)
exercise testing (exercise‑induced hypertension)
exercise testing (for risk assessment)
exercise testing (stress test)
exercise testing (symptom clarification)
exercise testing / exercise‑stress echocardiography
exercise testing as a standardized, reliable measure
exercise testing for clinical outcomes
exercise testing for competitive sports
exercise testing restriction in acute myocarditis
exercise therapy (home‑based)
exercise therapy (supervised)
exercise therapy for cardiovascular disease management
exercise therapy for pad
exercise tolerance
exercise tolerance / capacity
exercise tolerance / diurnal variation in exercise tolerance
exercise tolerance in fontan patients
exercise training
exercise training (continuous, interval, home‑based, pulmonary rehab)
exercise training (for fontan adults)
exercise training (high‑intensity aerobic, moderate‑intensity, extreme exercise)
exercise training (structured)
exercise training (supervised, graded)
exercise training / aerobic exercise
exercise training / exercise prescription
exercise training / resistance training in fontan and single‑ventricle patients
exercise training compliance
exercise training for blood‑pressure control
exercise training referral for hf (inpatient and outpatient)
exercise training – core component of cardiac rehabilitation
exercise treadmill abi
exercise treadmill test
exercise treadmill test (ett)
exercise treadmill testing
exercise tte
exercise tte for functional capacity and prognostic information
exercise volume (high-volume endurance athlete)
exercise-induced arrhythmia
exercise-induced atrial myopathy
exercise-related inflammation
exercise‑based cardiac rehabilitation
exercise‑based cardiac rehabilitation for aortic disease
exercise‑based cardiac telerehabilitation
exercise‑based cr programs
exercise‑based therapy
exercise‑induced angina
exercise‑induced arrhythmias
exercise‑induced cyanosis
exercise‑induced gradient
exercise‑induced hypertension
exercise‑induced hypoxemia
exercise‑induced ischemia
exercise‑induced ischemic electrocardiographic changes
exercise‑induced ischemic symptoms
exercise‑induced lv outflow tract gradient
exercise‑induced mitral regurgitation
exercise‑induced myocarditis
exercise‑limiting cardiovascular disease (cvd)
exercise‑provoked (fluid‑challenge) lv pressure assessment
exercise‑related acute cardiovascular events
exercise‑treadmill testing
exertional (claudication) pain
exertional angina
exertional dyspnea
exertional leg disorders
exertional leg symptoms
exertional performance / exercise capacity
exertional symptoms
expedited second stage of labor
experimental models of calcific as
expert consensus decision pathways for tobacco cessation
expert in ct (pre‑procedural assessment of valve disease)
expertise in cardiac mri (valve disease assessment)
expertise in ct (valve assessment and procedural planning)
exposure to adversity (violence, trauma)
exposure to cardiotoxic agents
extended (>24 h) ecg monitoring
extended aortic repair
extended cardiac monitoring
extended dapt
extended septal myectomy (esm)
extended therapy beyond one year post‑acs
extended‑release niacin
extension of the dissection flap
extensive left‑ventricular outflow tract calcification
extensive lge (≥ 15 % lv mass)
extensive neurological damage
extensive paravalvular infections
extent of late gadolinium enhancement (lge) on cmr
extent i – v classification (crawford & safi)
external cardiac monitors
external elastic lamina diameter
external iliac artery
extracardiac conduit
extracardiac fontan conversion
extracellular matrix expansion
extracellular matrix proteins
extracellular matrix remodeling
extracellular volume (ecv)
extracellular volume fraction
extracorporeal life support (ecls)
extracorporeal membrane oxygenation (ecmo)
extracorporeal ventricular assist devices
extracranial aneurysm
extract‑timi 25 trial
extramatch study
extra‑anatomic bypass
extra‑anatomic bypass (axillobifemoral, femorofemoral cross‑over)
extra‑anatomic reconstruction
extra‑anatomical bypass
extra‑aortic features
extreme heat exposure
extreme temperatures (heat and cold)
ex‑dhf pilot study
ezetimibe
ezetimibe (add‑on therapy)
ezetimibe (not explicitly cited but related to ldl‑c lowering)
ezetimibe (npc1l1 cholesterol‑absorption inhibitor)
ezetimibe therapy
ezetimibe‑first strategy
e‑cigarette use
e‑cigarette use (vascular remodeling)
e‑cigarettes
e‑cigarettes / electronic nicotine delivery systems (ends)















fabry disease
fabry’s disease cardiomyopathy
factor xa
factor xa inhibitors
factor xa inhibitor
factor xa inhibitors
factor xa inhibitors (apixaban, rivaroxaban, edoxaban, enoxaparin)
factor xa inhibitors (doacs)
failed reperfusion
failed surgical bioprosthetic valves
failing left ventricle
failing right ventricle
failure to rescue
fald (fontan‑associated liver disease)
fall risk
false lumen
false lumen expansion
false lumen flow
false lumen hemorrhage
false‑lumen diameter (> 20–22 mm)
false‑lumen thrombosis
fame (referenced in other literature)
fame study (fractional flow reserve vs angiography for multivessel evaluation)
fame‑2 trial
familial aneurysm risk
familial aortic dissection history
familial cardiomyopathies
familial cardiomyopathy
familial hypercholesterolemia
familial hypercholesterolemia (fh)
familial hypercholesterolemia (fh)
familial inheritance (autosomal dominant pattern)
familial thoracic aneurysms and dissections
familial thoracic aortic aneurysm
familial thoracic aortic aneurysm (no identified gene)
familial thoracic aortic aneurysm and dissection (ftad)
familial thoracic aortic aneurysms and dissections
familial thoracic aortic dilation
familial thoracic aortic disease (tad)
familial thoracic aortic disease genetics
family caregiver support (in hf care)
family clustering of bicuspid aortic valve and aortic dilation.
family heart
family history (3 generations)
family history (3‑generation pedigree)
family history (3‑generation)
family history (of aortic dissection)
family history (of peripheral artery disease)
family history / pedigree analysis
family history of aaa
family history of af
family history of aortic aneurysms and dissections
family history of aortic disease
family history of aortic disease.
family history of aortic dissection
family history of cardiovascular disease
family history of coronary artery disease
family history of coronary heart disease
family history of early hcm‑related scd
family history of hcm
family history of premature ascvd
family history of premature coronary heart disease
family history of premature hcm‑related sudden death
family history of premature hcm‑related sudden death, cardiac arrest, or sustained ventricular arrhythmias
family history of premature mi
family history of scd
family history of sudden death
family history of sudden death from hcm
family history of tad
family history of thoracic aortic disease
family history of type a aortic dissection
family management of heart disease
family planning in achd patients
family screening
family screening (first‑degree relatives)
family screening / clinical surveillance
family screening for bicuspid aortic valve and aortic aneurysm
family screening for cardiomyopathy
family screening for hypertrophic cardiomyopathy
family screening guidelines
famous‑nstemi trial
fasciotomy (therapeutic)
fasting lipid panel
fast‑mi program
fatigue
faust trial (femoral arterial access with ultrasound trial)
fbn1
fbn1 mutation
fda adverse event reporting in anticoagulation therapy
fda approval status (regulatory context for cardiovascular drugs)
fda approval status for reversal agents
fda labeling for statins (therapeutic recommendations)
fda – u.s. food and drug administration
fda‑approved devices (for endovascular taaa repair)
fda‑approved drugs
fda‑approved fenestrated device
fda‑approved lipid‑lowering drugs
fda‑approved stent graft devices
fdg pet/ct
fdg‑pet (fluorodeoxyglucose positron emission tomography)
fdg‑pet imaging
fdg‑pet – flurodeoxyglucose positron emission tomography
fecal excretion (potassium)
federal aviation administration (faa) guidelines
federal motor carrier safety administration (fmcsa) guidelines
feel free to add any additional terms that you find relevant to your clinical context.
felodipine
female predominance (≈80 % of rheumatic ms cases)
female sex (as a risk modifier)
female sex (sex category)
female sex / women (sex‑specific differences)
female under‑diagnosis of hcm
female‑sex cardiovascular risk
femoral access
femoral access (femoral artery approach)
femoral access (pci)
femoral access approach
femoral access vs non‑femoral access
femoral artery
femoral artery access
femoral cannulation
femoral endarterectomy
femoral pulse
femoral pulse delay
femoral vascular access
femoropopliteal arterial disease
femoropopliteal arterial segment
femoropopliteal bypass
femoropopliteal disease
femoropopliteal lesions
femoropopliteal segment
femoro‑popliteal angioplasty
femoro‑popliteal bypass
femoro‑popliteal disease
fenestrated aortic repair
fenestrated closure
fenestrated closure (fenestrated repair)
fenestrated endovascular aortic repair
fenestrated endovascular device
fenestrated endovascular repair
fenestrated fibromuscular membrane
fenestrated patch closure
fenestrated stent graft
fenestrated surgical repair
fenestrated transcatheter device
fenestrated/branched endovascular procedures (fevar/bevar)
fenestrated/endovascular aneurysm repair (fevar/evar)
fenestrated/obstructive membrane orifice
fenestrated‑branched endograft
fenestrated‑branched endovascular aortic repair (fevar)
fenestration‑associated liver disease (fald)
fenofibrate
fentanyl
ferric carboxymaltose
ferric carboxymaltose – iron therapy used in hf with iron deficiency
fertility
fetal complications
fetal counseling
fetal death
fetal echocardiography
fetal echocardiography (for diagnosis of fetal hcm)
fetal growth effects of atenolol in pregnancy with hypertension
fetal growth retardation
fetal intracranial bleeding
fetal intracranial hemorrhage
fetal loss / embryopathy
fetal malformations
fetal monitoring (during aortic surgery)
fetal outcome
fetal outcomes
fetal outcomes in pregnancy with prosthetic valves
fetal screening
fever
ffr derived from computed tomography angiography (ffr‑ct)
ffr – fractional flow reserve
ffr‑guided pci
ffr‑guided pci (fractional flow reserve ≤ 0.8)
fibrates
fibrin (matrix of thrombus)
fibrinogen
fibrinolysis
fibrinolysis / fibrinolytic therapy
fibrinolytic (thrombolytic) therapy
fibrinolytic agents
fibrinolytic therapy
fibrinolytic therapy (fibrinolysis)
fibrinolytic therapy (fibrinolytic agents)
fibrinolytics
fibrin‑specific fibrinolytic agents
fibroatheroma
fibroblast activation
fibroelastic deficiency
fibrofatty deposits
fibromuscular dysplasia
fibromuscular dysplasia (associated with scad)
fibrosis
fibrosis (gadolinium enhancement)
fibrosis imaging (via cmr)
fibrosis of internodal/interatrial tracts
fibrosis of the atria
fibrosis reduction
fibrosis‑targeted therapies (e.g., pirfenidone) in hfpef
fibrosis‑targeting therapies
fibrotic degeneration of the cor membrane
fibrotic thickening around coronary ostia
fick cardiac output
fick method
filamin‑c mutations
filling pressure / filling pressures
filling pressures (e.g., left‑systolic filling pressure)
financial strain
fincv study
first medical contact (fmc)
first medical contact (fmc) to device activation time
first trimester
first‑degree av block
first‑degree relative screening for aortic disease
first‑degree relatives
first‑degree relatives (screening)
first‑degree relatives screening
first‑detected af
first‑medical‑contact (fmc)
fish
fish oil
fish oil supplementation
fistula formation
fistula to bowel, esophagus, or airway
fistulae (paravalvular or intracardiac)
fitt‑stemi trial
five‑year survival rate < 50 %
fixed radiographic imaging system and flat‑panel fluoroscopy
fkbp7
flail leaflet
flail tricuspid leaflet
flank pain
flecainide
flecainide (antiarrhythmic)
flec‑sl (short‑term vs. long‑term antiarrhythmic trial)
flexenide (flecainide)
flna
floating aortic thrombus
flow assessment (qp:qs)
flow diagrams
flow diagrams for cardiac decision pathways
flow quantification
fluid administration
fluid and sodium restriction protocols
fluid balance
fluid balance management during radiofrequency ablation
fluid balance management in hf
fluid input/output monitoring
fluid management in shock
fluid overload
fluid removal rate
fluid restriction
fluid restriction therapy
fluid resuscitation strategies in hypotensive trauma patients
fluid retention / edema
fluid shifts
fluid status
fluid‑retention risk factors in diabetes treatment
fluorodeoxyglucose positron emission tomography (fdg‑pet)
fluorodeoxyglucose–positron emission tomography
fluoroquinolone use and aneurysm risk
fluoroquinolone use and aortic aneurysm risk
fluoroscopy
flurodeoxyglucose positron emission tomography (fdg‑pet)
fluvacs (flu vaccination in acute coronary syndromes) study
fluvastatin
fluvastatin (40 mg bid; 20‑40 mg)
fluvastatin (oral extended release, 40 mg, 80 mg, bid)
fluvastatin xl (80 mg)
fluvastatin xl (80 mg)
fmc‑to‑device time
focal aortic aneurysm, pseudoaneurysm, dissection
focal atherosclerotic lesions
focal atrial tachycardias
focal impulse modulation
focal intimal disruption
focal neurologic deficit
focused intimal disruption (fid)














follow‑up after discharge
follow‑up and monitoring
follow‑up and monitoring of bicuspid aortic valve
follow‑up aneurysm‑related mortality
follow‑up appointments
follow‑up arrhythmia monitoring
follow‑up assessment
follow‑up echocardiography
follow‑up exercise testing restriction
follow‑up imaging in myocarditis
follow‑up imaging intervals (1 month, 6 months, 12 months, annually, every 5 years)
follow‑up interval recommendations (e.g., 3‑month cmr, 196‑day imaging)
follow‑up intervals
follow‑up intervals (outpatient, ecg, tte)
follow‑up intervals (physiological stages a–d)
follow‑up intervals for asymptomatic severe or moderate as
follow‑up intervals for isolated branch pulmonary artery stenosis
follow‑up studies / treatment outcomes
fondaparinux
fontaine classification
fontan circulation
fontan circulation / fontan surgery
fontan circulation / univentricular physiology
fontan circulatory failure
fontan completion
fontan conduit stent‑angioplasty
fontan conversion
fontan conversion (total cavopulmonary fontan)
fontan conversion surgery
fontan failure
fontan obstruction
fontan operation
fontan palliation
fontan palliation / fontan circulation
fontan palliation of single‑ventricle physiology
fontan pathway
fontan pathway conduit (extracardiac conduit)
fontan pathway stenosis
fontan patient
fontan physiology
fontan physiology (single‑ventricle)
fontan physiology / fontan palliation / fontan circulation
fontan physiology / fontan patients
fontan pressure
fontan procedure
fontan procedure / fontan circulation
fontan procedure / fontan outcomes network
fontan revision
fontan stenosis
fontan surgery outcomes
fontan thrombus
fontan-associated complications
fontan-associated liver disease
fontan-associated liver disease (fald)
fontan-associated thrombosis
fontan-associated thrombus
fontan‑adult brompton clinical score
fontan‑associated liver disease
fontan‑associated liver disease (fald)
fontan‑pathway thrombosis
fontan‑related portal hypertension
fontan‑related transplantation indications
fontan‑screening for liver disease
food access / food security
food effect (high‑fat, high‑calorie meal)
food insecurity
food insecurity screeners
foot care
foot care (preventive and advanced)
foot care / preventive foot care
foot care / self‑foot care
foot deformities (e.g., bunions/hallux valgus, hammertoe, claw toe, flatfoot/pes planus, severe high‑arch foot/pes cavus, charcot foot, arthritic foot)
foot education resources (american diabetes association, cdc, niddk)
foot inspection & foot care for pad
foot inspection / foot surveillance
foot self‑care education – a non‑pharmacologic intervention to mitigate cardiovascular complications associated with pad
foot surgeon
foot surgery
foot temperature monitoring
foot ulcer
foot ulcer / diabetic foot ulcer
foot ulcer management (including diabetic foot ulcers)
foot ulceration and amputation
foot ulceration and amputation – sequelae of advanced peripheral arterial disease and systemic vascular compromise
foot ulcers
forced expiratory volume in 1 second (fev1)
formal exercise testing
forward cardiac output
forward stroke volume
fourier study
fourier study (clinical trial)
fourier trial
fourier trial (further cardiovascular outcomes research with pcsk9 inhibition in subjects with elevated risk)
fourth heart sound
fourth primitive dorsal aortic arch
four‑dimensional ct imaging (4d ct)
four‑dimensional flow magnetic resonance imaging
four‑factor prothrombin complex concentrate (pcc)
fractional area change
fractional flow reserve (assessment of haemodynamic significance)
fractional flow reserve (ffr)
fractional flow reserve versus angiographically guided management to optimise outcomes in unstable coronary syndromes (famous‑nstemi trial)
fractional flow reserve versus angiography for multivessel evaluation (fame trial)
fractional flow reserve vs. angiography‑guided strategy for management of non‑infarction related artery stenosis in patients with acute myocardial infarction (frame‑ami trial)
fractional shortening
fractional flow reserve (ffr)
fragmented qrs complex
frailty
frailty (as a risk factor for poor self‑care)
frailty (impacting survival <1 year)
frailty (including katz activities of daily living score)
frailty (predictor of outcomes in cad)
frailty / fragile tissue integrity
frailty / immobility
frailty and sarcopenia (muscle loss)
frailty assessment
frailty assessment (frailty indices)
frailty in achd
frailty in chronic heart failure
frailty score
framingham cvd risk score
framingham heart failure risk score
framingham heart study
framingham heart study (fhs)
framingham risk score
framingham risk score (cardiovascular risk profiling)
framingham risk score / study
framingham studies
framingham study risk metrics
free wall rupture
freedom from recurrent moderate/severe mr
freedom from reoperation
freedom study
freedom trial
fresh frozen plasma
fresh frozen plasma (ffp)
fresh frozen plasma in over‑anticoagulation
friction pericardial rub
fried foods
friedewald equation (ldl‑c estimation)
friedreich’s ataxia
front‑loaded alteplase administration
frozen elephant trunk
frozen elephant trunk (fet)
frozen elephant trunk procedure
frozen elephant trunk repair
frozen elephant trunk technique
fu – follow‑up
full neurological evaluation
full‑intensity anticoagulation
full‑intensity oral anticoagulation
fulminant myocarditis
functional and anatomic testing modalities
functional and structural cardiac assessment
functional assessment in elderly mi patients with multivessel disease (fire trial)
functional capacity
functional capacity (age‑ and sex‑adjusted)
functional capacity (e.g., exercise capacity, peak vo₂)
functional capacity / dyspnea on exertion
functional capacity assessment
functional capacity assessment (exercise capacity, symptom severity)
functional capacity improvement
functional class
functional class (nyha/who)
functional class assessment
functional class improvement post‑pulmonary valve replacement.
functional coronary assessment
functional decline
functional domain
functional exercise capacity
functional impairment
functional indices (e.g., new york heart association class)
functional ischemic mitral regurgitation
functional limitation (provocable lvoto, abnormal bp response, arrhythmias, etc.)
functional limitation grading
functional limitation of claudication
functional mitral regurgitation
functional outcome
functional outcome and survival
functional outcomes
functional status
functional status (decreased)
functional status (exercise tolerance)
functional status (hf)
functional status (nyha class i/ii)
functional status / functional class
functional status / mobility limitations
functional status / walking performance metrics
functional status and limitation
functional status decline in pad
functional status improvement
functional status measures in elderly cardiac patients
functional stenosis
functional tricuspid regurgitation
functional tricuspid regurgitation secondary to chronic atrial fibrillation
functional vs. structural valve causes
fungal aortitis
fungal endocarditis
fungal infection
fungal prosthetic valve endocarditis
furosemide
furosemide (oral loop diuretic)
fusiform aneurysm
future baffle occlusion
future directions in pad treatment
future research directions (hf)
future research needs (ccd)

















gadolinium enhancement (cardiac mri)
gadolinium-based contrast media
gadolinium‑based contrast agents
gadolinium‑based contrast media
galectin‑3
galileo trial
gangrene
gap in care
gaps in care
gaps in care delivery
gaps in management of pad
garfield‑af risk score
garfield‑af score
garfield‑af risk score
gastric / intestinal absorption of p2y12 inhibitors
gastric bypass surgery
gastric/ gastrointestinal bleeding
gastrointestinal bleeding
gastrointestinal malignancy
gastro‑intestinal bleeding
gated cardiac ct
gauss‑3 trial
gcm – giant cell myocarditis
gdmt (guideline‑directed medical therapy)
gdmt – guideline‑directed medical therapy
ge healthcare (cardiovascular imaging)
gender
gender differences in aortic aneurysm growth and outcomes
gender differences in rupture risk
gender disparities
gender, sex, and racial/ethnic disparities
gender‑affirming therapies (impact on arrhythmia)
gender‑affirming therapies in achd
gender‑identity disparities
gender‑related differences in imaging limits
gender‑specific risk models
gene carriers (hcm genetics)
gene expression profiling
gene therapy (cardiac)
gene variant carriers
general anesthesia
general anesthesia (associated with higher peri‑operative mortality)
general cardiologists (for local care)
general or epidural anesthesia (used during delivery)
generalized disease‑managing therapy (gdmt)
generalized ventricular dysfunction (progressive systemic rv dysfunction)
generator change
generic statin formulation
genes highlighted as causing or contributing to htad
genetic and environmental factors affecting natural history
genetic and pathobiological causes of valve dysfunction
genetic aortic disorder
genetic aortopathies
genetic aortopathy
genetic architecture of hcm
genetic associations
genetic basis for congenital heart disease
genetic basis of cardiomyopathy
genetic basis of congenital heart disease
genetic cardiomyopathies
genetic cardiomyopathy
genetic causes of aortic disease
genetic conditions: acta2, mylk
genetic confirmation of cardiomyopathy
genetic counseling
genetic counseling (including pre‑implantation counseling)
genetic counseling (pre‑pregnancy)
genetic counseling / preconception genetic counseling
genetic counseling and cascade screening in myocarditis
genetic counseling and testing guidelines
genetic counseling for inherited aortopathies
genetic counseling in cardiovascular disease.
genetic counseling services
genetic counselling
genetic counselling for congenital heart disease
genetic determinants of clopidogrel response
genetic evaluation
genetic evaluation for high‑risk phenotypes
genetic evaluation of cardiomyopathy
genetic evaluation referral
genetic factors
genetic factors influencing heart disease
genetic inheritance of aortopathy
genetic loci specific to af
genetic misdiagnosis
genetic mutations (lox, smad6, other aortopathy genes)
genetic mutations in myl2, sarcomeric proteins, and hcm susceptibility
genetic pathways
genetic pathways in cardiac disease
genetic penetrance
genetic predisposition to aortic disease
genetic predisposition to cardiomyopathy
genetic referral / genetic evaluation
genetic risk
genetic risk factors
genetic risk in arrhythmic/dilated cardiomyopathy
genetic sarcomere variant
genetic screening
genetic screening / testing
genetic screening for achd
genetic screening for cardiomyopathy
genetic screening for myocarditis patients
genetic screening for thoracic aortic disease
genetic sequencing (for amyloidosis)
genetic sequencing of the ttr gene
genetic susceptibility loci (gwas findings)
genetic susceptibility to af (polygenic risk score)
genetic syndrome and residual aortopathy assessment
genetic syndromes (e.g., noonan syndrome)
genetic syndromes screening
genetic syndromes screening (related to cardiac anomalies)
genetic testing
genetic testing (at time of new cardiomyopathy diagnosis)
genetic testing (cardiogenetics)
genetic testing (for syndromic features, family history, early onset)
genetic testing (hcm‑associated variants)
genetic testing (in myocarditis)
genetic testing (including exome sequencing, targeted gene panel)
genetic testing (multigene panel)
genetic testing / consumer‑based genetic testing
genetic testing / genotype status (pathogenic/likely pathogenic variants)
genetic testing for aortic disease (pathogenic mutations)
genetic testing for cardiac conditions
genetic testing for cardiomyopathy/arrhythmia genes
genetic testing for cardiomyopathy/ion‑channel disorders
genetic testing for hcm
genetic testing for hcm and hcm phenocopies
genetic testing for inherited cardiovascular disease
genetic testing for thoracic aortic disease
genetic testing for ttr mutation
genetic testing in aortic disease
genetic testing in aortic disease (cardiogenetics)
genetic testing outcomes
genetic triggers (of aortic disease)
genetic variant
genetic variant re‑analysis
genetic variant re‑contact guidelines
genetic variants for cardiomyopathy
genetic variants in aneurysm‑related genes
genetic variants in cardiomyopathy
genetic variants in lamin a/c
genetic variants in titin (ttn)
genetic variants: acta2, prkg1, myh11, mylk, lox
genetic variation in dilated cardiomyopathy
genetic, environmental, and metabolic etiologies of arrhythmia
genetic/acquired coagulopathy
genetically inherited heart diseases
genetics
genetics / heritability
genetics and family screening for hcm
genetics of atrial fibrillation
genetics‑mediated risk stratification
gene‑based management
gene‑based therapy
gene‑by‑environment interaction
gene‑expression profiling (for cardiac disease)
gene‑specific therapeutics
genital infections
genital mycotic infection
genitourinary infections (risk factor)
genome‑wide association studies (gwas) for af
genome‑wide association studies (gwas) for af risk
genome‑wide association study (gwas)
genome‑wide association study (gwas) loci
genomic/locus identification for af (e.g., kcnq1, kcnh2, gata4, myl3, etc.)
genomics
genotype
genotype (sarcomeric hcm)
genotype / genetic variants
genotype and phenotype of cardiomyopathies
genotype or race‑based cardiovascular risk
genotype positive
genotype status
genotype‑based burden of disease
genotype‑based risk stratification in hcm
genotype‑phenotype correlation
genotype‑positive / genotype‑negative
genotype‑positive / phenotype‑negative
genotype‑positive screening family member
genotype‑positive, phenotype‑negative individuals
genotype‑positive, phenotype‑negative status
genotype‑positive/phenotype‑negative screening
genotyping (cyp2c19 polymorphisms)
geographic availability of achd cardiologists
geographic disparities (urban vs rural, geographic isolation, clinician shortages)
geriatric 5ms (optimizing care in elderly cardiac patients)
geriatric 5‑ms (related to cardiovascular outcomes: mentation, mobility, medications, multicomplexity)
geriatric depression scale (gds) – gds ≥ 6
geriatric nutritional risk index (gnri)
geriatric syndromes
geriatric syndromes (frailty, mobility impairment)
german national register for congenital heart defects (gnhfd)
get with the guidelines (gwtg) registry
get with the guidelines‑heart failure registry
get with the guidelines–heart failure (gwtg‑hf) registry
giant cell aortitis
giant cell arteritis
giant cell arteritis (gca)
giant cell myocarditis
giant‑cell myocarditis
gissi‑hf trial
gissi‑prevenzione trial (n‑3 fatty acids & vitamin e)
gissi‑prevenzione trial (post‑mi outcomes)
gist (not present in list)
gla (fabry disease)
glasgow coma scale score < 8
glass (global limb anatomic staging system) classification tool
glass classification (global limb ankle and foot severity score)
glaxosmithkline
glenn shunt (bidirectional cavopulmonary anastomosis)
global burden of disease (cardiovascular focus)
global burden of disease (gbd) study
global burden of disease (gbd) study references
global burden of disease data on coronary disease
global cardiovascular health management therapy (gdmt)
global cardiovascular risk (e.g., reynolds score)
global guideline‑directed medical therapy (gdmt)
global leaders trial
global limb anatomic staging system (glass)
global longitudinal strain
global longitudinal strain (gls)
global longitudinal strain (gls) – implied by lv function tests
global registry of acute coronary events (grace) risk score
global registry of acute coronary events (grace) score
global risk
global sodium consumption
global use of strategies to open coronar‑y arteries (gusto)
global utilization of streptokinase and tissue plasminogen activator (gusto) classification
global vascular guidelines on chronic limb‑threatening ischemia
global‑dose management therapy (gdmt) for heart failure
glomerular filtration rate
glomerular filtration rate (gfr)
glomerulonephritis
glp‑1 receptor agonist
glp‑1 receptor agonist cardiovascular outcome trials
glp‑1 receptor agonists
glp‑1 receptor agonists (e.g., semaglutide, liraglutide)
glp‑1 receptor agonists (glucagon‑like peptide‑1 receptor agonists)
glucagon‑like peptide‑1 (glp‑1)
glucagon‑like peptide‑1 (glp‑1) agonists
glucagon‑like peptide‑1 (glp‑1) receptor agonist
glucagon‑like peptide‑1 (glp‑1) receptor agonists
glucagon‑like peptide‑1 (glp‑1) receptor agonists (liraglutide)
glucagon‑like peptide‑1 (glp‑1) receptor agonists (liraglutide, semaglutide, exenatide, lixisenatide, tirzepatide)
glucagon‑like peptide‑1 receptor (glp‑1r) agonist
glucagon‑like peptide‑1 receptor (glp‑1r) agonists – cardiovascular benefit agents
glucagon‑like peptide‑1 receptor agonists
glucagon‑like peptide‑1 receptor agonists (glp‑1 ra)
glucocorticoid therapy (prednisone)
glucocorticoid therapy (upstream therapy)
glucocorticoids
glucocorticoids (gc)
glucocorticoids (high‑dose)
glucose control
glucose control / abnormal glucose
glucose targets (hba1c)
glucose‑cotransporter‑2 (sglt2) inhibitors
glucose‑directed medical therapy (gdmt) / guideline‑directed medical therapy
glucose‑lowering medical therapy (gdmt) – often including antihypertensive, lipid‑lowering, antiplatelet agents
gluteal ischemia
glycaemic control
glycated hemoglobin (hba1c)
glycemic control
glycemic control (diabetes management)
glycemic control (diabetes mellitus) as a risk factor
glycemic control (hba1c targets)
glycemic control (hba1c)
glycemic control (in diabetic patients with elevated nt‑probnp)
glycemic control (in type 2 diabetes)
glycemic control (pre‑ablation, post‑ablation)
glycemic control agents affecting hf risk (metformin, insulin, sulfonylureas)
glycemic control guidelines
glycemic treatment strategies
glycemic‑controlled disease management (gdmt)
glycemic‑diabetes‑management therapy (gdmt) – (implicit in hf treatment)
glycogen storage disease
glycogen storage diseases
glycoprotein iib/iiia inhibitors
glycoprotein iib/iiia inhibitors (in the broader guideline context)
glycoprotein iib/iiia receptor
glycoprotein iib/iiia inhibitor
glycoprotein iib/iiia inhibitor (e.g., tirofiban)
gmdt (guideline‑directed medical therapy) for pad
goals (group oriented arterial leg study)
goals of care (e.g., symptom relief, quality of life, life prolongation)
gore tag device (device-based term)
gorlin equation (mitral area calculation)
gorlin formula
gout
gout and gallstones (adverse effect of bempedoic acid)
grace risk score
grace risk score >140
gracia‑1 trial
grade 1–4 baai (aortic injury grading)
grade‑rated clinical trial outcomes
grade 4 aortic injury
grade ≥ 2r rejection
gradient across coa (peak‑to‑peak, mean)
gradient across obstruction (mm hg)
gradient relief (lvot gradient)
gradient resistant to first‑line therapy
graft defect
graft dysfunction
graft enteric erosion
graft explant
graft failure
graft failure and technical factors
graft infection
graft infection (aortic graft)
graft migration
graft misalignment
graft patency
graft patency (primary, assisted primary, secondary)
graft porosity
graft revision
graft surveillance
graft thrombectomy
graft type comparison (prosthetic vs. autogenous)
graft‑related adverse events
graft‑related complications (reinfection, erosion, fistula)
graft‑site inflammation
granulomas
granulomatosis with polyangiitis
great arteries
great saphenous vein
green tea extract (observational therapy)
groin hematoma
group a streptococcus exposure risk
group therapy models
growth differentiation factor‑15 (gdf‑15)
growth hormone therapy
growth rate (aneurysm)
growth rate of aaa (mm/year)
growth rate of an aneurysm (≥0.3 cm/year, ≥0.5 cm/yr)
growth rate of aneurysm
growth rate of aortic aneurysms
growth‑differentiation factor‑15 (gdf‑15)
guided de‑escalation of dapt











guideline
guideline (for the diagnosis and management of atrial fibrillation)
guideline adherence in severe aortic regurgitation.
guideline advisor
guideline benchmarks (value thresholds)
guideline class 1 recommendation (2024 pad guideline)
guideline class 2 recommendation (pcsk9, ezetimibe)
guideline documents
guideline for management of valvular heart disease
guideline for the diagnosis and management of atrial fibrillation (2023)
guideline implementation in clinical practice
guideline peer‑review committee
guideline recommendation
guideline recommendations
guideline recommendations (acc/aha, 2020)
guideline recommendations (class 1, class 2)
guideline references (acc/aha, american college of chest physicians, aha/naspe‑cpt)
guideline science and methodology
guideline stages b, c, d
guideline-directed medical therapy
guideline-directed medical therapy (gdmt)
guidelines
guidelines (acc/aha)
guidelines (aha/acc, acc/aha/acc/aapa, etc.)
guidelines for acute coronary syndromes
guidelines for aortic diseases (acc/aha, esc, eacts/esvs)
guidelines for aortic valve and ascending aorta quality measures
guidelines for bicuspid aortic valve‑related aortopathy.
guidelines for blood cholesterol management (acc/aha)
guidelines for cholesterol management
guidelines for diagnosis and management of atrial fibrillation (acc/aha)
guidelines for diagnosis and management of thoracic aortic disease (accf/aha/aats/acr/asa/sca/scai/sir/sts/svm)
guidelines for diagnosis and treatment of aortic disease (acc/aha, esc, nice, etc.)
guidelines for endovascular aneurysm repair follow‑up
guidelines for evaluation and diagnosis of chest pain (acc/aha)
guidelines for high‑risk cardiovascular disease
guidelines for home‑based cardiac rehabilitation (acc/aha)
guidelines for management of chronic coronary disease (acc/aha)
guidelines for management of heart failure (acc/aha/hfsa)
guidelines for management of thoracic aortic aneurysm size thresholds
guidelines for multimodality imaging of thoracic aorta
guidelines for prevention of acute coronary syndrome.
guidelines for prevention of stroke in patients with stroke/tia (acc/aha)
guidelines for prevention, detection, and management of high blood pressure (acc/aha)
guidelines for primary prevention of cardiovascular disease (acc/aha)
guidelines for statin intolerance
guidelines for surveillance of abdominal aortic aneurysm
guidelines – aha/acc/hfsa, accf/aha, acc/aha/scai, acc/aha/sti, etc.
guidelines:
guideline‐based risk factors: bmi, waist circumference, weight management
guideline‑based clinical practice for heart disease
guideline‑based indications
guideline‑based medical therapy (gdmt)
guideline‑based referral for septal reduction therapy.
guideline‑based risk stratification
guideline‑based statin eligibility evaluation
guideline‑based therapy
guideline‑directed management and therapy
guideline‑directed management and therapy (gdmt)
guideline‑directed medical therapy
guideline‑directed medical therapy (gdmt)
guideline‑directed medical therapy (gdmt) for cardiovascular risk factors
guideline‑directed medical therapy (gdmt) for heart failure
guideline‑directed medical therapy (gdmt) for hfref
guideline‑directed medical therapy (gdmt) for hypertension
guideline‑directed medical therapy (gdmt) for pad
guideline‑directed medical therapy for hf
guideline‑recommended medications
guideline‑recommended therapies (mortality benefit)
guideline‑recommended therapy
guideline‑specific trial endpoints
guide‑hf study
guide‑hf trial
guide‑it (guiding evidence‑based therapy using biomarker‑intensified treatment)
guide‑it predictive model
gusto moderate or severe bleeding
gusto trial
gusto‑i trial (global utilization of streptokinase and tpa)
gwtg‑heart failure risk score
gwtg‑hf (get with the guidelines‑heart failure)
g‑protein‑coupled receptor blockers (arni)








h/cl (heart to contralateral chest ratio)
h2fpef score
h2f‑peff model (diagnostic algorithm)
hacek organisms (haemophilus spp., actinobacillus spp., cardiobacterium hominis, eikenella spp., kingella kingae)
half‑life
half‑life (range 9‑36 days)
halo catheter
handheld ecg device
handheld ecg early detection of recurrent af
handheld ecgs
hand‑carried echocardiography
hard ascvd endpoint
harmonize trial
harmonize trial (sodium zirconium cyclosilicate)
has‑bled bleeding risk score
has‑bled score
hatch score
hatch score (hypertension, age ≥ 75 years, tia or stroke, copd, heart failure)
hazard ratio
hazard ratio (hr)
hazard ratios and relative risk reductions (e.g., 49%, 56%)
hazard–benefit ratio
hba1c variability
hcm
hcm (hypertrophic cardiomyopathy)
hcm and advanced heart failure (hf)
hcm and atrial fibrillation (af)
hcm and ventricular arrhythmias
hcm center / comprehensive center
hcm guidelines (hypertrophic cardiomyopathy guideline)
hcm risk calculators (e.g., hcm‑risk‑cva)
hcm risk score (eg., hcm risk‑cva, hcm risk‑scd)
hcm risk-scd model
hcm risk‑kids model
hcm risk‑scd model
hcm screening (family screening)
hcm‑af risk score
hcm risk‑kids model
hdl cholesterol
hdl‑c (high‑density lipoprotein cholesterol)
hdl‑c / hdl
hdl‑cholesterol (hdl‑c)
heaal study (losartan dose comparison)
headache
health abc heart failure score
health and nutrition education
health behaviors (medication adherence, cardiac rehabilitation, diet, physical activity, sleep, smoking)
health care access & treatment adherence
health coaching
health disparities
health disparities / health inequalities
health disparities / vulnerable populations
health disparities affecting pad care
health disparities in diagnosis, treatment, and outcomes
health disparities in pad
health disparities in peripheral artery disease
health education
health equity / health disparities
health equity initiatives and policy actions (e.g., rural health advisories, primary‑care recommendations)
health inequities and barriers to care
health information technology tools
health literacy
health literacy (impaired)
health literacy / health numeracy
health literacy assessment
health literacy in heart failure patients
health outcomes
health policy / quality metrics
health service expenditures
health services accessibility
health services research
healthcare cost burden of cardiovascular disease (>$200 billion us annually)
healthcare disparities
healthcare disparity gap
healthcare resource utilization (er visits, etc.)
healthcare system data burden (hf assessment)
healthcare transition for youth with heart disease
healthcare utilization (related to cardiovascular conditions)
healthy diet
healthy dietary habits
healthy dietary pattern
healthy dietary patterns
healthy lifestyle behaviors (in heart‑failure management)
health‑benefit outcomes study
health‑care resource utilization
health‑care utilization in achd
health‑care utilization in achd patients
health‑related quality of life
health‑related quality of life (hrqol)
health‑related quality of life (qol)
health‑related quality of life after vascular procedures
health‑related quality of life assessment tools (e.g., sf‑36)
health‑status outcomes (quality of life, angina relief)
heart
heart & vascular center
heart & vascular institute
heart & vascular center
heart (as part of institution name)
heart (implicitly through “heart association”)
heart and blood vessel disease
heart and heart rhythm care
heart and lung institute (hci)
heart and vascular center
heart and vascular center (emory)
heart and vascular institute
heart arrest
heart attack
heart block
heart block (conduction disturbances)
heart center
heart center director of education
heart centre
heart disease
heart disease (general term)
heart disease (general)
heart disease / heart‑disease statistics
heart disease and stroke statistics (circulation data)
heart disease disclosure policies (acc/aha)
heart disease imaging modalities
heart disease management
heart disease prevention
heart disease prevention and therapy terms (e.g., lipid management, anti‑platelet therapy, statins)
heart disease risk factors
heart disease terminology
heart diseases
heart disease–related terms extracted from the text
heart failure
heart failure (advanced)
heart failure (as a potential outcome)
heart failure (congestive heart failure)
heart failure (congestive)
heart failure (congestive, reduced ef, preserved ef)
heart failure (gradual onset)
heart failure (hf)
heart failure (hf) hospitalization
heart failure (hf) in the context of hcm
heart failure (hf) secondary to coronary disease
heart failure (hf) specialist
heart failure (hf) symptoms
heart failure (hf) with lv systolic dysfunction
heart failure (hf) with rv dysfunction
heart failure (hf) – acute or chronic severe regurgitation; nyha class iii/iv symptoms
heart failure (hf) – symptom management, gdmt
heart failure (including chronic heart failure)
heart failure (inferred from cardiology focus)
heart failure (moderate to severe, acute)
heart failure (preserved or reduced ejection fraction)
heart failure (reduced/ preserved ejection fraction)
heart failure algorithm
heart failure and transplantation
heart failure as a risk factor for death
heart failure associated with new‑onset atrial fibrillation in cancer
heart failure association (hfa) of the european society of cardiology (esc)
heart failure class ii‑iv symptoms
heart failure clinics
heart failure consultation
heart failure disease management
heart failure disparities
heart failure during pregnancy
heart failure events
heart failure guideline
heart failure guideline (aha/acc/hfsa)
heart failure guidelines
heart failure guidelines (aha/acc/hfsa, 2022)
heart failure hospitalization
heart failure hospitalizations
heart failure in american indian/alaska native adults
heart failure in asian american/pacific islander adults
heart failure in black patients
heart failure in hispanic/latino adults
heart failure in older adults
heart failure in type 2 diabetes mellitus
heart failure in women
heart failure incidence
heart failure management
heart failure management (gdmt, angiotensin‑receptor neprilysin inhibitor)
heart failure mortality
heart failure mortality & readmission rates
heart failure outcomes
heart failure patients
heart failure programme (if inferred)
heart failure referrals
heart failure registry (e.g., champ‑hf, everest, i‑preserve, solvd)
heart failure rehabilitation
heart failure related to ebstein malformation
heart failure remission
heart failure research
heart failure risk
heart failure risk scoring
heart failure society of america
heart failure society of america (hfsa)
heart failure survival
heart failure survival score
heart failure symptoms
heart failure therapy (guideline‑directed medical therapy)
heart failure treatment and recovery
heart failure with improved ejection fraction
heart failure with improved ejection fraction (hfimpef)
heart failure with improved ejection fraction (hfimphf)
heart failure with mid‑range ejection fraction (hfmref)
heart failure with mildly reduced ejection fraction
heart failure with mildly reduced ejection fraction (hfmref)
heart failure with preserved ejection fraction
heart failure with preserved ejection fraction (hfpef)
heart failure with preserved ejection fraction (hfpef) in coarctation patients
heart failure with preserved ejection fraction (hf‑pef)
heart failure with recovered left ventricular ejection fraction (hfrecef)
heart failure with reduced ef (hfref)
heart failure with reduced ejection fraction
heart failure with reduced ejection fraction (hfref)
heart failure with reduced ejection fraction (hfref) – contraindication for diltiazem and verapamil
heart failure with reduced left ventricular ejection fraction (lvef)
heart failure with systemic right ventricular failure
heart failure – recovered ejection fraction (hf‑recovered ef)
heart failure, prognostic markers
heart failure, secondary to myocardial infarction
heart failure, stage b (pre‑symptomatic)
heart failure, stage c (symptomatic)
heart failure, stage d (advanced)
heart failure, type 2 diabetes mellitus
heart failure, with mid‑range ejection fraction (hfmref)
heart failure, with preserved ejection fraction (hfpef)
heart failure, with reduced ejection fraction (hfref)
heart failure-action study
heart failure/transplantation team
heart function
heart function and transplant program
heart function tests
heart health
heart health & performance program
heart hospital
heart institute
heart institute (dual reference)
heart medicine/heart disease (general term)
heart murmur
heart or multiorgan transplant evaluation & listing
heart outcomes evaluation prevention (hope‑3)
heart outcomes prevention (hope) trial
heart outcomes prevention evaluation (hope) trial
heart pathway
heart protection study (hps)
heart quality of life instrument










heart rate
heart rate (hr)
heart rate (resting heart rate, target heart rate)
heart rate (resting, per‑5‑bpm increments)
heart rate (≥ 70 bpm at rest)
heart rate control
heart rate management
heart rate metrics (e.g., heart rate >120 bpm, goal <90 bpm)
heart rate recovery
heart rate recovery (post‑exercise)
heart rate reserve
heart rate variability (hrv)
heart rhythm
heart rhythm (as a clinical context)
heart rhythm (as in heart rhythm society)
heart rhythm abnormalities (arrhythmia)
heart rhythm assessment
heart rhythm assessment (electrocardiography, holter, event monitoring)
heart rhythm awareness
heart rhythm disorder
heart rhythm disorders
heart rhythm disturbances (irregular rhythm, arrhythmia)
heart rhythm institute
heart rhythm management in achd
heart rhythm society
heart rhythm society (hrs)
heart rhythm society guidelines.
heart septal defects (e.g., ventricular septal defect)
heart team
heart team (interventional cardiology, cardiac surgery, cardiovascular specialists)
heart team approach
heart team decision making
heart team multidisciplinary decision making
heart transplant
heart transplant (htx)
heart transplant allocation policy changes
heart transplant list
heart transplant listing criteria for hcm
heart transplant recipient
heart transplant recipients
heart transplant rejection
heart transplant waiting list
heart transplantation
heart transplantation (htx)
heart transplantation (orthotopic)
heart transplantation / heart transplant
heart transplantation / heart transplant recipients
heart transplantation / transplant evaluation
heart transplantation candidates
heart transplantation for complex congenital heart disease
heart transplantation in achd
heart transplantation outcomes in cardiomyopathy
heart valve
heart valve centers of excellence
heart valve disease
heart valve disorders
heart valve dysfunction
heart valve multidisciplinary team (mdt)
heart valve programs
heart valve prosthesis
heart valve repair classification systems (e.g., bicommissural repair)
heart valve replacement
heart valve surgery
heart valve team
heart valve team (cardiologists, surgeons, anesthesiologists, maternal‑fetal medicine obstetricians)
heart valve voice
heart valves
heartflow
heartflow (cardiovascular imaging/diagnostics platform)
heartflow (non‑invasive coronary artery disease assessment)
hearthealth (women‑heart)
heart team
heart‑disease clinical trials
heart‑disease genetic counseling
heart‑disease management strategies
heart‑disease pathophysiology
heart‑disease prognosis
heart‑disease registry data
heart‑disease related terms extracted from the guideline text
heart‑disease related terms extracted from the text
heart‑disease related terms identified in the text
heart‑disease risk factors
heart‑disease–related key terms extracted from the text
heart‑disease–related terms
heart‑disease–related terms extracted from the guideline text
heart‑disease–related terms extracted from the text
heart‑failure (hf) hospitalization
heart‑failure biomarker (natriuretic peptides)
heart‑failure guidelines
heart‑failure hospitalization
heart‑failure management in adults (acc/aha 2005 updated)
heart‑failure morbidity and mortality
heart‑failure pharmacology (implied by trials addressing icd/crt in patients with reduced ef)
heart‑failure prevention
heart‑failure progression in hcm
heart‑failure readmission intervention (e.g., thrive, thrive)
heart‑failure society of america (hfsa) consensus
heart‑failure symptom improvement
heart‑failure with reduced ejection fraction (hfref)
heart‑failure‑related hospital admissions
heart‑failure‑related mortality
heart‑healthy diet / nutrition, including supplements
heart‑healthy dietary pattern
heart‑healthy lifestyle factors
heart‑kidney transplantation
heart‑liver transplantation
heart‑lung transplantation
heart‑mate 3
heart‑rate control
heart‑rate reserve during exercise
heart‑related clinical practice guidelines
heart‑related morbidity and mortality
heart‑related quality of life (hrqol)
heart‑versus‑liver transplantation (in fontan patients)
heart‑ware ventricular assist system (hvad)
heart–lung transplantation
heart–lung transplantation in achd
heart valve and achd expert teams
heat wave
heat‑related hospitalisation
heavy alcohol use
height
height (indexing aortic dimensions)
height >1 standard deviation criterion
helical computed tomography
helical ct grading of aortic injury
hematocrit & haemostasis
hematocrit (hct)
hematocrit >65 %
hematocrit level
hematogenous spread
hematologic abnormality
hematology‑guided antiplatelet therapies
hematoma expansion
hematoma thickness
hematoma volume
hematopoietic stem cell transplantation (hsct)
hemiarch repair
hemiarch replacement
hemochromatosis
hemochromatosis‑related hf
hemodialysis
hemodialysis (used for dabigatran clearance)
hemodialysis dependency
hemodialysis patients with coronary disease
hemodinamically significant intracardiac shunt
hemodyamics / hemodynamic progression
hemodynamic abnormalities
hemodynamic alterations
hemodynamic and hormonal changes in pregnancy
hemodynamic assessment
hemodynamic assessment (arterial ultrasound)
hemodynamic assessment (catheterization)
hemodynamic assessment (doppler interrogation)
hemodynamic assessment (right heart catheterization)
hemodynamic assessment during heart failure management
hemodynamic assessment of valve disease
hemodynamic benefits / data
hemodynamic blood flow to foot
hemodynamic blood pressure variation between arms
hemodynamic burden (chronic heart failure, rv dysfunction)
hemodynamic catheterization
hemodynamic changes
hemodynamic changes after asd closure
hemodynamic compromise
hemodynamic consequences
hemodynamic consequences of asd
hemodynamic criteria for shock (sbp <90 mm hg, map <60 mm hg, ci <2.2 l/min/m², pcw >15 mm hg, cpo <0.6 w)
hemodynamic decompensation
hemodynamic demands (surgery, pregnancy, infection, anemia, bleeding)
hemodynamic determinants of aerobic capacity
hemodynamic durability
hemodynamic effects
hemodynamic effects of continuous infusion
hemodynamic effects of pregnancy
hemodynamic evaluation (cardiac catheterization)
hemodynamic evaluation (for shunts)
hemodynamic evaluation (lvot stenosis – valvular and subvalvular)
hemodynamic evaluation/monitoring
hemodynamic exercise testing
hemodynamic flow disturbances
hemodynamic function
hemodynamic instability
hemodynamic intervention
hemodynamic load
hemodynamic measurement (invasive filling pressures)
hemodynamic measurements
hemodynamic measurements (systolic pressure, systemic pressure)
hemodynamic mismatch (resting vs. clinical symptoms)
hemodynamic monitoring
hemodynamic monitoring & profiling
hemodynamic monitoring (invasive)
hemodynamic monitoring after valve intervention
hemodynamic monitoring during transport
hemodynamic outcomes
hemodynamic overload
hemodynamic parameters (e.g., pulmonary vascular resistance, left heart filling pressures)
hemodynamic parameters (gradient ≥ 50 mm hg)
hemodynamic parameters: ejection fraction, reduced vs preserved ejection fraction
hemodynamic predictors of surgical success
hemodynamic profile (including transpulmonary gradient)
hemodynamic progression
hemodynamic response
hemodynamic response / hemodynamics
hemodynamic risk profile
hemodynamic sequelae
hemodynamic sequelae of childhood repair
hemodynamic severity
hemodynamic severity of valvular lesions
hemodynamic shear stress
hemodynamic shunt assessment (qp:qs)
hemodynamic significance
hemodynamic stability
hemodynamic stability (blood pressure, intracardiac volume)
hemodynamic stabilization
hemodynamic stress
hemodynamic study
hemodynamic success
hemodynamic valve deterioration
hemodynamically insignificant shunt
hemodynamically poorly tolerated af
hemodynamically severe obstruction** (≥15 mm hg gradient)
hemodynamically significant aortic regurgitation
hemodynamically significant arrhythmias
hemodynamically significant intrathoracic shunt (qp:qs ≥ 1.5, chamber enlargement)
hemodynamically significant lesion
hemodynamically significant pulmonary regurgitation
hemodynamically significant stenosis
hemodynamically stable
hemodynamically stable af
hemodynamically stable patient
hemodynamically unstable aortic patients
hemodynamics
hemodynamics (cardiac catheterization)
hemodynamics (hemodynamic monitoring, monitoring of pulmonary pressures, systemic vascular resistance)
hemodynamics (intracardiac pressures, cardiac output)
hemodynamics (optimization)
hemodynamics of congenital lesions
hemodynamics of fontan failure
hemodynamics of rv‑to‑pa conduit
hemodynamics of valve function
hemodynamics of valve type and size
hemoglobin & oxygen saturation dynamics
hemoglobin a1c
hemoglobin a1c (hba1c)
hemoglobin level
hemoglobin level (10 g/dl target)
hemoglobin level (≥ 10 g/dl, < 7–8 g/dl)
hemoglobin targeting (>10 g/dl)
hemoglobin a1c
hemolysis
hemolytic anemia / intractable hemolysis
hemopericardium
hemoptysis
hemoptysis (lung parenchyma rupture)
hemorr2hages score
hemorrhage
hemorrhage / bleeding risk
hemorrhage / major bleeding
hemorrhage control
hemorrhage control (vascular)
hemorrhagic risk
hemorrhagic shock
hemorrhagic shock pathophysiology
hemorrhagic stroke
hemorrhagic transformation (stroke)
hemostasis
hemostasis / bleeding cessation
hemostasis/ hemostatic effectiveness
hemostatic abnormalities (coagulation factor deficiencies, hyperfibrinolysis, platelet dysfunction)
hemostatic alterations
hemothorax
heparin
heparin (unfractionated heparin, ufh)
heparin infusion
heparin management
heparin use in endovascular aortic repair
heparin‑induced thrombocytopenia
heparin‑induced thrombocytopenia (hit)
hepatic congestion
hepatic disease
hepatic dysfunction
hepatic dysfunction (elevated bilirubin, alt/ast/ap, cirrhosis)
hepatic dysfunction (fontan‑associated)
hepatic dysfunction (right‑hf‑related)
hepatic fibrosis / cirrhosis
hepatic function
hepatic metabolism
hepatic screening
hepatic testing
hepatic toxicity (dronedarone)
hepatic toxicity (liver)
hepatic transaminase elevation
hepatic vein systolic flow reversal
hepatocellular carcinoma
hepatocellular carcinoma & liver cirrhosis (in fontan patients)
hepatologist
hepatologist consultation
hepatology (transplant hepatology)
hepatorenal dysfunction
hepatotoxicity
hepatotoxicity (amiodarone‑associated)
heritable bicuspid aortic valve
heritable thoracic aortic aneurysm (taa)
heritable thoracic aortic aneurysm/dissection (htad)
heritable thoracic aortic disease
heritable thoracic aortic disease (htad)
heterogeneity of repolarization
heterogeneous conduction velocity
heterogeneous myocardial infarction outcomes
heterotaxy
heterotaxy syndrome
heterozygous familial hypercholesterolemia (fh)













hf
hf (heart failure)
hf as an independent risk factor for stroke, systemic embolism, mortality
hf hospitalization
hf hospitalization (re‑hospitalization)
hf hospitalizations
hf incidence
hf mortality
hf nurses
hf readmission / rehospitalization
hf registry participation
hf risk scoring
hf self‑care
hf staging
hf transplant centers
hf with improved ef (hfimpef)
hf with mildly reduced ef (hfmref)
hf with preserved ef (hfpef)
hf with preserved ejection fraction (hfpef)
hf with reduced ef (hfref)
hf with reduced ejection fraction (hfref)
hf – heart failure
hfa‑peff diagnostic algorithm (heart failure association – european society of cardiology)
hfmref (heart failure with mildly reduced ejection fraction)
hfpef (heart failure with preserved ejection fraction)
hfpef (heart‑failure with preserved ejection fraction)
hfpef – heart failure with preserved ejection fraction
hfref (heart failure with reduced ejection fraction)
hfref (heart‑failure with reduced ejection fraction)
hfref – heart failure with reduced ejection fraction
hfsa (heart failure society of america)
hfsa (heart failure society of america) guideline
hfsa heart failure guideline
hf‑action (heart failure: a controlled trial investigating outcomes of exercise training)
hf‑action predictive risk score
hibernating myocardium
high bleeding risk
high bleeding risk estimators
high bleeding‑risk procedures
high blood cholesterol
high blood pressure
high blood pressure (bp)
high blood pressure (hypertension)
high blood pressure / hypertension in adults
high blood pressure / hypertension management
high blood pressure prevention
high cardiovascular risk
high cha₂ds₂‑vasc score (>5)
high ef with diastolic dysfunction (≥40 %)
high gastrointestinal bleeding risk
high la pressure
high mortality
high or prohibitive surgical risk
high physical performance occupations (law enforcement, firefighters)
high pressure (right‑sided or left‑sided)
high procedural risk
high pulmonary vascular resistance (pvr)
high success rate
high surgical risk
high thrombotic risk
high-grade lvot gradients (80–100 mm hg)
high-volume aortic center
high-volume surgeon
highly penetrant risk
highly resistant organisms
high‐value economic therapy
high‑altitude exposure
high‑burden atrial fibrillation
high‑carbohydrate diet
high‑complexity coronary artery disease (cad)
high‑cost therapies
high‑degree atrioventricular (av) block
high‑density lipoprotein (hdl)
high‑density lipoprotein cholesterol (hdl‑c)
high‑dose aspirin
high‑dose aspirin (162‑325 mg)
high‑dose aspirin therapy
high‑dose diuretics
high‑dose glucocorticoid induction
high‑dose glucocorticoids
high‑flow oxygen in suspected acute coronary syndrome
high‑grade atrioventricular block
high‑gradient as
high‑gradient severe as
high‑impact area (improving patient outcomes)
high‑intensity anticoagulation
high‑intensity endurance training (≥3 h/day)
high‑intensity exercise‑based cardiac rehabilitation
high‑intensity immunosuppressive therapy
high‑intensity interval training
high‑intensity interval training (exercise)
high‑intensity interval training (hiit)
high‑intensity interval training (hit)
high‑intensity or competitive exercise
high‑intensity statin
high‑intensity statin therapy
high‑negative predictive value (>99.5 %)
high‑output heart failure
high‑output state
high‑potency (high‑intensity) statin
high‑pressure inlet chamber (rv)
high‑quality communication
high‑quality integrated multidisciplinary care
high‑quality, drug‑specific evidence for cardiotoxicity screening and monitoring
high‑risk acs (lvef ≤ 40 %, hypertension, diabetes mellitus, anterior stemi)
high‑risk anatomy (aaoca)
high‑risk anatomy (ostial/proximal stenosis, slit‑like orifice, acute angle of takeoff, intramural course)
high‑risk aortopathies (high‑risk cardiac conditions)
high‑risk aortopathy
high‑risk ascvd
high‑risk cardiac conditions
high‑risk cardiac disease in pregnancy
high‑risk cardiac surgery
high‑risk cardiovascular profile
high‑risk clinical findings
high‑risk clinical scenarios (comorbid conditions, social factors)
high‑risk conditions
high‑risk conditions for ascvd (age ≥ 65, familial hypercholesterolemia, prior coronary interventions, etc.)
high‑risk drinking
high‑risk features
high‑risk features (e.g., ventricular arrhythmias, atrioventricular conduction abnormalities)
high‑risk features (in myocarditis)
high‑risk features (in uncomplicated cases)
high‑risk features for adverse aortic events
high‑risk features for myocarditis
high‑risk features of rupture
high‑risk imaging features
high‑risk imaging findings
high‑risk left‑sided valve disease
high‑risk non‑cardiac surgery
high‑risk pathways
high‑risk patient populations (male predominance, older age)
high‑risk patient selection for aortic procedures
high‑risk patients
high‑risk plaque
high‑risk procedures during pregnancy
high‑risk reintervention (e.g., porcelain aorta, prior radiation)
high‑risk surgery
high‑risk, moderate‑risk, high‑probability categories
high‑sensitive cardiac troponin t (ctnt)
high‑sensitivity cardiac troponin (hs‑ctn)
high‑sensitivity crp ≥ 2.0 mg/l
high‑sensitivity c‑reactive protein (hscrp)
high‑sensitivity c‑reactive protein (hs‑crp)
high‑sensitivity troponin
high‑sensitivity troponin (tnt / tni)
high‑sensitivity troponin t (hs‑tnt)
high‑value clinical interventions
high‑velocity severe as (stage d1)
high‑volume aortic center
high‑volume aortic/heart‑valve center
high‑volume surgeons / high‑volume centers
high‑volume transplant centers with achd accreditation
high‑volume valve‑surgery centers
high‑volume versus low‑volume surgeons
high‑volume vs. low‑volume surgical centers
high blood cholesterol
hinge points for ascending aorta (≥ 5.25 – 5.75 cm)
his bundle displacement
his bundle pacing
hispanic/latino populations
histiocytes
histologic diagnosis (in myocarditis)
histopathologic criteria (dallas criteria)
history and physical examination
history of coa (coarctation of the aorta)
history of major bleeding
history of stroke
history of tia
his‑bundle pacing
his‑bundle pacing (his‑sp) / his‑bundle correction
hiv
hiv infection and cardiovascular risk
hiv‑associated cardiac disease
hiv‑associated cardiovascular disease risks (e.g., abacavir, protease inhibitors, ritonavir, dolutegravir)
hlhs (hypoplastic left heart syndrome)
hoarseness (recurrent laryngeal nerve compression)
holodiastolic flow reversal in abdominal aorta
holosystolic eccentric jet mr
holter monitor
holter monitor (24‑hour, 10‑day)
holter monitoring
holter‑based electrocardiographic monitoring
holt‑oram syndrome
holt‑oram syndrome (tbx5)
home or community setting for exercise
homelessness
home‑based cardiac rehabilitation
home‑based cr programs
home‑based exercise program
home‑based exercise programs
home‑based exercise training program
home‑based mobile cardiac rehabilitation
home‑based walking exercise
home‑based walking program
home‑delivered meals
homocysteine
homocysteine‑lowering therapy (folic acid & b‑vitamins)
homograft (aortic or pulmonary)
homograft aortic root replacement
homograft valve
homografts
hope study (heart outcomes prevention evaluation)
hope trial
hope trial (ramipril)
hope‑2 trial (heart outcomes prevention evaluation‑2)
hormonal contraception & risk of venous thromboembolism
hormonal contraception cardiovascular risk
hormonal influences on cardiac rhythm (e.g., elevated progesterone)
hormonal therapies → growth hormone, testosterone
hormonal therapy
hormone replacement therapy in achd patients
hormone therapy (estrogen, estrogen‑progesterin, oral contraceptives, hormonal contraceptives)
horner’s syndrome (sympathetic chain compression)
hospice care
hospice enrollment
hospice referral for advanced hf with <6 month survival
hospital admission outcomes for af/flutter
hospital cost analysis in aortic surgery
hospital discharge / early after discharge management
hospital discharge criteria
hospital discharge in acs management
hospital discharge planning
hospital length of stay
hospital length of stay (as outcome of rate‑control efficacy)
hospital morbidity/mortality
hospital mortality rate
hospital or outpatient facility setting for exercise
hospital performance metrics (30‑day all‑cause readmission)
hospital procedural volume
hospital procedural volume (quintiles)
hospital readmission
hospital readmission / re‑hospitalization
hospital volume
hospital volume outcomes
hospitalization
hospitalization & mortality rates (related to hf management)
hospitalization (all‑cause, cardiovascular, hf)
hospitalization (all‑cause, hf‑specific)
hospitalization (cardiac, hf, acs)
hospitalization (hf hospitalization, hfh)
hospitalization (hf‑related)
hospitalization / hospitalisations
hospitalization / readmission
hospitalization / rehospitalization
hospitalization and readmission (rehospitalization)
hospitalization due to heart failure
hospitalization due to heart failure (hf)
hospitalization for antiarrhythmic initiation
hospitalization for heart failure
hospitalization for hf
hospitalization for ischemia or hf
hospitalization for unstable angina
hospitalization for worsening heart failure
hospitalization rate (hf hospitalizations)
hospitalization rates for hf
hospitalization risk
hospitalization trends & health‑resource utilization
hospitalizations
hospitalizations (all‑cause)
hospitalized heart failure
hospitalized patients with af and rvr
hospital‑based discharge medication program
hospital‑based stemi care
hospital‑to‑home initiative
hospital‑to‑home initiatives
host‑exam trial
hot cafe trial
housing insecurity
housing instability
housing stability
housing status
how to treat chronic atrial fibrillation (hot cafe)
hps2‑thrive trial (niacin + laropiprant)












hrs (heart rhythm society)
hrs expert consensus on arrhythmogenic cardiomyopathy
htad (heritable thoracic aortic disease)
htad (heritable thoracic aortic disease) incidence among reintervention patients
htx – heart transplant
human immunodeficiency virus (hiv)
human immunodeficiency virus (hiv) (as a cardiovascular risk factor)
human leukocyte antigen (hla)
human leukocyte antigen class ii (hla‑ii) associations
human leukocyte antigen haplotypes
hurst’s the heart online
hybrid and convergent ablation procedures
hybrid approach
hybrid approach (combining endovascular and open methods)
hybrid approaches (combined surgical/endovascular)
hybrid arch exclusion (zone 0‑0)
hybrid cardiac rehabilitation (cr)
hybrid cardiovascular procedures
hybrid catheterization laboratory
hybrid cr models
hybrid endovascular approach
hybrid epicardial‑endocardial ablation
hybrid imaging (pet/spect with ct, mri)
hybrid operating room
hybrid operating room (or) laboratory
hybrid or bridging approach
hybrid percutaneous coronary intervention (pci)
hybrid procedure
hybrid procedure (closed‑chest epicardial + endocardial ablation)
hybrid procedure (combination of open and endovascular)
hybrid programs (facility‑based & community/home‑based)
hybrid repair (endovascular + open)
hybrid repair of aortic aneurysm
hybrid revascularization
hybrid revascularization strategies
hybrid surgery (endovascular + open)
hybrid surgical repair of coa
hybrid technique
hybrid techniques
hybrid techniques (open, percutaneous, or combined)
hydralazine
hydralazine + nitrate therapy
hydralazine and isosorbide dinitrate
hydralazine and isosorbide dinitrate (hydral‑nitrates)
hydralazine and isosorbide dinitrate therapy for hfref in black or african american patients
hydralazine‑isosorbide dinitrate (h‑isdn)
hydralazine‑isosorbide dinitrate combination
hydralazine‑isosorbide dinitrate for black patients with heart failure
hydralazine‑isosorbide therapy in hf (african american and non‑african american)
hydration (pre‑contrast)
hydration status
hydrochlorothiazide
hydrocortisone
hydroxychloroquine (dmard)
hyperacute aortic dissection
hyperbaric oxygen therapy
hypercholesterolemia
hypercholesterolemia (as a risk factor)
hypercholesterolemia (high cholesterol)
hypercholesterolemia (primary severe hypercholesterolemia)
hypercholesterolemia / familial hypercholesterolemia
hypercoagulability
hypercoagulable state
hypercoagulable state (e.g., active malignancy, genetic thrombophilia)
hypercoagulable state in hf
hypercoagulable states
hypercoagulable syndromes
hyperkalemia
hyperkalemia (serum potassium >5.0 meq/l)
hyperkalemia (serum potassium ≥ 5.5 meq/l)
hyperlipidemia
hyperlipidemia (high ldl‑c, low hdl‑c)
hypersensitivity syndrome
hypertelorism
hypertension
hypertension (antihypertensive therapy)
hypertension (arterial hypertension)
hypertension (as a cardiovascular comorbidity)
hypertension (as a risk factor for aortic dissection)
hypertension (as a risk factor)
hypertension (blood‑pressure control)
hypertension (high blood pressure)
hypertension (high blood pressure) management
hypertension (high blood pressure) – includes systolic bp (sbp), diastolic bp (dbp)
hypertension (htn)
hypertension (immunology and neurohumoral effects)
hypertension (post‑coa)
hypertension (pre‑existing and pregnancy‑related)
hypertension (resting bp >140/90 mm hg or treated)
hypertension (risk factor)
hypertension (systemic and exercise‑induced)
hypertension (systolic >140 mm hg)
hypertension / blood pressure (bp)
hypertension / blood pressure management
hypertension / high blood pressure
hypertension / high blood pressure (bp)
hypertension / high blood pressure (hbp)
hypertension / uncontrolled hypertension
hypertension as a cardiovascular risk factor
hypertension control
hypertension definition (seventh report/jnc7)
hypertension guideline
hypertension in aortic stenosis
hypertension in hfpef
hypertension management (beta‑blockers, acei/arb)
hypertension management (restenosis‑free)
hypertension management in elderly/elderly consensus documents
hypertension management in pregnancy
hypertension prevalence in black patients
hypertension screening (office, home, ambulatory)
hypertension‑associated aortic disease (htad)
hypertensive cardiomyopathy
hypertensive diseases of pregnancy
hypertensive disorders of pregnancy
hypertensive therapy
hyperthyroidism
hyperthyroidism (cardiac effects)
hyperthyroidism / thyrotoxicosis
hyperthyroidism‑related hf
hypertriglyceridemia
hypertriglyceridemia (≥500 mg/dl)
hypertrophic cardiomyopathy
hypertrophic cardiomyopathy (hcm)
hypertrophic cardiomyopathy registry (hcmr)
hypertrophic obstructive cardiomyopathy
hypertrophic subaortic stenosis
hypertrophic subaortic stenosis (sas)
hypertrophied muscle bundles
hypertrophied papillary muscles
hyperuricemia
hyperventilation
hyperviscosity
hyperviscosity management (rehydration, iron replacement, phlebotomy)
hyperviscosity symptoms
hyperviscosity symptoms (headache, visual disturbance)
hyperviscosity syndrome
hyper‑ or hypothyroidism
hypoattenuation of valve leaflets
hypocoagulability
hypoglycemia risk
hypokalaemia
hypokalemia
hypokinetic hypertrophic cardiomyopathy
hypomagnesemia
hyponatremia
hyponatremia (serum sodium < 134 meq/l)
hyponatremia? (not in the excerpt)
hypoperfusion
hypoperfusion (resting, low pulse pressure)
hypoplasia of the proximal segment
hypoplastic aorta
hypoplastic aortic root
hypoplastic left heart syndrome (hlhs)
hypoplastic left heart syndrome (hlhs) – norwood repair
hypoplastic right or left ventricle
hyporesponder status
hypotension
hypotension (as a side‑effect of rhythm‑control drugs)
hypotension (drug‑induced)
hypotension (refractory, leading to cardiac arrest)
hypotension (sbp < 100 mm hg)
hypotension (symptomatic)
hypotension (systemic and pulmonary)
hypotension / shock
hypotensive events
hypotensive management in hf
hypothermic circulatory arrest
hypothyroidism
hypothyroidism (cardiac effects)
hypothyroidism‑related hf
hypovolemia
hypoxemia
hypoxemia (mild, moderate, severe)
hypoxemia (resting spo₂ ≤ 92 %)
hypoxia (oxygen saturation < 90 %)
hypoxia (tissue oxygenation inadequate)
hypo‑ or hyperthyroidism
h₂fpef score (diagnostic composite score for hfpef)
h₂fpef score components (obesity, af, age, antihypertensive meds, e/e′, pa pressure)















iabp‑shock ii study
iabp‑shock ii trial
iatrogenic dissection of right coronary artery
iatrogenic etiologies (device leads, endomyocardial biopsy)
ibrutinib (bruton’s tyrosine kinase inhibitor)
ibrutinib‑associated atrial fibrillation
ibuprofen
ibutilide
ibutilide (class iii agent)
ica‑l (l‑type ca²⁺ channel)
icd
icd (implantable cardioverter‑defibrillator)
icd (implantable cardioverter‑defibrillator) therapies
icd and crt indications
icd cost‑effectiveness
icd implantation for primary prevention
icd implantation in adults and children
icd lead failure / lead infection
icd placement for sports participation (contraindicated)
icd programming
icd shock
icd shock rates
icd shocks
icd shocks (appropriate and inappropriate)
icd shocks (appropriate icd shocks)
icd shocks (appropriate/inappropriate)
icd shocks (inappropriate)
icd therapies reduction
icd therapy (appropriate shocks)
icd therapy compliance
icd utilization
icd – implantable cardioverter‑defibrillator
icosapent ethyl
icosapent ethyl (eicosapentaenoic acid ethyl ester)
icosapent ethyl (epa ethyl ester)
icosapent ethyl (epa)
icosapent ethyl (purified epa)
icosa­pent ethyl (epa‑only formulation)
icu (intensive care unit)
icu/multidisciplinary team (mdt) involvement
id (indeterminate entry tear, e.g., i9)
idarucizumab
idarucizumab (dabigatran antidote)
idarucizumab (dabigatran reversal agent)
ideal cardiovascular health
identification of health disparities in pad (qm‑5)
idiopathic dilated cardiomyopathy
idiopathic dilated cardiomyopathy (dcm)
idiopathic giant cell myocarditis
idiopathic hypertrophic subaortic stenosis
idiopathic pulmonary arterial hypertension
idorsia
ife (immunofixation electrophoresis)
ifr‑guided pci (instantaneous wave‑free ratio > 0.89)
ik1 (inward rectifier k⁺ current)
ikach (acetylcholine‑activated k⁺ channel)
ikr (rapid delayed rectifier k⁺ current)
ikr inhibitor
iks (slow delayed rectifier k⁺ current)
ikur (ultra‑rapid delayed rectifier k⁺ current)
iliac access
iliac access parameters
iliac artery aneurysm
iliac artery aneurysm (common, internal, external)
iliac artery conduit
iliac artery graft conduit
iliac artery recanalization
iliac artery stenting
iliac artery/iliofemoral access
iliac seal diameter
iliac stenting
iliofemoral bypass
iloprost
iloprost therapy
imagine trial
imaging and engineering advances for valve diagnosis and treatment.
imaging assessment of neopulmonary outflow tract obstruction
imaging assessment of pulmonary stenosis and regurgitation
imaging biomarkers
imaging diagnostic criteria for stenosis severity
imaging diagnostics: fdg‑pet/ct, ct angiography, mri, indium‑labeled wbc scan
imaging evolution (ct follow‑up)
imaging features: high‑risk, focal intimal disruption, tiny intimal disruption
imaging for aortic disease (ct, mri, echocardiography)
imaging for assessment of laao efficacy
imaging for lv thrombus detection
imaging for pad (angiography, duplex ultrasound, etc.)
imaging for reinfection (axial imaging, identification of inflammatory changes, fluid or air collections, pseudoaneurysm formation)
imaging frequency guidelines (cmr imaging every 1–5 years)
imaging guidance in pci
imaging in large‑vessel vasculitis (e.g., pet, ct, mr)
imaging in loeys‑dietz syndrome
imaging interval based on aortic diameter and growth rate
imaging intervals (5‑year, 10‑year, 2‑3‑year, annual)
imaging intervals based on aortic size and progression
imaging intervals for long‑term surveillance
imaging laboratory records
imaging modalities
imaging modalities (ct, cmr, pet, mpi)
imaging modalities (mri, ct, angiography)
imaging modalities for aortic surveillance
imaging modalities:
imaging modalities: 2‑d echocardiography, 3‑d echocardiography, cardiac mri (cmr)
imaging modalities: computed tomography (ct), magnetic resonance imaging (mri), transthoracic echocardiography (tte)
imaging modalities: ecg, chest x‑ray, tte, ct, cmr, stress testing, tee, cardiac catheterization
imaging modality
imaging modality for myocardial hypertrophy pattern (apical, atypical, etc.)
imaging modality for pannus detection
imaging of postsurgical aorta
imaging of the aorta (ct, mri, tee)
imaging phenotype
imaging studies
imaging surveillance
imaging surveillance (ct, mri, pet‑ct, tee)
imaging techniques (ct, mri, echocardiography, intravascular ultrasound, abdominal ultrasound)
imaging: computed tomography (ct)
imaging: magnetic resonance imaging (mri)
imaging: transthoracic echocardiogram (tte)
imaging‑only evidence of malperfusion
imatinib
immediate (early) surgical outcomes
immediate (single‑procedure) multivessel pci
immediate mortality risk (per hour)
immediate revascularization
immune checkpoint blockade
immune checkpoint inhibitors
immune checkpoint inhibitors (ici)
immune checkpoint inhibitors (treatment implications)
immune checkpoint‑inhibitor‑associated myocarditis
immune phenotyping
immune polarization
immune tolerance
immune‑checkpoint inhibitors
immune‑checkpoint‑inhibitor–induced myocarditis
immune‑checkpoint–related myocarditis
immune‑mediated inflammatory reaction
immunization (vaccine recommendations)
immunization for cardiovascular risk reduction (e.g., influenza vaccine, pneumococcal vaccine)
immunizations (in the context of cardiovascular risk)
immunocompromised hosts (fungal or tuberculous aortitis)
immunofixation electrophoresis (ife)
immunogenicity
immunoglobulin g4‑related disease
immunologic phenomena (immune complex deposition, rheumatoid factor)
immunological tolerance
immunomodulators
immunomodulatory drugs (lenalidomide, interleukin‑2)
immunophenotyping
immunosuppressive drugs (cyclosporine, tacrolimus, everolimus, sirolimus)
immunosuppressive therapies
immunosuppressive therapy
immunosuppressive therapy (e.g., for sarcoidosis, eosinophilic, giant‑cell myocarditis)
immunosuppressive therapy in myocarditis
impact of coronary artery anatomy on surgical outcomes
impact‑af program (computerized decision support for af care).
impaired chronotropic response (chronotropic incompetence)
impella device
implantable cardiac devices
implantable cardiac monitor
implantable cardiac monitor sensitivity for af
implantable cardiac monitors
implantable cardioverter defibrillator (icd)
implantable cardioverter-defibrillator (icd) therapy
implantable cardioverter‑defibrillator
implantable cardioverter‑defibrillator (icd)
implantable cardioverter‑defibrillator (icd) implantation
implantable cardioverter‑defibrillator (icd) in achd
implantable cardioverter‑defibrillator (icd) infection
implantable cardioverter‑defibrillator (icd) outcomes
implantable cardioverter‑defibrillator (icd) placement
implantable cardioverter‑defibrillator (icd) placement counseling for hfref
implantable cardioverter‑defibrillator (icd) shocks
implantable cardioverter‑defibrillator (icd) – shock risk
implantable cardioverter‑defibrillator leads
implantable cardioverter‑defibrillator lead–induced tricuspid regurgitation
implantable cardioverter‑defibrillator programming and testing
implantable cardioverter‑defibrillator shock appropriateness in repaired tof
implantable cardioverter‑defibrillator therapy
implantable cardioverter‑defibrillators
implantable cardioverter‑defibrillators (icd)
implantable cardioverter‑defibrillators (icds)
implantable cardioverter–defibrillator (icd)
implantable cardioverter–defibrillators (icds)
implantable cardio‑defibrillator (icd)
implantable defibrillator
implantable defibrillator complications
implantable defibrillator therapy
implantable devices
implantable devices (including cardiac resynchronization)
implantable electrical interventions (e.g., multipoint pacing, non‑excitatory electrical impulses)
implantable loop recorder
implantable loop recorder (implantable recorder)
implantable loop recorder clinical yield in af detection
implantable loop recorders
implantable cardioverter‑defibrillator (icd)
implantation timing of icd
implantation‑related complications
implanted defibrillator (icd)
implanted device
implanted electronic devices (icds, crt‑ds)
implementation science
implementation strategies
impless‑stic study (impella plus iabp for cardiogenic shock)
implicit bias in clinical decision‑making
implicit bias training in healthcare
impotence
improve‑it study (clinical trial)
improve‑it trial
improve it trial
in situ graft repair
in situ reconstruction
in situ venous reconstruction
in vitro fertilization with preimplantation genetic diagnosis (pgd)
in-hospital morbidity and outcomes
in-line blood flow
ina (sodium channel)
inadequate housing conditions
inadequate or excessive anticoagulation
inadequate social support
inappropriate icd shock
inappropriate icd shocks (e.g., in tetralogy of fallot)
inappropriate shock
inappropriate shocks
inappropriate vasodilatation
inari medical
inari medical (vascular interventions)
ina‑l augmentation
incarda
incidence
incidence (of cardiovascular conditions)
incidence of af
incidence of drug use–associated ie
incidence of heart failure
incidence of valve deterioration after 10 years
incidence/size thresholds for rupture or dissection
incident atrial fibrillation
incident heart failure (hf)
incident hf risk
inclisiran
inclisiran (monoclonal antibody)
inclisiran (small interfering rna pcsk9 inhibitor)
inclusion in clinical trials
inclusion of diverse patient groups
inclusion‑wrap technique
income level
incomplete penetrance
incomplete revascularization
inconvenience of monitoring
increased filling pressures
incremental cost‑effectiveness ratio
incremental cost‑effectiveness ratio (icer)
incremental decrease through aggressive lipid lowering (ideal) study
incremental increases in walking intensity
index of microcirculatory resistance (imr)
index of microvascular resistance (imr)
indexed right ventricular end‑diastolic volume (rvedv)
indexed right ventricular end‑systolic volume (rvesv)
indications for surgery based on lung biopsy in vsd/pda with severe ph
individual‑patient data meta‑analysis.
indomethacin therapy for pericarditis
inducible atrial fibrillation
inducible atrial fibrillation (at ablation)
inducible sustained ventricular arrhythmia
inducible ventricular arrhythmia
infant of mother with gestational diabetes
infarct size
infarction anterior cerebral artery
infarction middle cerebral artery
infarction posterior cerebral artery
infarct‑related artery
infected aneurysm
infected aortic aneurysm
infection
infection (advanced or bone/soft‑tissue involvement)
infection (as a precipitant for af)
infection (infective endocarditis, ie) – contraindication to transcatheter therapy, requires antibiotics before surgery
infection (prosthetic valve endocarditis)
infection management
infection management in pad patients
infection prevention guidelines for infective endocarditis
infection‑related complications
infection‑related heart disease indicators (fever >38 °c, vascular phenomena, immunologic phenomena)
infectious aneurysm
infectious aortitis
infectious aortitis (mycotic aneurysm)
infectious disease
infectious disease specialist
infectious disease specialists (mdt)
infectious disease specialists (role in ie care)
infective endocarditis
infective endocarditis (ie)
infective endocarditis (ie) prophylaxis
infective endocarditis (post‑valve or post‑repair)
infective endocarditis (risk factor)
infective endocarditis (valvular vegetation)
infective endocarditis (with vsd involvement)
infective endocarditis prophylaxis
infective endocarditis risk factors
infective material limiting valve occluder motion
inferior infarction
inferior vena cava (ivc) diameter
inferior vena cava (ivc) stenosis
infiltrative cardiac disease (amyloid, sarcoid, hemochromatosis)
infiltrative cardiomyopathies
infiltrative cardiomyopathies (e.g., amyloid)
infiltrative cardiomyopathy (e.g., amyloidosis)
infiltrative disorders
inflammation
inflammation (and inflammatory markers)
inflammation (as a cardiovascular risk factor)
inflammation (e.g., il‑6)
inflammation / metabolic derangement
inflammation and oxidative stress
inflammation biomarkers (related to heart failure prognosis)
inflammation‑induced ion channel dysfunction
inflammatory aortitis
inflammatory arthritis (cardiovascular events)
inflammatory biomarkers (e.g., crp, esr)
inflammatory bowel disease (acute coronary syndrome risk)
inflammatory cardiomyopathy
inflammatory cardiomyopathy (chronic)
inflammatory cells (within thrombus)
inflammatory cytokines
inflammatory cytokines (exercise‑induced)
inflammatory disease of the heart
inflammatory infiltrate (on emb)
inflammatory infiltrate classification
inflammatory infiltrate risk for vas
inflammatory infiltrates
inflammatory mechanisms (e.g., crp elevation, nlrp3 inflammasome)
inflammatory pathways
inflammatory response
inflammatory signaling
inflammatory signalling
inflammatory state
inflammatory aortitis
inflow disease
inflow lesions













influenza vaccination
influenza vaccination (as a preventive measure for cardiovascular risk)
influenza vaccination as secondary prevention for cardiovascular disease
influenza vaccination in heart failure
influenza vaccination status
influenza vaccine
infragenicular arterial bypass
infrainguinal autogenous vein bypass grafts
infrainguinal bypass graft
infrapopliteal arterial disease
infrapopliteal arterial segment
infrapopliteal arteries (tibial, pedal)
infrapopliteal balloon angioplasty
infrapopliteal bypass
infrapopliteal disease
infrapopliteal intervention
infrarenal aaa
infrarenal aorta
infrarenal aortic ulcer therapy
infra‑popliteal disease
infra‑popliteal procedures
infundibular right ventricular outflow obstruction / double‑chamber right ventricle
infundibulotomy
infundibulum (outflow tract)
infuse‑ami trial
inhaled iloprost
inhaled nitric oxide (pre‑operative test)
inheritable cardiomyopathies
inherited cardiomyopathies
inherited cardiomyopathy genes
inherited channelopathies (e.g., brugada, catecholaminergic polymorphic ventricular tachycardia)
inherited connective‑tissue disorders with cardiac manifestations (e.g., marfan syndrome, hypertrophic cardiomyopathy)
inherited heart disease
inherited ion‑channel disorders
inherited vascular connective tissue disorder
injection drug use (risk factor for ie)
injection drug users (idu)
injection drug use–associated ie
injection‑site reaction (adverse effect of pcsk9 therapies)
injury after pci
inner‑edge measurement
inner‑edge to inner‑edge measurement
innominate artery
innominate artery cannulation
inoperable severe aortic stenosis
inotersen (drug for attrv)
inotersen therapy
inotrope dependence
inotrope strategies
inotropes
inotropes (intravenous)
inotrope‑dependent advanced hf
inotropic agents
inotropic agents (milrinone, dobutamine, dopamine, epinephrine, norepinephrine)
inotropic infusion
inotropic support
inotropic support (e.g., dobutamine, milrinone)
inotropic support / inotropes
inotropic support trials
inotropic therapy
inotropic therapy (intravenous inotropes)
inotropic/pressor support
inoue balloon‑dilation method
inpatient care setting – cardiovascular care context
inpatient monitoring of heart failure
inr (international normalized ratio)
inr goal (2–3)
inr monitoring
inr target ranges
inr target ranges (1.5‑2.0, 2.5, 2.0‑3.0)
insertable cardiac monitor
insomnia and risk of cardiovascular disease
inspiratory muscle strength
inspiratory muscle training
instantaneous wave‑free ratio (ifr)
instantaneous wave‑free ratio (ifr)
instead (investigation of stent grafts in patients with type b aortic dissection)
institutional expertise in congenital heart disease (chd)
institutional imaging availability
institutional volume
insufficient blood flow to the heart muscle
insulin resistance
insulin sensitivity
insurance barriers
insurance reimbursement for exercise therapy
insurance status / health insurance coverage
intact ventricular septum
integrated cardio‑oncology framework
integrated chronic care models
integrated lifestyle and risk‑factor modification programs (lrfm)
integrated systems biology models for hf diagnosis, prognosis, and therapy targeting.
intense endurance exercise
intensity rating of breathlessness
intensive blood pressure lowering
intensive blood‑pressure control
intensive blood‑pressure control (sprint)
intensive blood‑pressure lowering
intensive blood‑pressure management
intensive blood‑pressure reduction
intensive blood‑pressure reduction studies
intensive bp control
intensive bp control (<120 mm hg)
intensive cardiac rehabilitation
intensive care setting
intensive care unit
intensive care unit (icu)
intensive care unit (icu) admission
intensive care unit (icu) coverage
intensive care unit (icu) monitoring
intensive care unit (icu) organization
intensive care unit (icu) patients with cardiac rhythm issues
intensive care unit (icu) services (as a readmission risk factor)
intensive care unit (icu) specialized in acute aortic/heart disease management
intensive care unit (icu) stay
intensive glucose lowering
intensive lifestyle intervention (diet, exercise)
intensive lipid lowering
intensive sbp goal (<120 mm hg)
intensive statin intensity (moderate‑intensity, high‑intensity)
intensive/statistically significant risk reduction
intensivists
interarterial course of coronary artery
interatrial baffle
interatrial conduction time
interatrial shunt
interfacility transfer of patients with acute type a aortic dissection
interleukin (il)
interleukin‑17 (il‑17)
interleukin‑2 receptor (soluble il‑2r)
interleukin‑37 (il‑37)
interleukin‑4 (il‑4)
interleukin‑6 (il‑6)
interleukin‑6 receptor (il‑6r)
intermacs
intermacs (interagency registry for mechanically assisted circulatory support)
intermacs profiles
intermacs profiles (1–7, interagency registry for mechanically assisted circulatory support)
intermacs profiles (cardiogenic shock, inotropic dependence, etc.)
intermacs profiles of advanced hf
intermacs profiling
intermacs registry for adult chd patients on mcs
intermediate care unit
intermediate care unit (icu)
intermediate risk (≥7.5 %–<20 %)
intermediate, high, and low risk of ischemic events
intermediate‑risk patients
intermittent claudication
intermittent claudication management
intermittent pneumatic compression
intermittent pneumatic compression device (arterial pump)
intermittent walking
internal iliac artery
internal iliac artery exclusion
internal mammary coronary artery anastomosis
internal medicine specialist
international classification of diseases (icd)
international guidelines (e.g., circulation acs guideline)
international journal of cardiology
international multicenter angina exercise (image) study
international normalised ratio (inr)
international normalized ratio (inr)
international normalized ratio (inr) monitoring
international paediatric and congenital cardiac code
international registry of acute aortic dissection
international registry of acute aortic dissection (irad)
international registry of acute aortic dissection (irad) score
international registry of patients with tgfbr1/tgfbr2 mutations (montalcino aortic consortium).
international society for adult congenital heart disease (isachd)
international society for heart lung transplantation (ishlt) listing criteria
international society for the advancement of cardiovascular surgery (isachd)
international society of heart & lung transplantation (ishlt) guidelines
international standardization of diagnostic criteria for microvascular angina
international standardization of diagnostic criteria for vasospastic angina
internet‑based education
interpersonal safety
interposition graft
interposition grafting
interposition grafts
interrupted aortic arch
interrupted aortic arch type b
intersectionality (combined risk factor impact)
intersocietal accreditation commission (iac)
intersocietal accreditation commission (iac) accreditation
intersocietal accreditation commission (iac) echocardiography laboratory accreditation
interstitial changes
interstitial edema
interstitial fibrosis
interstitial fibrosis (conduction heterogeneity)
interstitial lung disease
interstitial space characteristics
interval change
intervention (cardiac care)
intervention criteria in congenital heart conditions
intervention threshold
intervention threshold (≥10 cm²/m)
intervention thresholds (e.g., lvesd >50 mm, indexed >25 mm/m²)
intervention thresholds for valve repair/replacement
interventional and cardiovascular programs
interventional candidates
interventional cardiac systems
interventional cardiologist
interventional cardiologists
interventional cardiology
interventional cardiology in achd
interventional cardiology techniques
interventional cardiovascular procedures
interventional closure of ventricular septal defect
interventional echocardiographer (formalized role)
interventional echocardiographer (imaging guidance)
interventional procedures
interventional procedures (e.g., septal reduction)
interventional radiology
interventional radiology for aortic disease
interventional radiology for vascular disease
interventional radiology in aortic disease management
interventional techniques (arterial embolization, endovascular therapy)
interventional therapy (surgical or transcatheter lvot stenosis relief)
interventionist procedures for chd
interventions
interventions / policies
intervention‑free survival
interventricular septal thickness in diastole
intima
intima (intimal tear)
intimal defect
intimal disruption
intimal flap mobility
intimal injury
intimal medial hematoma (imh)
intimal tear
intimate partner violence
intraatrial placement of mitral prosthesis
intracardiac abscess
intracardiac arrhythmias
intracardiac conduit
intracardiac device
intracardiac echocardiography
intracardiac electrocardiograms (ecgs)
intracardiac mass
intracardiac mural thrombi
intracardiac pressures
intracardiac prosthetic materials (pacemaker leads)
intracardiac repair
intracardiac repair of congenital defects
intracardiac rhythm devices
intracardiac shunt
intracardiac shunt (e.g., patent foramen ovale)
intracardiac shunts
intracardiac shunts (other than apvc)
intracardiac surgery
intracardiac thrombi
intracardiac thrombosis
intracardiac thrombosis / embolism
intracardiac thrombus
intracavitary gradients
intracavitary pressure
intracellular sodium overload
intracerebral hemorrhage
intracerebral hemorrhage (ich)
intracerebral hemorrhage (iph)
intracoronary (ic) blockade
intracoronary abciximab
intracoronary drug delivery
intracoronary glycoprotein iib/iiia inhibitors
intracoronary imaging
intracoronary imaging (general)
intracoronary imaging (plaque assessment & regression)
intracoronary imaging guidance
intracoronary infusion of abciximab
intracoronary ultrasound‑enhancing contrast
intracoronary versus intravenous drug administration
intracranial aneurysm
intracranial aneurysm screening
intracranial aneurysm screening (mri/ct)
intracranial aneurysms (brain mri/ct angiography)
intracranial aneurysms screening
intracranial bleeding
intracranial haemorrhage (ich)
intracranial hemorrhage
intracranial hemorrhage (as a contraindication to fibrinolysis)
intracranial hemorrhage (ich)
intracranial hemorrhage recurrence risk
intracranial hemorrhage risk score
intracranial hemorrhage survivors
intracranial malignancy
intractable pain
intragastric (intracaval) imaging terms related to vascular pathology.
intralaminar hematoma (imh)
intralaminar intimal tear
intraluminal imaging
intraluminal thrombus
intramural arterioles (density)
intramural blood pool
intramural coronary artery abnormalities
intramural coronary course
intramural hematoma
intramural hematoma (imh)
intramyocardial muscle bundles
intraoperative atrial fibrillation
intraoperative decision making
intraoperative echocardiographic guidance
intraoperative echocardiography
intraoperative tee
intraoperative transesophageal echocardiography
intraoperative transesophageal echocardiography (tee)
intraoperative trans‑esophageal echocardiography (tee)
intraparenchymal bleeding
intrapericardial lvad
intraplaque hemorrhage (implied by bleeding risk contexts)
intraprocedural anticoagulation strategies
intraprocedural echocardiography
intraprocedural guidance
intraprocedural intravenous anticoagulation
intraprocedural ischemic events
intraprocedural myocardial contrast echocardiography
intraprocedural outcomes
intrapulmonary hemorrhage
intrathecal papaverine
intravascular catheter–associated bacteremia
intravascular complications (e.g., pulmonary vein stenosis)
intravascular filling defects (e.g., thrombus, dissection flap)
intravascular imaging
intravascular imaging‑guided pci
intravascular magnesium
intravascular pressure measurements
intravascular procedure
intravascular ultrasound
intravascular ultrasound (ivus)
intravascular ultrasound (ivus) for graft assessment
intravascular ultrasound (ivus) guidance
intravascular ultrasound assisted sizing
intravascular ultrasound imaging
intravenous (iv)
intravenous (iv) drug administration
intravenous (iv) platelet blockade
intravenous amiodarone
intravenous antiarrhythmic therapy
intravenous antibiotic treatment
intravenous anticoagulation
intravenous antimicrobial therapy
intravenous anti‑arrhythmic therapy
intravenous beta‑blocker use prior to reperfusion
intravenous beta‑blockers (e.g., esmolol, metoprolol, labetalol)
intravenous bolus
intravenous calcium channel blockers
intravenous cangrelor during pci
intravenous cangrelor trials (rcts 1–3)
intravenous catheter–associated bacteremia.
intravenous digoxin (digitalis glycoside)
intravenous diltiazem
intravenous diuretics
intravenous diuretics (bolus or continuous infusion)
intravenous drug delivery
intravenous drug use–associated endocarditis
intravenous drug use–related endocarditis
intravenous esmolol
intravenous flecainide
intravenous glycoprotein iib/iiia inhibition
intravenous glycoprotein iib/iiia inhibitors
intravenous heparin
intravenous heparin infusion (continuous or slow‑infusion)
intravenous ibutilide
intravenous ibutilide therapy
intravenous infusion
intravenous infusion of abciximab
intravenous infusion of eptifibatide
intravenous infusion of tirofiban
intravenous inotropes
intravenous inotropic agents
intravenous inotropic support
intravenous iron replacement for iron deficiency in hf
intravenous iron therapy
intravenous iron therapy (ferric carboxymaltose)
intravenous loading of sotalol
intravenous loop diuretics
intravenous magnesium
intravenous magnesium (as rate‑control therapy)
intravenous magnesium sulfate
intravenous methylprednisolone
intravenous nitroglycerin
intravenous nitroprusside
intravenous non‑dihydropyridine calcium‑channel blockers (e.g., verapamil, diltiazem)
intravenous p2y12 inhibition
intravenous pressure gradient (within rv)
intravenous procainamide
intravenous propafenone
intravenous prostacyclin
intravenous sotalol
intravenous sotalol therapy
intravenous streptokinase
intravenous thrombolysis
intravenous vasodilators (e.g., nicardipine, clevidipine, sodium nitroprusside)
intravenous verapamil
intravenous vitamin k
intravenous vitamin k
intravenous vs oral p2y12 inhibition
intravenous/intravenous drug hold (drug “hold” of 48 h)
intravenous/oral factor xa inhibitors (e.g., rivaroxaban)
intraventricular gradients
intraventricular myocardial stiffness
intra‑abdominal surgery
intra‑annular rv pacemaker or implantable cardioverter‑defibrillator leads
intra‑aortic balloon counterpulsation
intra‑aortic balloon counterpulsation (iabc)
intra‑aortic balloon counterpulsation (iabp)
intra‑aortic balloon pump
intra‑aortic balloon pump (iabp)
intra‑aortic balloon pump/support
intra‑aortic debris










intra‑atrial reentrant arrhythmias
intra‑atrial reentrant tachycardia (iart)
intra‑atrial re‑entrant tachycardia
intra‑atrial re‑entrant tachycardia (scar‑mediated)
intra‑cranial tumor / vascular abnormality
intra‑mural course
intra‑operative imaging
intrinsic cardiac risks
intrinsic coronary flow reserve (crf)
intrinsic flow compromise in myocardium
intrinsic mitral valve disease
intrinsic myocardial performance
intrinsic pulmonary vascular disease
invasive approach (routine invasive strategy)
invasive bacterial pathogens
invasive cardiac evaluation (catheterization)
invasive cardiac procedures
invasive cardiology
invasive coronary angiography
invasive coronary angiography (ica)
invasive coronary angiography prior to discharge
invasive coronary function testing (cormica trial)
invasive coronary physiology testing
invasive electrophysiology procedures
invasive hemodynamic assessment
invasive hemodynamic assessment (cardiac catheterization)
invasive hemodynamic characteristics
invasive hemodynamic evaluation
invasive hemodynamic measurement (rest or exercise)
invasive hemodynamic measurements
invasive hemodynamic monitoring
invasive hemodynamics
invasive lvot gradient measurement.
invasive lvoto evaluation
invasive management
invasive management of acute mi complicated by cardiogenic shock
invasive management of acute mi with cardiogenic shock (specific to acute mi)
invasive management of acute myocardial infarction
invasive management of obstructive hcm
invasive measurement (direct invasive measurement)
invasive measurement (of pah)
invasive measurements of pulmonary artery pressures
invasive monitoring
invasive pressure measurements
invasive procedure
invasive procedures
invasive risk stratification
invasive srt
invasive srts (myectomy, alcohol septal ablation)
invasive strategy
invasive strategy (angiography, revascularization)
invasive strategy for acs (including pci)
invasive treatment decisions (revascularization, amputation)
invasive treatment for obstructive hcm (e.g., surgical myectomy, alcohol septal ablation)
invasive versus non‑invasive treatment strategy
invasive vs. selective invasive strategy (routine invasive approach)
invest (international verapamil‑srv trandolapril) study
invest trial (international recommendations for bp management)
investigational device exemption (ide)
investigational devices
investigational stent graft devices
invictus trial
inward current (automaticity / early afterdepolarization)
inward rectifier potassium currents (i<sub>ka</sub>)
in‑hospital and 30‑day mortality (<1%)
in‑hospital mortality
in‑hospital mortality rate
in‑hospital stay
in‑situ reconstruction
in‑stent restenosis
in‑stent re‑stenosis
iodinated contrast
iodinated contrast agent
iodinated contrast allergy
iodinated contrast media
iodinated contrast nephrotoxicity (from ct)
ion channelopathy genes
ionis
ionizing radiation exposure
ionizing radiation exposure (from ct)
ipragliflozin
irad database
irad risk score
irbesartan
iron deficiency
iron deficiency (annual screening)
iron deficiency anemia
iron deficiency anemia in achd
iron deficiency therapy
iron metabolism & homocysteine levels
iron overload
iron studies (serum iron, total iron‑binding capacity, ferritin)
iron supplementation
ironout hf trial
ironwood
iron‑deficiency anemia
irreversible hepatic disease
irreversible neurological disease
irreversible renal disease
isachd (international society for adult congenital heart disease)
isar‑safe trial
ischaemia
ischaemic cardiomyopathy
ischaemic heart failure
ischaemic mitral regurgitation
ischemia
ischemia (e.g., myocardial or limb ischemia)
ischemia (general term encompassing myocardial, limb, and other tissue ischemia)
ischemia (general)
ischemia (heart ischemia)
ischemia (identified by myocardial perfusion imaging)
ischemia (irreversible, prolonged)
ischemia (limb and systemic)
ischemia (vascular‑related tissue hypoxia)
ischemia / severe recurrent ischemia
ischemia burden
ischemia extent
ischemia severity
ischemia severity (noninvasive testing)
ischemia trial
ischemia trial (stable cad, ischemia)
ischemia trial results
ischemia with no obstructive coronary artery disease (inoca)
ischemia with nonobstructive coronary arteries (inoca)
ischemia with non‑obstructive coronary arteries
ischemia with non‑obstructive coronary arteries (inoca)
ischemia with non‑obstructive coronary artery (inoca)
ischemia‑ckd study (invasive vs medical treatment for ckd)
ischemia‑driven revascularization
ischemia‑driven target vessel revascularization
ischemia‑reperfusion injury
ischemia without obstructive coronary artery disease (inoca)
ischemic adverse events
ischemic and bleeding risk assessment
ischemic burden
ischemic cardiomyopathy
ischemic cardiomyopathy / ischemic left‑ventricular dysfunction
ischemic cardiovascular events
ischemic changes on ecg
ischemic chronic secondary mr
ischemic colitis
ischemic events
ischemic events (myocardial infarction, stroke)
ischemic events (non‑fatal ischemia, myocardial infarction)
ischemic events / ischemic efficacy
ischemic foot ulcer in diabetic patients
ischemic heart disease
ischemic heart disease (ihd)
ischemic heart disease (stable ischemic heart disease)
ischemic heart failure
ischemic hf
ischemic insult
ischemic left ventricular dysfunction
ischemic limb
ischemic limb outcomes
ischemic mitral regurgitation
ischemic mr
ischemic myocardium
ischemic neurologic events
ischemic outcomes
ischemic rest pain
ischemic risk
ischemic skin changes
ischemic skin changes (wounds, ulceration)
ischemic stroke
ischemic stroke (relevant contraindication)
ischemic stroke in hcm
ischemic stroke risk
ischemic symptoms
ischemic symptoms (moderate‑to‑severe claudication pain)
ischemic symptoms assessment
ischemic time
ischemic cardiomyopathy
ischemix (ischemic vascular therapy)
isolated branch pulmonary artery stenosis
isolated or concomitant tricuspid valve repair or replacement
isolated pulmonary regurgitation
isolated pulmonary stenosis
isolated systolic hypertension
isolated tr (associated with af, preserved lvef)
isolated tricuspid regurgitation
isolated tricuspid regurgitation surgery
isolated tricuspid valve surgery
isolated ventricular septal defect
isolated pulmonary regurgitation
isometric exercise
isometric exercise training
isometric exercise training for blood‑pressure management
isometric resistance exercise
isoproterenol challenge
isosorbide dinitrate
isosorbide dinitrate (iso)
isosorbide dinitrate plus hydralazine (fixed‑dose combination)
isosorbide mononitrate
isotonic fluid replacement.
isthmus (crista terminalis)
ito (transient outward k⁺ current)
ivabradine
ivabradine (i‑channel inhibitor)
ivabradine therapy (targeting heart rate ≥ 70 bpm)
i‑aκ (mhc ii molecule on apcs)
i‑preserve (irbesartan in heart failure with preserved ejection fraction) study
i‑preserve score (irbesartan in heart failure with preserved ejection fraction study)













jacc (journal of the american college of cardiology)
jacc review topic of the week (cardiac shock care centers)
jacc state‑of‑the‑art review on cardiovascular drugs in pregnancy
jama (medical journal covering cardiovascular topics)
janeway lesions
janssen pharmaceuticals
janus kinase inhibitors
jcpm (joint commission on practice‑mediated)
jet velocities
jet width (percentage of lvot)
jnk2 signaling
johnson & johnson
joint british societies (jbs3) consensus
joint committee on clinical practice guidelines** (guideline‑development body)
joint committee on performance measures
journal of cardiovascular pharmacology
journal of clinical lipidology
journal of the american college of cardiology (jacc)
jugular venous distention
jugular venous pressure (jvp)
jump extension grafts
jupiter (justification for the use of statins in prevention) trial
juxtarenal aorta
j‑curve risk pattern for vigorous activity
j‑point definition
j‑shaped relationship (alcohol vs. cardiovascular outcomes)
j‑shaped relationship between alcohol and cardiovascular risk














kaneka pharma america llc
kansas city cardiomyopathy questionnaire (kccq)
kaplan‑meier method (used for af recurrence analysis)
kawasaki disease
kawasaki disease (congenital coronary involvement)
kawasaki disease (coronary sequelae)
kawashima procedure
kcnq1 (potassium voltage‑gated channel subfamily q member 1) variants
ketoacidosis (perioperative)
ketoconazole
key biomarkers
key clinical concepts from the text:
key clinical trials mentioned
key crt trials: companion, madit‑crt, reverse, block‑hf, care‑hf, raft, mustic‑af, spare, pave
key guideline terms
key heart disease–related terms
key heart disease–related terms extracted
key heart‑/vascular‑disease terms extracted from the guideline text
key heart‑disease related terms
key heart‑disease related terms (from the provided guideline text)
key heart‑disease related terms extracted
key heart‑disease related terms extracted from the document
key heart‑disease related terms extracted from the guideline text
key heart‑disease related terms extracted from the guidelines text
key heart‑disease related terms extracted from the provided text
key heart‑disease related terms extracted from the text
key heart‑disease related terms found in the text
key heart‑disease related terms from the guideline excerpt
key heart‑disease related terms from the text
key heart‑disease related terms identified in the text
key heart‑disease terms (from the hcm guideline excerpt)
key heart‑disease terms extracted
key heart‑disease terms extracted from the guideline
key heart‑disease terms extracted from the guideline text
key heart‑disease terms extracted from the guidelines
key heart‑disease terms extracted from the guidelines and cited studies
key heart‑disease terms extracted from the text
key heart‑disease terms extracted:
key heart‑disease terms found in the guideline excerpt
key heart‑disease terms identified
key heart‑disease terms identified in the excerpt
key heart‑disease terms identified in the guideline excerpt
key heart‑disease terms identified in the guideline text
key heart‑disease terms identified in the text
key heart‑disease terms mentioned in the text
key heart‑disease‑related terms
key heart‑disease‑related terms extracted from the guideline text
key heart‑disease–related terms
key heart‑disease–related terms extracted
key heart‑disease–related terms extracted from the guideline
key heart‑disease–related terms extracted from the text
key heart‑disease–related terms identified
key heart‑disease–related terms identified in the guideline excerpt
key heart‑disease–related terms identified in the text
key heart‑vascular terms extracted from the text
key medical‑device and pharmaceutical entities:
key terms related to heart (aortic) disease:
key terms related to heart (cardiovascular) disease in the guideline text
key terms related to heart disease
key terms related to heart disease (and vascular complications) in the guideline:
key terms related to heart disease (as extracted from the guideline excerpt)
key terms related to heart disease (as extracted from the guideline text)
key terms related to heart disease (as extracted from the provided text)
key terms related to heart disease (from the excerpt provided):
key terms related to heart disease (from the provided guideline excerpt)
key terms related to heart disease (from the provided text)
key terms related to heart disease (peripheral artery disease & related care):
key terms related to heart disease (primarily peripheral artery disease)
key terms related to heart disease (valvular and hemodynamic):
key terms related to heart disease (vascular/ischemic disease) extracted from the guideline text
key terms related to heart disease / cardiovascular care:
key terms related to heart disease extracted from the guideline text
key terms related to heart disease extracted from the guideline text:
key terms related to heart disease extracted from the guideline:
key terms related to heart disease extracted from the text
key terms related to heart disease found in the text
key terms related to heart disease found in the text:
key terms related to heart disease in the guideline
key terms related to heart disease in the text
key terms related to heart disease:
kidney disease / chronic kidney disease
kidney disease as a risk factor for cardiovascular disease
kidney disease management guidelines (neoerica, etc.)
kidney disease progression (as a benefit)
kidney excretion
kidney failure / end‑stage renal disease
kidney function (for dose adjustment and monitoring)
killip class
killip class (ii–iv)
killip class ii‑iv acute heart failure
klinefelter syndrome
klinefelter syndrome (47,xxy) – patent ductus arteriosus, asd, mitral valve prolapse
knowledge chunk format
knowledge of lifelong cardiac care
knowledge‑chunk format for cardiovascular guideline presentation
kommerell diverticulum (aneurysmal dilation of anomalous subclavian artery)
kommerell’s diverticulum












l-type ca²⁺ current
la (left atrium)
la anterior‑posterior dimension
la appendage excision
la appendage occlusion / exclusion
la appendage occlusion/exclusion/amputation
la compliance
la ejection fraction
la emptying fraction
la emptying function
la end‑diastolic volume
la enlargement
la non‑compliance
la strain
la thrombus
la volume / left atrial volume
laa (left atrial appendage)
laa closure
laa device implantation (plaao)
laa occlusion (laao)
laao (left atrial appendage occlusion)
laaos iii trial
laaos study
laaos iii (left atrial appendage occlusion study)
labetalol
labetalol (intravenous)
labile inr
labile inr (time in therapeutic range < 60%)
lack of contractile reserve / flow reserve
lack of social support
lactate (elevated lactate)
lactate metabolism
lactation
lactmed (lactation medications database)
lake louise criteria (cmr findings)
lake louise criteria (2009 & 2018)
laminated (in‑situ) thrombi
lamp2 (danon disease)
lamp2 cardiomyopathy
landing zone
landing zone 0 (0a, 0b, 0c)
landing zone assessment
lansoprazole
laplace’s law in aortic wall stress
large anterior infarction
large area of myocardium at risk
large cohort study
large infarct territory
large septal defects
large sheath access
large thrombus burden
large vessel vasculitis
large vessel vasculitis (lvv)
large‑bore access
large‑vessel vasculitis
large‑vessel vasculitis (lvv)
laryngeal nerve palsy
laser capture microdissection
laser doppler flowmetry
laser speckle imaging
late aortic complications
late aortic rupture (incidence >5% through 8 years)
late assessment of thrombolytic efficacy (late) study
late atrial tachycardia
late complications
late coronary artery complications post‑arterial switch
late death
late gadolinium enhancement
late gadolinium enhancement (lge)
late gadolinium enhancement cardiovascular magnetic resonance
late gadolinium enhancement imaging
late gadolinium enhancement on cardiac mri
late gadolinium‑enhancement cmr
late graft infection (>3 months)
late heart failure
late intervention
late mortality
late mortality associated with bioprosthetic valves
late myocardial ischemia
late outcomes
late phase sodium currents
late postoperative complications
late post‑closure pah
late pregnancy assessment
late presentation of myocardial infarction
late presenters (12‑24 hours after symptom onset)
late reintervention
late results of vsd closure (30–35 years)
late rupture
late sodium current
late sodium current (ina,l)
late sodium current (mechanism of ranolazine)
late thrombotic events
late/ delayed myocardial enhancement quantification
latent lvoto detection
lateral e′ velocity
lateral medullary syndrome
lateral velocity ratio threshold (≤0.25)
late‑onset complete heart block
lbbb (left bundle branch block)
lbbb – left bundle branch block
lcz696 (lcz)
lcz696 (sacubitril/valsartan)
ldl cholesterol
ldl cholesterol lowering
ldl testing / monitoring
ldlr
ldl‑c (low‑density lipoprotein cholesterol)
ldl‑c / ldl
ldl‑c level targets
ldl‑c lowering efficacy (≥50 %, 30‑49 %, <30 %)
ldl‑c lowering strategy (rapid, intensive)
ldl‑c reduction
ldl‑c reduction goals (≥ 50 % with high‑intensity statin)
ldl‑c target levels
ldl‑c target ≤ 70 mg/dl
ldl‑c threshold for therapy intensification (≥ 70 mg/dl, persistent ≥ 100 mg/dl)
ldl‑c thresholds: ≥70 mg/dl, <70 mg/dl, <50 mg/dl
ldl‑c ≥ 190 mg/dl (≥ 4.9 mmol/l)
ldl‑cholesterol (ldl‑c)
ldl‑cholesterol (ldl‑c) management
ldl‑cholesterol lowering
ldl‑cholesterol target levels
ldl‑lowering therapy guidelines
lead dislodgement
lead extraction
lead failure
lead placement
leader trial
leading‑edge measurement
leadless atrioventricular synchronous pacing
leadless pacemaker implantation
leaflet abnormalities (excessive leaflet length, anomalous papillary muscle insertion)
leaflet calcification
leaflet calcification / aortic‑valve calcium
leaflet degeneration
leaflet flail
leaflet length (ct measurement for tavi planning)
leaflet mobility
leaflet number
leaflet perforation
leaflet prolapse
leaflet restriction
leaflet tear / perforation
leaflet tethering
leaflet tethering height
leaflet thinning/calcification/tear
leaflet thrombosis
lean mass
lecompte maneuver
leflunomide (dmard)
left anterior descending (lad) artery
left anterior descending (lad) artery disease
left anterior descending artery
left anterior descending artery (lad)
left anterior descending artery (lad) involvement
left atrial (la)
left atrial (la) appendage ligation
left atrial (la) compliance
left atrial (la) dilatation
left atrial (la) dilation
left atrial (la) mechanics
left atrial (la) pressure
left atrial (la) size
left atrial (la) size / thrombus
left atrial (la) size and function
left atrial (la) size/volume
left atrial (la) thrombus
left atrial (la) volume
left atrial (la)–esophageal fistula
left atrial appendage
left atrial appendage (laa)
left atrial appendage (laa) closure
left atrial appendage (laa) function and anatomy
left atrial appendage (laa) imaging
left atrial appendage (laa) thrombus / laa stunning
left atrial appendage closure
left atrial appendage closure devices
left atrial appendage exclusion
left atrial appendage isolation
left atrial appendage occlusion
left atrial appendage occlusion (laao)
left atrial appendage occlusion (laao) devices
left atrial appendage occlusion / closure
left atrial appendage occlusion devices
left atrial appendage stunning
left atrial appendage thrombus
left atrial appendage thrombus resolution on follow‑up tee
left atrial blood flow characteristics
left atrial compliance
left atrial diameter
left atrial diameter z‑score
left atrial dilatation
left atrial dysfunction
left atrial enlargement
left atrial enlargement (lae)
left atrial enlargement / left atrial size
left atrial functional measures (strain, volume)
left atrial functional recovery
left atrial hypertension
left atrial mechanical function
left atrial membrane
left atrial noncompliance
left atrial or left atrial appendage thrombus (la/ laa)
left atrial posterior wall ablation
left atrial pressure
left atrial remodeling
left atrial remodeling / enlargement
left atrial scar
left atrial signal loss
left atrial size
left atrial size / left atrial volume index
left atrial size reduction
left atrial strain
left atrial thrombus
left atrial thrombus / left atrial appendage thrombus
left atrial volume
left atrial volume / diameter
left atrial volume index (lavi)
left atrioventricular valve regurgitation
left atrium (la)
left atrium and left atrial appendage anatomy (stroke implications)
left bundle area pacing
left bundle branch area pacing
left bundle branch area pacing leads
left bundle branch block (lbbb / lbbb)
left bundle branch block (lbbb)
left bundle branch block (lbbb) pacing
left bundle branch block management
left bundle‑area pacing
left bundle‑branch block (lbbb)
left cardiac sympathetic denervation (lcs)
left circumflex occlusion
left heart bypass
left heart bypass circuit
left heart disease
left heart enlargement / dilation
left internal mammary artery (lima)
left internal mammary artery (lima) coronary bypass graft
left internal mammary artery (lima) graft
left internal thoracic artery graft
left main artery lesions
left main coronary artery cad (≥50% luminal diameter reduction)
left main coronary artery disease
left main coronary artery lesion
left main coronary artery stenosis
left main coronary disease
left main disease
left main disease / left main cad
left main stenosis
left mitral isthmus flutter
left subclavian artery
left subclavian artery coverage
left superior vena cava
left upper‑extremity dialysis access
left ventricle
left ventricle (lv)
left ventricle (lv) dysfunction
left ventricle ejection fraction (lvef ≤ 40%)
left ventricle strain imaging
left ventricle‑to‑aorta baffle
left ventricular (lv)
left ventricular (lv) afterload
left ventricular (lv) anatomy
left ventricular (lv) chamber dilatation
left ventricular (lv) compliance
left ventricular (lv) diastolic pressure
left ventricular (lv) dilation
left ventricular (lv) dilation / chamber size
left ventricular (lv) dilation / volume overload
left ventricular (lv) dysfunction
left ventricular (lv) dysfunction (post‑tof)
left ventricular (lv) dysfunction / lv function
left ventricular (lv) dysfunction / severe lv dysfunction
left ventricular (lv) function
left ventricular (lv) function assessment
left ventricular (lv) hypertrophy
left ventricular (lv) mass
left ventricular (lv) mass / lv mass index
left ventricular (lv) outflow tract diameter/area
left ventricular (lv) outflow tract obstruction
left ventricular (lv) outflow tract obstruction (lvoto)
left ventricular (lv) pressure overload
left ventricular (lv) remodeling
left ventricular (lv) response to overload
left ventricular (lv) size
left ventricular (lv) size and function
left ventricular (lv) structural/functional alterations
left ventricular (lv) systolic dysfunction
left ventricular (lv) systolic function
left ventricular (lv) systolic function / left ventricular ejection fraction (lvef)
left ventricular (lv) systolic function / lv dysfunction
left ventricular (lv) thrombus
left ventricular (lv) thrombus after mi
left ventricular (lv) volume
left ventricular (lv) volume overload
left ventricular (lv) volumes
left ventricular (lv) wall thickness
left ventricular apical aneurysm
left ventricular assist device
left ventricular assist device (lvad)
left ventricular assist device support in transposition of the great arteries
left ventricular assist device trends and outcomes
left ventricular cardiomyopathy
left ventricular compliance
left ventricular diastolic dysfunction
left ventricular diastolic dysfunction assessment
left ventricular diastolic function
left ventricular diastolic pressure
left ventricular dilatation and remodeling
left ventricular dilation / dilatation
left ventricular dysfunction
left ventricular dysfunction (ischemic)
left ventricular dysfunction (lv dysfunction)
left ventricular dysfunction (lvd)
left ventricular dysfunction (lvef < 50 %)
left ventricular dysfunction / lv dysfunction
left ventricular dysfunction / lv dysfunction / left ventricular systolic dysfunction
left ventricular dysfunction / systolic dysfunction
left ventricular dysfunction assessment
left ventricular dysfunction, asymptomatic
left ventricular ejection fraction
left ventricular ejection fraction (ef)
left ventricular ejection fraction (ef) < 50%
left ventricular ejection fraction (lvef)
left ventricular ejection fraction (lvef) / ef < 40%
left ventricular ejection fraction (lvef) / ejection fraction (ef)
left ventricular ejection fraction (lvef) < 40 %
left ventricular ejection fraction (lvef) < 50%
left ventricular ejection fraction (lvef) – >40 %
left ventricular ejection fraction (lvef) – threshold <50 %
left ventricular ejection fraction (lvef) ≤ 35%
left ventricular ejection fraction (lvef) ≤ 35 %
left ventricular ejection fraction (lvef) < 50%
left ventricular ejection fraction (lv ef)
left ventricular ejection fraction (reduced & preserved)
left ventricular ejection fraction (reduced vs preserved)
left ventricular end‑diastolic diameter (lvedd)
left ventricular end‑diastolic dimension (lvedd)
left ventricular end‑diastolic volume (lvedv)
left ventricular end‑systolic diameter
left ventricular end‑systolic diameter (lvesd)
left ventricular end‑systolic dimension
left ventricular end‑systolic dimension (lvesd)
left ventricular end‑systolic volume
left ventricular enlargement
left ventricular failure (lvf)
left ventricular filling
left ventricular filling pressures
left ventricular free‑wall rupture
left ventricular function
left ventricular function (systolic & diastolic)
left ventricular function recovery
left ventricular global longitudinal strain (gls)
left ventricular hypertrophy
left ventricular hypertrophy (interventricular septum)
left ventricular hypertrophy (lvh)
left ventricular longitudinal strain
left ventricular longitudinal strain (lvls)
left ventricular mass
left ventricular mass and geometry assessment
left ventricular mass index (lvmi)
left ventricular mid‑range preserved ejection fraction
left ventricular morphology / wall thickness
left ventricular outflow obstruction
left ventricular outflow tract (lvot)
left ventricular outflow tract (lvot) disease
left ventricular outflow tract (lvot) gradient
left ventricular outflow tract (lvot) obstruction
left ventricular outflow tract (lvot) obstruction (lvoto)
left ventricular outflow tract gradient
left ventricular outflow tract gradients
left ventricular outflow tract obstruction
left ventricular outflow tract obstruction (lvoto)
left ventricular pacing
left ventricular performance
left ventricular performance post‑surgery
left ventricular posterior wall thickness
left ventricular pressure gradient
left ventricular recovery
left ventricular recovery (lv recovery)
left ventricular relaxation
left ventricular relaxation abnormalities
left ventricular remodeling
left ventricular remodeling / reverse remodeling
left ventricular reverse remodeling
left ventricular strain
left ventricular strain, speckle‑tracking echocardiography
left ventricular systolic dysfunction
left ventricular systolic dysfunction (ef < 50 %)
left ventricular systolic dysfunction (lvsd)
left ventricular systolic function
left ventricular systolic function / depressed left ventricular function
left ventricular systolic volume
left ventricular systolic‑diastolic coupling
left ventricular thrombosis
left ventricular thrombus
left ventricular thrombus management
left ventricular volume
left ventricular volume overload
left ventricular volumes
left ventricular wall thickness
left ventricular wall thickness measurement
left ventricular–based cardiac stimulation post‑av nodal ablation
left ventriculography
left vertebral artery
left-valvar morphology (mitral)
left ventricular dysfunction
left‐main coronary artery disease
left‑atrial compliance
left‑atrial cox maze iii procedure
left‑axis deviation pattern
left‑bundle‑area pacing
left‑heart obstructive lesions
left‑heart valve surgery














left‑main coronary artery disease
left‑main coronary artery revascularization outcomes
left‑main equivalent coronary artery disease
left‑sided chamber size
left‑sided endocarditis
left‑sided failure (exertional dyspnea, coughing, fatigue, orthopnea, paroxysmal nocturnal dyspnea)
left‑sided filling pressures
left‑sided heart failure (hf) / pulmonary edema
left‑sided icd implant
left‑sided infective endocarditis
left‑sided infective endocarditis (ie)
left‑sided mechanical prosthetic heart valve
left‑sided obstructive lesions
left‑sided obstructive lesions (e.g., mitral and aortic stenosis)
left‑sided prosthetic valve
left‑sided regurgitant lesions (mitral regurgitation, aortic regurgitation)
left‑sided valve
left‑sided valve disease
left‑sided valve regurgitation
left‑sided valve surgery
left‑sided valve surgery (mitral, aortic)
left‑to‑right atrial k<sup>+</sup> gradient
left‑to‑right atrial shunt
left‑to‑right shunt
left‑to‑right shunt (clinical significance)
left‑to‑right shunt (qp:qs ratio)
left‑to‑right shunt (qp:qs)
left‑to‑right shunt defects
left‑to‑right shunting
left‑to‑right shunting (shunts)
left‑ventricle characteristics
left‑ventricular (lv) diastolic dysfunction
left‑ventricular (lv) dysfunction
left‑ventricular (lv) remodeling (regional/global)
left‑ventricular (lv) systolic dysfunction
left‑ventricular (lv) systolic pressure
left‑ventricular (lv) volume overload
left‑ventricular assist device (lvad)
left‑ventricular compliance
left‑ventricular diastolic dysfunction
left‑ventricular dilatation / hypertrophy
left‑ventricular dilation
left‑ventricular dysfunction
left‑ventricular dysfunction (systolic or diastolic)
left‑ventricular dysfunction / ejection fraction
left‑ventricular ejection fraction
left‑ventricular ejection fraction (lvef)
left‑ventricular function / cardiac output
left‑ventricular hypertrophy / hypertrophic cardiomyopathy
left‑ventricular hypertrophy pathophysiology
left‑ventricular outflow tract (lvot) obstruction
left‑ventricular outflow tract (lvot) stenosis / obstruction
left‑ventricular outflow tract obstruction (lvot obstruction)
left‑ventricular outflow tract obstruction (lvoto)
left‑ventricular pacing
left‑ventricular remodeling
left‑ventricular remodeling (reverse remodeling)
left‑ventricular systolic dysfunction
left‑ventricular systolic dysfunction prevalence (11–40%)
left‑ventricular systolic function
left‑ventricular volume overload
left‑ventricular–based cardiac stimulation (pave)
left atrial thrombus
left ventricular ejection fraction (lvef)
leg edema
leg ischemia
leg pressure monitoring
leg symptoms
legal and ethical considerations (state laws, medicare eligibility)
leg‑lift maneuver
length of hospital stay
length of hospitalization
lenient rate control
lesion complexity
lesion length
lethal arrhythmic events
level of evidence
level of evidence (b‑nr, c‑eo, etc.)
level of evidence (clinical research grading)
level of evidence (c‑eo, b‑nr, c‑ld, b‑r, c‑ld)
level of evidence (e.g., class 1, 2, 3)
level of evidence (loe)
level of evidence in cardiovascular guidelines
level of evidence: b‑r
levosimendan therapy
lge (late gadolinium enhancement)
lge (late gadolinium enhancement) on cmr
lge extent and location
lge mid‑wall localization
lge persistence/reciprocal changes (increase, decrease, resolution)
lge present (late gadolinium enhancement)
lge without edema (predictor of adverse events)
lge – late gadolinium enhancement
lge‑cmr (late gadolinium‑enhanced cardiovascular magnetic resonance)
lianbio
liberal transfusion strategy
lidocaine
life expectancy
life expectancy / actuarial tables
life expectancy / longevity
life expectancy < 1 year
life expectancy considerations
life expectancy increase (>1.4 years)
life simple 7
lifelong anticoagulation
lifelong clinical and imaging follow‑up for coa patients
lifelong continuum of congenital heart disease care
lifelong or extended prophylaxis (≥ 10 years or until 40 years of age)
lifelong serial imaging (echocardiography, cmr, ct)
lifelong specialized chd care by achd cardiologists
lifelong surveillance
lifelong surveillance imaging
lifelong surveillance imaging for endoleaks
lifelong surveillance imaging of the aorta
lifelong surveillance
lifespan risk of cardiovascular disease
lifestyle
lifestyle / exercise / training / walking
lifestyle / physical activity
lifestyle and activity modification
lifestyle and risk factor modification (lrfm) for af
lifestyle changes
lifestyle considerations for hcm (recreational physical activity, competitive sports)
lifestyle counseling
lifestyle counseling (diet, exercise)
lifestyle disease prevention
lifestyle factors
lifestyle factors impacting cardiovascular risk
lifestyle factors: diet, exercise, physical activity
lifestyle goal setting (dietary modification, exercise plans)
lifestyle improvements (diet, exercise, smoking cessation)
lifestyle interventions
lifestyle interventions (e.g., hartcoach, proactive heart, moodcare)
lifestyle interventions (heart‑healthy lifestyle, diet, exercise)
lifestyle interventions for blood‑pressure control (aerobic exercise, isometric training, potassium supplementation)
lifestyle interventions for cardiovascular health
lifestyle management
lifestyle management (diet, exercise)
lifestyle management (dietary counseling, smoking cessation, weight control)
lifestyle management to reduce cardiovascular risk
lifestyle modification
lifestyle modification (diet, exercise, smoking cessation)
lifestyle modification (e.g., smoking cessation)
lifestyle modification (risk factor reduction)
lifestyle modification / dietary behavior changes
lifestyle modification for aortic disease
lifestyle modification for cardiovascular health
lifestyle modifications
lifestyle modifications (diet, exercise)
lifestyle modifications (smoking cessation, physical activity)
lifestyle modifications (weight loss, heart‑healthy diet, sodium reduction, physical activity, alcohol moderation)
lifestyle optimization (diet, activity, tobacco avoidance)
lifestyle physical activities (e.g., gardening, office‑based movement, stair climbing)
lifestyle preventive therapies
lifestyle risk factors (e.g., smoking cessation, diet, exercise tolerance, alcohol and substance use, environmental exposures)
lifestyle risk factors (e.g., smoking, hypertension)
lifestyle therapy
lifestyle‑focused interventions (diet, exercise, weight management)
lifestyle‑related blood‑pressure factors
lifetime ascvd risk
lifetime costs
lifetime major adverse cardiovascular events reduction ("fewer lifetime mace")
lifetime qalys
lifetime risk of ascvd
lifetime risk of cardiovascular disease
life‑expectancy reduction
life‑extending therapies in hf
life‑sciences technology
life‑space mobility
life‑sustaining therapies (initiation, continuation, deactivation)
life‑sustaining treatments (hospitalization, tube feeding, medication)
life‑table analysis for late hf
life‑threatening arrhythmia
life‑threatening arrhythmias
life‑threatening bleeding
life‑threatening bradycardia with verapamil in neonates
life‑threatening conditions
life‑threatening hyperkalemia
life‑threatening ventricular arrhythmias
life‑threatening ventricular tachyarrhythmia
life‑threatening/uncontrolled bleeding
life‑time risks of valve therapy
life’s essential 8 (aha)
life’s essential 8 (aha lifestyle recommendations)
life’s essential 8 (cardiovascular health metrics)
life’s simple 7 (cardiovascular metrics)
life’s simple 7 (ideal cardiovascular health metrics)
ligament of marshall
ligation/closure of coronary artery at the pulmonary artery level
light chain (al) amyloidosis
light‑chain (al) amyloidosis
light‑chain amyloidosis
light‑chain amyloidosis (al‑cm)
light‑intensity physical activity
light‑to‑moderate alcohol consumption (5–25 g/d)
likely pathogenic variant
likely pathogenic variant (in htad genes)
limb amputation
limb ischemia
limb ischemia (ischemic complications)
limb loss
limb loss (prevention)
limb outcomes
limb preservation/limb salvage
limb salvage
limb salvage rate
limb survival
limb viability
limb‑ischaemia evaluation and device deployment
limb‑preservation strategies
limb‑salvage procedures
limb‑threatening infection
limb‑threatening ischemia
limited english proficiency
limited life expectancy (<1‑2 years)
linagliptin
linear dimensions
lipid
lipid clinic (cardiovascular disease prevention)
lipid disorders
lipid goals (ldl‑c, hdl‑c, triglycerides)
lipid levels
lipid lowering therapy
lipid management
lipid management (statins, etc.)
lipid management (statins, ldl‑c reduction)
lipid management / dyslipidemia
lipid management / statins
lipid management guidelines
lipid management post‑acs
lipid metabolomics
lipid monitoring (fasting lipids, triglycerides)
lipid monitoring / lipid testing
lipid presence
lipid profile
lipid profile (cholesterol, triglycerides)
lipid profile / dyslipidemia
lipid profile measurement
lipid screening (family members)
lipid targets (ldl, hdl, triglycerides)
lipids
lipids (total cholesterol, ldl, hdl, triglycerides)
lipids / dyslipidemia
lipid‐lowering intensity
lipid‑increasing effect of statins (ldl‑c lowering)
lipid‑lowering (statin) therapy
lipid‑lowering agents
lipid‑lowering agents (e.g., ezetimibe, pcsk9 inhibitors)
lipid‑lowering agents (e.g., pravastatin, atorvastatin, rosuvastatin, simvastatin)
lipid‑lowering medication
lipid‑lowering therapy
lipid‑lowering therapy (high‑intensity statins)
lipid‑lowering therapy (statins, ezetimibe, combination therapy)
lipid‑lowering therapy (statins, ezetimibe, pcsk9 inhibitors)
lipid‑lowering therapy (statins, ezetimibe, rosuvastatin)
lipid‑lowering therapy (statins, pcsk9 inhibitors)
lipid‑lowering therapy (statins, pcsk9 inhibitors, etc.)
lipid‑lowering therapy for pad (high‑intensity statins) (pm‑5)
lipid‑lowering therapy guidelines.
lipid‑profiling methods (friedewald formula, direct ldl measurement)
lipid‑risk scoring
lipoprotein (a)
lipoprotein (ldl) cholesterol
lipoprotein apheresis
lipoprotein apheresis (used in familial hypercholesterolemia)
lipoprotein profile
lipoprotein(a)
lipoprotein(a) (lp(a))
lipoprotein(a) / lp(a)
lipoprotein(a) [lp(a)]
lipoproteins
liraglutide
lisinopril
lite (low intensity exercise intervention in pad) trial
literature review
lithotripsy (intravascular lithotripsy)
lithotripsy for calcified iliacs
liver biopsy
liver cancer
liver cirrhosis
liver congestion
liver disease
liver disease (anticoagulation considerations)
liver disease (cirrhosis)
liver disease (cirrhosis, hepatic impairment, non‑alcoholic fatty liver disease)
liver disease severity (cirrhosis)
liver dysfunction
liver fibrosis
liver fibrosis (assessment via biopsy)
liver fibrosis / cirrhosis
liver function testing
liver metabolism
liver nodules
lmna (lamin a/c) variants
loading dose
loading dose (300 mg then 75 mg daily)
loading dose (aspirin, clopidogrel, prasugrel, ticagrelor)
lobar intraparenchymal hemorrhage (iph)
local anesthesia
local anesthesia (preferred to reduce peri‑operative mortality in cardiac patients)
local inflammatory response
local quality improvement initiatives
lodoco trial
lodoco2 trial
loeys‑dietz syndrome
loeys‑dietz syndrome (lds)
loeys‑dietz syndrome with smad3 mutation
loeys‑dietz syndrome with tgfb2 mutation
loeys‑dietz syndrome with tgfb3 mutation
loeys‑dietz syndrome with tgfbr1 mutation
loeys‑dietz syndrome with tgfbr2 mutation






lone af
long duration of diabetes (≥10 yr for t2dm; ≥20 yr for type 1)
long life expectancy
long qt syndrome
long stent length
longitudinal cardiac screening
longitudinal cohort studies of aortic surgery outcomes
longitudinal evaluation of hcm patients
longitudinal follow‑up
longitudinal follow‑up for pad
longitudinal imaging surveillance (transthoracic echocardiography, cmr, ct angiography)
longitudinal spending on aortic repair
longitudinal strain by echocardiography
longitudinal strain of the systemic right ventricle
long‑acting nitrate (e.g., isosorbide dinitrate, nitroglycerin)
long‑acting nitrates
long‑acting thiazide diuretics
long‑chain n‑3 polyunsaturated fatty acids (protective factor for heart disease)
long‑standing persistent af
long‑standing persistent atrial fibrillation
long‑term anticoagulation
long‑term anticoagulation complications
long‑term anticoagulation in acs
long‑term behavior / outcomes
long‑term beta blockers
long‑term beta‑blocker use (> 1 year)
long‑term chromosomal damage
long‑term clinical outcome of antithrombotic therapy
long‑term clinical outcomes
long‑term complications
long‑term complications of congenital heart disease
long‑term complications of icd therapy
long‑term continuous monitoring
long‑term cvd outcomes (mortality, morbidity)
long‑term durability of revascularization
long‑term effect of goal‑directed weight management in atrial fibrillation
long‑term follow‑up
long‑term follow‑up of patients undergoing pulmonary‑ventricle to pulmonary artery conduits
long‑term follow‑up outcomes
long‑term follow‑up studies (10‑year, 3‑year)
long‑term heart failure after radiotherapy
long‑term maintenance of sinus rhythm
long‑term maintenance of sinus rhythm (rhythm‑control strategy)
long‑term mortality
long‑term myocardial infarction outcomes in adults with congenital heart disease
long‑term natural history of pulmonary stenosis after surgical repair
long‑term oral anticoagulation
long‑term oral antihypertensive regimens
long‑term outcome
long‑term outcome after atrioventricular valve surgery following modified fontan operation
long‑term outcomes
long‑term outcomes (8‑year freedom from ie)
long‑term outcomes (mechanical prosthesis durability, valve repair durability)
long‑term outcomes (up to 25–40 years)
long‑term outcomes (≤ 50 years)
long‑term outcomes after heart transplantation.
long‑term outcomes after pci vs cabg in octogenarians
long‑term outcomes of unrepaired papvr with intact atrial septum
long‑term outcomes of valve interventions
long‑term outcomes of vsd repair
long‑term pah therapies
long‑term pah therapy
long‑term patency / long‑term success (angioplasty/bypass)
long‑term prognosis
long‑term prognosis after myocardial infarction
long‑term prognosis of neo‑aortic root
long‑term rate control
long‑term rate control in af
long‑term risk
long‑term secondary prevention
long‑term surveillance
long‑term surveillance after endovascular repair
long‑term surveillance imaging of the aorta
long‑term survival
long‑term survival / actuarial survival
long‑term survival / prognosis
long‑term survival after aortic aneurysm repair
long‑term survival after arterial switch
long‑term survival after atrial switch / arterial switch
long‑term survival after fontan procedure
long‑term survival and freedom from coronary artery reintervention post‑arrest
long‑term survival in hcm
long‑term survival of valve‑repair patients
long‑term survival rates (e.g., 91–94 % at 15–30 years)
long‑term survival, mortality, and morbidity after heart transplantation in chd
long‑term valve survival
long‑term ventricular function
long‑term vka anticoagulation
long‑term vka therapy
loop diuretic
loop diuretic (furosemide)
loop diuretic dose
loop diuretics
loop diuretics (bumetanide, furosemide, torsemide)
loop diuretics (e.g., furosemide, torsemide, torasemide)
loop diuretics (intravenous)
loop of henle
losartan
losartan (angiotensin ii type‑1 receptor blocker)
losartan (angiotensin receptor blocker)
loss of atrial rhythm
loss of coaptation
loss of pregnancy
loss of pulses in an extremity
loss of sinus rhythm
loss to care
loss to care (attrition)
lovastatin
lovastatin (20 mg, 40 mg, 80 mg)
lovastatin (40–80 mg)
lovastatin (40 mg; 20 mg)
low birth weight
low bleeding risk
low bleeding‑risk procedures
low blood pressure (sbp ≤ 90 mm hg)
low blood pressure in hfref
low cardiac index
low cardiac output
low cardiac output state / cardiogenic shock risk
low early morbidity
low ef threshold (≤35 %, ≤30 % in esc criteria)
low flow (graft compromise indicator)
low hdl‑cholesterol
low health literacy (as a risk factor for poor self‑care)
low household income / low socioeconomic status
low molecular weight heparin (lmwh)
low output
low peak vo₂ (< 14–16 ml/kg/min)
low risk
low surgical risk
low systemic blood pressure
low systolic blood pressure (≤90 mm hg)
low-dose rivaroxaban
low-volume surgeon
low/reduced abi
lower extremity
lower extremity amputation
lower extremity amputation (amputation, major amputation)
lower extremity arterial disease
lower extremity arterial revascularization
lower extremity bypass
lower extremity bypass grafting
lower extremity edema
lower extremity functioning
lower extremity gangrene
lower extremity hypoperfusion
lower extremity hypotension
lower extremity ischemia
lower extremity manifestations of pad
lower extremity non‑healing wounds
lower extremity pad
lower extremity peripheral artery disease
lower extremity pulse assessment (femoral, popliteal, dorsalis pedis, posterior tibial)
lower extremity revascularization
lower extremity surveillance after revascularization
lower extremity surveillance procedure
lower extremity threatened limb
lower extremity threatened limb classification system
lower extremity vein bypass graft surveillance
lower limb wound healing
lower morbidity
lower procedural risk (surgical morbidity & mortality)
lower‑extremity amputation
lower‑extremity amputations
lower‑extremity amputations – reduction strategies
lower‑extremity arterial disease
lower‑extremity arterial waveform nomenclature
lower‑extremity arteries
lower‑extremity bypass revascularization
lower‑extremity ischemia
lower‑extremity malperfusion
lower‑extremity pad
lower‑extremity peripheral arterial disease
lower‑extremity peripheral artery disease
lower‑extremity pulse examination
lower‑extremity rest pain
lower‑extremity revascularization
lower‑extremity surveillance after revascularization (qm‑7)
lower‑extremity thrombosis
lower‑limb aerobic exercise
lower extremity peripheral artery disease
low‑attenuation plaque
low‑attenuation plaque (mean ct < 30 hu)
low‑calorie sweetened beverages
low‑carbohydrate diet
low‑carbohydrate diets
low‑density lipoprotein
low‑density lipoprotein (ldl)
low‑density lipoprotein (ldl) cholesterol
low‑density lipoprotein (ldl) target <70 mg/dl
low‑density lipoprotein cholesterol
low‑density lipoprotein cholesterol (ldl‑c)
low‑density lipoprotein cholesterol (ldl‑c) goals
low‑dose aspirin
low‑dose aspirin (75–100 mg daily)
low‑dose aspirin (75–100 mg)
low‑dose aspirin (75–162 mg daily)
low‑dose aspirin (75–162 mg/d)
low‑dose aspirin (aspirin + rivaroxaban)
low‑dose aspirin (pregnancy safety)
low‑dose colchicine therapy
low‑dose diuretics for congestion in hcm
low‑dose dobutamine echocardiography
low‑dose dobutamine stress testing
low‑dose dopamine therapy
low‑dose dual‑source ct for ventricular function
low‑dose infusion strategies
low‑dose lmwh (low‑molecular‑weight heparin)
low‑dose oral diuretics
low‑dose rivaroxaban
low‑dose thrombolytic therapy
low‑dose warfarin
low‑flow aortic stenosis
low‑flow as
low‑flow low‑gradient aortic stenosis
low‑flow states
low‑flow versus high‑flow states in as
low‑flow, low‑gradient aortic stenosis
low‑flow, low‑gradient severe aortic stenosis (as)
low‑flow, low‑gradient severe as
low‑gradient aortic stenosis
low‑gradient as
low‑gradient severe mitral stenosis
low‑income populations
low‑intensity anticoagulation
low‑intensity lifestyle activity (walking breaks, reduced sedentary time)
low‑intensity statin
low‑intensity statin therapy
low‑intensity vs. high‑intensity anticoagulation
low‑molecular‑weight heparin
low‑molecular‑weight heparin (anticoagulation)
low‑molecular‑weight heparin (enoxaparin)
low‑molecular‑weight heparin (enoxaparin, dalteparin)
low‑molecular‑weight heparin (lmwh)
low‑molecular‑weight heparin (lmwh) – alternative anticoagulant (not directly mentioned but relevant)
low‑molecular‑weight heparin (lmwh) – dalteparin
low‑molecular‑weight heparin (lmwh) – e.g., enoxaparin
low‑output low‑gradient aortic stenosis
low‑pressure outlet chamber (rv outflow)
low‑right atrial isthmus flutter
low‑risk ascvd
low‑risk chest pain evaluation
low‑risk favourable metrics (lrfm) programme
low‑risk features for myocarditis
low‑risk patients
low‑salt diet
low‑sodium diet
low‑to‑moderate‑risk patients
low‑voltage areas
low‑voltage ecg findings
lox
lox gene mutation
lox mutation (lysyl oxidase)
lumbar spinal stenosis
lumbosacral dural ectasia (co‑existing condition)
luminal stenosis
lumiracoxib
lung biopsy utility in congenital heart disease management
lung disease (concomitant)
lung function & gas exchange in pah/eisenmenger
lung transplantation (with cardiac repair)
lung ultrasound (in acs)
lv (left ventricle)
lv (left ventricular)
lv (left ventricular) filling pressures
lv afterload
lv and left atrial (la) reverse remodeling
lv aneurysm
lv apical aneurysm
lv cavity dimensions
lv cavity size / dimensions (e.g., ≥46‑50 mm)
lv chamber dilation
lv compliance
lv diastolic dysfunction
lv diastolic function
lv dilatation
lv dilation
lv dilation / end‑systolic diameter >40 mm
lv dilation / left ventricular dilation
lv disease (left‑ventricular disease)
lv dysfunction
lv dysfunction from chronic pressure overload
lv dysfunction thresholds for teer
lv ejection fraction (lvef)
lv end‑diastolic diameter (lvedd)
lv end‑diastolic dimension (lvedd)
lv end‑diastolic dimension/volume (lvedd/lvedv)
lv end‑diastolic pressure
lv end‑diastolic volume
lv end‑diastolic volume <50 ml/m² (small cavity definition)
lv end‑systolic diameter (lvesd)
lv end‑systolic dimension (lvesd)
lv end‑systolic dimension index (mm²/m²)
lv end‑systolic volume (lvesv)
lv fibrosis
lv filling
lv filling pressures
lv function
lv functional thresholds (lvef ≤ 60 %, lvesd ≥ 40 mm)
lv hypertrophy
lv hypertrophy (cardiomyocyte hyperplasia)
lv lge extent
lv longitudinal strain
lv mass
lv non‑compaction
lv outflow obstruction (post‑mitral viv)
lv outflow tract (lvot)
lv outflow tract obstruction (lvoto)
lv posterior wall thickness
lv pressure overload
lv remodeling
lv remodeling (hypertrophy, fibrosis, impaired relaxation, impaired compliance, impaired contractility)
lv remodeling (left‑ventricular remodeling)
lv remodeling (proportionate vs. disproportionate mr)
lv remodeling (ventricular cavity enlargement, wall thinning)
lv remodeling and its effect on mr
lv reverse remodeling
lv segment involvement
lv size
lv size (volumes vs. dimensions)
lv strain (function)
lv strain (speckle‑track)
lv stroke volume
lv stroke volume <30 ml/m² (small cavity definition)
lv systolic dysfunction
lv systolic dysfunction (ef < 50 %)
lv systolic dysfunction (lvef ≤55%)
lv systolic dysfunction (lvef ≤ 55%)
lv systolic dysfunction (lvef ≤ 40%)
lv systolic dysfunction / severe lv dysfunction (ejection fraction ≤ 35%)
lv systolic function
lv volume overload / lv volume measurements
lv volumes
lv wall thickness
lv wall thickness measurement in any segment
lv wall thickness ≥ 14 mm
lv wall‑thickness measurement
lvad (left ventricular assist device)
lvad recovery
lvad – left ventricular assist device
lvef
lvef (<50%)
lvef (left ventricular ejection fraction)
lvef (left ventricular ejection fraction) < 45 %
lvef < 50%
lvef measurement in various modalities (echo, cmr, ct, radionuclide)
lvef on initial cmr
lvef recovery
lvef thresholds (≤ 35 % and ≤ 40 %) predictive of icd benefit
lvef trajectories and monitoring
lvef ≤ 35%
lvef ≤ 40 % (left‑ventricular ejection fraction)
lvef < 50 %
lvef ≤ 30 %
lvef ≤ 35 %
lvef ≤ 40 %
lvesd index (indexed lvesd, mm/m²)
lvh (left ventricular hypertrophy)
lvot (left ventricular outflow tract) obstruction
lvot gradient
lvot gradient (peak ≥50 mm hg, mean ≥40 mm hg)
lvot gradient (≥30 mm hg)
lvot gradient / lvot peak gradient
lvot gradient reduction post‑ablation
lvot gradients
lvot obstruction
lvot obstruction (lvoto)
lvot peak gradient ≥ 50 mm hg
lvot stenosis
lvoto (left ventricular outflow tract obstruction)
lvsd – left ventricular systolic dysfunction
lyme carditis
lymphatic abnormalities (fontan)
lymphatic fistula
lymphocytic myocarditis
lymphopenia
lyon diet heart study
lyon diet heart study (mediterranean diet intervention)
lysosomal storage disease
lysosomal storage diseases
lytic agent (used in thrombolysis)
l‑type calcium channel activity

























mace (major adverse cardiac events)
mace (major adverse cardiovascular events)
mace risk reduction
machine learning in risk prediction
machine‑learning assessment of systemic right ventricle
machine‑learning‑based trials
machine‑learning–based imaging analysis for aortic assessment
macitentan
macitentan (endothelin‑1 receptor antagonist)
macitentan therapy
macitentan therapy for pulmonary hypertension
macroalbuminuria
macrolide or azalide antibiotics (for penicillin‑allergic patients)
macronutrient intake
macroreentrant atrial arrhythmias
macroreentrant atrial tachycardia
macroreentrant atrial tachycardia (at)
macroreentrant circuit
macrovascular blood flow
macrovascular outcomes
madit (multicenter automated defibrillator implantation trial)
madit‑crt trial
madit‑ii (multicenter automatic defibrillator implantation trial ii)
madit‑ii trial
madit ii (multicenter automatic defibrillator implantation trial)
maf‑app (mobile health technology)
maggic (meta‑analysis global group in chronic heart failure)
maggic (meta‑analysis global group in chronic heart failure) risk calculator
maggic risk score
maggic score
magnesium
magnesium infusion (prophylaxis for torsades de pointes)
magnesium sulfate (intravenous)
magnetic navigation & robotic ablation (atrial tachyarrhythmias)
magnetic resonance
magnetic resonance (mr)
magnetic resonance (mr) angiography
magnetic resonance angiography
magnetic resonance angiography (mra)
magnetic resonance elastography
magnetic resonance imaging
magnetic resonance imaging (four‑dimensional)
magnetic resonance imaging (mri)
magnetic resonance imaging (mri) / mra
magnetic resonance imaging (mri) in cardiac imaging
magnetic resonance imaging (mri) of the aorta
magnetic resonance imaging (mri) of the brain
magnetic resonance imaging (mri) of the thoracic aorta
magnetic resonance imaging (mri) – (implied by imaging discussions)
magnetic resonance imaging (mri) – high diagnostic accuracy for endoleaks, requires plain radiograph for stent strut assessment
magnetically levitated left ventricular assist device (lvad)
maintenance dose
maintenance dose (aspirin, clopidogrel, prasugrel, ticagrelor)
maintenance of sinus rhythm
major adverse cardiac events (mace)
major adverse cardiovascular event (mace)
major adverse cardiovascular events
major adverse cardiovascular events (mace)
major adverse event rate
major adverse events
major adverse limb event (male)
major adverse limb events
major adverse limb events (male)
major amputation
major arterial branches
major bleeding
major bleeding / life‑threatening bleeding
major bleeding complications
major bleeding risk with mcs devices
major cardiovascular events
major cardiovascular events (stroke, myocardial infarction, heart failure)
major coronary event
major coronary events
major depression therapy (escitalopram, sertraline)
major histocompatibility complex (mhc)
major limb amputation (mla)
major noncerebral bleeding
major pulmonary artery anomalies
major vascular complications
major vascular events
major/minor bleeding criteria
maladaptive cardiac remodeling
malaise
malapposition
male sex
malignancy
malignant arrhythmia risk stratification (share score)
malignant arrhythmias
malignant arrhythmias (e.g., sustained ventricular tachycardia)
malnutrition
malnutrition / nutritional index (predicts mortality post‑pci)
malnutrition / obesity
malperfusion
malperfusion (clinical evidence)
malperfusion (malperfusion syndrome)
malperfusion resolution
malperfusion syndrome
malperfusion syndromes
malperfusion syndromes associated with aortic dissection
management
management of acute aortic dissection (surgical vs endovascular)
management of anticoagulation (vitamin k antagonist)
management of anticoagulation in cardiac patients
management of aortic aneurysm
management of aortic diseases (guideline recommendations)
management of blood cholesterol
management of comorbidities
management of comorbidities in hcm
management of concomitant cardiac conditions in hcm
management of congenital heart disease
management of hcm and af
management of heart failure
management of heart failure guidelines
management of high bleeding risk patients (master dapt trial)
management of intramural hematoma (acute and subsequent)
management of lower extremity pad
management of pad
management of patients at risk for and with left ventricular thrombus (acc/aha)
management of patients with af and ich.
management of patients with chronic coronary disease
management of patients with left ventricular thrombus
management of patients with vhd
management of refractory angina
management of right atrial strain
management of rv‑to‑pa conduit failure
management of symptoms in hcm
management of valvular heart disease
management of venous/arterial access in cardiac patients
management strategies
mantra‑af study
manual labor / heavy lifting occupational consideration
manufacturer’s instructions for use (ifu)
marfan surgical outcomes (early and 1‑year)
marfan syndrome
marfan syndrome (aortic root evaluation)
marfan syndrome (mfs)
marfan syndrome (mild systemic features)
marfan syndrome – a connective‑tissue disorder affecting the aorta
marijuana / cannabis / medical marijuana
markov decision analysis
markov decision model
martin/hopkins method (ldl‑c calculation)
massive left ventricular hypertrophy
massive lvh
massive lvh (≥ 30 mm in any lv segment)
mat2a mutation
maternal adverse outcome
maternal and fetal cardiac risk
maternal and fetal complications of pregnancy
maternal and fetal morbidity/mortality
maternal and fetal risk balance
maternal and fetal safety
maternal cardiac death
maternal cardiac disease
maternal cardiac outcomes (in pregnancy)
maternal cardiac risk
maternal cardiac risk management
maternal complications during pregnancy
maternal cor triatriatum management during pregnancy
maternal counseling
maternal death
maternal heart disease
maternal hemorrhage risk
maternal morbidity
maternal morbidity / mortality
maternal morbidity and mortality
maternal mortality
maternal mortality in hcm pregnancy (very low)
maternal mortality risk (~1 %)
maternal outcomes
maternal outcomes in congenital heart disease‑associated pulmonary hypertension
maternal rubella exposure
maternal thrombotic complications
maternal/fetal risk assessment
maternal‑fetal medicine (specialist care coordination)
maternal‑fetal medicine / obstetric cardiology
maternal‑fetal medicine obstetricians
maternal‑fetal medicine specialist
maternal‑fetal medicine surveillance
maternal‑fetal medicine team
maternal‑fetal mri
maternal‑fetal outcomes
maternal–fetal decision making in aortopathy
maternal–fetal outcome optimization
matrix metalloprotease‑9
matrix metalloproteinase (mmp) activity
matrix metalloproteinases (mmp‑2, mmp‑9)
matrix metalloproteinase‑9 (mmp‑9)
matrix remodeling
matrix remodeling biomarkers (related to heart failure prognosis)
matrix trial
mavacamten
mavacamten (contraindicated in pregnancy)
mavacamten (myosin inhibitor)
mavacamten (myosin inhibitor) for obstructive hcm
mavacamten (myosin‑inhibitor drug)
maximal aortic diameter
maximal aortic diameter (> 40 mm)
maximal instantaneous lvot gradient
maximal left ventricular (lv) wall thickness
maximal left‑ventricular wall‑thickness measurement
maximal tolerated statin therapy
maximal workload
maximally tolerated doses (of acei/arb/arni)
maximally tolerated statin therapy
maximum aortic diameter
maximum diameter
maximum pau depth
maximum pau diameter
maximum tolerated statin
maximum velocity
maximum velocity (vmax)
maze operation
maze procedure
maze procedure (atrial maze)
mcha2ds2‑vasc score
mean arterial pressure (map)
mean arterial pressure targets
mean gradient
mean mitral gradient
mean mitral valve gradient > 15 mm hg during exercise
mean pressure gradient
mean pressure gradient (mm hg)
mean pressure gradient (δp)
mean pressure gradient ≥ 40 mm hg
mean pulmonary artery pressure (mpap)
mean pulmonary artery pressure > 20 mm hg
mean systolic pressure gradient (∆pmean)
mean transvalvular gradient
mean transvalvular gradient >10 mm hg
mean δp ≥40 mm hg or <20 mm hg
measurement
measurement attributes (evidence‑based, reliability, validity, feasibility)
measurement protocols (electrocardiographic‑synchronized, perpendicular to flow axis, multiplanar reformats)
measurement techniques (leading‑edge to leading‑edge, inner‑wall to inner‑wall)
measurement variability
mechanical aortic root replacement
mechanical aortic valve replacement
mechanical aortic valve replacement (avr)
mechanical aortic valve replacement in women of childbearing age
mechanical atrial systole
mechanical bileaflet avr
mechanical bridge to definitive treatment
mechanical circulatory support
mechanical circulatory support (bridge to transplant, lvad)
mechanical circulatory support (bridge‑to‑transplant)
mechanical circulatory support (e.g., lvad)
mechanical circulatory support (e.g., temporary circulatory support devices)
mechanical circulatory support (e.g., ventricular assist devices)
mechanical circulatory support (impella, short‑term mechanical support)
mechanical circulatory support (lvad, vad)
mechanical circulatory support (mcs)
mechanical circulatory support (mcs) devices
mechanical circulatory support (mcs) in achd (intermacs, unos)
mechanical circulatory support device
mechanical complications (e.g., mechanical valve failure, ventricular rupture)
mechanical complications (of the heart)
mechanical complications of acs
mechanical complications of acute myocardial infarction
mechanical complications of acute myocardial infarction (e.g., rupture, pseudo‑aneurysm)
mechanical complications of ami
mechanical complications of mi
mechanical complications of mi (e.g., lv free‑wall rupture, papillary muscle rupture)
mechanical complications of mi (e.g., ventricular septal defect, free‑wall rupture)
mechanical complications of myocardial infarction
mechanical disc prosthesis
mechanical dyssynchrony (detected by echocardiography)
mechanical heart valve
mechanical heart valve (bileaflet)
mechanical heart valve prosthesis
mechanical heart valves
mechanical heart valves (mechanical valvular prostheses)
mechanical mitral valve
mechanical mitral valve replacement
mechanical mitral‑valve replacement
mechanical prostheses
mechanical prosthesis
mechanical prosthesis monitoring
mechanical prosthetic aortic valve
mechanical prosthetic heart valves
mechanical prosthetic valve
mechanical prosthetic valve complications
mechanical prosthetic valve thrombosis
mechanical prosthetic valves
mechanical reperfusion
mechanical support
mechanical support utilization trends
mechanical therapy
mechanical valve
mechanical valve (prosthetic)
mechanical valve (surgical)
mechanical valve dysfunction
mechanical valve implantation
mechanical valve leaflet imaging
mechanical valve prostheses
mechanical valve prosthesis
mechanical valve replacement
mechanical valve stenosis
mechanical valve surgery
mechanical valve thrombogenicity
mechanical valve thrombosis
mechanical valve thrombosis management during pregnancy
mechanical valve thrombosis prevention
mechanical valved conduit
mechanical valves
mechanical valve‑associated bleeding risk
mechanical ventricular assist device
mechanical vs. bioprosthetic valve durability in young women
mechanisms of action (ina inhibition, ikr inhibition, late ina augmentation)
med-oriented and surgery strategies for multivessel coronary artery disease (mass ii)
media
medial degeneration
medial degeneration of the aortic wall
medial radiation effects on cardiac surgery
medial smooth muscle
mediastinal hematoma
mediastinal widening
medical device manufacturers related to cardiac care:
medical devices
medical devices for heart disease
medical management (antihypertensive therapy, anticoagulant clearance, etc.)
medical management of aneurysm disease
medical management of aortic aneurysm/dissection
medical management of sporadic or degenerative aortic aneurysm
medical management/therapy
medical surveillance (aortic)
medical therapy
medical therapy (best medical treatment)
medical therapy (e.g., diltiazem)
medical therapy (for pad)
medical therapy (including guideline‑directed medical therapy, gdmt)
medical therapy (optimal management)
medical therapy (optimal medical therapy)
medical therapy after avr (ventricular and vascular function)
medical therapy alone
medical therapy for aortic aneurysm disease
medical therapy for aortic disease
medical therapy for aortic dissection management
medical therapy for loeys‑dietz syndrome
medical therapy for progressive valve disease (stage b)
medical therapy for relief of angina
medical therapy for systemic right ventricle
medical therapy for valve disease
medical therapy optimization
medical therapy to prevent cardiovascular events
medical therapy uptitration (hf)
medical therapy: guideline‑directed medical therapy (gdmt)


















medical treatment
medical, percutaneous, or surgical intervention
medically and surgically managed loeys‑dietz syndrome patients
medicare beneficiaries
medicare claims registry data
medicare coverage of exercise therapy
medicare coverage of set
medication adherence
medication adherence / medication‑taking
medication adherence / non‑adherence in hf
medication adherence and optimization
medication adherence interventions
medication adherence/ compliance in cardiac disease
medication interactions
medication management for pad
medication non‑adherence
medication optimization / reconciliation
medication reconciliation
medication therapy
medication therapy for stable coronary disease
medication therapy management
medications (rx)
medications alone
medications associated with myocarditis:
medications with negative inotropic effect (e.g., verapamil)
mediterranean diet
mediterranean diet (extra‑virgin olive oil, nuts)
mediterranean diet and aneurysm prevention
mediterranean‑style diet (primary & secondary prevention of cvd)
mediterranean‑type dietary plan (plant‑based, lean protein, fish)
mediter­rainian dietary pattern (high‑score mediterranean diet)
medium‑ and large‑vessel vasculitis
medium‑term functional status
medtronic
medtronic (cardiovascular device manufacturer)
medtronic (cardiovascular devices)
medtronic (device manufacturer for heart conditions)
medtronic (device manufacturer for heart valve procedures)
medtronic (device manufacturer relevant to cardiovascular therapy)
medtronic talent stent graft (device-based term)
medtronic** (heart‑device manufacturer)
med‑ahf study
melody valve
membrane orifice
membranous obstruction (subaortic obstruction)
men >40 years
mendelian genetic variants
mendelian randomization (mr) findings
mendelian randomization studies (genetic determinants)
mental component summary (mcs)
mental health (comorbidity)
mental health (depression)
mental health (for ccd)
mental health / psychosocial stressors
mental health conditions (depression, anxiety, anger/hostility, general distress, type d personality)
mental health disorders and aortic dissection
mental health screening (phq‑4, etc.)
mental illness (comorbid)
mental retardation
mental‑health screening in achd clinics
mentation (altered mentation)
merck
merit‑hf
merit‑hf (metoprolol in patients with heart failure)
merlin trial
merlin‑timi 36 trial
merlin‑timi 36 trial (cardiac biomarker assessment)
mesa (multi‑ethnic study of atherosclerosis)
mesenteric (visceral) malperfusion
mesenteric artery stenosis
mesenteric malperfusion
metabolic abnormalities
metabolic acidosis
metabolic and energetic abnormalities in hcm.
metabolic complications (acidosis, liver function tests)
metabolic disorders affecting the heart
metabolic equivalent (met)
metabolic equivalent-hours per week
metabolic equivalents (mets)
metabolic equivalents (mets) – light, moderate, vigorous
metabolic equivalents of task (mets)
metabolic risk
metabolic risk profile
metabolic stress
metabolic syndrome
metabolic syndrome, heart disease risk
metabolic therapies
metabolic transformation (liver biotransformation)
metabolism pathways (cyps, p‑gp)
meta‑analyses
meta‑analysis
meta‑analysis (individual patient data)
meta‑analysis (individual‑patient data, randomized trial)
meta‑analysis / systematic review
meta‑analysis / systematic review (methodology in cardiology)
meta‑analysis and systematic review (reference to methodology)
meta‑analysis findings on mortality
meta‑analysis of acs trials
meta‑analysis of af incidence post‑ablation
meta‑analysis of clopidogrel in acs undergoing pci
meta‑analysis of individual patient data for aaa
meta‑analysis of mcs devices
meta‑analysis of obesity and atrial fibrillation
meta‑analysis of pad interventions
meta‑analysis of randomised controlled trials concerning cardiovascular risk
meta‑analysis of randomized controlled trials (rcts)
meta‑analysis of randomized trials
meta‑analysis of reperfusion strategies
meta‑analysis on clopidogrel pretreatment
meta‑analysis studies
meta‑synthesis of women’s experiences with cardiac disease in pregnancy
metformin
metformin (first‑line therapy for diabetes)
metformin (implied via glycemic control)
methamphetamine abuse
methamphetamine use
methamphetamine‑associated cardiomyopathy
methicillin‑resistant *staphylococcus aureus* (mrsa)
methicillin‑resistant staphylococcus aureus (mrsa)
methicillin‑sensitive staphylococcus aureus (mssa)
methodology manual
methotrexate
methotrexate (cardiovascular risk modifier)
methotrexate (dmard)
methotrexate (mtx)
metolazone
metolazone (thiazide‑like diuretic)
metoprolol
metoprolol (cr/xl, extended‑release)
metoprolol (dose escalation)
metoprolol cr/xl
metoprolol high‑dose iv/po therapy
metoprolol succinate
metoprolol succinate (merit‑hf)
metoprolol tartrate
mets (metabolic equivalents)
mexiletine
mhealth education interventions for heart failure
mi
mi (myocardial infarction)
microalbuminuria
microaxial flow pump
microaxial flow pump (intra‑aortic balloon pump, v‑ax, impella, etc.)
microaxial flow pump (mcp)
microaxial intravascular flow pump (microaxial pump)
microaxial lvad (impella lp5.0)
micronutrient deficiency
micronutrient intake
micronutrient supplementation
micronutrient‑deficiency screening
microreentry circuit
microrna
micrornas (e.g., mmu‑mir‑721)
micrornas (mmu‑mir‑721)
microrna‑155 (mir‑155)
microrna‑21 (mir‑21)
microvascular
microvascular angina
microvascular angina (mva)
microvascular blood flow
microvascular complications
microvascular disease
microvascular disease (retinopathy, neuropathy, nephropathy)
microvascular dysfunction
microvascular ischemia
microvascular outcomes
microvascular resistance (high)
midterm mortality rate
midterm outcomes
midventricular obstruction
mid‑range ejection fraction
mid‑range lvef (40 – 49%)
mid‑rv obstruction
mid‑term outcomes (10–20 years)
mid‑to‑late systolic jets
mid‑wall lge
migalastat (small‑molecule therapy for fabry)
mild ar
mild to moderate aortic stenosis
mild, moderate, and severe mr definitions
mild/moderate heart failure
mildly reduced ejection fraction
mild‑to‑moderate intensity exercise
milrinone
milrinone (oral)
milrinone (phosphodiesterase inhibitor)
milrinone infusion
mineral oil placebo
mineralocorticoid receptor antagonist
mineralocorticoid receptor antagonist (mra)
mineralocorticoid receptor antagonist (mra) therapy for hfref
mineralocorticoid receptor antagonists
mineralocorticoid receptor antagonists (mra)
mineralocorticoid receptor antagonists (mras)
mineralocorticoid receptor antagonists (mras) – spironolactone
mineralocorticoid receptor antagonists (spironolactone)
mineralocorticoid‑receptor antagonist – e.g., spironolactone, eplerenone
mineralocorticoid‑receptor antagonists
mineral‑corticoid receptor antagonists (for af)
minerva study
minimally interrupted anticoagulation
minimally invasive approach
minimally invasive direct coronary artery bypass
minimum stent area (msa)
minimum training duration (≥12 weeks)
minimum vessel diameter (>2.5 mm)
minneapolis heart institute
minnesota living with heart failure questionnaire (mlhfq)
minor amputation (inframalleolar level)
minor and major amputation (foot, digit)
minor bleeding
minor procedures (e.g., dental extraction, cataract removal)
minorities (racial/ethnic representation)
minority communities
minute ventilation to co₂ production (ve/vco₂)
miracl trial
miracle score
miscarriage
mission: lifeline stemi system
mistral study
mitochondrial density and activity
mitochondrial disorders
mitochondrial myopathies
mitraclip (transcatheter mitral valve repair)
mitraclip device
mitraclip therapy
mitral (left atrioventricular) valve regurgitation
mitral annular calcification
mitral annular dilation
mitral annular dilation and valve adaptation
mitral annulus calcification
mitral commissurotomy
mitral insufficiency
mitral intervention (repair or replacement)
mitral leaflet‑base calcification
mitral pressure half‑time
mitral prosthesis
mitral regurgitation
mitral regurgitation (functional mr)
mitral regurgitation (functional/secondary)
mitral regurgitation (in combined valvular studies)
mitral regurgitation (mr)
mitral regurgitation (mr) associated with lvoto
mitral regurgitation (mr) – moderate or greater, normal lv systolic function, pulmonary artery systolic pressure < 50 mm hg
mitral regurgitation (mr) – secondary
mitral regurgitation (mr) ≤ 2 +
mitral regurgitation (progression)
mitral repair for primary mr (posterior leaflet)
mitral stenosis
mitral stenosis (ms)
mitral stenosis (ms) – rheumatic, moderate or greater, pulmonary artery systolic pressure < 50 mm hg
mitral stenosis (shared pathophysiology)
mitral subvalvular apparatus
mitral transcatheter edge-to-edge repair
mitral transcatheter edge‑to‑edge repair (teer)
mitral valve
mitral valve (and its components: commissures, leaflets)
mitral valve (mv)
mitral valve (mv) area
mitral valve (mv) clipping
mitral valve abnormalities
mitral valve abnormalities (mitral regurgitation, papillary muscle insertion)
mitral valve anatomy
mitral valve anatomy and function
mitral valve annuloplasty
mitral valve annulus calcification
mitral valve apparatus
mitral valve area
mitral valve area (mva)
mitral valve area measurement
mitral valve area score
mitral valve area ≤ 1.5 cm²
mitral valve area ≤ 1.5 cm²
mitral valve attachments
mitral valve disease
mitral valve disease / mitral valve repair
mitral valve disease associated with tgfb2 mutations
mitral valve endocarditis
mitral valve gradient
mitral valve injury
mitral valve insufficiency (due to papillary muscle infarction)
mitral valve intervention
mitral valve leaflet abnormalities
mitral valve leaflet calcification
mitral valve leaflet scallops
mitral valve leaflets malcoaptation
mitral valve lesions
mitral valve morphology
mitral valve morphology score
mitral valve orifice geometry
mitral valve plication
mitral valve prolapse
mitral valve regurgitation
mitral valve regurgitation (mr)
mitral valve repair
mitral valve repair (surgical)
mitral valve repair feasibility
mitral valve repair strategies
mitral valve replacement
mitral valve replacement (mvr)
mitral valve replacement (mv replacement)
mitral valve replacement (within 1 year of procedure)
mitral valve replacement strategy
mitral valve replacement vs repair
mitral valve resistance
mitral valve stenosis
mitral valve stenosis progression
mitral valve structural abnormalities
mitral valve surgery
mitral valve surgery (repair or replacement)
mitral valve surgery (repair, commissurotomy, replacement)
mitral valve surgery (repair, replacement)
mitral valve surgery (repair/replacement)
mitral valve surgery / repair
mitral valve surgery with ablation
mitral valve systolic anterior motion (sam)
mitral‑aortic discontinuity
mitra‑fr study
mitra‑fr trial
mitra‑fr trial outcomes













mixed aortic stenosis (as) and aortic regurgitation (ar)
mixed dyslipidemia
mixed mitral stenosis and aortic regurgitation (ms‑ar)
mixed mitral stenosis and aortic stenosis (ms‑as)
mixed mitral stenosis and mitral regurgitation (ms‑mr)
mixed moderate as/ar
mixed pulmonary valve disease
mixed severe as and mitral regurgitation (mr)
mixed valve disease
mixed valve disease (combined mr + aortic stenosis)
mixed valvular disease
mobile atheroma
mobile electrocardiogram
mobile health (mhealth) technologies
mobile health devices
mobile health technology for af
mobile telemetry
mobile‑health–delivered educational interventions
mobility challenges
mobility impairment
mobility issues / procedural risk
mode of delivery (in pregnancy context)
mode of delivery in aortic disease
model duration
moderate aortic stenosis
moderate ar
moderate ar (stage b)
moderate ischemic mitral regurgitation
moderate la enlargement
moderate mr (ero ≥ 20 mm²)
moderate or greater mitral stenosis
moderate pulmonary regurgitation
moderate regurgitation
moderate stenosis
moderate to severe heart failure
moderate to severe rheumatic mitral stenosis
moderate tricuspid regurgitation
moderate/high‑intensity statin
moderate‑intensity aerobic activity
moderate‑intensity aerobic exercise (≥150 min/week)
moderate‑intensity aerobic physical activity
moderate‑intensity continuous training
moderate‑intensity exercise
moderate‑intensity physical activity
moderate‑intensity statin
moderate‑intensity statin therapy
moderate‑sodium diet
moderate‑to‑vigorous exercise
moderate‑to‑vigorous physical activity
moderation of alcohol intake
modifiable cardiovascular risk factors
modifiable risk factors
modified bentall procedure
modified duke criteria
modified duke criteria (major and minor criteria for ie diagnosis)
modified duke criteria (major and minor criteria)
modified frailty index
modified konno procedure
modified konno procedure (high‑risk children)
modified who risk classification
modified world health organization (who) classification system
modularity in guideline presentation (knowledge chunk format)
molecular autopsy
molecular autopsy for sudden death
molecular diagnosis
molecular genetic testing / pathogenic variant detection
molecular profiling
monitoring
monitoring and management of cardiovascular disease during labor, delivery, and postpartum.
monitoring of anticoagulation
monitoring of anti‑xa trough levels >0.6 iu/ml
monitoring of coronary artery patency
monitoring of exercise progress
monitoring of pulmonary artery anatomy
monitoring of valve function
monitoring of ventricular function
monoamine oxidase inhibitor (mao‑i)
monoclonal antibodies to pcsk9
monoclonal antibody (rituximab)
monocyte chemoattractant protein‑1 (mcp‑1)
monogenic disease
monomorphic ventricular tachycardia
monomorphic ventricular tachycardia (vt)
monomorphic ventricular tachycardia
monophasic waveform
monotherapy
monotherapy in pah
monotherapy, dual therapy, triple therapy (gdmt combinations)
monounsaturated fat
monounsaturated fatty acids
morbid obesity
morbidity
morbidity (cardiovascular morbidity)
morbidity (disease burden)
morbidity and mortality
morbidity and mortality (cardiovascular outcomes)
morbidity and mortality associated with pad
morbidity and mortality discussions
morbidity and mortality in eisenmenger syndrome
morbidity and mortality rates
morbidity and mortality related to heart failure
morbidity reduction
morbidity related to af and other cardiac events
moricizine
morphine
morphologic tricuspid valve
morphological domain
mortality
mortality & morbidity (associated with surgical/endovascular intervention)
mortality (all‑cause death)
mortality (all‑cause, cardiovascular)
mortality (all‑cause, cardiovascular, hf‑specific)
mortality (all‑cause, cardiovascular, sudden cardiac death)
mortality (all‑cause, hf‑specific, short‑ and long‑term)
mortality (aorta‑related and all‑cause)
mortality (cardiac and all‑cause)
mortality (cardiac‑related)
mortality (cardiovascular mortality)
mortality (cardiovascular)
mortality (death from stroke, heart disease, or other vascular disease)
mortality (death)
mortality (elective surgery)
mortality (hf‑related)
mortality (high rates of mortality associated with ali)
mortality (in-hospital and long‑term)
mortality (in‑hospital, short‑term, 1‑year, long‑term)
mortality (short‑ and long‑term)
mortality (short‑term, 1‑year, 5‑year, overall)
mortality / death
mortality / morbidity in adult fontan patients
mortality / survival outcomes
mortality / survival rate
mortality advantage with multidisciplinary programs
mortality and morbidity
mortality and morbidity in acs
mortality and morbidity in aortic regurgitation
mortality and morbidity risks
mortality and survival analysis
mortality and transplant event rates in complicated vs. fulminant myocarditis.
mortality benefit (in cabg context)
mortality benefit of cabg over gdmt
mortality following ventricular arrhythmia suppression
mortality from heart failure
mortality in ebstein’s anomaly
mortality outcomes
mortality post‑myocardial infarction
mortality prediction
mortality prediction / risk models
mortality prediction in cardiogenic shock
mortality prediction in hf patients
mortality predictors in endocarditis
mortality rate
mortality rate (30‑day, midterm)
mortality rate (30‑day, overall)
mortality rate (age‑adjusted death rate)
mortality rate (in-hospital)
mortality rate (increase to 20% by day 2, 25% by day 30)
mortality rate post‑avr
mortality rates
mortality reduction
mortality reduction at >20–25 or >50 procedures per year
mortality related to aortic disease
mortality risk
mortality risk associated with af and cardiovascular conditions
mortality risk associated with moderate mixed disease
mortality risk associated with valvular lesions
mortality risk in pad patients
mortality risk score
mortality – cardiovascular, all‑cause
most study
motion artifact
motivational interviewing
mount sinai
moyamoya disease
mr
mr angiography
mr imaging
mr severity (effective regurgitant orifice area)
mra (mineralocorticoid receptor antagonist)
mra therapy (mineralocorticoid‑receptor antagonist)
mri (aortic imaging)
mri (magnetic resonance imaging)
mri angiography (non‑contrast, free‑breathing)
mri scan
mrna‑based covid‑19 vaccination
muffled closing clicks
multicenter automatic defibrillator implantation trial (madit)
multicenter clinical trials (e.g., capricorn, albatross)
multicenter cohort studies
multicenter diltiazem post‑infarction trial
multicenter diltiazem post‑infarction trial (mdpit)
multicenter pregnancy outcome registries (ropac, registry of pregnancy and cardiac disease)
multicenter prospective study
multicenter randomized clinical trial (acute study)
multicenter randomized trials in aortic surgery
multicenter registry
multicenter study
multicenter un‑sustained tachycardia trial (must)
multicentre study
multicomponent integrated care (combination of quality improvement strategies)
multidetector computed tomography (ct) angiography – wall thickness, coronary anatomy
multidetector computed tomography (mdct)
multidetector computed tomography coronary angiography
multidetector ct angiography (imaging of aortic stenosis)
multidetector ct imaging
multidetector ct scanners
multidetector‑row computed tomography (ct)
multidisciplinary achd team
multidisciplinary aortic team
multidisciplinary aortic teams
multidisciplinary approaches
multidisciplinary cardiac care
multidisciplinary cardiac surgical procedures (non‑transplant)
multidisciplinary cardio‑obstetric care
multidisciplinary cardio‑obstetrics team
multidisciplinary cardio‑oncology team
multidisciplinary care
multidisciplinary care / team
multidisciplinary care in vascular disease
multidisciplinary care program
multidisciplinary care strategy
multidisciplinary care team
multidisciplinary care teams
multidisciplinary care teams (hf, critical care, interventional cardiology, cardiac surgery)
multidisciplinary collaboration (achd, anesthesiology, surgery, ep)
multidisciplinary collaborative approach (cardiology, obstetrics, neonatology, genetics)
multidisciplinary discussion (treatment approach)
multidisciplinary expertise
multidisciplinary hcm centers
multidisciplinary heart failure team
multidisciplinary heart team
multidisciplinary heart valve team
multidisciplinary heart valve team (mdt)
multidisciplinary heart‑failure management
multidisciplinary heart‑failure team (cardiologist, surgeon, nurse, pharmacist, dietitian, palliative specialist, social worker)
multidisciplinary interventions
multidisciplinary interventions for heart failure
multidisciplinary management strategies for hf
multidisciplinary management team (e‑team)
multidisciplinary risk assessment and management
multidisciplinary shock team
multidisciplinary subspecialties (pulmonary medicine, gastroenterology)
multidisciplinary team
multidisciplinary team (cardiologists, interventionalists, cardiac anesthesiologists, obstetricians)
multidisciplinary team (complex‑care decision making)
multidisciplinary team (mdt)
multidisciplinary team (mdt) evaluation
multidisciplinary team (mdt) involvement
multidisciplinary team approach (mda)
multidisciplinary team evaluation
multidisciplinary team evaluation (for clti)
multidisciplinary team evaluation for clti patients (qm‑8)
multidisciplinary team follow‑up
multidisciplinary team for pregnancy management
multidisciplinary transplant committee
multidisciplinary transplant team
multidisciplinary valve team
multidisciplinary vascular care teams
multidisciplinary vascular team
multidisciplinary wound‑care team (for clti)
multidisciplinary/team‑based care for chronic limb‑threatening ischemia
multidrug immunosuppression
multidrug‑resistant microorganisms
multifocal enhanced external counterpulsation study (must‑eecp)
multigenerational families with thoracic aortic aneurysms and dissections
multigenerational family history of tad
multileaf lesion
multilevel disease
multimodal imaging
multimodal pharmacologic therapy (e.g., beta‑blockers, calcium channel blockers, antiarrhythmic drugs)
multimodality cardiovascular imaging
multimodality imaging
multimodality imaging (echocardiography, cmr, ct, scintigraphy)
multimodality imaging during follow‑up care of congenital heart disease
multimodality imaging for cor triatriatum sinister
multimodality imaging guidelines (echocardiography, cmr, ct)
multimodality imaging guidelines (echocardiography, mri, ct)
multimorbidity
multimorbidity in acs patients
multimorbidity in hf (≥2 chronic conditions)
multimorbidity, frailty, cognitive impairment in hf patients
multinucleated giant cells
multiorgan dysfunction
multiorgan failure
multiorgan phenotype
multiorgan transplantation
multiorgan transplantation (heart‑lung, heart‑kidney, heart‑liver)
multiparameter severity grade
multiple comorbidities
multiple lesions
multiple operative interventions
multisite pacing
multislice computed tomography
multislice computed tomography (ct)
multisociety guideline for prevention, detection, evaluation, and management of high blood pressure in adults
multispecialty / multisocietal collaboration
multispecialty care team
multispecialty care team (vascular, wound care, cardiology)
multispecialty care team / team‑based care for clti
multispecialty heart valve team
multispecialty, team‑based care for pad
multivalve disease
multivalve operations
multivariable analysis
multivariable risk scores
multivariate risk scores
multivessel cad
multivessel coronary artery disease
multivessel coronary artery disease (cad)
multivessel coronary artery disease (mvd)
multivessel coronary disease
multivessel coronary disease management in acs
multivessel disease
multivessel disease (mvd)
multivessel pci
multivessel pci vs culprit‑only pci comparison
multivessel percutaneous coronary intervention (pci)
multivessel revascularization
multivitamin supplementation
multivitamin‑mineral supplementation
multi‑center clinical studies
multi‑ethnic study of atherosclerosis (mesa)
multi‑organ transplantation in achd
multi‑specialty care team
multi‑system disease
multi‑valve disease
multi‑vessel coronary disease
multi‑vessel disease
mural thrombus
murmur
mus musculus microrna (mmu‑mir)
muscle fiber adaptations
muscle flaps
muscle‑related adverse effects (increased with concomitant statins)
muscular dystrophy
muscular dystrophy (cardiac involvement)
musculoskeletal limitations
mustard operation (surgical correction of transposition of great arteries)
mustt (multicenter unsustained tachycardia trial)
mv transcatheter edge‑to‑edge repair
mwho (modified world health organization) cardiac risk classification
mybpc3
mycophenolate mofetil
mycotic (infectious) aortic aneurysm
mycotic aneurysm
mycotic aneurysms
mycotic aortic aneurysm
myectomy
myectomy (surgical myectomy)
myectomy outcomes
myeloperoxidase (mpo)
myeloperoxidase (mpo) activity
myeloperoxidase activity












myh11
myh11 mutation (myosin heavy chain 11)
myh11‑associated aortopathy
myh6 (myosin heavy chain 6) variants
myh7
myh7 (myosin heavy chain 7) variants
myh7 gene
myl2
myl2 (myosin light chain 2)
myl3
myl3 (myosin light chain 3)
mylk
mylk mutation
mylk mutation (myosin light chain kinase)
mylk variant
mylk‑associated aortopathy
myocardial
myocardial arterial blood supply
myocardial blood flow at stress
myocardial blood flow reserve (mbfr)
myocardial bridging
myocardial collagen turnover (diastolic hf evidence)
myocardial contractility
myocardial contraction
myocardial crypts
myocardial damage
myocardial dysfunction
myocardial dysfunction / left‑ventricular dysfunction
myocardial edema
myocardial energetics
myocardial energy impairment during exercise
myocardial fibrosis
myocardial fibrosis assessment
myocardial fibrosis assessment (cmr)
myocardial function assessment
myocardial hibernation
myocardial hypertrophy
myocardial infarction
myocardial infarction (ami)
myocardial infarction (heart attack)
myocardial infarction (mi / ami)
myocardial infarction (mi)
myocardial infarction (mi) / acute coronary syndrome (acs)
myocardial infarction (mi) / acute myocardial infarction
myocardial infarction (mi) / heart attack
myocardial infarction (mi) / myocardial infarct
myocardial infarction (mi) / reinfarction
myocardial infarction (mi) size
myocardial infarction (mi) – previous and new
myocardial infarction (mi, sometimes referred to as ami)
myocardial infarction (non‑obstructive)
myocardial infarction / infarction
myocardial infarction after alcohol binge
myocardial infarction outcome measures
myocardial infarction risk
myocardial infarction with nonobstructive coronary arteries (minoca)
myocardial infarction with non‑obstructive coronary arteries (minoca)
myocardial infarction with non‑obstructive coronary artery disease (minoca)
myocardial infarction with normal coronary arteries
myocardial infarction, acute
myocardial infarction, chronic
myocardial infarction, evidence‑based interventions
myocardial infarction, non‑st‑elevation (nstemi)
myocardial infarction, revascularization outcomes
myocardial infarction, st‑elevation (stemi)
myocardial inflammation
myocardial injury
myocardial injury biomarkers
myocardial injury/death (procedure‑related)
myocardial ischemia
myocardial ischemia / ischemic changes
myocardial ischemia and transfusion (mint) trial
myocardial ischemia attributable to aaoca
myocardial ischemia detection
myocardial mass quantification
myocardial metabolism
myocardial necrosis
myocardial necrosis (myonecrosis)
myocardial oxygen demand
myocardial oxygen demand reduction (via heart rate, blood pressure, contractility)
myocardial oxygen supply
myocardial oxygen supply‑demand mismatch
myocardial performance
myocardial performance index (mpi)
myocardial perfusion
myocardial perfusion imaging
myocardial perfusion imaging (mpi)
myocardial perfusion reserve
myocardial perfusion single‑photon emission computed tomography (spect)
myocardial replacement fibrosis
myocardial revascularization
myocardial salvage
myocardial scar
myocardial scar / late‑gadolinium enhancement
myocardial scar heterogeneity
myocardial scarring
myocardial stiffness
myocardial strain abnormalities
myocardial strain imaging
myocardial stress perfusion mri (regadenoson)
myocardial structure
myocardial stunning
myocardial viability
myocardial work analysis (biventricular performance)
myocardial infarction
myocarditis
myocardium
myocardium (myocardial structure/function)
myocyte necrosis
myofibroblast activity
myofilament protein degradation
myokardia
myokardia (myocardial therapy)
myonecrosis
myopathic process in ebstein anomaly
myopathy (muscle disease)
myopathy, rhabdomyolysis
myopericarditis
myosin heavy chain 6 (myh6)
myosin inhibitor
myosin inhibitor (e.g., mavacamten)
myosin inhibitors
myosin‑binding protein c3 (mybpc3)
myxomatous changes
myxomatous degeneration
myxomatous disease
myxomatous mitral valve





















n-acetylprocainamide (napa)
n-terminal pro-bnp (nt‑probnp)
n-terminal pro‑brain natriuretic peptide (nt‑probnp)
n-terminal pro–b-type natriuretic peptide (nt‑probnp) – (implicit in hf assessment)
nadolol (oral)
naltrexone/bupropion (weight‑loss drug)
napkin‑ring sign
naproxen
narrow therapeutic range
nasogastric tube deviation
national academy of medicine (formerly institute of medicine) – cardiology standards
national behavioral risk factor surveillance system (brfss)
national cardiogenic shock initiative
national cardiovascular data registries
national cardiovascular data registry (ncdr)
national cardiovascular data registry (ncdr) action registry
national cardiovascular data registry (ncdr) – pvi registry
national center for catastrophic sports injury research
national cholesterol education program (ncep) adult treatment panel iii
national cholesterol education program adult treatment panel iii (ncep atp iii)
national forum for heart disease & stroke prevention (heart‑related focus)
national guidelines (aortic disease guideline)
national health and nutrition examination survey (nhanes)
national heart association/american college of cardiology guidelines (e.g., acc/aha)
national heart, lung, and blood institute (nhlbi)
national heart, lung, and blood institute (nhlbi) gentac registry
national heart, lung, and blood institute (nhlbi) – heart disease funding
national heart, lung, and blood institute (nhlbi) – key cardiovascular research institute
national institutes of health (nih)
national lipid association (nla)
national lipid association expert panel on familial hypercholesterolemia
national minority cardiovascular alliance
national physical activity plan (american heart association)
national registries and cohort studies (e.g., af‑risk, pinnacle, cabana)
national registry of nontraumatic amputations
national surgical quality improvement program (nsqip) data on aortic aneurysm
national trends in hf hospitalization and readmission
national/american heart association (aha), american college of cardiology (acc), heart rhythm society (hrs) guideline documents
nationwide registry data (e.g., dutch, japanese, uk national registries)
native american and alaskan native populations
native aortic infection
native valve
native valve disease
native valve endocarditis
native valve endocarditis (nve)
native valve heart disease (excluding rheumatic mitral stenosis)
native valve repair
native valves in pregnancy
native valvular heart disease, excluding mitral stenosis
native valvular regurgitation
native‑valve endocarditis
natriuretic peptide
natriuretic peptide (np)
natriuretic peptide biomarker
natriuretic peptide biomarkers
natriuretic peptide levels
natriuretic peptides
natriuretic peptides (bnp)
natriuretic peptides (bnp, nt‑probnp)
natriuretic peptides (bnp/nt‑probnp)
natriuretic peptides (e.g., bnp, nt‑probnp)
natural history
natural history (of pau and imh)
natural history of aortic aneurysm
natural history of aortic disease
natural history of aortic root aneurysm in marfan syndrome
natural history of arteriosclerosis
natural history of congenital ventricular septal defect
natural history of mitral regurgitation
natural history of moderate mixed vhd
nausea
navigate** (cardiac navigation system)
neat‑hfpef trial
nebivolol
neck angulation
neck length
necrotizing vasculitis on arterial biopsy
nect (n/a)
need for achd cardiac anesthesia and icu support
negative atrial remodeling
negative dromotropic agents
negative inotropes (verapamil, diltiazem, disopyramide)
negative inotropic effects
negative pressure wound therapy (npwt)
negative risk markers (e.g., cac=0)
negative u waves
neighborhood deprivation
neighborhood deprivation index (adi)
neighborhood disadvantage
neighborhood environment
neighborhood environment / access to facilities
neoaorta
neoaortic diameter
neoaortic dilation
neoaortic insufficiency
neoaortic insufficiency (regurgitation)
neoaortic obstruction
neoaortic regurgitation
neoaortic regurgitation (insufficiency)
neoaortic root dilation
neoaortic root intervention
neoaortic root replacement
neoaortic size/diameter
neoaortic valve stenosis
neoaortic valvular dysfunction
neoaortic‑root pathology
neochord (transcatheter mitral valve repair system)
neointimal hyperplasia
neonatal and pediatric outcomes after arterial switch
neovasc medical inc.
neo‑aortic insufficiency
neo‑aortic regurgitation
neo‑aortic root diameter
neo‑aortic root growth
neo‑intimal hyperplasia
nephrogenic systemic fibrosis
nephrogenic systemic fibrosis (nsf)
nephron blockade
nephropathy
nephrotoxic exposure
neprilysin inhibition
neprilysin inhibitor
net adverse clinical events
net atrial‑ventricular compliance
net atrioventricular compliance (nac)
net clinical benefit
net clinical benefit (mace + bleeding)
net clinical benefit / harm
net clinical outcome
net clinical outcomes (stroke, transient ischemic attack)
net harm (prasugrel vs clopidogrel in certain subgroups)
net left‑to‑right shunt
net left‑to‑right shunt (qp:qs ≥ 1.5:1)
net right‑to‑left shunt
network meta‑analysis
neuraxial anesthesia
neuraxial local anesthetic agents
neuraxial local anesthetics
neurocognitive adverse effects
neurocognitive and mental‑health considerations in achd (depression, anxiety, ptsd, cognitive decline, frailty)
neurocognitive and psychological outcomes in adults with corrected d‑tga
neurocognitive decline
neurocognitive dysfunction
neurocognitive events
neurocognitive screening in achd
neurodevelopmental evaluation in chd
neurodevelopmental outcomes
neurodevelopmental outcomes for individuals with congenital heart disease
neurodevelopmental outcomes in congenital heart disease
neuroendocrine activation
neurofibromatosis
neurohormonal
neurohormonal activation (targeted by neprilysin inhibitor)
neurohormonal activation in heart failure
neurohormonal antagonists
neurohormonal antagonists (e.g., acei, arbs, beta‑blockers, mras)
neurohormonal blockade
neurohormonal modulation (gdmt)
neurohormonal therapies for cardioprotection
neurohormonal therapy
neurohumoral and hemodynamic effects of lower body negative pressure
neuroischemic wounds
neurologic complications (brain abscess, stroke)
neurologic complications (perfusion‑related, stroke)
neurologic deficits
neurologic events
neurologic recovery / prognosis
neurologic toxicity (neurologic)
neurological outcomes
neurological toxicity
neurologist
neurology stroke team
neuromodulation
neuromuscular assessment
neuropathy
neuroprotection
neurosurgical monitoring
neurosurgical procedures
neuro‑hormonal guideline‑directed medical therapy (gdmt)
neuro‑modulation
neuro‑psychological complications
neutropenia
new cardiovascular horizons
new heart failure treatment strategies (sglt2 inhibitors, arni)
new or increased left‑sided valve regurgitation
new oral anticoagulants (doacs)
new partial dehiscence of prosthetic valve
new pharmacological therapy for heart failure
new york heart association
new york heart association (nyha)
new york heart association (nyha) class
new york heart association (nyha) class ii symptoms
new york heart association (nyha) class iii symptoms
new york heart association (nyha) class ii‑iv
new york heart association (nyha) class ii–iv
new york heart association (nyha) class i‑ii
new york heart association (nyha) class i–ii
new york heart association (nyha) class i–iii symptoms
new york heart association (nyha) class ii, iii, iv
new york heart association (nyha) class ii–iii
new york heart association (nyha) class iv
new york heart association (nyha) class ≥ iii/iv
new york heart association (nyha) functional class
new york heart association (nyha) functional class ii, iii, iv
new york heart association (nyha) functional class iii–iv
new york heart association (nyha) functional classes iii & iv heart failure
new york heart association (nyha) functional classes i–iv
new york heart association (nyha) functional classification
new york heart association (nyha) functional class iii/iv
new york heart association class (nyha)
new york heart association functional class (nyha fc)
newborn metabolic screening
new york heart association (nyha) class
new york heart association (nyha) functional classes ii–iv, iii–iv, iv
new york heart association (nyha) functional class iii/iv
new york heart association (nyha)
new york heart association (nyha) classification
new‑generation anticoagulants
new‑generation direct oral anticoagulants (doacs)
new‑guideline recommendations (ng)
new‑onset af (<1 year)
new‑onset af (within 3 months of valve surgery)
new‑onset af burden
new‑onset af diagnostic trials (e.g., east‑afnet 4)
new‑onset atrial arrhythmias
new‑onset atrial fibrillation
new‑onset heart failure
new‑onset heart failure (nyha classes iii–iv)
new‑onset myocardial infarction (mi)
new‑onset postoperative af
new‑tarry “high‑value” cardiac therapeutic economics (qaly)
new‑york heart association (nyha) class
new‑york heart association (nyha) class (i–iv)
new york heart association (nyha) functional class
new york heart association (nyha) functional classification
new york heart association (nyha) class
new york heart association (nyha) classification
new york heart association (nyha) functional class
new york heart association (nyha) functional class (ii–iii)
new york heart association (nyha) functional classes i–iv
new york heart association (nyha) class
new york heart association (nyha) class i–iv
new york heart association (nyha) classification
new york heart association (nyha) functional classification
nf‑κb (nuclear factor kappa‑b)
nhlbi (national heart, lung, and blood institute)
niacin
niacin (with or without laropiprant)
nicardipine
nicotine
nicotine dependence / addiction
nicotine replacement therapy
nicotine replacement therapy (nrt)
nicotine replacement therapy (patch, gum, lozenge)
nicotine‑replacement therapy
nicotine‑replacement therapy (nrt)
niemann‑pick c1‑like 1 protein (npc1l1)
nifedipine
nifedipine (long‑acting)
night‑time or weekend surgical effect
nih (national institutes of health)
nih (national institutes of health, many cardiovascular research programs)
nikaidoh procedure
nitrate medications
nitrate therapy
nitrates
nitrates (e.g., isosorbide mononitrate)
nitrates (e.g., nitroglycerin)
nitrates (pharmacologic therapy)
nitrates (routine use contraindicated, class iii)
nitrate‑responsive angina
nitric‑oxide release
nitroglycerin
nitroglycerin (nitroglycerin spray, sublingual tablets, intravenous)
nitroglycerin consumption
nitroglycerin spray
nitroglycerin‑sildenafil interaction (tadalafil, avanafil, sildenafil citrate)
nitroprusside
nitro‑sodic‑acid‑dependent peptides (dpp‑4) inhibitors
nitro‑vasodilators
nkx2‑5 mutation
nla (national lipid association)
nlrp3 (nod‑lrr‑pyrin domain containing protein 3)
nlrp3 inflammasome
nlrp3‑blocking drugs
noac (novel oral anticoagulant)
noble trial
nocebo effect (patient expectation of harm with statin)
nocturnal oximetry abnormalities
nocturnal oxygenation
nomograms
nonapical site pacing
noncardiac conditions
noncardiac surgery in vhd patients
noncompaction cardiomyopathy
noncompressible abi (> 1.40)
noncompressible vessels
nondihydropyridine calcium channel blocker
nondihydropyridine calcium channel blockers
nondihydropyridine calcium channel blockers (e.g., verapamil, diltiazem)
nondihydropyridine calcium channel blockers (verapamil, diltiazem)
nondihydropyridine calcium‑channel blocker
nondihydropyridine calcium‑channel blockers
nondihydropyridine calcium‑channel blockers (diltiazem, verapamil)
nonfamilial hcm
nonfatal mi
nonfatal stroke
nonfulminant myocarditis
nonhealing wounds
nonimaging parameters (serum markers, novel approaches)
nonintact circle of willis
noninvasive cardiac imaging
noninvasive cardiac testing
noninvasive diagnostic testing
noninvasive doppler interrogation
noninvasive imaging
noninvasive imaging (e.g., doppler echocardiography)
noninvasive risk markers
noninvasive stress imaging
noninvasive stress testing
nonischemic cardiomyopathy
nonischemic cardiomyopathy (nicmp)
nonischemic intermediate lesions
nonlethal arrhythmias
nonobstructive coronary arteries
nonobstructive coronary artery disease (nonobstructive cad)
nonobstructive hcm
nonobstructive hcm with preserved ejection fraction (ef)













nonparoxysmal atrial fibrillation
nonpharmacological interventions
nonpharmacological interventions for hypertension
nonpharmacological treatment
nonprescription nutrition/dietary supplements
nonrheumatic calcific mitral stenosis
nonsteroidal anti‑inflammatory drugs (nsaids)
nonsustained ventricular tachycardia (nsvt)
nonsustained ventricular tachycardia (nsvt) episodes
nonsyndromic heritable thoracic aortic aneurysm (nshtad)
nonsyndromic heritable thoracic aortic disease
nonsyndromic heritable thoracic aortic disease (nshtad)
nonsyndromic htad
nonthrombogenic valve surfaces
nonthrombogenic valves
nontraumatic amputation
nontraumatic lower extremity amputation
nontraumatic lower‑extremity amputation
nonvalvular atrial fibrillation
non‑adherence and subtherapeutic drug levels
non‑alcoholic fatty liver disease (nafld)
non‑aortic cardiovascular events
non‑arrhythmic deaths following icd implantation or mi
non‑aspirin non‑steroidal anti‑inflammatory drugs (nsaids) – their impact on mace risk
non‑a‑non‑b dissection (european consensus)
non‑calcified plaque
non‑calcified plaque burden
non‑cardiac comorbidities affecting treatment choice.
non‑cardiac organ dysfunction
non‑cardiac procedures
non‑cardiac procedures at achd centers
non‑cardiac surgery
non‑cardiac surgery (in the context of cardiac risk)
non‑cardiac surgery (perioperative context)
non‑cardiac surgery in high‑risk populations (ap classes ic–d, iia–d, iiia–d)
non‑cardiac surgery in vhd patients
non‑cardioembolic stroke
non‑cardiothoracic surgery
non‑cardiovascular death
non‑coding rnas (e.g., microrna)
non‑competitive β‑blocker
non‑conclusive tte → tee or cmr
non‑contrast mri
non‑coronary atherosclerotic disease
non‑coronary revascularization procedure
non‑culprit lesion
non‑culprit lesion pci
non‑deferrable major surgery on dapt
non‑dental invasive procedures (transthoracic/ transesophageal echocardiography, esophagogastroduodenoscopy, colonoscopy, cystoscopy)
non‑dihydropyridine calcium channel blocker (ndcc)
non‑dihydropyridine calcium channel blockers
non‑dihydropyridine ccb (verapamil, diltiazem)
non‑familial hypertrophic cardiomyopathy
non‑fatal cardiac failure
non‑fatal events
non‑fatal mi
non‑fatal myocardial infarction (mi)
non‑fatal reinfarction
non‑fatal stroke
non‑fibrin‑specific agents
non‑hdl cholesterol
non‑hdl‑c
non‑hdl‑c (total cholesterol – hdl‑c)
non‑hdl‑cholesterol
non‑healing ischemic ulcers
non‑healing lower extremity wound
non‑healing lower‑extremity wounds
non‑hyperemic pressure ratios
non‑infarct‑related arteries
non‑inferiority trial design
non‑invasive diagnostic testing before discharge
non‑invasive evaluation of valvular disease
non‑invasive filling pressure assessment (diastolic imaging)
non‑invasive global and regional ventricular function
non‑invasive imaging
non‑invasive imaging limitations (parallel intercept angle, image quality)
non‑invasive imaging-assisted management
non‑invasive management of acs
non‑invasive modalities (e.g., myocardial perfusion imaging, stress testing)
non‑invasive respiratory monitoring for congenital heart disease.
non‑invasive risk stratification
non‑invasive scd risk assessment
non‑invasive stress imaging
non‑invasive stress testing
non‑invasive testing (e.g., doppler, ultrasound)
non‑invasive testing (nuclear imaging, stress echo)
non‑invasive testing prior to discharge
non‑invasive vascular assessment
non‑ischemic cardiomyopathy
non‑ischemic chronic secondary mr
non‑ischemic dilated cardiomyopathy (non‑ischemic heart failure)
non‑ischemic hf
non‑ischemic mr
non‑ischemic myocardial inflammation
non‑laminar blood flow
non‑lbbb pattern
non‑left bundle branch block (non‑lbbb)
non‑major clinically relevant bleeding
non‑obstructive cad
non‑obstructive coronary arteries
non‑obstructive coronary arteries (inoca)
non‑obstructive coronary artery disease
non‑obstructive coronary artery disease (minoca)
non‑obstructive coronary artery disease (nocad)
non‑obstructive hcm
non‑obstructive hypertrophic cardiomyopathy
non‑pci‑capable hospital
non‑pharmacologic interventions
non‑pharmacologic therapy for mental health
non‑prescription dietary supplement
non‑q‑wave myocardial infarction
non‑randomized comparative studies
non‑reconstructable peripheral arterial disease
non‑restrictive ventricular septal defect
non‑restrictive vsd
non‑restrictive vsds (large, associated with eisenmenger)
non‑salvageable limb
non‑segregating heritable thoracic aortic disease (nshtad)
non‑selective beta‑blockers
non‑shockable rhythm (asystole, pulseless electrical activity)
non‑st elevation myocardial infarction (nstemi)
non‑statin lipid‑lowering therapies
non‑statin lipid‑lowering therapy
non‑stemi (implied as other acs presentations)
non‑stemi (nstemi)
non‑stemi acute coronary syndromes (nste‑acs)
non‑steroidal anti‑inflammatory drug (nsaid)
non‑steroidal anti‑inflammatory drug (nsaid) use
non‑steroidal anti‑inflammatory drugs (nsaids)
non‑steroidal anti‑inflammatory drugs (nsaids) for pericardial effusion
non‑steroidal selective mineralocorticoid receptor antagonists (mra) in hf
non‑st‑elevation acs (nste‑acs)
non‑st‑elevation acute coronary syndrome (nste‑acs)
non‑st‑elevation acute coronary syndromes
non‑st‑elevation acute coronary syndromes (nste‑acs)
non‑st‑elevation acute coronary syndromes (nst‑acs)
non‑st‑elevation mi
non‑st‑elevation myocardial infarction (nstemi)
non‑st‑segment elevation acs (nstemi)
non‑st‑segment elevation acs (nste‑acs)
non‑st‑segment elevation acute coronary syndrome (nste‑acs)
non‑st‑segment elevation acute coronary syndrome / nstemi (nste‑acs)
non‑st‑segment elevation acute coronary syndromes (nste‑acs)
non‑st‑segment elevation myocardial infarction (nstemi)
non‑st‑segment elevation myocardial infarction (nstemi/nste‑acs)
non‑st‑segment‑elevation myocardial infarction (nstemi)
non‑st‑segment–elevation acs (nste‑acs)
non‑sustained ventricular tachycardia
non‑sustained ventricular tachycardia (nsvt)
non‑syndromic aneurysm
non‑syndromic hereditary thoracic aortic disease (nshtad)
non‑syndromic heritable thoracic aortic disease (nshtad)
non‑syndromic thoracic aortic aneurysm
non‑traditional risk factors
non‑traditional risk markers
non‑valvular af
non‑valvular atrial fibrillation
non‑viable myocardium
non‑vitamin k antagonist oral anticoagulants
non‑vitamin k antagonist oral anticoagulants (noacs)
non‑vitamin k oral anticoagulant (doac)
non‑vitamin k oral anticoagulants (noacs)
non‑vitamin‑k antagonist oral anticoagulants trial (noah)
non‑vitamin‑k oral anticoagulant (noac)
non‑vitamin k antagonist oral anticoagulant (noac)
non‑vitamin k antagonist oral anticoagulants (noacs)
non‑vitamin k oral anticoagulant (noac)
non–st-elevation myocardial infarction (nstemi)
non–st‑elevation acute coronary syndrome (nst‑acs) / acute coronary syndrome (acs)
non–st‑segment elevation acs (nste‑acs)
non–st‑segment elevation acute coronary syndromes (nste‑acs)
non–st‑segment–elevation myocardial infarction (nstemi)
noonan syndrome
noonan syndrome (ptpn11, kras, sos1, raf1, nras, braf, map2k1) – pulmonary stenosis, asd, hypertrophic cardiomyopathy, avsd
noradrenaline (norepinephrine)
norcaad (nordic consortium for acute type a aortic dissection)
nordistemi study
norepinephrine
normal abi (1.00–1.40)
normal coaptation
normal coronary arteries
normal saline (for aki prevention)
normal sinus rhythm (nsr)
normotension (normal blood pressure)
northwestern university
norwood repair
norwood repair (hlhs/norwood)
norwood repair (stage 1)
nosocomial s. aureus bacteremia
notch1 gene mutation
notch1 mutation
note:** these terms encapsulate the core concepts, disease processes, interventions, complications, and diagnostic strategies relevant to cardiovascular (aortic) disease discussed in the provided guideline excerpts.
novartis
novartis (cardiovascular therapeutics)
novel agents for diabetes, obesity, and hyperlipidemia
novel cardiovascular risk‑reduction therapies
novel lipid‑lowering drugs (for pad)
novel lipid‑lowering drugs for pad (qm‑4)
novel oral anticoagulants
novel oral anticoagulants (noacs)
novo nordisk
no‑clamp technique
no‑reflow
no‑reflow phenomenon
nsaids (non‑steroidal anti‑inflammatory drugs)
nsr (normal sinus rhythm)
nstemi (non‑st‑elevation myocardial infarction)
nste‑acs (non‑st‑segment elevation acute coronary syndrome)
nt-probnp (biomarker)
nt‑probnp
nt‑probnp (biomarker for hf severity)
nt‑probnp (biomarker)
nt‑probnp (n‑terminal pro b‑type natriuretic peptide)
nt‑probnp (n‑terminal pro‑b‑type natriuretic peptide)
nt‑probnp level ≥ 5314 pg/ml (high‑risk subgroup)
nt‑probnp levels
nuclear cardiology
nuclear factor‑kappa b (nf‑κb)
nuclear imaging (myocardial perfusion)
nuclear magnetic resonance imaging (nmri)
nuclear myocardial perfusion imaging
nuclear myocardial perfusion imaging (mpi)
nuclear perfusion scans
nuclear scintigraphy
null‑please score
number needed to treat (nnt)
nupulse cv (cardiovascular technology)
nurse
nurse navigator
nurse practitioner / physician assistant
nurses with exercise training experience
nurse‑led af clinics
nurse‑led care programs
nurse‑led interventions
nutraceuticals / supplements → coenzyme‑q10, l‑carnitine, taurine, thiamine
nutrient‑related risk of cardiovascular disease
nutrition
nutrition (including supplements)
nutrition / diet
nutrition and diet (heart‑healthy diet)
nutrition and supplements
nutritional adequacy
nutritional counseling
nutritional counseling (cachexia, malnutrition)
nutritional management (diet, sodium, fluid)
nutritional risk factors (low‑carbohydrate diet, caloric reduction)
nutritional status
nutritional status / malnutrition in pad patients
nutritionist / dietitian
nuts and seeds
nuvasive
nyha (new york heart association)
nyha (new york heart association) classification
nyha (new york heart association) class
nyha (new york heart association functional classification)
nyha (new york heart association)
nyha class
nyha class (i–iv)
nyha class (new york heart association functional classification)
nyha class i
nyha class ii
nyha class ii & iii
nyha class iii
nyha class iii and iv heart‑failure (hf) symptoms
nyha class iii heart failure
nyha class iii–iv
nyha class ii‑iv symptoms
nyha class ii–iv heart failure
nyha class iv
nyha class ii or iii heart failure
nyha class iii
nyha class iv
nyha functional class
nyha functional class (i–iv)
nyha functional class i and iii
nyha functional class iii/iv
nyha functional class iii‑iv
nyha functional class iii–iv heart failure
nyha functional class ii–iv
nyha functional class i‑ii
nyha functional class i–iv
nyha functional classes (i, ii, iii, iv)
nyha functional classification
nyha functional classification (i–iv)
nyha functional class iii–iv
nyha ii‑iii symptoms / nyha class
nyha – new york heart association class
n‑3 polyunsaturated fatty acids (omega‑3)
n‑acetyl‑l‑cysteine (nac)
n‑of‑1 trial (caffeine)
n‑terminal probnp (nt‑probnp)
n‑terminal prohormone of b‑type natriuretic peptide (nt‑probnp)
n‑terminal pro‑b natriuretic peptide (nt‑probnp)
n‑terminal pro‑b type natriuretic peptide (nt‑probnp)
n‑terminal pro‑b-type natriuretic peptide (nt‑probnp)
n‑terminal pro‑bnp (nt‑probnp)
n‑terminal pro‑brain natriuretic peptide (nt‑probnp)
n‑terminal pro‑b‑natriuretic peptide (nt‑probnp)
n‑terminal pro‑b‑type natriuretic peptide
n‑terminal pro‑b‑type natriuretic peptide (nt‑probnp)
n‑terminal pro–brain natriuretic peptide (nt‑probnp)
n‑terminus pro‑bnp (nt‑probnp)



















oac (oral anticoagulant)
oac monotherapy
oasis, atoll, futura/oasis‑8, stenic, bright, gusto‑iib, etc. (key clinical trials/registries)
oasis‑5 trial
oasis‑6 trial
obesity
obesity & cardiac remodeling in hcm
obesity (as a risk factor)
obesity (bmi ≥ 30 kg/m²)
obesity (bmi ≥ 30 kg/m²)
obesity (class iii)
obesity (dose adjustment)
obesity (increased transthoracic impedance)
obesity (overweight/obese patients)
obesity (reduces bnp/nt‑probnp levels, impacting hf diagnosis)
obesity (risk factor)
obesity (weight, bmi)
obesity / cachexia / nutritional status – hf risk factors
obesity / elevated body mass index (bmi)
obesity / metabolic syndrome
obesity / overweight
obesity / weight control
obesity / weight loss (overweight)
obesity epidemic
obesity paradox in heart failure
obesity, social obstacles, substance use (barriers to transplant)
obesity‑mediated structural atrial changes
obesity‑related suppression of bnp
objective exercise capacity
objective exercise intolerance
objective limb‑threat classification tools
objective measures of cardiac dysfunction
obligates carriers
oblique imaging
obliquely arranged myocytes
observational and registry data
observational cohort studies
observational cohort studies on peripartum cardiomyopathy outcomes
observational studies
observational studies (cohort, registry)
observational studies on af and heart rate
observational studies vs randomized controlled trials (rcts)
observational studies/trials
observation‐based therapeutic strategies
obstetric and anesthesia coordination for anticoagulation
obstetric anesthesia
obstetric anticoagulation strategy (e.g., warfarin shift, lmwh use)
obstetric cardiac surveillance (cardiac monitoring during pregnancy)
obstetric outcomes
obstruction (clinical threshold for intervention)
obstructive cad
obstructive cad (≥ 50 % diameter stenosis, ffr ≤ 0.80)
obstructive cardiomyopathy
obstructive hcm
obstructive hcm / lvoto (left ventricular outflow tract obstruction)
obstructive hypertrophic cardiomyopathy
obstructive physiology
obstructive sleep apnea
obstructive sleep apnea (osa)
obstructive sleep apnea (pulmonary/ cardiac impact)
obstructive sleep apnea (risk factor for ph)
obstructive uropathy
obstructive vs. non‑obstructive hcm classification
occluded artery trial (oat)
occlusion
occlusive lesions
occlusive vascular disease
occlutech
occult (silent) atrial fibrillation
occult left ventricular dysfunction
occupation
occupational considerations for patients with hcm
occupational therapist
octogenarian surgery outcomes
odds ratio
odds ratio (or)
odyssey outcomes study (clinical trial)
odyssey outcomes trial
odyssey outcomes trial (evaluation of cardiovascular outcomes after an acute coronary syndrome during treatment with alirocumab)
odyssey outcomes trial
office‑based abi measurement
offloading
off‑pump bypass
off‑pump coronary bypass
off‑pump myocardial revascularization
off‑the‑shelf branched repair
ohca score (out‑of‑hospital cardiac arrest score)
older adults
older adults (≥ 80 years, ≥ 65 years)
older age
older age (aging)
older age (≥75 years)
older age (≥ 75 years)
older‑adult heart disease risk
oliguria
omapatrilat
omapatrilat (neprilysin inhibitor/acei combination)
omecamtiv mecarbil for advanced (stage d) hfref
omega‑3 fatty acid supplements
omega‑3 fatty acids
omega‑3 fatty acids (epa, dha)
omega‑3 fatty acids (fish oil)
omega‑3 fatty acids (n‑3 fatty acids)
omega‑3 fatty acids (n‑3 polyunsaturated fatty acids, marine omega‑3)
omega‑3 polyunsaturated fatty acids
omega‑3 polyunsaturated fatty acids (omega‑3 pufa)
omega‑3 polyunsaturated fatty acids (pufa)
omental coverage
omeprazole
omics and molecular markers for hf diagnosis and prognosis
ongoing ischemia
ontarget (ongoing telmisartan alone and in combination with ramipril global endpoint trial)
ontarget (telmisartan alone and in combination with ramipril)
on‑x aortic valve
on‑x avr
open (surgical) repair
open aneurysm repair
open aortic aneurysm repair
open aortic reconstruction
open aortic repair
open aortic surgery
open aortic surgery (open repair)
open bypass
open commissurotomy
open distal anastomosis
open heart surgery
open infrainguinal bypass
open infrarenal aortic repair
open mitral commissurotomy (oc)
open repair
open repair (surgery, aortic cross‑clamping)
open repair of the aorta
open repair technique
open repair versus endovascular repair
open surgery
open surgical aortic repair
open surgical cutdown
open surgical intervention
open surgical repair
open surgical repair (arch or ascending aorta)
open surgical repair (in situ reconstruction, aortic resection)
open surgical repair (osr)
open surgical repair of aaa
open surgical repair of aorta
open surgical repair of coa
open surgical repair of the aorta
open surgical replacement
open surgical revascularization
open‑distal technique
open‑label trial (comparative efficacy of prasugrel vs. ticagrelor)
operability assessment in adult congenital heart disease
operating room (or)
operative and mortality risk in valve surgery
operative intervention (aortic surgery)
operative mortality
operative mortality (8–20 %)
operative mortality / operative risk
operative mortality rate
operative repair of type a aortic dissection
operative risk (low, intermediate, high)
operative risk models (irad score)
operative risk reduction (advanced surgical techniques)
operative survival (5‑year actuarial survival)
operative volume & surgical learning curve
operator/institutional case volume
ophthalmologic procedures
opiate medications
opioid substitution therapy
opioid substitution treatment (ost)
opioid use
opioid use (including opioid‑associated out‑of‑hospital cardiac arrest)
opioids
opioids (adjunct)
opioid‑dependent patients
optic neuropathy
optic neuropathy (amiodarone‑associated)
optic trial (optimal pharmacological therapy in cardioverter defibrillator patients)
optical coherence tomography (oct)
optical frequency domain imaging (ofdi)
optimal beta‑blocker duration in preserved lvef patients.
optimal blood pressure targets after valve intervention
optimal bp thresholds
optimal dosing
optimal exercise protocols
optimal gdmt
optimal medical management (study term)
optimal medical therapy (omt)
optimal timing of intervention
optimize‑hf (organized program to initiate lifesaving treatment in hospitalized patients with heart failure)
optimize‑hf registry
optimize‑hf study
optim‑um registry (surgically ineligible patients)
optmize‑hf registry (organized program to initiate lifesaving treatment in hospitalized patients with heart failure)
oral amiodarone
oral antibiotic treatment
oral anticoagulant
oral anticoagulant (oac)
oral anticoagulant discontinuation
oral anticoagulant therapy
oral anticoagulants
oral anticoagulants (doacs)
oral anticoagulants (e.g., rivaroxaban, direct oral anticoagulants)
oral anticoagulants (e.g., warfarin, doacs)
oral anticoagulants (oac)
oral anticoagulants (oacs)
oral anticoagulation
oral anticoagulation (oac)
oral anticoagulation (oac) therapy
oral anticoagulation / anticoagulant therapy
oral anticoagulation therapy
oral anticoagulation with a vka (vitamin k antagonist)
oral anti‑xa agents
oral aspirin
oral beta‑blockers
oral bioavailability
oral diuretics
oral dofetilide safety
oral factor xa inhibitors
oral gdmt
oral gdmt (guideline‑directed medical therapy)
oral glucose‑lowering agents in heart disease
oral health / oral hygiene (brushing teeth, flossing)
oral health maintenance
oral iron repletion
oral iron supplementation
oral loading dose (propafenone, flecainide)
oral p2y12 inhibitor
oral p2y12 inhibitors
oral p2y12 inhibitors (clopidogrel, ticagrelor, prasugrel, etc.)
oral prostacyclin analog selexipag
oral prostacyclin receptor analogs
oral sotalol
oral suppressive antimicrobial therapy (lifelong)
oral suppressive therapy
orbita medication‑adherence sub‑study
orbita trial
orbit‑af ii registry
orbit‑af trial
organ dysfunction (renal, hepatic, lymphatic)
organ hypoperfusion
organ malperfusion
organ meats
organ system compromise
organic mitral regurgitation
organisation of care for pregnancy in congenital heart disease
orthopedic surgeon
orthopedic surgery
orthopedics
orthopnea
orthotics
orthotopic branched endovascular arch repair
orthotopic heart transplantation
ortner’s syndrome
oscillating intracardiac mass
osler’s nodes
osteoplasty (coronary)
osteoplasty (surgical technique)
ostia of a branch vessel
ostial stenosis
ostium primum asd
outcome measures
outcome measures: survival, hospitalization, quality of life
outcome of atrioventricular valve surgery post‑fontan
outcome prediction
outcome prediction in hcm patients
outcome studies
outcome tracking
outcomes after specialty care for pah
outcomes of ablation in hcm patients
outcomes of atrial tachycardia ablation in fontan patients
outcomes of pacing
outcomes of percutaneous transluminal coronary angioplasty in chronic renal failure
outcomes of staged procedures (tavi → teer)
outcomes studies of arterial switch operation
outcomes studies of biventricular right‑ventricle–pulmonary‑artery conduits
outcomes studies of double‑root translocation
outcomes studies of nikaidoh/rev procedures
outcomes studies of pulmonary‑to‑pulmonary conduits
outcomes studies of rastelli repair
outcomes: mortality at 30 days, 6 months, 1 year, 6 years
outcomes: mortality, reduced mace, bleeding rates, rehospitalisation.
outer‑edge to outer‑edge measurement
outflow disease
outflow lesions
outflow tract gradient
outflow tract gradient variability
outflow tract obstruction
outflow tract‑to‑aortic velocity ratio
outlet vsd
outpatient ambulatory rhythm monitoring
outpatient antiarrhythmic therapy
outpatient care setting
outpatient care setting – cardiovascular care context
outpatient follow‑up
out‑of‑hospital cardiac arrest
out‑of‑hospital cardiac arrest management guidelines
out‑of‑hospital cardiovascular event
out‑of‑pocket costs
overall survival
oversensing (post‑exercise)
overt dosing (over‑dosing)
overt right ventricular failure
overweight
overweight and obesity in adults
overweight/obesity
over‑ or underestimation of risk by pce
oxidative stress
oxidative stress biomarkers (related to heart failure prognosis)
oxidative‑stress‑associated kinases (e.g., camkii, jun‑kinase)
oxidized low‑density lipoprotein















oxygen consumption
oxygen consumption measurements
oxygen consumption/oxygen uptake (vo₂)
oxygen saturation
oxygen saturation (spo₂)
oxygen saturation measurement (oximetry)
oxygen saturations
oxygen therapy
oxygen therapy effect on exercise performance
oxygen uptake (vo₂)
oxygen uptake / peak vo₂
oxygenation / ventilation parameters
oxygenation strategies in acute myocardial infarction
oxygen‑free radicals











p/lp (pathogenic/likely pathogenic) variants
p/lp genetic variants (predisposing pathogenic/likely pathogenic variants)
p2y12 antagonist
p2y12 inhibitor
p2y12 inhibitor (clopidogrel, ticagrelor, etc.)
p2y12 inhibitor therapy
p2y12 inhibitors
p2y12 inhibitors (clopidogrel, prasugrel, ticagrelor)
p2y12 inhibitors (e.g., clopidogrel, ticagrelor)
p2y12 inhibitors (oral & parenteral)
p2y12 inhibitors (oral and intravenous)
p2y12 receptor antagonists
pa catheter monitoring
pa hypoplasia
pa systolic pressure >35 mm hg
pac (premature atrial contraction)
pace score
pace termination
pacemaker
pacemaker (av junction ablation, vvir)
pacemaker (permanent)
pacemaker (pm)
pacemaker endocarditis
pacemaker implantation
pacemaker implantation (before age 65)
pacemaker implantation (right‑ventricular pacing, biventricular pacing)
pacemaker implantation / ventricular pacing effects
pacemaker implantation for post‑operative complete heart block
pacemaker implantation risk
pacemaker lead
pacemaker lead–induced tricuspid regurgitation
pacemaker lower‑rate programming (80–90 bpm)
pacemaker or defibrillator infection
pacemaker placement
pacemaker therapy
pacemakers
pacemakers and defibrillators
paces risk score
pace‑support rate setting
pacing
pacing (general term for cardiac pacing)
pacing algorithm
pacing algorithms (general)
pacing burden
pacing complications
pacing method (e.g., vvir, cardiac resynchronization therapy)
pacing percentage (≥ 98 % biventricular pacing)
pacing strategies
pacing strategies (rv pacing, crt pacing)
pacing strategies (systemic right ventricle / fontan)
pacing thresholds
pacing‑related atrioventricular dysfunction
packer et al. emperor‑preserved (2021)
paclitaxel‑coated devices
paclitaxel‑eluting stent
paclitaxel‑eluting stents
pad
pad (peripheral artery disease)
pad guideline (2024 acc/aha/aacvpr/apma/abc/scai/svm/svn/svs/sir/vess)
pad national action plan
pad “at risk” population pulse examination
pad “at‑risk” pulse examination
pad‑specific quality of life (padqol)
paf (paroxysmal atrial fibrillation)
paf or persistent af
pah crises (post‑partum)
pah progression
pah‑directed medications
pah‑directed therapy
pain control (analgesia)
pain control (for ischemic rest pain)
pain levels (moderate to severe claudication pain)
pain‑free walking distance
pain‑induced rest periods
pallas trial
palliated single ventricle physiology
palliation
palliative and supportive care (advanced hf)
palliative and supportive care in heart failure
palliative care
palliative care (in the context of advanced heart failure)
palliative care (limb)
palliative care for advanced heart failure
palliative care for heart disease
palliative care for patients with hf
palliative care in hf
palliative care in prohibitive surgical risk patients
palliative care interventions (e.g., pal‑hf)
palliative care team
palliative inotropic therapy
palliative medicine specialist
palliative‑care referral
palm (provider assessment of lipid management) registry
palpitations
palpitations (symptom of af)
palpitations (symptom)
pannus formation
pannus ingrew
pantoprazole
pao₂ (oxygen partial pressure)
papillary muscle abnormalities
papillary muscle displacement
papillary muscle insertion (antero‑mitral leaflet)
papillary muscle morphology
papillary muscle rupture
papillary muscle tear
papillary muscles (abnormal positioning, insertion)
papillary‑muscle rupture
paq (peripheral artery questionnaire) – assessment of limb function
parachute mitral valve
paradigm‑hf
paradigm‑hf (prospective comparison of arni with ace inhibitor in heart failure)
paradigm‑hf trial
paradigm‑hf trial (prospective comparison of angiotensin ii antagonist–drug interventions in the management of heart failure)
paradise‑mi trial
paradise‑mi trial (nt‑probnp prognostication)
paradoxical emboli
paradoxical embolism
paradoxical embolism (right‑to‑left shunts)
paradoxical embolism prevention (asd closure)
paradoxical embolization
paradoxical low‑flow severe as
paraganglioma
paragon‑hf study
paragon‑hf trial
paralysis (neurologic complication)
paramount‑hf trial
paraparesis
paraplegia
parasympathetic nerve remodeling
parasympathetic stimulation
paravalvular abscess
paravalvular extension
paravalvular infection
paravalvular invasion
paravalvular leak
paravalvular leak / regurgitation
paravalvular leakage
paravalvular regurgitation
para‑anastomotic aneurysm (post‑open aaa repair)
para‑anatomorrhatic aneurysm
parenteral antibiotics
parenteral anticoagulation
parenteral anticoagulation (heparin, enoxaparin, etc.)
parenteral anticoagulation strategies
parenteral vasodilator therapy
paris risk score
paroxysmal af
paroxysmal atrial fibrillation
paroxysmal supraventricular tachycardia (svt)
partial anomalous pulmonary venous connection
partial anomalous pulmonary venous drainage
partial anomalous pulmonary venous return
partial anomalous pulmonary venous return (papvr)
partial avsd (incomplete atrioventricular canal / primum asd)
partial defect closure (fenestrated closure)
partial oral treatment of endocarditis (poet) trial
partial/transition av septal defect
partially hydrogenated oils
parvovirus b19 infection
par‑anastomotic aneurysm
passive leg‑raising maneuver
passive smoking (second‑hand smoke)
patch angioplasty
patch leaks (vsd repair)
patency
patency (vascular graft patency)
patency rate
patency rates
patent ductus arteriosus
patent ductus arteriosus (pda)
patent ductus arteriosus closure (surgical & transcatheter)
patent foramen ovale
patent foramen ovale (implied in shunting context)
patent foramen ovale (pfo) closure
pathogenesis
pathogenic cardiac sarcomere genetic variant
pathogenic sarcomeric variant
pathogenic variant
pathogenic variant (in htad genes)
pathogenic variants
pathogenic variants in aortic disease genetics
pathogenic/likely pathogenic (p/lp) variants
pathogens: staphylococcus aureus, streptococcus pneumoniae, escherichia coli, salmonella, candida, aspergillus, mycobacterium tuberculosis
pathophysiologic mechanisms
pathophysiology
pathophysiology of functional mr
pathway (ablation)
pathway obstruction
patient activation
patient age
patient and caregiver goals
patient care (in the context of cardiovascular practice)
patient counseling and education
patient decision aids
patient demographics
patient education
patient education (for ccd)
patient education (on symptom management, lifestyle, medications)
patient education (symptom monitoring, return to daily routine, psychosocial considerations)
patient education and readiness
patient education and social determinants of health (contextual factors influencing care)
patient education strategies in acs
patient engagement
patient engagement and retention
patient engagement in cardiac treatment planning
patient health questionnaire – phq‑9 / phq‑8
patient height ratio (aortic root area to height)
patient monitoring
patient outcomes
patient out‑of‑pocket costs
patient preference
patient preference (vascular access)
patient registries for heart‑failure quality improvement
patient registry studies
patient selection for icd placement
patient self‑care education for hf
patient sex
patient values and preferences
patient-centered outcomes research institute (pcori)
patients and family members (care coordination)
patient‑centered approaches
patient‑centered care
patient‑centered decision making
patient‑centered outcomes
patient‑centered research
patient‑centered transition education
patient‑centered transitional care for hospitalized heart failure
patient‑centered treatments
patient‑centeredness
patient‑centric recommendations
patient‑characteristics influencing mcs outcomes
patient‑engagement tools
patient‑prosthesis mismatch
patient‑reported health status
patient‑reported health status measures
patient‑reported measures
patient‑reported outcome and health status measurement in hf
patient‑reported outcomes
patient‑reported outcomes (pros)
patient‑reported pre‑procedural physical and mental health
patient‑reported quality of life (rate‑af trial)
patient‑specific biomechanical simulation of stent‑graft deployment
patient–caregiver decision delegation
patient–prosthesis mismatch
patiromer (potassium binder)
patisiran (drug for attrv)
patisiran therapy (rna interference)
pause protocol
pause study
pave study
payors (insurance carriers)
pay‑for‑performance (p4p) programs
pay‑for‑performance programs
pce (pooled cohort equations)
pci (percutaneous coronary intervention)
pci strategies
pci‑capable facility
pci‑capable hospital
pcna (prevention of cardiovascular disease network)
pcna (preventive cardiovascular nurses association)
pcna (primary care cardiovascular nursing association)
pcp‑hf (pooled cohort equations to prevent hf)
pcr (polymerase chain reaction) as a diagnostic tool in myocarditis
pcsk9 inhibition (evolocumab)
pcsk9 inhibitor
pcsk9 inhibitor therapy
pcsk9 inhibitor therapy (alirocumab, evolocumab)
pcsk9 inhibitors
pcsk9 inhibitors (evolocumab, alirocumab)
pcsk9 inhibitors (monoclonal antibodies)
pcsk9 monoclonal antibody
pcsk9 monoclonal antibody (e.g., alirocumab, evolocumab)
pcsk9 monoclonal antibody (pcsk9 mab)
pcsk9 monoclonal antibody therapy
pcsk9‑directed small interfering rna (inclisiran)
pcv13 (pneumococcal conjugate vaccine)
pda insertion point
peace trial
peak and mean pressure gradients across aortic stenosis
peak aortic wall stress
peak doppler gradients (≥ 50 mm hg)
peak exercise oxygen consumption
peak gradient
peak gradient (mm hg, m/s)
peak lvot gradient
peak oxygen consumption
peak oxygen consumption (peak vo₂)
peak oxygen consumption (vo₂ peak)
peak oxygen consumption (vo₂)
peak oxygen consumption (vo₂ peak)
peak oxygen uptake (vo₂ max)
peak oxygen uptake (vo₂ peak)
peak rate‑pressure product
peak transvalvular jet velocity
peak vo₂
peak vo₂ (< 14 ml/kg/min or < 50 % predicted)
peak vo₂ (cardiac exercise capacity)
peak vo₂ (peak oxygen consumption/uptake)
peak vo₂ (peak oxygen uptake)
peak vo₂ improvement.
peak vo₂ post‑operative
peak vo₂ pre‑operative
peak vo₂ ≤ 12 ml/kg/min with beta‑blocker therapy (transplant cutoff)
peak vo₂ ≤ 14 ml/kg/min (transplant cutoff)
peak vo₂ ≤17 ml/kg/m²
pearl study
pearl‑hf trial
pearl‑hf trial (rly5016 potassium binder)
ped-fog (edifoligide prevention study)
pedal acceleration time
pediatric & congenital electrophysiology (paces) – related to cardiac conduction
pediatric and adult outcomes after coarctation repair
pediatric aortic dilation
pediatric aortic root replacement
pediatric arrhythmic events
pediatric atrial tachyarrhythmia
pediatric cardiology
pediatric cardiology / paediatric cardiology
pediatric cardiology/heart centers
pediatric cardiomyopathy
pediatric electrophysiology
pediatric exercise testing (≥ 7–8 years old)
pediatric hcm
pediatric hcm management strategies
pediatric hcm risk indicators (e.g., maximal wall thickness z‑score ≥ 20, age ≤ 50 yr for family history)
pediatric hypertrophic cardiomyopathy
pediatric icd decision‑making (cor 2b)
pediatric icd implantation
pediatric risk assessment
pediatric risk calculator
pediatric subvalvular aortic stenosis risk factors
pediatric vs. adult surgical indications
pediatric‑specific risk markers
peer review
pegasus‑timi 54 trial
pegasus‑timi 54 trial
pelvic floor exercise
pelvic surgery
penentrating atherosclerotic ulcer (pau)
penetrance
penetrance (high/low)
penetrance of hypertrophic cardiomyopathy
penetrating aortic ulcer
penetrating aortic ulcer (pau)
penetrating atherosclerotic ulcer
penetrating atherosclerotic ulcer (pau)
penetrating atherosclerotic ulcer of the thoracic aorta
penicillin g benzathine (intramuscular)
penicillin v potassium (oral)
pentoxifylline
penumbra

















peptic ulcer disease
pep‑chf
percutaneous / off‑label endovascular devices
percutaneous access
percutaneous alcohol ablation
percutaneous aortic balloon dilation
percutaneous aortic balloon dilation (balloon aortic valvuloplasty)
percutaneous aortic imaging
percutaneous aortic valve balloon dilation
percutaneous atrial fibrillation interventions
percutaneous atrial septal defect (asd) closure
percutaneous balloon aortic valvuloplasty (pba)
percutaneous balloon commissurotomy
percutaneous balloon dilatation
percutaneous balloon dilatation of the aortic valve
percutaneous balloon dilatation vs. surgical correction
percutaneous balloon dilation of the mitral valve
percutaneous balloon mitral commissurotomy (pmbc)
percutaneous balloon mitral valvuloplasty (pbmv)
percutaneous balloon valvuloplasty
percutaneous balloon valvuloplasty (balloon pulmonary valvuloplasty)
percutaneous circulatory assist device
percutaneous closure
percutaneous closure devices
percutaneous closure procedures
percutaneous coronary angioplasty
percutaneous coronary intervention
percutaneous coronary intervention (pci)
percutaneous coronary intervention (pci) / angioplasty
percutaneous deep vein arterialization (pdva)
percutaneous device closure
percutaneous device closure of vsd
percutaneous femoral access
percutaneous fenestrated asd closure
percutaneous intervention
percutaneous intervention in hcm
percutaneous intervention outcomes for coarctation
percutaneous interventions
percutaneous laao (plaao)
percutaneous laser myocardial revascularization
percutaneous lead & external power supplies (device complications)
percutaneous lead extraction
percutaneous left atrial appendage closure
percutaneous left atrial appendage occlusion (laao)
percutaneous lvad (plvad)
percutaneous mechanical thrombectomy
percutaneous mitral balloon commissurotomy
percutaneous mitral balloon commissurotomy (pmbc)
percutaneous mitral balloon dilation
percutaneous mitral clip
percutaneous mitral commissurotomy (pmc)
percutaneous mitral valve dilatation
percutaneous mitral valve repair
percutaneous mitral valve repair (e.g., mitraclip)
percutaneous mitral valve repair (tmr)
percutaneous mitral valvuloplasty
percutaneous paravalvular leak closure
percutaneous revascularization registry data
percutaneous structural intervention
percutaneous translational angioplasty
percutaneous transluminal angioplasty
percutaneous transluminal angioplasty (pta / balloon angioplasty)
percutaneous transluminal angioplasty (pta)
percutaneous transluminal angioplasty (ptca)
percutaneous transluminal balloon angioplasty
percutaneous treatment
percutaneous valve repair
percutaneous valve repair / replacement
percutaneous valve therapies
percutaneous vascular access
percutaneous ventricular assist devices (vad)
percutaneous coronary intervention (pci)
perforation (of myocardium)
perforation during angioplasty
performance attribution
performance improvement initiative
performance measure (pm)
performance measurement / quality metrics in heart failure care
performance measures
performance measures (cardiovascular performance metrics)
performance measures (cardiovascular/vascular)
performance measures (class i recommendations)
performance measures (pm) for hf
performance measures (pm‑1 to pm‑6)
performance measures (pm‑1 to pm‑7)
performance‑measure benchmarks (real‑time feedback)
perfusion
perfusion adequacy
perfusion assessment
perfusion cmr
perfusion imaging
perfusion imaging techniques
perfusion to the wound bed
perianeurysmal obstruction
periaortic hematoma
pericardial disease (implicit in heart failure context)
pericardial effusion
pericardial effusion / fluid
pericardial tamponade
pericardiectomy
pericardiotomy
pericardioversion thromboembolic event
pericarditis
pericarditis (acute & late)
pericarditis (acute)
pericarditis after myocardial infarction
pericarditis after myocardial infarction (mi)
pericarditis diagnostic criteria
pericardium
perimembranous ventricular septal defect
perimembranous vsd
perimount bioprosthesis
perimount pericardial bioprosthesis
perinatal (pregnancy continuum) hf management strategies
perinatal cardiac outcomes in valvular disease
perindopril
perindopril (ace inhibitor)
perindopril (in elderly hf)
periodic echocardiographic and electrocardiographic screening for relatives
periodic imaging
periodic imaging after valve intervention
periodic imaging schedule
periodic imaging surveillance
periodic longitudinal evaluation (cmr)
periodic monitoring and patient education
periodic reassessment of scd risk
periodical reassessment (first 2 years and yearly thereafter)
periop2 trial
perioperative antibiotic suppression
perioperative atrial fibrillation
perioperative bridging anticoagulation
perioperative cardiovascular evaluation
perioperative cardiovascular evaluation and management
perioperative cardiovascular evaluation and management (acc/aha 2014)
perioperative cardiovascular management
perioperative cardio‑vascular evaluation and management
perioperative complications
perioperative complications (in the context of heart disease)
perioperative considerations/management for non‑cardiac surgery
perioperative death
perioperative death/mortality (in cardiac surgical context)
perioperative events
perioperative hemorrhagic conversion
perioperative management
perioperative management of as patients.
perioperative management of pulmonary hypertension
perioperative morbidity
perioperative morbidity and complications of aortic repair
perioperative morbidity and mortality
perioperative mortality
perioperative mortality (10–25 %)
perioperative mortality rate
perioperative mortality rates
perioperative mortality risk
perioperative outcomes
perioperative outcomes of aortic repair
perioperative period / peri‑operative hemodynamics
perioperative risk
perioperative stroke
perioperative valve outcomes
peripartum cardiomyopathy
peripartum cardiomyopathy (cause and targeted therapies)
peripartum cardiomyopathy (ppcm)
peripheral access (ct peripheral)
peripheral aneurysm
peripheral arterial bypass
peripheral arterial cannulation (femoral, axillary)
peripheral arterial disease
peripheral arterial disease (pad)
peripheral arterial disease (pad) – implied by “atherosclerotic disease”
peripheral arterial disease (pad) – the overarching vascular disorder linked to coronary disease
peripheral arterial disease epidemiology
peripheral arterial disease severity
peripheral arterial occlusive disease
peripheral artery disease
peripheral artery disease (as a manifestation of cvd)
peripheral artery disease (lower extremity)
peripheral artery disease (pad)
peripheral artery disease measures
peripheral artery disease quality‑of‑care improvement and patient‑reported outcomes
peripheral artery disease risk factors (hypertension, diabetes, dyslipidemia)
peripheral artery disease – pad
peripheral artery intervention (endovascular)
peripheral artery questionnaire (paq)
peripheral atherosclerotic vascular disease
peripheral cardiovascular complications (e.g., perioperative af)
peripheral dissection
peripheral edema
peripheral embolization
peripheral neuropathy
peripheral neuropathy (associated with phenocopies)
peripheral neuropathy (in patients with diabetes)
peripheral neuropathy – a neurological complication often secondary to vascular disease
peripheral occlusive disease
peripheral oxygen extraction
peripheral percutaneous coronary intervention (pci)
peripheral pulmonary artery stenosis
peripheral resistance
peripheral vascular complications
peripheral vascular disease
peripheral vascular disease (broader term)
peripheral vascular disease (claudication, aortic or limb interventions, arterial/venous thrombosis)
peripheral vascular disease (general term)
peripheral vascular disease (pvd)
peripheral vascular resistance (pvr)
peripheral vascular surveillance testing
peripheral vascular ultrasound
periprocedural anticoagulation
periprocedural antithrombotic therapy
periprocedural bleeding
periprocedural care
periprocedural cerebral thromboembolism
periprocedural complications
periprocedural events
periprocedural management
periprocedural phase
periprocedural planning
periprocedural planning in cardiac patients
periprocedural risk
periprocedural stroke risk
periprosthetic leak
periprosthetic leakage
perivalvular abscess
peri‑cardioversion anticoagulation
peri‑device leak
peri‑graft air
peri‑operative complications
peri‑operative morbidity in fontan surgery
peri‑operative mortality
peri‑operative outcomes
peri‑operative risk
peri‑pregnancy intervention for vhd
peri‑procedural ischemic events
permanent af
permanent atrial fibrillation
permanent pacemaker
permanent pacemaker (ppm)
permanent pacemaker (ppm) implantation
permanent pacemaker implantation
permanent pacemaker insertion
permanent pacemaker leads
permanent pacemaker risk
permanent pacing
permanent pacing / pacemaker
permanent/persistent af
permissive hypotension
permissive hypotension (used in hemodynamically unstable cardiac/vascular emergencies)
peroxisome proliferator‑activated receptor‑γ (ppar‑γ)
peroxisome proliferator‑activated receptor γ (ppar‑γ)
perpendicular measurement to aortic axis
persistent af
persistent atrial fibrillation
persistent chest pain symptoms
persistent infection
persistent infection (bacteremia, fevers >5 days)
persistent inflammation
persistent inflammation in myocarditis
persistent left superior vena cava
persistent shunts (right‑to‑left shunts)
personal history of arrhythmic syncope
personal history of cardiac arrest or sustained ventricular arrhythmias
pet (positron emission tomography)
pet/ct imaging
pfizer
pfizer (cardiovascular drugs)
ph (pulmonary hypertension)
pharmaceutical companies with cardiac indications:
pharmacist
pharmacist interventions in cardiovascular care
pharmacist involvement
pharmacists
pharmacist‑administered intervention
pharmacist‑led interventions
pharmacodynamic variability
pharmacodynamics of oral antiplatelet therapy
pharmacogenomics (xpnpep2 polymorphism)
pharmacoinvasive strategy
pharmacokinetics (half‑life, liver/kidney elimination, crcl)
pharmacokinetics in pregnancy (absorption, volume of distribution, protein binding, clearance, uteroplacental flow, fetal metabolism)
pharmacologic (optimal medical) management
pharmacologic agents for af prevention (e.g., mras, acei/arb)
pharmacologic antiarrhythmics (e.g., amiodarone, amiodarone vs icd)
pharmacologic delay of p2y12 inhibitor effects by opioids (morphine, fentanyl)
pharmacologic interventions for aneurysm prevention
pharmacologic management of atrial fibrillation
pharmacologic management of heart failure
pharmacologic management of obstructive hcm
pharmacologic management of symptomatic patients with obstructive hcm
pharmacologic modulation of preload and afterload in hcm therapy.
pharmacologic therapies
pharmacologic therapy
pharmacologic therapy (beta‑blockers, ace inhibitors, arbs, diuretics, anticoagulants)
pharmacologic therapy (beta‑blockers, etc.)
pharmacologic therapy for hcm
pharmacologic therapy for mental health
pharmacologic therapy in heart failure guidelines
pharmacologic treatment
pharmacologic treatment options
pharmacological cardioversion
pharmacological interventions (e.g., iron, ace inhibitors, beta‑blockers, arni)
pharmacological management for exercise capacity
pharmacological smoking cessation therapies (nicotine patch, varenicline, bupropion)
pharmacological therapy for cardiovascular risk reduction
pharmacological treatment
pharmacological treatments
pharmacomechanical thrombectomy
pharmacotherapy for tobacco cessation
pharmaco‑invasive approach (fibrinolysis followed by pci)
pharmaco‑invasive strategy
phase ii re‑align study (dabigatran vs. warfarin in valve replacement)
phendimetrazine
phenocopies of hypertrophic cardiomyopathy (hcm)
phenocopy (mimic) of hcm
phenotype
phenotype conversion
phenotype negative
phenotype severity assessment
phenotype‑negative / genotype‑positive status for hcm
phenotype‑specific risk algorithms
phenotype–genotype correlation in cardiomyopathy
phenotypic expression
phenotypic heterogeneity
phenotypic spectrum
phenotypic spectrum of tgfb3 disease‑causing variants
phenprocoumon anticoagulation
phentermine
phenylephrine
phenylephrine (intravenous vasoconstrictor)
phenylephrine, norepinephrine (vasopressors)
phenytoin
pheochromocytoma
pheochromocytoma / paraganglioma
pheochromocytoma‑associated cardiomyopathy















philips
philips healthcare** (cardiac imaging equipment)
phlebitis
phosphodiesterase iii inhibitor
phosphodiesterase inhibition
phosphodiesterase type 5 inhibitors (pde5i)
phosphodiesterase‑5 (pde5) inhibitors
phosphodiesterase‑5 inhibition (e.g., sildenafil)
phosphodiesterase‑5 inhibitor
phosphodiesterase‑5 inhibitor (tadalafil)
phosphodiesterase‑5 inhibitor therapy
phosphodiesterase‑5 inhibitors
phosphodiesterase‑5 inhibitors (class iii)
phosphodiesterase‑5 inhibitors (e.g., sildenafil)
phosphodiesterase‑5 inhibitors (pde‑5i)
phosphodiesterase‑type 5 inhibitors
phosphodiesterase 3 inhibitors (pde3)
phospholamban regulation
photoplethysmographic af inference
photoplethysmographic waveform
photoplethysmography
photoplethysmography (ppg)
photoplethysmography (smartphone / smartwatch)
photosensitivity
phpvd (pulmonary hypertension with pulmonary vascular disease)
phrenic nerve paralysis
physical activity
physical activity (exercise)
physical activity (general)
physical activity (moderate‑intensity, vigorous)
physical activity / exercise
physical activity / exercise prescription
physical activity / exercise prescription for aortic disease patients
physical activity counseling
physical activity guidelines for adults and children
physical activity guidelines for americans
physical activity guidelines for ccd
physical activity intensity levels (mets) (e.g., 1.6–2.9 mets for light, 3.0–5.9 mets for moderate, ≥6 mets for vigorous)
physical activity level
physical activity promotion
physical activity recommendations for aortic disease
physical activity, exercise, sports participation
physical activity/exercise
physical component summary (pcs)
physical exam of pulses
physical examination
physical examination (pulse palpation)
physical examination findings (weight change, exam signs of congestion)
physical examination findings in tr
physical exercise training (within cr)
physical fitness
physical functioning
physical inactivity
physical inactivity / sedentary lifestyle
physical medicine and rehabilitation clinician
physical performance / endurance
physical signs of fluid retention
physical therapist
physical, mental, and emotional health impact of aortic disease
physician and patient preferences
physician education / patient education
physician market concentration
physician‑ and industry‑sponsored clinical trials
physician‑estimated outcomes
physiologic pacing
physiologic pacing versus right ventricular pacing evaluation
physiological assessment (e.g., fractional flow reserve) of non‑culprit stenosis
physiological changes
physiological impact / assessment
physiological repair (surgical or transcatheter)
physiological stage (a, b, c, d) in achd classification.
physiological stage (a–d)
physiological stages (a, b, c, d) in achd follow‑up
physiological stages of follow‑up (stages a–d)
physiological tests of myocardial perfusion
physiologically significant cad
physiology‑guided pci
physiopathology
ph‑specific therapies
pico[ts] structure (clinical question format)
pill‑in‑the‑pocket (pitp) approach
pill‑in‑the‑pocket strategy
pill‑in‑the‑pocket therapy
piloting an aircraft (occupational consideration)
pinnacle flx trial
pioglitazone
pioneer af‑pci
pioneer trials (not explicitly mentioned but implied by pcsk9 inhibitors)
pioneer‑hf (prospective study of arni in acute heart failure)
pioneer‑hf trial
pioneer‑hf trial (phase ii/iii study evaluating novel therapies in decompensated heart failure)
pitavastatin
pitavastatin (1‑4 mg)
pitavastatin (1–4 mg)
pitavastatin (statin therapy)
pitp (pill‑in‑the‑pocket)
pitp strategy (pulmonary‑influenced termination protocol)
pivotal (positive impact of endovascular options for treating aneurysm early)
pivotal doac trials (e.g., averroes, aristotle, spaf iii)
pkcβ (protein kinase c beta)
plaao (percutaneous left atrial appendage occlusion)
placebo comparison
placental crossing of medication
plain chest x‑ray
plakophilin‑2 (pkp2)
planimetric area
plant protein
plant protein (e.g., nuts, whole‑grain breads)
plant‑based diet
plant‑based diets
plaque
plaque burden
plaque contents exposure
plaque erosion
plaque index
plaque instability
plaque length
plaque regression / plaque components
plaque rupture
plaque stabilization
plaque volume
plasma concentration
plasma fractionated metanephrines
plastic surgery
platelet activation
platelet activation (in drug‑induced cardiac events)
platelet activation / aggregation
platelet activation / inhibition
platelet activation pathways
platelet adenosine diphosphate receptor (p2y12)
platelet adenosine diphosphate receptor (p2y12) agents
platelet aggregation
platelet aggregation inhibition
platelet antiplatelet therapy (apt)
platelet count (thrombocytopenia)
platelet count/function
platelet dysfunction (in the context of noonan syndrome)
platelet function assays
platelet function testing
platelet inhibition
platelet inhibition (irreversible)
platelet inhibition / pharmacodynamic response
platelet inhibition loading dose
platelet inhibition variability in clopidogrel
platelet microparticles
platelet reactivity
platelet‑activated receptor‑1 (par‑1)
platelet‑activating factor p2y12 receptor inhibitors
platelet‑leukocyte interaction
plato trial
plato trial (p2y12 inhibitor study of ticagrelor vs. clopidogrel)
pleiotropic effects of statins
plethysmographic pulse volume recording (pvr)
pleural coverage
pleural effusion
pleuritic chest pain
pm2.5 (particulate matter ≤ 2.5 µm)
pneumococcal polysaccharide vaccination (as a preventive measure for cardiovascular risk)
pneumococcal polysaccharide vaccine (ppv)
pneumococcal vaccination
pneumonia
pneumonia (post‑procedure)
pocket hematoma
podiatrist
podiatry
podiatry / podiatrist
poet study (patient outcome evaluation)
point‑of‑care cardiac ultrasound
point‑of‑care lung ultrasound
point‑of‑care ultrasound
policies and procedures for transfer, referral, and tracking of patients
policy development
policy impact on mortality and outcomes
policy recommendations for pad
policy statement
polyester graft
polygenic and monogenic contributions to af risk
polygenic risk scores
polygenic susceptibility
polymerase chain reaction (pcr)
polymorphic pvcs
polymorphic ventricular tachycardia (vt)
polypharmacy
polypharmacy, multimorbidity, cognitive decline, frailty
polytetrafluoroethylene (ptfe) grafts
polytetrafluoroethylene (ptfe) prosthetic graft
polyunsaturated fat
polyunsaturated fatty acid (pufa)
polyunsaturated fatty acids
polyunsaturated fatty acids (pufa)
polyvascular disease
polyvascular disease (disease in ≥2 arterial beds)
pooled cohort equation (pce)
pooled cohort equations (acc/aha)
pooled cohort equations (pce)
pooled cohort equations (pce) – ascvd risk estimation
pooled individual patient data
pooled individual patient data analysis
poor adherence to pharmacotherapy
poor candidate for rehabilitation
poor-quality runoff
poorly controlled hypertension
popliteal artery
popliteal entrapment/ aneurysm
popliteal pulse
population attributable fraction (paf) for af
population health management (hf risk stratification)
population screening
population screening / risk stratification
population‑based analysis
population‑based cohorts
population‑based data collection
population‑based study
population‑based study of wpw syndrome
porcelain aorta
portal hypertension
portal hypertension (cause of ph)
portrait pad registry
positive airway pressure therapy
positive family history of cardiomyopathy
positive remodeling (remodeling index > 1.1)
positron emission tomography
positron emission tomography (pet)
positron emission tomography (pet) with fdg
positron emission tomography (pet) – myocardial perfusion
positron emission tomography myocardial perfusion imaging
positron emission tomography myocardial perfusion imaging (pet mpi)
positron emission tomography‑based myocardial perfusion imaging
positron emission tomography‑ct (pet‑ct)
positron emission tomography–computed tomography (pet‑ct)
post-treatment surveillance of lvot gradients
postcapillary pulmonary hypertension
posterior circulation
posterior circulation perfusion
posterior leads (v7–v9)
posterior leaflet pathology
posterior left pericardiotomy
posterior left pericardiotomy (atrial fibrillation prevention)
posterior mediastinum
posterior stemi
posterior tibial pulse
postmenopausal hormone therapy
postmenopausal hormone therapy and cardiovascular outcomes
postmenopausal women
postmortem genetic testing
postmortem testing / molecular autopsy
postnatal genetic testing
postoperative atrial fibrillation
postoperative atrial fibrillation (poaf)
postoperative outcomes
postoperative outcomes.
postoperative surveillance
postoperative β‑blocker use
postpartum aortic complications
postpartum cardiac decompensation
postpartum cardiomyopathy
postpartum cardiovascular outcomes
postprandial exercise
postprandial exercise stress testing
postprocedural care
posttest genetic counseling
posttraumatic stress disorder (ptsd)
post‑ablation blanking period complications
post‑acute care planning
post‑acute management of acs
post‑acute mi complications
post‑capillary pulmonary hypertension
post‑cardiac arrest care
post‑cardioversion thromboembolic risk
post‑closure hemodynamic assessment
post‑conversion bradycardia
post‑discharge antiplatelet therapy
post‑discharge follow‑up
post‑discharge mortality
post‑discharge prescription medications
post‑discharge prognosis
post‑discharge risk
post‑exercise abi
post‑hoc analyses
post‑implant monitoring
post‑infarction mechanical complications
post‑infarction mitral regurgitation
post‑it registry
post‑marketing retrospective studies
post‑mi management
post‑mi pericarditis
post‑myocardial infarction (post‑mi) patients
post‑operative adhesions
post‑operative af
post‑operative af after vhd intervention
post‑operative anticoagulation
post‑operative arrhythmias after fontan operation
post‑operative atrial fibrillation
post‑operative atrial fibrillation (after cardiac surgery)
post‑operative cardiac complications
post‑operative cardiac event
post‑operative complications
post‑operative fontan physiology
post‑operative heart failure
post‑operative hemodialysis
post‑operative hemodynamic instability
post‑operative imaging for vascular ring/pa sling
post‑operative left ventricular function
post‑operative mortality
post‑operative outcomes
post‑operative outcomes for repair of truncus arteriosus, dorv, and fontan surgeries
post‑operative outcomes in asymptomatic patients with lv dysfunction
post‑operative outcomes of pulmonary valve replacement
post‑operative pain
post‑operative pericardial effusion
post‑operative prognosis
post‑operative quality of life in aortic patients
post‑operative risk factors
post‑operative survival
post‑partum aortic dissection risk
post‑partum cardiovascular disease
post‑pci
post‑pericardiotomy syndrome
post‑prandial hemodynamics
post‑prandial upright exercise echocardiography
post‑pregnancy cardiovascular management
post‑procedural care
post‑procedural complications of coronary interventions
post‑procedural residual leak assessment
post‑procedure combination therapies
post‑repair mitral stenosis
post‑revascularization arrhythmic risk
post‑savr survival
post‑stroke mortality
post‑tavi mitral repair potential
post‑tavi survival
post‑therapy imaging
post‑transplant outcomes
post‑traumatic stress disorder (ptsd) in achd
post–cardiac arrest care
potassium
potassium binders (patiromer, sodium zirconium cyclosilicate)
potassium binders to optimize guideline‑directed medical therapy (gdmt)
potassium intake
potassium intake / potassium supplementation
potassium levels
potassium‑sparing diuretics (spironolactone)
poultry
pparα modulator (pemafibrate)
ppsv23
pr index (pulmonary regurgitation index)
pr interval
pr interval / first‑degree heart block
pr interval > 0.24 ms
practice patterns for adult congenital heart disease management
prague‑17 trial
praise‑1 (prospective randomized amlodipine survival evaluation‑1)
praise‑2 (prospective randomized amlodipine survival evaluation‑2)
prasugrel
prasugrel (p2y12 inhibitor)
pravastatin
pravastatin (10 mg, 20 mg, 40 mg, 80 mg)
pravastatin (40‑80 mg; 10‑20 mg)
pravastatin (40–80 mg)
precipitants (of af)
precise and individualized hf management
precision medicine
precision medicine and patient‑centered care for aortic disease
precision medicine in cardiology
precision medicine in heritable thoracic aortic disease
precision medicine/genetic testing in hf management
preclinical hcm
preclose technique (percutaneous closure)
precombat trial
preconception counseling
preconception evaluation
preconception genetic counseling & testing for heritable cardiac conditions
preconception management of valvular disease
preconception transthoracic echocardiography (tte)
preconceptional genetic counseling
prediabetes
predicted 1‑year mortality (> 20 %)
predicted maximum heart rate
predicted survival
prediction of outcomes after valve intervention
predictive biomarkers for heart failure
predictive model for hfpef (e.g., h2f‑peff).
predictive model for long‑term survival
predictive risk scores (5‑year scd risk)
predictive scores (e.g., wilkins, integrated approach)
predictive value of cardiac biomarkers for incident hf
predictors of cerebrovascular events in valvular heart disease
predictors of disease progression
predictors of heart failure progression
predictors of major af endpoints
predictors of mortality
predictors of post‑discharge outcomes in acute heart failure
predimed study
predimed trial
















prednisone
prednisone therapy for pericarditis
preeclampsia
preeclampsia (shared risk with ppcm)
preeclampsia prevention
preexcitation
preexcitation syndromes
preexcited atrial fibrillation (af)
preexisting cardiomyopathy
pregnancy
pregnancy (in eisenmenger)
pregnancy (in hcm)
pregnancy (obstetric considerations for hcm)
pregnancy and cardiovascular disease program
pregnancy and lactation labeling rule
pregnancy anticoagulation dilemma
pregnancy cardiovascular risk tools
pregnancy counseling
pregnancy heart team
pregnancy in aortic disease
pregnancy in cardiomyopathy
pregnancy in chd patients
pregnancy in pah
pregnancy in vhd (management/anticoagulation)
pregnancy in women with cardiomyopathy
pregnancy in women with ischemic heart disease
pregnancy in women with severe valve disease
pregnancy management in hcm
pregnancy outcomes
pregnancy outcomes in eisenmenger syndrome
pregnancy outcomes in heart disease
pregnancy outcomes in women with heart disease
pregnancy outcomes in women with heart disease (carpreg)
pregnancy risk assessment (including who class iv)
pregnancy risk assessment/management
pregnancy risk category iii (world health organization)
pregnancy with heart failure
pregnancy‑associated aortic complications
pregnancy‑associated aortic disease
pregnancy‑associated cardiac risk
pregnancy‑associated cardiovascular changes (blood volume, heart rate, stroke volume, cardiac output)
pregnancy‑associated heart disease
pregnancy‑associated scad
pregnancy‑focused obstetric–cardiologic outcomes
pregnancy‑related acute aortic dissection
pregnancy‑related anticoagulation
pregnancy‑related anticoagulation considerations
pregnancy‑related aortic dissection
pregnancy‑related aortic risk
pregnancy‑related cardiac complications
pregnancy‑related cardiac risk in hcm
pregnancy‑related cardiovascular complications
pregnancy‑related cardiovascular complications (in vascular ehlers‑danlos and turner’s syndrome)
pregnancy‑related cardiovascular risk in connective‑tissue disorders
pregnancy‑related complications (iugr, hypertensive disorders of pregnancy, gestational diabetes)
pregnancy‑specific anticoagulation strategy
pregnant individuals with heart disease
pregnant women with mechanical prostheses
prehospital
prehospital 12‑lead electrocardiography (ecg)
prehospital assessment and management
prehospital assessment and management of suspected acs
prehospital notification/advance notification
prehospital serial ecgs
prehospital setting
prehospital stemi care
preimplantation genetic testing
prejudice
preload
preload / afterload management
preload optimization
preloading / pre‑administration of p2y12 inhibitors
preloading of oral p2y12 inhibitors (loading dose prior to angiography)
premature atrial contraction (pac)
premature atrial contractions (pacs)
premature coronary artery disease
premature death (associated with ascvd)
premature menopause (before age 40)
premature mortality
premature ventricular complexes (pvc)
premature ventricular complexes (pvcs)
premature ventricular contraction (pvc)
premature ventricular contractions (pvcs)
premier trial
prenatal genetic counseling
preoperative assessment of vein adequacy
preoperative cardiovascular evaluation
preoperative coronary angiography for cardiac surgery
preoperative echocardiography
preoperative fasting in cardiac patients
preoperative left ventricular dysfunction
preoperative planning
preoperative predictors (e.g., fractional shortening, lv dimensions)
preoperative predictors of death
preoperative renal dysfunction
preoperative renal insufficiency / stage 3 chronic kidney disease (ckd)
preoperative symptoms
preoperative trial of anticoagulation
preoperative β‑blockers
preprocedural evaluation
preprocedural glycemic control
preprocedural planning for surgical or catheter‑based interventions (srt)
presence of apical aneurysm on imaging
preserved ef (hfpef)
preserved ejection fraction
preserved ejection fraction (ef)
preserved ejection fraction (hfpef)
preserved ejection fraction heart failure
preserved heart function
preserved left ventricular ejection fraction (lvef)
preserved lvef
preserved lvef (≥ 50 %)
pressure drop/flow slope
pressure gradient
pressure gradient (rvot)
pressure gradient across the aortic valve
pressure half‑time
pressure half‑time (pht)
pressure offloading
pressure offloading devices (non‑removable vs removable)
pressure overload
pressure overload (hypertension, athletic conditioning)
pressure recovery
preterm delivery
pretest genetic counseling
pretest probability of cad
pretreatment (loading dose)
pretricuspid shunt
prevail study
prevail trial
prevalence
prevalence (of cardiovascular conditions)
prevalence of angina or chd
prevalence of atrial fibrillation
prevalence of chd
prevalence of peripheral arterial disease
prevent
prevent iii study
prevention
prevention (of af and related cardiovascular conditions)
prevention and risk reduction guidelines (e.g., aha/acc/accp/aspc/nla/pcna chronic coronary disease guideline)
prevention guidelines
prevention of af after cardiac surgery.
prevention of amputation
prevention of cardiovascular disease
prevention of cardiovascular disease in adults
prevention of cardiovascular disease in women
prevention of complications (e.g., need for permanent pacing, endocarditis, thromboembolic events)
prevention of events with ace inhibition (peace)
prevention of heart disease
prevention of heart failure
prevention of postoperative atrial fibrillation
prevention of progression of arterial disease and diabetes (popadad) trial
prevention of sudden death in williams‑beuren syndrome
prevention of valve disease
prevention strategies
prevention strategies in specialty populations (rheumatoid arthritis, diabetes)
prevention, detection, evaluation, and management of high blood pressure in adults
prevention‑achd acronym (icb‑vsd)
prevention‑achd risk score
preventive angioplasty
preventive cardiology
preventive cardiovascular nurses association (pcna)
preventive foot care
preventive foot care (in pad)
preventive foot care for pad (qm‑3)
preventive icd therapy
preventive medical therapy
preventive strategies (e.g., acei/arb, β‑blockers, carvedilol, spironolactone)
preventive strategies (e.g., indoor air purifiers, n95 masks)
preventive surgery
previous anthracycline exposure
previous bleeding
previous cardiac surgery with at‑risk grafts
previous chest irradiation
previous chest radiation
previous infective endocarditis (ie)
previous stroke
previous stroke or transient ischemic attack (tia)
pre‑capillary pulmonary hypertension
pre‑cise dapt (risk score)
pre‑cuffed ptfe vs. vein‑cuffed ptfe graft
pre‑eclampsia
pre‑excitation syndromes
pre‑excited atrial fibrillation
pre‑excited atrial fibrillation (e.g., wolff‑parkinson‑white)
pre‑hf (stage b)
pre‑hf (stage b)
pre‑hospital abciximab
pre‑hospital ecg
pre‑hospital fibrinolysis
pre‑hospital ticagrelor
pre‑operative arrhythmia management
pre‑operative cardiac imaging
pre‑operative catheterization for shunt feasibility
pre‑operative coronary angiography assessment
pre‑operative criteria for surgery
pre‑operative evaluation
pre‑operative functional capacity assessment
pre‑operative left ventricular function
pre‑operative optimization for cardiac risk
pre‑operative pah therapy
pre‑operative renal insufficiency
pre‑operative resting 12‑lead ecg
pre‑operative risk factors
pre‑participation athletic screening
pre‑pci pretreatment
pre‑pregnancy assessment (echocardiography)
pre‑pregnancy counseling for heart disease
pre‑reperfusion era trials
pre‑risk stratification / risk scores for cardiac patients in pregnancy
pre‑term delivery
pre‑therapy lvef assessment
pre‑transplant cardiac evaluation
pre‑treated p2y12 inhibitors
pre‑tricuspid shunts
pre‑vention and control of hypertension
primary (degenerative) mr
primary and secondary prevention of cardiovascular disease
primary angioplasty
primary ascvd prevention
primary care clinician role
primary clinical cardiologist
primary disorders of the tricuspid apparatus
primary endpoint of death or hospitalization
primary hcm center
primary hcm centers
primary hypercholesterolemia
primary mitral regurgitation
primary mitral regurgitation (mr)
primary mr
primary mr (organic mitral valve disease)
primary mr stages (b–d)
primary myocardial disease
primary or comprehensive heart valve center
primary patency
primary pci
primary pci (ppci)
primary pci triage strategy
primary pci versus thrombolysis
primary percutaneous coronary intervention
primary percutaneous coronary intervention (pci)
primary percutaneous coronary intervention (ppci / ppci)
primary percutaneous coronary intervention (ppci or ppci)
primary percutaneous coronary intervention (ppci)
primary percutaneous coronary intervention (ppci) / pci
primary percutaneous coronary intervention (primary pci)
primary prevention
primary prevention (cardiovascular disease)
primary prevention (secondary prevention)
primary prevention for hf stages a/b
primary prevention icd criteria (lvef > 0.35, <3 months of gdmt)
primary prevention of arrhythmias
primary prevention of ascvd
primary prevention of cad
primary prevention of cardiovascular disease
primary prevention of cardiovascular diseases
primary prevention of cvd
primary prevention of cvd/ascvd
primary prevention of drug‑induced cardiomyopathy
primary prevention of stemi/pcr
primary prophylactic implantable cardio‑electrical defibrillator (icd) implantation
primary regurgitation
primary severe mr
primary stenosis
primary tr
primary valve center
primary valve center, comprehensive valve center, valve surveillance programs
primary/comprehensive heart valve center
primary/secondary chordal support
primary‑care aortic aneurysm screening
primary‑care clinicians
primary‑prevention icd
primary‑prevention icd placement
primary‑prevention implantable cardioverter‑defibrillator (icd)
prime‑ffr study
primordial prevention
prior infective endocarditis
prior mediastinal radiation
prior mitral valve surgery
prior revascularization
prior sternotomy
prior stroke
prism‑plus trial
prkag2 (glycogen‑storage disease)
prkg1
prkg1 mutation
prkg1 mutation (protein kinase g)
prkg1‑associated aortopathy
proact xa trial
proactive intervention strategy
proarrhythmia
proarrhythmia (drug‑induced arrhythmia)
proarrhythmic effects
proarrhythmic events
probable myocarditis
procainamide
procedural / device terms
procedural aspects of pad care
procedural complications
procedural complications of ablation (2–5%)
procedural mi (type 4a)
procedural mortality
procedural optimization
procedural or surgical risk of savr/tavi
procedural planning
procedural risk
procedural risk‑scoring systems
procedural success
procedural treatment
procedural treatments
procedural treatments (surgical or interventional procedures)
procedural type 4a mi
procedural type 4b mi
procedural type 4c mi
procedural volume
process measures
processed meats (cured bacon, hot dogs)
processed meats (e.g., bacon, salami, ham, hot dogs, sausage)
processed meats (smoked, cured, salted)
processed red meat
process‑of‑care measures
procoagulant and hypofibrinolytic state
professional societies (guideline authors)
prognosis
prognosis (hf)
prognosis in hf
prognosis of asymptomatic left‑ventricular dysfunction
prognosis of heart failure
prognosis of hypertrophic cardiomyopathy
prognosis studies
prognostic assessment after primary angioplasty
prognostic biomarkers
prognostic determinants
prognostic discussions (“hope for the best, plan for the worst”)
prognostic factors
prognostic factors (age, atrial size, fibrosis)
prognostic factors for aortic complications in marfan syndrome.
prognostic factors for residual lesions after surgery
prognostic impact of lv function in aortic stenosis
prognostic implications
prognostic implications of arrhythmias
prognostic implications of imaging findings
prognostic implications of left‑ventricular strain
prognostic implications of valvular dysfunction
prognostic importance of aortic dilation
prognostic importance of quantitative exercise doppler
prognostic indicators
prognostic information (from emb)
prognostic markers
prognostic medications (gdmt)
prognostic predictors
prognostic relevance
prognostic risk scores (e.g., seattle heart failure model, rematch, etc.)
prognostic risk scores (e.g., syntax score, ischemia, heart team decision tools)
prognostic risk stratification tools
prognostic score
prognostic significance
prognostic significance of aortic root dilation pattern
prognostic significance of exercise testing
prognostic significance of heart failure stages
prognostic value
prognostic value in asymptomatic valve disease
prognostic value of bnp/nt‑probnp ratios
prognostic value of cmr
programming antitachycardia pacing
progression of atrial fibrillation
progressive af
progressive aneurysmal dilation
progressive aortic dilation
progressive atherosclerosis
progressive decline in lvef
progressive decline in lvef (to 55‑60%)
progressive exercise intolerance
progressive heart failure
progressive increase in aortic velocity
progressive lv dilation (lvedd >65 mm)
progressive lv enlargement
progressive stenosis
progressive systemic rv dysfunction
progressive training to 30‑45 min of active walking
progressive valve dysfunction
prohibit trial






















prolactin cleavage (cathepsin‑d cleaved prolactin)
prolapse of the right coronary cusp (aortic valve)
proliferation‑signal inhibitor
prolonged av conduction
prolonged continuous monitoring
prolonged dual antiplatelet therapy
prolonged hv interval
prolonged intubation (>24 h)
prolonged qtc
prominent trial
promise minimal‑risk tool
promise trial
promis‑plus‑hf (patient‑reported outcomes measurement information system‑plus‑heart failure)
propafenone
propafenone (antiarrhythmic)
propensity‑matched analysis
propensity‑matched comparison
propensity‑matched comparison studies in aortic surgery
prophylactic antibiotics
prophylactic aortic repair
prophylactic aortic replacement
prophylactic aortic root replacement
prophylactic aortic surgery
prophylactic aspirin (low‑dose/high‑dose)
prophylactic fasciotomy
prophylactic implantable cardioverter‑defibrillator (icd) implantation
prophylactic intervention
prophylactic repair
prophylactic root replacement
prophylactic surgery
prophylactic surgical replacement (aortic root/ascending aorta)
proportional hazards regression
proportionate functional mitral regurgitation
propranolol
propranolol (oral and iv)
propranolol therapy
proprotein convertase subtilisin/kexin type 9 (pcsk9)
proprotein convertase subtilisin/kexin type 9 (pcsk9)
proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors
prospective and retrospective cohort studies on achd outcomes
prospective comparison of arni with acei to determine impact on global mortality and morbidity in heart failure (paradigm‑hf)
prospective epidemiological study of myocardial infarction (prime)
prospective multicenter rct (aortic)
prospective multicenter study
prospective observational studies
prospective observational study
prospective randomised trial
prospective randomized controlled trial (rct)
prospective randomized open‑label study
prospective randomized study
prospective randomized trial
prospective study
prospective study (prevention‑achd)
prostacyclin analogs
prostacyclin analogs / receptor agonists
prostacyclin therapy
prostacyclin therapy (inhaled, subcutaneous, intravenous)
prostacyclin therapy (inhaled/subcutaneous)
prostaglandin therapy
prostanoids (in the context of clti)
prostanoids (pharmacologic agents in arterial disease)
prostanoids (prostacyclin, iloprost)
prosthesis‑patient mismatch
prosthesis–patient mismatch
prosthetic (mechanical) heart valves
prosthetic aortic graft
prosthetic aortic graft infection
prosthetic aortic valve
prosthetic bypass failure
prosthetic bypass graft
prosthetic bypass grafts
prosthetic cardiac valves
prosthetic conduit (prosthetic graft material)
prosthetic graft
prosthetic graft allograft replacement
prosthetic heart valve
prosthetic heart valve (phv)
prosthetic heart valve complications
prosthetic heart valves
prosthetic material for valve repair (annuloplasty rings, chords, clips)
prosthetic mechanical heart valves
prosthetic mitral valve
prosthetic mitral valve; prosthetic aortic valve
prosthetic patch or prosthetic device
prosthetic rehabilitation / ambulation
prosthetic valve
prosthetic valve deterioration
prosthetic valve durability
prosthetic valve dysfunction
prosthetic valve endocarditis
prosthetic valve endocarditis (pve)
prosthetic valve endocarditis (see section 12.3)
prosthetic valve evaluation
prosthetic valve obstruction
prosthetic valve paravalvular leak closure
prosthetic valve regurgitation
prosthetic valve regurgitation (transvalvular & paravalvular)
prosthetic valve replacement versus medical therapy
prosthetic valve selection factors (durability, anticoagulation risk, patient preference)
prosthetic valve stenosis
prosthetic valve thrombosis
prosthetic valves
prosthetics
protease inhibitors
protease inhibitors (drug interaction impacting cardiovascular drugs)
protect af study
protect trial (renal function in acute hf)
protective factors
protective footwear / therapeutic footwear
protect‑af trial
protect af trial
protein restriction
proteinase‑3 (pr‑3)
proteinuria
proteinuria (>150 mg/24 h)
protein‑based biomarkers
protein‑losing enteropathy
protein‑losing enteropathy (ple)
proteolysis of the extracellular matrix
proteolysis pathways
proteomics
prothena
prothesis graft (surgical context)
prothrombin complex concentrate
prothrombin complex concentrate (pcc)
prothrombin complex concentrate (used in reversal of anticoagulation)
prothrombin time (pt)
prothrombotic changes in the la
prothrombotic state
prothrombotic states
proton pump inhibitor (ppi)
proton pump inhibitors (ppis)
proton‑pump inhibitor (ppi) therapy
proved trial (digoxin withdrawal in chf)
prove‑it‑timi 22 study
prove it‑timi 22 trial
provocative maneuvers (valsalva, squat‑to‑stand, standing)
provocative maneuvers for lvot gradient assessment
provocative stimuli (acetylcholine, ergot)
proximal aortic dilatation
proximal aortic surgery
proximal cad (≥70% luminal diameter reduction)
proximal control with clamp or balloon
proximal coronary artery disease
proximal descending aorta dilation
proximal isovelocity surface area (pisa)
proximal sealing zone
proximal thoracic aortic surgery
proximal tubular ascending aorta
pro‑bnp (biomarker)
pro‑bnp (n‑terminal pro‑brain natriuretic peptide)
pro‑vegetarian food pattern (protective factor for heart disease)
pseudoaneurysm
pseudoaneurysm formation after coa repair
pseudomonas aeruginosa
pseudo‑coarctation of the aorta
pseudo‑myocardial‑infarction pattern
psoriasis
psoriasis (as a cardiovascular risk factor)
psychiatry
psychoeducation
psychological distress (in the context of hf management)
psychological functioning in icd patients
psychological health in cardiovascular disease (mind‑heart connection)
psychological impact of icd implantation
psychological interventions
psychological outcomes and interventions for congenital heart disease
psychological outcomes in congenital heart disease
psychological status and cardiovascular health
psychological support (depression & anxiety screening)
psychological trauma related to icd shocks
psychologist
psychosocial care for inherited cardiovascular disease
psychosocial deprivation
psychosocial management
psychosocial stressors
psychosocial support (limitations)
psychosocial well‑being
ptfe bypass (peripheral bypass)
pthlh gene locus (chromosome 12p11.22)
public health
public health initiative
public policy for cardiovascular disease
public reporting
public reporting of performance measures
publicly available controlled‑temperature environments
pubmed
pulmonary arterial hypertension
pulmonary arterial hypertension (low‑risk, intermediate‑risk, high‑risk)
pulmonary arterial hypertension (mean pa pressure ≥ 20 mm hg, pawp ≤ 15 mm hg, pvr ≥ 2 wu)
pulmonary arterial hypertension (pah)
pulmonary arterial hypertension (pulmonary hypertension)
pulmonary arterial hypertension guidelines (pah guidelines)
pulmonary arterial hypertension guidelines for adults
pulmonary arterial hypertension related to congenital heart disease
pulmonary arterial hypertension risk categories (3‑strata)
pulmonary arterial pressure
pulmonary arterial pressures
pulmonary arterial pressures (pa pressures)
pulmonary arterial resistance
pulmonary arterial saturation
pulmonary arterial thrombosis
pulmonary arterial trunk
pulmonary arterial wedge pressure
pulmonary arterial wedge pressure ≤ 15 mm hg
pulmonary arteries (pas)
pulmonary arteriovenous malformation
pulmonary artery
pulmonary artery (pa)
pulmonary artery (pa) catheterization
pulmonary artery (pa) line
pulmonary artery (pa) pressure
pulmonary artery (pa) pressures
pulmonary artery (pa) sling
pulmonary artery (pa) stenosis
pulmonary artery (pa) systolic pressure
pulmonary artery catheter
pulmonary artery catheterization (pa catheter)
pulmonary artery catheterization / pulmonary artery pressure monitoring
pulmonary artery compliance
pulmonary artery diastolic pressure (padp)
pulmonary artery evaluation
pulmonary artery gradient
pulmonary artery hemodynamic monitoring
pulmonary artery hypertension
pulmonary artery pressure
pulmonary artery pressure (pap)
pulmonary artery pressure gradient
pulmonary artery pressure measurement
pulmonary artery pressure monitoring catheter
pulmonary artery pressure ≥ 50 % of systemic
pulmonary artery pulsatility index (papi) <1.0
pulmonary artery pulse index (papi)
pulmonary artery sling
pulmonary artery sling repair
pulmonary artery slings
pulmonary artery stenosis (pas)
pulmonary artery stenosis after arterial switch
pulmonary artery stiffness
pulmonary artery systolic pressure
pulmonary artery systolic pressure (pasp)
pulmonary artery systolic pressure (≥ 50 mm hg)
pulmonary artery systolic pressure > 50 mm hg
pulmonary artery thrombosis
pulmonary artery wedge pressure
pulmonary artery wedge pressure > 25 mm hg
pulmonary atresia
pulmonary atresia (all forms)
pulmonary atresia with intact ventricular septum
pulmonary atresia with intact ventricular septum (pa‑ivs)
pulmonary autograft (ross procedure)
pulmonary balloon valvuloplasty
pulmonary blood flow
pulmonary blood flow measurement
pulmonary branch stenosis
pulmonary capillary wedge pressure
pulmonary capillary wedge pressure (pcw)
pulmonary capillary wedge pressure (pcwp)
pulmonary circulation
pulmonary circulation pressure
pulmonary circulatory support
pulmonary complications (covid‑19, pneumococcal pneumonia) as cardiovascular event risk enhancers
pulmonary congestion
pulmonary congestion (clinical, cxr, lung us)
pulmonary disease
pulmonary disease (comorbidity)
pulmonary edema
pulmonary edema (postpartum, labor, pregnancy)
pulmonary embolism
pulmonary embolism (cardiovascular event)
pulmonary embolism (pe)
pulmonary embolism (pulmonary embolic–related cardiac strain)
pulmonary embolism response team (pert)
pulmonary embolism / inherited thrombophilia (implied by embolism context)
pulmonary fibrosis
pulmonary function testing
pulmonary homograft
pulmonary hypertension
pulmonary hypertension (> 50 mm hg)
pulmonary hypertension (commonly associated with heart disease)
pulmonary hypertension (general)
pulmonary hypertension (group 2)
pulmonary hypertension (implied in thoracic aortic disease)
pulmonary hypertension (moderate)
pulmonary hypertension (pah)
pulmonary hypertension (ph)
pulmonary hypertension (post‑capillary, pre‑capillary, combined)
pulmonary hypertension (primary or secondary to left‑sided heart disease)
pulmonary hypertension (relevant for cardiovascular risk)
pulmonary hypertension / pulmonary vascular disease
pulmonary hypertension / right hf
pulmonary hypertension association
pulmonary hypertension expertise
pulmonary hypertension guidelines
pulmonary hypertension in chd
pulmonary hypertension in congenital heart disease
pulmonary hypertension management
pulmonary hypertension management (post‑ and precapillary)
pulmonary hypertension management strategies.
pulmonary hypertension specialist
pulmonary hypertension specialist care
pulmonary hypertension specialists
pulmonary hypertension therapies (pharmacologic)
pulmonary hypertensive crisis
pulmonary mitral balloon commissurotomy (pmbc)
pulmonary or systemic venous congestion
pulmonary or urinary tract infections (as precipitants of hf)
pulmonary outflow tract obstruction (poto)
pulmonary outflow tract obstruction (pvr)
pulmonary overcirculation
pulmonary over‑pressure
pulmonary perfusion testing
pulmonary pressures
pulmonary pressures (mean pulmonary artery pressure, systolic, diastolic)
pulmonary pressures / pulmonary hypertension
pulmonary regurgitation
pulmonary regurgitation (conduit related)
pulmonary regurgitation (if applicable)
pulmonary regurgitation (pr)
pulmonary regurgitation (pulmonary insufficiency)
pulmonary regurgitation after repair of pulmonary stenosis
pulmonary sarcoidosis (cardiac involvement)
pulmonary sequestration
pulmonary stenosis
pulmonary stenosis (associated defect)
pulmonary stenosis (ps)
pulmonary stenosis severity (moderate/severe)
pulmonary stump
pulmonary systolic pressure
pulmonary toxicity
pulmonary toxicity (lung)
pulmonary translocation
pulmonary translocation (surgical technique)
pulmonary valve
pulmonary valve (pv)
pulmonary valve and aortic root translocation / en‑bloc rotation procedures
pulmonary valve atresia
pulmonary valve conduit stenting
pulmonary valve disease
pulmonary valve dysfunction
pulmonary valve dysfunction (moderate pr, pr >25% by cmr)
pulmonary valve function
pulmonary valve gradients
pulmonary valve implantation
pulmonary valve insufficiency
pulmonary valve intervention
pulmonary valve regurgitation
pulmonary valve regurgitation quantification
pulmonary valve replacement
pulmonary valve replacement (in tof)
pulmonary valve replacement (pvr)
pulmonary valve replacement (surgical & transcatheter)
pulmonary valve replacement (surgical or transcatheter)
pulmonary valve replacement (surgical)
pulmonary valve replacement (transcatheter)
pulmonary valve replacement risks and complications
pulmonary valve replacement timing
pulmonary valve stenosis
pulmonary valve stenosis (pvs)
pulmonary vascular disease
pulmonary vascular disease (phpvd)
pulmonary vascular obstructive disease
pulmonary vascular resistance
pulmonary vascular resistance (pvr)
pulmonary vascular resistance (pvr) > 2 wood units
pulmonary vascular resistance (pvr) – wood units
pulmonary vascular resistance (≤ 2 wood units; 2–5 wood units)
pulmonary vascular resistance ratio (pvr to systemic resistance)
pulmonary vasculature
pulmonary vasodilators
pulmonary vasodilatory therapy efficacy
pulmonary vasomodulators
pulmonary vein (pv) isolation
pulmonary vein (pv) stenosis
pulmonary vein ectopy / ectopic action potentials
pulmonary vein isolation
pulmonary vein isolation (pvi)
pulmonary vein isolation (pvi) effectiveness in afl
pulmonary vein isolation techniques
pulmonary vein stenosis
pulmonary vein stenosis / baffle stenosis
pulmonary veins
pulmonary veins (pvs) as af drivers
pulmonary veins (pvs) of the left atrium (la)
pulmonary vein‑driven af genesis (haïssaguerre et al. finding)
pulmonary venous congestion
pulmonary venous connections
pulmonary venous flow reversal
pulmonary venous pathway stenosis
pulmonary venous pathways
pulmonary venous stasis
pulmonary/renal comorbidity (e.g., renal insufficiency)
pulmonary‑mural balloon commissurotomy (pmbc)
pulmonary‑to‑systemic blood flow ratio (qp:qs)
pulmonary‑to‑systemic blood flow ratio (qp:qs) ≥ 1.5
pulmonary‑vein isolation (for af)
pulmonary artery dilation
pulmonary hypertension
pulmonary valve dysfunction
pulmonary valve intervention
pulmonary valve replacement (surgical / transcatheter)
pulmonic autograft (ross procedure)
pulmonic homograft
pulmonic regurgitation
pulmonic stenosis
pulmonic valve disease
pulse deficit
pulse deficits (absent, diminished, normal, bounding)
pulse examination for pad “at risk” patients (qm‑2)
pulse flow (direct revascularization)
pulse palpation
pulse pressure
pulse volume recording (pvr)
pulse wave analysis
pulsed field ablation
pulsed‑wave doppler
pulseless electrical activity (pea)
pulse pressure
pulse‑wave and conduction abnormalities (heart block, permanent pacing)
pump mechanisms (mechanically assisted circulatory support)
pump thrombosis
pump thrombus
pure study (prospective urban rural epidemiology)
pursuit risk score
pv (pulmonary veins)
pv-to-la reconnection
pvcs (premature ventricular complexes)
pvi (pulmonary vein isolation)
pvi registry (peripheral vascular intervention)
pvr (pulmonary vascular resistance)
pvr wood units (e.g., 2–5, <5, <10, >8, >10)
pyp (pyrophosphate) scintigraphy
p‑2y12 inhibitors
p‑glycoprotein
p‑glycoprotein (p‑gp)
p‑glycoprotein inhibitors
p‑gp (p‑glycoprotein) substrate/inhibitor activity
p‑wave dispersion















qaly (quality‑adjusted life year)
qalys (quality‑adjusted life years)
qol (quality of life)
qol (quality of life) improvement
qol (quality of life) – health outcome metric
qp:qs (pulmonary to systemic flow ratio)
qp:qs (pulmonary‑to‑systemic blood flow ratio)
qp:qs ratio
qp:qs ratio (left‑to‑right shunt ratio)
qp:qs ratio (pulmonary to systemic flow)
qp:qs ratio (pulmonary/systemic flow ratio)
qp:qs ≥ 1.5
qrisk / jbs3
qrs complex / width
qrs duration
qrs duration & qrs width (>130 ms, >150 ms)
qrs duration (narrow qrs, <120 ms; 120–130 ms; non‑lbbb 120–149 ms)
qrs duration (≥120 ms)
qrs duration (≥150 ms)
qrs duration <120 ms
qrs duration <150 ms
qrs duration > 180 ms
qrs duration and fragmentation
qrs duration ≥120 ms
qrs duration ≥180 ms
qrs fragmentation
qrs morphology (e.g., right bundle branch block)
qrs prolongation (>120 ms)
qrs‑based outcome prediction
qt dispersion ≥70 ms
qt interval
qt interval monitoring
qt interval prolongation
qt interval prolongation (qtc prolongation)
qt interval prolongation / qtc prolongation
qt prolongation
qtc interval
qtc interval prolongation
qtc prolongation
qtc prolongation / qt‑prolonging agents
quality & health it (related to cardiovascular care)
quality control in echocardiographic measurement
quality improvement / performance measures
quality improvement initiatives
quality improvement metrics
quality improvement projects
quality indicators
quality measure (qm)
quality measure (qm‑7)
quality measure (qm‑8)
quality measurement
quality measures
quality measures (clinical practice guideline‑based)
quality measures (qm) for hf
quality measures (qm‑1 to qm‑8)
quality measures (qm‑3 to qm‑8)
quality measures for pad care
quality metrics and patient‑reported outcomes
quality of care
quality of care in heart failure
quality of care metrics
quality of life
quality of life (af‑related)
quality of life (cardiac context)
quality of life (qol)
quality of life (qol) and functional capacity in hf
quality of life (qol) data
quality of life (qol) enhancement
quality of life (qol) improvement
quality of life (qol) improvement in hf care
quality of life (qol) in cardiovascular patients
quality of life (qol) measures
quality of life (qol) measures in hf/af patients
quality of life (qol) outcomes
quality of life (qol) outcomes in limb loss
quality of life after aortic surgery
quality of life in atrial fibrillation
quality of life in cardiac care
quality of life in cardiac patients
quality of life in icd patients
quality of life in peripheral vascular disease
quality of life outcomes
quality of life (qol)
quality of treatment decisions (hf)
quality outcomes
quality‑adjusted life year
quality‑adjusted life year (qaly)
quality‑adjusted life years (qaly)
quality‑adjusted life years (qalys)
quality‑adjusted life‑year (qaly)
quality‑adjusted life‑years (qalys)
quality‑improvement programs
quality‑of‑life (qol) in af patients
quality‑of‑life considerations post‑intervention
quality‑of‑life improvement
quality‑of‑life outcomes after neonatal arterial switch operation
quantification of lge (≥ 15 % lv mass)
quantitative doppler assessment
quantitative exercise doppler
quantitative exercise doppler echocardiography
quantitative kappa and lambda free‑light‑chain assays
quantitative risk estimation
quidel (diagnostics)
quinapril
quinidine
quinidine sulfate
quitline (telephone‑based smoking cessation resource)
q‑symbio (coenzyme q₁₀ as adjunctive treatment of chronic heart failure)
q‑symbio trial (coenzyme q10)
q‑waves













r wave prominence or r/s ratio >1
r3f registry
raas inhibitors (raasi)
race 3 trial
race 4 trial
race and ethnicity in hf outcomes
race ii study
race, ethnicity, and gender/sex disparities in af outcomes
race/ethnicity related risk variation
race ii study (lenient vs. strict rate control)
race‑specific risk estimation (non‑hispanic white, non‑hispanic black, other ethnic groups)
race 3 trial (targeted therapy for underlying conditions)
racial and ethnic differences in heart disease outcomes
racial and ethnic disparities (hispanic, black, white, american indian)
racial and ethnic disparities in af management
racial and ethnic disparities in cardiovascular risk
racial and ethnic disparities in hcm prevalence
racial and ethnic minority populations
racial and sex disparities in acs care
racial disparities
racial disparities in cardiovascular care
racial disparities in endovascular aortic repair
racial disparities in peripheral artery disease
racial/ethnic disparities in cardiovascular outcomes
racial/ethnic disparities in heart‑failure outcomes (e.g., non‑hispanic black, non‑hispanic white, hispanic, asian/pacific islander)
radial access
radial access (for pci)
radial access (pci)
radial access (radial artery approach)
radial access approach (radial artery)
radial access vs. femoral access (transradial vs. transfemoral approach)
radial approach for coronary angiography
radial artery
radial artery access
radial artery graft vs. saphenous vein graft
radial vascular access
radiating groin pain
radiation dose/exposure
radiation dose‑reduction strategies (low‑dose ionizing radiation)
radiation exposure
radiation exposure (ct)
radiation exposure / ionizing radiation dose
radiation exposure from ct
radiation exposure risks
radiation heart disease
radiation‑induced cardiovascular disease
radiation‑induced heart disease
radiation‑induced mitral stenosis
radiation‑induced tr
radiofrequency ablation
radiofrequency catheter ablation
radiofrequency irrigation
radiofrequency perforation & balloon decompression
radiographic contrast media safety
radiologic findings
radiologic protocols (avoid false‑negative/false‑positive)
radiological assessment of aortic annulus, sinuses, and ascending aorta
radiological findings
radiology
radiomics
radiomics in cardiac imaging
radionuclide imaging
radionuclide imaging (indirectly referenced via radiation concerns)
radionuclide ventriculography
radionuclide ventriculography (rvg)
radiotherapy‑associated heart disease
raft study
raft trial
raft‑af (rhythm control–catheter ablation with or without anti‑arrhythmic drug control of maintaining sinus rhythm versus rate control with medical therapy and/or atrio‑ventricular junction ablation and pacemaker treatment for atrial fibrillation)
raft‑af trial
ramipril
ramipril (ace inhibitor)
randomised clinical trial
randomized aldactone evaluation study (rales)
randomized clinical trial
randomized clinical trials
randomized clinical trials (rcts)
randomized clinical trials on quality of life after aortic repair
randomized controlled trial
randomized controlled trial (rct)
randomized controlled trial (rct) evidence on ppcm and bromocriptine
randomized controlled trial (rct) – in the context of cardiovascular studies
randomized controlled trials
randomized controlled trials (rcts)
randomized controlled trials (rcts) in cardiology
randomized controlled trials (rcts) in pad therapy evaluation
randomized controlled trials of bromocriptine in peripartum cardiomyopathy
randomized double‑blind study
ranges of coronary artery disease severity
ranolazine
ranolazine therapy
rapid aneurysm growth
rapid aneurysm growth (≥ 0.5 cm/y)
rapid aortic growth
rapid aortic growth (≥ 0.3 cm/y)
rapid aortic growth (≥ 0.3 cm/year)
rapid aortic growth (≥ 0.5 cm / year)
rapid aortic growth ≥ 0.3 cm/year
rapid aortic root growth
rapid atrial flutter (1:1 afl)
rapid bedside bnp testing
rapid coverage of the descending aorta
rapid fluid resuscitation for torso trauma
rapid infusion systems in trauma care
rapid rule‑out strategies
rapid ventricular rate
rapid ventricular rate control
rapid ventricular response
rapid ventricular response (rvr)
rare genetic variants in cardiomyopathy and arrhythmia genes
ras/erk signaling pathway
rash
rasmussen cardiovascular disease prevention center
rasopathies
rasopathies (e.g., neurofibromatosis, noonan syndrome)
rastelli procedure
rastelli repair
rastelli repair/operation
rate control
rate control (rate‑control strategies)
rate control (target <100 bpm)
rate control in af
rate control strategies
rate control strategy
rate control therapies
rate control therapy
rate of aortic dilation
rate‑control drugs
rate‑control medications
rate‑control strategy
rate‑slow‑ing agents
rct (randomized controlled trial)
reach (reduction of atherothrombosis for continued health)
reach registry
reactive oxygen species
readiness and utilization of cardiac rehabilitation
readiness for transfer of care
readmission
readmission (30‑day readmission)
readmission (clinical outcome)
readmission / rehospitalization
readmission / rehospitalization after acs
readmission burden
readmission for heart failure
readmission prediction for heart failure
readmission rates
readmission risk
readmissions
real‑time 3‑d tee
real‑time 3‑d transesophageal echocardiography
real‑world outcomes after transfusion strategies (reality trial)
reboa (resuscitative endovascular balloon occlusion of the aorta)
reboa contraindication
reboot‑cnic
rebound anticoagulation after cessation
recent major surgery or trauma (within 30 days)
recent myocardial infarction (mi)
recipient mortality
recoarctation
recombinant tissue plasminogen activator (rt‑pa) / tissue plasminogen activator (tpa)
reconstruction options
recreational physical activity
recreational physical activity (moderate–vigorous intensity)
recreational substance use (cocaine, marijuana)
recumbent stepping
recurrence rate of afl post‑ablation
recurrent acute coronary syndromes (acs)
recurrent aortic reintervention
recurrent aortic stenosis (post‑repair)
recurrent arrhythmia / recurrence of atrial arrhythmia
recurrent atrial arrhythmias (af or svt)
recurrent atrial fibrillation
recurrent atrial fibrillation (recurrent af)
recurrent atrial tachyarrhythmias after ablation
recurrent cardiac events
recurrent cardiovascular events
recurrent coronary artery stenosis or suboptimal flow
recurrent coronary events
recurrent dcrv
recurrent endocarditis
recurrent fever
recurrent gradients
recurrent heart failure
recurrent hemorrhage
recurrent ie
recurrent ischemia
recurrent ischemic events
recurrent ischemic symptoms
recurrent mace
recurrent mi
recurrent mitral regurgitation
recurrent morbidity and mortality rates
recurrent myocardial infarction
recurrent myocardial infarction (mi)
recurrent or residual functional regurgitation
recurrent outflow tract obstruction
recurrent pericarditis
recurrent scad
recurrent stroke
recurrent valve thrombosis
recurrent ventricular arrhythmias
red and processed meat (risk factor for heart disease)
red blood cell transfusion
red meat
red meats
redirection of care to interventional strategies
redo aortic valve surgery
redo sternotomies
reduced ef (<40%)
reduced ef (<50%)
reduced ef / hfref
reduced egfr (<45 ml/min/1.73 m²)
reduced ejection fraction
reduced ejection fraction (ef)
reduced ejection fraction (hfref)
reduced ejection fraction heart failure
reduced exercise capacity (in achd patients)
reduced functional capacity
reduced left ventricular ejection fraction
reduced left ventricular ejection fraction (lvef < 50 %)
reduced left‑ventricular function
reduced left‑ventricular systolic function
reduced lvef (<50%)
reduced lvef (≤40%/≤50%)
reduced mortality in heart failure trials (cha‑rm, topcat)
reduced valve motion due to pannus or thrombus
reduce‑it (reduction of cardiovascular events with icosapent ethyl)
reduce‑it trial
reduce‑it trial (icosapent ethyl)
reduce‑swedeheart
reentrant arrhythmia
reentrant supraventricular tachyarrhythmias (svts)
reentry (arrhythmic circuit)
reentry mechanism
reentry tear
reevaluation of long‑term anticoagulation
referral for advanced imaging beyond local expertise
referral for cardiothoracic surgery
referral for diagnostic/interventional therapies
referral for electrophysiology studies
referral for transplant evaluation
referral for worsening heart failure
referral pathways
referral policies to achd care
refined carbohydrates
refined carbohydrates (white bread, white rice, refined cereals)
refined european guidelines instrument for risk prediction in pah
refined grains
refractory angina
refractory arrhythmias
refractory heart failure
refractory hypertension
refractory or recurrent angina
refractory pain (symptom of acute dissection)
refractory pain duration (> 12 h)
refractory ventricular arrhythmias
regadenoson stress cmr perfusion
regards study
regards study (reasons for geographic and racial differences in stroke)
regeneron
regional cardiac autonomic remodeling
regional stemi care
regional stemi care systems
regional stemi system
regional wall motion
regional wall motion abnormalities
regionalization of stemi care
registered dietitian / nurse‑coached dietetic intervention
registered nurse
registries
registries: lombardy registry, itamy (italian study in myocarditis)
registry data
registry data (e.g., ropac, share) in hcm research
registry data on peripartum cardiomyopathy
registry data on preloading efficacy
registry study (great, medpar)
registry‑based research
registry‑based thresholds for aortic repair in female patients
regression tree (cart) model
regular exercise
regular physical activity
regulatory approval of cardiac drugs and devices in the united states.
regulatory compliance (us approval status)
regulatory support
regulatory t cells (treg)
regulatory/industry advisory organizations:
regurgitant flow
regurgitant fraction
regurgitant fraction (%)
regurgitant fraction (rf)
regurgitant lesions
regurgitant orifice area
regurgitant orifice area (ero)
regurgitant volume
regurgitant volume (ml/beat)
regurgitant volume (rvol)
regurgitant volume (≥45 ml)
regurgitant volume quantification
regurgitation
regurgitation (moderate or severe)
regurgitation (valvular)
rehabilitation
rehabilitation protocols
rehabilitation strategies
rehospitalization
rehospitalization (cardiovascular & non‑cardiovascular)
rehospitalization for cardiovascular causes
rehospitalization for ischemia
rehospitalization risk
reimplantation (aortic valve)
reimplantation technique
reinfarction
reinitiation of anticoagulation after bleeding
reintervention
reintervention (rv‑to‑pa reoperation)
reintervention / reoperation
reintervention outcomes
reintervention rate after tevar
reintervention rates
reintervention risk
reinterventions
rein‑2 trial













relapse/recurrence of heart failure
relapsing polychondritis
relative risk
relative risk (rr)
relative risk reduction (e.g., 15 %, 19 %)
relative risk reduction (rrr)
relative wall thickness (rwt)
relax trial
relevant industry / technology terms (often linked to heart disease management)
remission (clinical criteria)
remodeling (aortic root)
remodeling technique
remote algorithm‑based cardiovascular risk management
remote cardiac rehabilitation
remote disease‑management programs
remote monitoring
remote monitoring / telemonitoring
remote monitoring data
remote patient monitoring / telemonitoring
remote patient‑monitoring devices (wearables, smart devices)
renal artery stenosis
renal artery stenting
renal branch grafts
renal clearance (crcl)
renal comorbidities
renal denervation
renal denervation (for af)
renal denervation (renal sympathetic modulation)
renal disease
renal disease / kidney dysfunction
renal dysfunction
renal dysfunction & cardiovascular outcomes after myocardial infarction
renal dysfunction (comorbidity)
renal dysfunction (crcl)
renal dysfunction (high serum creatinine, dialysis, kidney transplant)
renal dysfunction (kidney disease)
renal dysfunction (post‑operative)
renal dysfunction (right‑hf‑related)
renal dysfunction in advanced heart failure
renal dysfunction in heart failure
renal excretion (crcl‑dependent dosing for dofetilide)
renal failure
renal failure (associated risk in pci)
renal failure (cardiovascular comorbidity)
renal failure (contrast‑related)
renal failure with neuropathy
renal function
renal function (baseline kidney health)
renal function (ckd stages)
renal function (crcl)
renal function (creatinine clearance)
renal function (e.g., serum creatinine, egfr)
renal function (glomerular filtration, kidney disease)
renal function (impact on anticoagulant dosing)
renal function (renal insufficiency)
renal function (worsening renal function, tubule injury)
renal function / creatinine
renal function / creatinine clearance (crcl)
renal function / glomerular filtration rate (gfr)
renal function assessment (crcl)
renal function considerations
renal function indices (egfr, crcl)
renal function monitoring
renal function testing
renal impairment monitoring
renal injury (post‑operative)
renal injury after cardiac surgery
renal insufficiency
renal insufficiency (as risk factor for hf)
renal insufficiency / chronic kidney disease (ckd)
renal malperfusion
renal outcomes
renal protection during thoracoabdominal aneurysm repair
renal protection strategies
renal replacement therapy
renal replacement therapy (as outcome endpoint)
renal replacement therapy (used in advanced hf)
renal replacement therapy / kidney failure in pci context
renal toxicity / contrast‑induced nephropathy
renin‑angiotensin system
renin‑angiotensin system agents
renin‑angiotensin system blockade (ace inhibitors, arbs)
renin‑angiotensin system inhibition
renin‑angiotensin system inhibitors
renin‑angiotensin‑aldosterone inhibitors (raasi)
renin‑angiotensin‑aldosterone system (raas)
renin‑angiotensin‑aldosterone system (raas) antagonists
renin‑angiotensin‑aldosterone system (raas) inhibitor therapy
renin‑angiotensin‑aldosterone system (raas) inhibitors
renin‑angiotensin‑aldosterone system (raas) inhibitors (ace inhibitors, arbs, aldosterone antagonists)
renin‑angiotensin‑aldosterone system (ras) effects
renin‑angiotensin‑aldosterone system blockade
renin‑angiotensin‑aldosterone system inhibitor (raasi)
renin‑angiotensin‑aldosterone system inhibitors (raas inhibitors)
renin‑angiotensin‑aldosterone system inhibitors (raasi)
renin‑angiotensin‑inhibitor safety
renin–angiotensin system blocker
renin–angiotensin system blockers
renin–angiotensin system inhibition
renin–angiotensin‑aldosterone system (raas) inhibition
renin–angiotensin–aldosterone system (raas)
renin–angiotensin–aldosterone system (raas) antagonists
renin–angiotensin–aldosterone system (raas) blockade
renin–angiotensin–aldosterone system (raas) drugs
renin–angiotensin–aldosterone system (raas) inhibition
renin–angiotensin–aldosterone system (raas) inhibitors
renin–angiotensin–aldosterone system inhibitors (raasi)
reoperation
reoperation (late re‑intervention, redo surgery)
reoperation (post‑surgical)
reoperation (surgical recurrence)
reoperation / reintervention
reoperation / repeat intervention
reoperation after aortic repair
reoperation for lvot obstruction
reoperation outcomes
reoperation risk
reoperation risk (reoperation frequency, freedom from reoperation)
reoperation with isolated tricuspid valve surgery
reoperative avr
reoperative cardiac surgery outcomes
reoperative mortality
reoperative savr (surgical aortic valve replacement)
reoperative surgery mortality and morbidity
reoperative tricuspid surgery
reoperative valve surgery
repair quality
repair threshold (≥5.5 cm for men, ≥5.0 cm for women)
repaired coa
repaired congenital heart disease with residual shunts or valvular regurgitation
repaired native valves
repaired tetralogy of fallot
repaired tetralogy of fallot (arrhythmias)
repaired tof
repaired vs unrepaired congenital defects
repeat echocardiography (tte/tee)
repeat hospitalization
repeat intervention risk
repeat procedure rate for srts
repeat revascularization
repeat tee (before completion of oral therapy)
repeated hospitalizations
reperfusion
reperfusion benefit
reperfusion delay
reperfusion injury
reperfusion metabolites
reperfusion modality
reperfusion strategy
reperfusion syndrome
reperfusion therapy
reperfusion therapy (pci, thrombolysis)
reperfusion time
reperfusion timing metrics
replacement fibrosis
repolarization changes
repolarization duration
reproducibility issues with nyha classification
reproductive health (pregnancy & contraception)
reproductive health education
reproductive health in congenital heart disease
reproductive health, pregnancy, and contraception (cardiovascular considerations)
reproductive health, pregnancy, and delivery
reproductive issues & pregnancy considerations in valve disease
reproductive options (informed decision‑making)
rescue angioplasty / rescue pci
rescue or bail‑out therapy
rescue pci
research / implementation terms
residual anatomic sequelae
residual anatomical abnormalities post‑repair
residual aortic disease monitoring
residual aortopathy / aortopa
residual baffle leaks
residual cardiovascular risk
residual coronary/arterial gradients
residual gradients
residual heart disease
residual leak (≤5 mm, >5 mm)
residual lesions / residual disease
residual lesions / residual shunt
residual mitral regurgitation (moderate or greater)
residual mr
residual regurgitation
residual regurgitation assessment post‑device placement
residual risk
residual sam post‑myectomy or ablation
residual shunt
residual shunts
residual shunts after repair
residual thrombus monitoring
residual unrevascularized coronary artery disease (cad)
residual valve dysfunction
residual ventricular septal defects (vsds)
residual vsd
residual ventricular septal defects (vsds)
resistance (strength) training (≥2 days/week)
resistance exercise
resistance training
resistance training (muscle‑strengthening)
resistance training (strength training)
resistive training with light weights
respect‑epa (randomized trial for evaluation in secondary prevention efficacy of combination therapy – statin and eicosapentaenoic acid)
respiratory symptoms
respiratory‑related fluctuations
respire study (sleep apnea incidence in pacemakers)
rest or provoked left ventricular outflow tract (lvot) gradient <50 mm hg
rest pain
rest pain (ischemic pain at rest)
restenosis
restenosis (stent restenosis)
restenosis‑related mi (type 4c)
resting abi
resting echocardiographic findings
resting electrocardiogram (ecg)
resting heart rate
resting heart rate (j‑shaped relationship with af)
resting hypoxemia / cyanosis
resting lvot gradient
resting oxygen saturation
resting peak lvot gradient < 50 mm hg
resting vs. provoked pressure gradients
resting, exercise, and ambulatory hypertension
restrictive cardiomyopathy
restrictive diastolic filling
restrictive lung disease in chd
restrictive physiology
restrictive physiology / restrictive cardiomyopathy phenotype
restrictive rv physiology
restrictive transfusion strategy
restrictive valve involvement
restrictive vsd
restrictive vsds (pressure‑ and/or volume‑restrictive)
rest‑ventricular ejection fraction (lvef)
resuscitated cardiac arrest
resuscitative endovascular balloon occlusion of the aorta
resuscitative endovascular balloon occlusion of the aorta (reboa)
retained valves
reteplase
reteplase (rpa)
retinopathy
retransplantation
retrograde extension of dissection
retrograde perfusion obstruction (implied in malperfusion)
retrograde propagation
retrograde type a aortic dissection
retrograde type a dissection
retrospective analysis
retrospective cohort study
retrospective outcomes (10‑year follow‑up)
retrospective series / case study data (guideline evidence)
retro­active studies on bav outcomes
return of spontaneous circulation (rosc)
return‑to‑play protocols for athletes with heart disease
revascularisation
revascularisation (pci/cabg)
revascularization
revascularization (both endovascular and open surgical)
revascularization (e.g., coronary revascularization)
revascularization (e.g., endovascular or surgical)
revascularization (e.g., pci, cabg)
revascularization (e.g., percutaneous coronary intervention – pci)
revascularization (e.g., percutaneous coronary intervention)
revascularization (early, routine, optimal)
revascularization (endovascular and surgical)
revascularization (endovascular or surgical)
revascularization (endovascular, surgical)
revascularization (endovascular, surgical, hybrid)
revascularization (endovascular, surgical, infrainguinal bypass)
revascularization (endovascular/surgical)
revascularization (for pad)
revascularization (including cabg and pci)
revascularization (interventional/surgical)
revascularization (pci vs cabg)
revascularization (pci, cabg)
revascularization (stenting, cabg)
revascularization (surgical & endovascular)
revascularization (surgical bypass, endovascular)
revascularization (surgical or catheter‑based)
revascularization (surgical or endovascular)
revascularization (urgent/refractory)
revascularization (vascular)
revascularization (when not an option)
revascularization + set combination therapy
revascularization / valve replacement options (mitral valve replacement)
revascularization as standard therapy for clti
revascularization benefits (pci, cabg)
revascularization decision‑making with ffr
revascularization failure
revascularization for coronary artery disease (cad)
revascularization guidelines
revascularization guidelines (acc/aha/scai)
revascularization indications (categories i, iia, iib)
revascularization of vertebral artery
revascularization planning
revascularization planning strategy
revascularization procedures
revascularization procedures (e.g., angioplasty, bypass, endovascular therapy)
revascularization readmissions
revascularization strategies
revascularization strategies in cardiogenic shock
revascularization strategy
revascularization strategy recommendations (cabg vs pci)
revascularization techniques
revascularization therapy
revascularization, coronary revascularization
reversal agents
reversal drugs
reversal of anticoagulation
reversal of pah
reversal of vasomotor paralysis
reverse bernheim effect (ventricular‑ventricular interaction)
reverse remodeling
reverse remodeling (left ventricular/left atrial)
reverse remodeling after surgical repair
reverse study
reverse trial
reverse typical afl (clockwise circuit)
reverse‑edge ventricular outflow tract (rev) procedure
reverse‑typical atrial flutter
reversible factor management
revived‑bcis 2 trial
reynolds risk score
re‑ablation
re‑align trial
re‑coarctation
re‑coarctation (restenosis of aortic isthmus)
re‑dual pci
re‑hospitalization with mi
re‑infarction (reinfarction)
re‑infarction risk reduction
re‑initiation of anticoagulation
re‑ly, rocket af (pivotal doac trials)
re‑occlusion
re‑operative cardiac procedures
re‑stenosis (post‑interventional)
re‑thoracotomy
rf (radiofrequency)










rhabdomyolysis
rheumatic disease
rheumatic fever
rheumatic fever prophylaxis
rheumatic heart disease
rheumatic heart disease‑associated atrial fibrillation
rheumatic mitral disease
rheumatic mitral stenosis
rheumatic mitral stenosis (ms)
rheumatic mitral valve disease
rheumatic valve changes
rheumatic valve disease
rheumatic valvular disease
rheumatoid arthritis
rheumatoid arthritis (inflammatory cardiovascular risk)
rheumatoid arthritis (ra)
rheumatoid arthritis and cardiovascular events
rheumatologic or autoimmune disease
rhythm
rhythm abnormalities
rhythm and rate control in af
rhythm control
rhythm control (rhythm‑control strategies)
rhythm control in af
rhythm control of atrial fibrillation (af)
rhythm control strategies
rhythm control strategies (pharmacologic, ablation, electrical cardioversion)
rhythm control strategy
rhythm control therapies
rhythm control therapy
rhythm conversion (to sinus rhythm)
rhythm evaluation for anticoagulation with continuous monitoring (reactcom)
rhythm management
rhythm monitoring
rhythm monitoring tools
rhythm‑af study
rhythm‑control drugs
rhythm‑control strategies
rhythm‑control strategy
rhythm‑control therapy
rhythm‑restoration outcomes
rhythm control strategy
ribonucleic acid (rna)
rifampin
rifampin‑impregnated prosthetic graft
rifampin‑soaked graft
rifampin‑soaked grafts
right atrial (ra)
right atrial (ra) dilation
right atrial (ra) pathology in repaired complex achd
right atrial area
right atrial contraction
right atrial dysfunction
right atrial enlargement
right atrial enlargement (rae)
right atrial function
right atrial involvement in avsd
right atrial pressure
right atrial size
right atrial strain
right bundle branch block
right coronary artery
right heart anatomy
right heart catheterization
right heart dysfunction
right heart failure
right heart function
right heart overcirculation
right hemiarch replacement
right internal mammary artery (rima) graft
right subclavian artery
right ventricle
right ventricle (rv)
right ventricle (rv) size
right ventricle‑to‑pulmonary artery (rv‑to‑pa)
right ventricle‑to‑pulmonary artery (rv‑to‑pa) conduit
right ventricle‑to‑pulmonary artery conduits
right ventricular (rv)
right ventricular (rv) dilation
right ventricular (rv) dimensions
right ventricular (rv) dysfunction
right ventricular (rv) dysfunction (systolic and diastolic)
right ventricular (rv) dysfunction / dilatation
right ventricular (rv) failure
right ventricular (rv) function
right ventricular (rv) hypertension
right ventricular (rv) involvement
right ventricular (rv) pacing
right ventricular (rv) pressure
right ventricular (rv) pressure load
right ventricular (rv) pressure overload
right ventricular (rv) response to overload
right ventricular (rv) size
right ventricular (rv) size and function
right ventricular (rv) systolic dysfunction
right ventricular (rv) systolic function
right ventricular (rv) systolic pressure
right ventricular (rv) thinning/fatty replacement
right ventricular activation
right ventricular cavity
right ventricular dilatation
right ventricular dilation
right ventricular dilation / enlargement
right ventricular dimensions
right ventricular dysfunction
right ventricular dysfunction / failure
right ventricular dysfunction secondary to tricuspid regurgitation
right ventricular ejection fraction (rvef)
right ventricular ejection fraction (rvef) – threshold <46 %
right ventricular end‑diastolic volume (referenced)
right ventricular end‑diastolic volume (rvedv)
right ventricular end‑diastolic volume (rvedv) – indexed rvedv (rvedvi)
right ventricular end‑systolic volume (>80 ml/m²)
right ventricular end‑systolic volume index (rvesvi)
right ventricular enlargement
right ventricular enlargement (rve)
right ventricular failure
right ventricular failure (implied in fontan context)
right ventricular fibrosis
right ventricular filling pressure
right ventricular free‑wall strain
right ventricular function
right ventricular function / rv systolic dysfunction
right ventricular function evaluation
right ventricular hypertension
right ventricular hypertrophy
right ventricular infarction
right ventricular infarction (rv infarction)
right ventricular involvement
right ventricular loading
right ventricular outflow tract (rvot)
right ventricular outflow tract (rvot) dysfunction
right ventricular outflow tract (rvot) obstruction
right ventricular outflow tract dysfunction
right ventricular outflow‑tract dysfunction / akinetic length
right ventricular pacing
right ventricular pacing (rvp)
right ventricular pressure
right ventricular remodeling
right ventricular size
right ventricular size assessment
right ventricular systolic function
right ventricular systolic pressure (rvsp)
right ventricular to pulmonary arterial coupling
right ventricular unloading
right ventricular volume
right ventricular volume / left ventricular volume ratio
right ventricular volume overload
right ventricular volume/pressure overload
right ventricular/left ventricular function parameters
right ventricular–to‑pulmonary artery (rv‑to‑pa) conduit
right ventriculography
right ventriculotomy
right vertebral artery
right-sided chamber enlargement
right/left coronary artery involvement
right‑atrial maze procedure
right‑heart catheterization
right‑heart chamber enlargement
right‑heart decompression
right‑heart monitoring
right‑heart pressure / right‑ventricular dysfunction
right‑heart pressure assessment
right‑sided diastolic pressures
right‑sided endocarditis
right‑sided failure (elevated central venous pressure, hepatomegaly, dependent edema)
right‑sided filling pressures
right‑sided heart failure
right‑sided heart failure (hf)
right‑sided heart remodeling
right‑sided hf signs and symptoms
right‑sided icd implant
right‑sided ie
right‑sided infective endocarditis
right‑sided prosthetic valve
right‑sided staphylococcus aureus endocarditis
right‑to‑left atrial shunt
right‑to‑left shunt
right‑to‑left shunt / bidirectional shunting
right‑to‑left shunting
right‑ventricular (rv) dysfunction
right‑ventricular (rv) failure
right‑ventricular (rv) pacing
right‑ventricular (rv) pressure overload
right‑ventricular (rv) remodeling
right‑ventricular (rv) shock
right‑ventricular (rv) strain
right‑ventricular (rv) systolic dysfunction
right‑ventricular afterload (pulmonary vascular resistance)
right‑ventricular assist device (rvad)
right‑ventricular compliance
right‑ventricular dilation
right‑ventricular dysfunction
right‑ventricular ejection fraction (rvef)
right‑ventricular failure
right‑ventricular function (ejection fraction, volumes)
right‑ventricular heart failure (rv hf)
right‑ventricular mass, volume and function assessment
right‑ventricular measures (cvp >15 mm hg, cvp‑pcw >0.6)
right‑ventricular outflow tract (rvot)
right‑ventricular pacing
right‑ventricular strain and deformation
right‑ventricular systolic dysfunction
right‑ventricular systolic dysfunction prevalence (50–80%)
right‑ventricular volume overload
right‑ventricular/biventricular pacing (rv/bivp)
right atrial size
right ventricular (rv) volumes
right ventricular dysfunction
right ventricular outflow tract (rvot)
rime (randomized ischemic mitral evaluation) trial
ring annuloplasty (aortic root)
riociguat
riociguat (sgc stimulator)
risk
risk amplifiers (clinical definitions for pad)
risk amplifiers (≥ 1 of the above factors)
risk amplifiers for pad (guideline‑defined)
risk analysis index
risk assessment
risk assessment (dissection risk)
risk assessment (for cardiovascular risk)
risk assessment / risk stratification
risk assessment and management (pulmonary hypertension specialists)
risk assessment and therapeutic decision‑making
risk assessment for thrombolysis
risk assessment frequency (every 4–6 years)
risk assessment tools
risk assessment tools (e.g., 3‑strata, 4‑strata models)
risk calculators
risk calculators (e.g., pce, framingham, reynolds, score, qrisk/jbs3)
risk calibration
risk categories: low, intermediate, high risk
risk discrimination
risk discrimination and calibration in prediction models
risk discussion
risk discussion / shared decision making
risk estimation
risk estimation tools (e.g., ascvd risk estimator, pce, 30‑year/lifetime risk estimator)
risk estimators (e.g., pooled cohort equations – pce)
risk evaluation and mitigation strategy
risk factor
risk factor (tobacco use)
risk factor algorithms for specific populations (e.g., veterans affairs, women’s health initiative, china‑par, korean risk model)
risk factor burden at age 50
risk factor burden at age 70
risk factor clustering (age, sex, smoking, diabetes, hyperlipidemia, hypertension)
risk factor control (lipids, blood pressure, diabetes)
risk factor education and counseling
risk factor evaluation for af complications
risk factor for aortic dissection
risk factor for reoperation
risk factor identification
risk factor management
risk factor modification
risk factor modification (e.g., smoking cessation, physical activity, healthy diet)
risk factor modification (smoking, cholesterol, blood pressure)
risk factor optimization
risk factor prediction models
risk factors
risk factors (e.g., for af, scd)
risk factors (for cardiovascular disease)
risk factors (general)
risk factors for aortic dilation
risk factors for aortic disease
risk factors for arrhythmia in achd
risk factors for avr timing
risk factors for cardiovascular disease
risk factors for claudication
risk factors for development of vhd
risk factors for dissection
risk factors for familial tad (age < 60 y, family history, sudden death)
risk factors for hf
risk factors for infective endocarditis
risk factors for loss to follow‑up
risk factors for mechanical complications post‑mi
risk factors for pad (e.g., diabetes, smoking, hyperlipidemia)
risk factors for peripheral artery disease
risk factors for rupture (endoleak, sac enlargement)
risk factors for sudden death
risk factors for valve degeneration (younger age, diabetes, renal failure)
risk factors for valve disease
risk factors: maternal age >30 yr, african ancestry, multiparity, multigestation, preeclampsia/eclampsia, anemia, diabetes, obesity, prolonged tocolysis
risk factors: young age (<60 yr), smoking, diabetes mellitus, chronic kidney disease, initial mean gradient ≥15 mm hg, valve type.
risk model
risk modelling
risk modifiers (stroke risk)
risk of adverse aortic events (dissection, rupture, sudden death)
risk of adverse events (rupture, dissection, death)
risk of af
risk of aortic rupture
risk of bleeding in p2y12 inhibitor therapy
risk of cardiomyopathy with family history
risk of death or renal failure with multivessel pci
risk of graft failure
risk of major adverse cardiac events (maces) in pad
risk of noncardiac intervention
risk of operative intervention
risk of progression from left‑ventricular dysfunction to overt heart failure
risk of recurrent ich
risk of rupture
risk of systemic thromboembolism in af
risk of thromboembolic recurrence
risk prediction
risk prediction (aortic disease)
risk prediction factors and stratification categories
risk prediction functions
risk prediction model
risk prediction models
risk prediction models (e.g., vascular study group of new england)
risk prediction models for af
risk prediction models for children with hcm
risk prediction models for peripartum cardiomyopathy
risk prediction models for scd
risk prediction performance (validity, calibration, discrimination)
risk prediction tools (tool‑specific)
risk ratio & confidence interval (statistical outcomes)
risk reclassification
risk reclassification & discrimination
risk reduction
risk reduction discussion
risk reduction of cardiovascular events
risk reduction strategies
risk reduction therapy
risk score
risk score (predicting death or need for surgery)
risk score / risk factors
risk score application for ventricular arrhythmia & scd
risk score assignment (0–3 points)
risk score development
risk score for af
risk score recalibration / customization
risk scores
risk scores (comprehensive, contemporary)
risk scores (e.g., cha₂ds₂‑vasc, chads‑vasc)
risk scores (e.g., for need of intensive care, predicting length of stay)
risk scores for death/recurrent mi prediction
risk scoring (e.g., precise‑dapt, paris)
risk scoring for major clinical events (post‑atrial switch)
risk scoring system for prosthetic valve procedures
risk stage a (patients at risk of hf)










risk stratification
risk stratification (e.g., cha₂ds₂‑vasc, has‑bled)
risk stratification (for ccd)
risk stratification (for icd decision‐making)
risk stratification (ischemic risk, bleeding risk)
risk stratification (pediatric and adult)
risk stratification (serious comorbidities, advanced age)
risk stratification / mortality prediction models
risk stratification / prognostic assessment
risk stratification after myocardial infarction
risk stratification and early diagnosis of aortic disease
risk stratification and population screening for af
risk stratification by exercise testing
risk stratification for achd patients
risk stratification for aortic disease
risk stratification for cardiac patients
risk stratification for icd placement
risk stratification for mortality and major events
risk stratification for pah
risk stratification for scd
risk stratification for sudden cardiac death
risk stratification for sudden cardiac death (scd)
risk stratification for vt/scd
risk stratification in coronary disease
risk stratification in heart failure
risk stratification models
risk stratification of asymptomatic valvular disease
risk stratification of sudden cardiac death
risk stratification scores
risk stratification scores (validated risk models)
risk stratification scores – conventional risk‑factor analysis, clinical risk scores
risk stratification tools
risk stratification tools (e.g., timi, grace scores)
risk stratification using cpet variables
risk thresholds (low < 5 %, borderline 5 %–< 7.5 %, intermediate ≥ 7.5 %–< 20 %, high ≥ 20 %)
risk treatment discussion
risk-benefit assessment
risk-enhancing factors
risk‑adjusted annual risk (>2% risk for stroke)
risk‑adjusted mortality rate (a/p ratio)
risk‑adjusted odds ratio (or) for mortality
risk‑amplifying comorbidities
risk‑assessment tools (e.g., 6mwd, hemodynamic parameters)
risk‑based foot screening intervals (annual, every 3–6 months, every 1–3 months)
risk‑based selection of oral anticoagulation
risk‑benefit assessment
risk‑benefit calculation.
risk‑benefit ratio (tavi vs. savr)
risk‑benefit ratio for intervention
risk‑benefit ratio of aspirin
risk‑enhancing factors
risk‑enhancing factors (e.g., elevated lipoprotein (a), metabolic syndrome, inflammatory diseases, hiv, protease inhibitors)
risk‑enhancing factors (family history of premature ascvd, elevated hscrp, lipid‑rich environment)
risk‑estimate calculator (5‑year scd risk)
risk‑estimation for ascvd (10‑year ascvd risk score)
risk‑factor algorithm
risk‑factor categories (aortic dilation, bav, aortic coarctation, hypertension)
risk‑factor control
risk‑factor control/optimization: lifestyle modification, pharmacologic therapy (statins, antihypertensives, antidiabetic drugs)
risk‑factor modification
risk‑factor modification (blood‑pressure control, medication)
risk‑factor modifications (diet, exercise, smoking cessation)
risk‑stratification for anticoagulation
risk‑stratification tools
risk–benefit balance of intervention timing
risk–benefit tradeoff
ritonavir
rivaroxaban
rivaroxaban (anticoagulant drug)
rivaroxaban (direct oral anticoagulant)
rivaroxaban (full‑dose)
rivaroxaban (low‑dose)
rivaroxaban + aspirin combination
rivaroxaban therapy
rly5016 (polysorbate potassium binder)
robo4 gene mutation
robotics‑assisted epicardial left atrial appendage exclusion
roche
roche diagnostics
rocket af trial
rocket‑af trial
rocket af study (predictors of mortality)
rofecoxib
role of primary hcm centers in procedural excellence
root aneurysm
root diameter
root enlargement with avr
root phenotype aortopathy
root‑sparing ascending replacement
ropac registry
ropac registry (registry of pregnancy and cardiac disease)
ropac registry (registry on pregnancy and cardiac disease)
rose angina (rose questionnaire)
rose trial
rosiglitazone
ross operation
ross procedure
ross procedure (aortic root autograft)
ross procedure (pulmonary autograft)
ross procedure (pulmonic autograft)
rossipril (ramipril)
rosuvastatin
rosuvastatin (20‑40 mg)
rosuvastatin (20–40 mg)
rosuvastatin (5‑10 mg)
rosuvastatin (5 mg, 10 mg, 20 mg, 40 mg)
rosuvastatin (≥ 20 mg)
roth’s spots
rotor or rotor‑modulation ablation (firm, confirm, firmap)
rotors (focal drivers)
routine cesarean delivery policy
routine clinical or imaging follow‑up
routine diagnostic studies
routine follow‑up
routine follow‑up (physiological stages a–d)
routine follow‑up / monitoring
routine follow‑up coronary angiography
routine follow‑up for valvular pulmonary stenosis
routine follow‑up imaging after valve intervention
routine follow‑up intervals
routine follow‑up intervals (physical, electrocardiogram, echocardiogram)
routine follow‑up visits
routine functional stress testing
routine invasive strategy
routine invasive vs selective invasive approach in nste‑acs
routine patient‑reported health status assessment
routine versus selective stenting
routine vs. conservative oxygen administration
rubidium‑82 pet imaging
rupture
rupture (aortic)
rupture (contained rupture)
rupture (of the aorta)
rupture of aortic aneurysm
rupture protocols (early imaging, rapid transfer, imaging‑guided repair)
rupture risk
rupture threshold (≥5.5 cm men, ≥5.0 cm women)
ruptured aaa
ruptured abdominal aortic aneurysm
ruptured abdominal aortic aneurysm (raaa)
ruptured aortic aneurysm
ruptured cerebral aneurysm
rural dwelling status / urban‑rural disparities
rural health disparities in vascular care
rurality / geographic remoteness
rutherford classification
rv (right ventricle)
rv apical pacing
rv dilatation
rv dilation
rv dilation (right‑ventricular dilation)
rv dysfunction
rv end‑systolic area
rv enlargement
rv free wall
rv hypertension
rv hypertrophy
rv lge present
rv pressure
rv pressure overload
rv pressure/volume overload
rv remodeling
rv size and function assessment
rv systolic dysfunction
rv systolic function
rv systolic pressure
rv volume
rv volume loading
rv volume overload
rv volume overload (shunts/high‑output states)
rv volumes
rvot anatomy (native vs conduit)
rvot dysfunction
rvot obstruction
rvot pressure ≥47 mm hg
rvot reintervention
rvot resection
rvot obstruction
rvp (right ventricular pacing)
rv‑dependent coronary circulation
rv‑to‑pa conduit
rv‑to‑pa conduit regurgitation
rv‑to‑pa conduit stenosis
rv‑to‑pa shunt
rv‑to‑pulmonary artery (rv‑to‑pa) conduit
rv systolic function
rv systolic pressure
rwi (relationships with industry)
ryanodine receptor dysfunction









s. aureus endocarditis
s.* aureus bacteremia
saccular aaa
saccular aneurysm
saccular aneurysm morphology
sacubitril/valsartan
sacubitril/valsartan (arni)
sacubitril/valsartan (arni) in adult complex chd
sacubitril/valsartan (entresto)
sacubitril/valsartan (lcz‑696, lcz‑696)
sacubitril/valsartan therapy (heart failure)
sacubitril/valsartan use in systemic rv failure
sacubitril‑valsartan
sacubitril‑valsartan (arni)
sacubitril‑valsartan (lcz‑dppv)
sacubitril‑valsartan (valsartan‑based arni)
sacubitril–valsartan (arni)
sad, etc. (implied in references)
safety and effectiveness of antithrombotic therapy in coronary artery disease
safety and efficacy
safety and harm statements (e.g., arni/acei overlap within 36 h)
safety and outcomes of catheter ablation in achd
safety laboratory checks
safety of sheath insertion
safety profile
safety profile of verapamil and diltiazem in hcm
safety study
safety trial (af‑specific management strategy)
safe‑t trial
safe‑t trial (sotalol vs. amiodarone)
safire‑d study
safire‑d study (dofetilide trial)
salt restriction
salvageable limb
same‑day discharge
sano shunt
sanofi
sanofi‑aventis
saphenous vein
saphenous vein (autogenous conduit)
saphenous vein (great saphenous vein)
saphenous vein assessment
saphenous vein assessment before leg revascularization
saphenous vein assessment before leg revascularization (qm‑6)
saphenous vein graft
saphenous vein graft (great, small, or femoral)
saphenous vein graft occlusion
saphenous vein grafts
sapien 3 transcatheter heart valve
sapien s3 transcatheter heart valve
sarcoid (sarcoidosis)
sarcoid cardiomyopathy (cardiac sarcoidosis)
sarcoidosis
sarcoidosis (cardiac form)
sarcoidosis (cardiac involvement)
sarcoidosis‑related hf
sarcolipin regulation
sarcoma of the aorta / primary aortic tumor
sarcomere contractility inhibitors
sarcomere gene
sarcomere gene variant carriers
sarcomere gene variant.
sarcomere genes
sarcomere mutation
sarcomere mutation carriers.
sarcomere proteins
sarcomere variant
sarcomere‑related structures
sarcomeric genes
sarcomeric genetic variants
sarcomeric human cardiomyopathy registry (share)
sarcopenia
sarcopenia (predicts adverse outcomes in cad)
sarcoplasmic reticulum ca<sup>2+</sup> leak
sarcoplasmic reticulum calcium atpase (serca)
sarcoplasmic reticulum calcium load
sarcoplasmic reticulum dysfunction in af
sars‑cov‑2 infection and mrna vaccination
sars‑cov‑2 vaccination
sars‑cov‑2 vaccine effectiveness (high‑risk population)
sarver heart center
satisfactory procedural success (>95%)
saturated fat
saturated fat (< 6 % of total calories)
saturated fat intake
saturated fats
saturated fatty acids
save study (captopril after mi)
savor‑timi 53 (dpp‑4 inhibitor outcomes)
savr (surgical aortic valve replacement)
sawtooth flutter waves (ecg finding)
saxagliptin
sbp < 100 mm hg (systolic blood pressure)
scai
scai (society for cardiovascular angiography & interventions)
scai (society for cardiovascular angiography and interventions)
scai (society for cardiovascular angiography and interventions) guidelines
scai cardiogenic shock stages (a–e)
scai device‑selection guideline
scai expert consensus on shock stage classification
scai expert consensus statement on out‑of‑hospital cardiac arrest
scai grade
scai grade for cardiac arrest
scai guidelines (device selection, endovascular specialists)
scai position statement on achd interventional training
scai shock stage classification update
scai shock stages (c, d, e)
scai stage classification
scai/aats/acc/sts operator and institutional requirements
scar burden
scar formation
scar re‑entry circuits
scar tissue
scar‑mediated reentrant tachycardia
scar‑related vt
scd (sudden cardiac death)
scd rate increase with rv‑dependent circulation
scd risk assessment
scd risk assessment in adults with hcm
scd risk assessment in children/adolescents with hcm
scd risk calculator
scd risk calculator (e.g., from concor registry)
scd risk markers (clinical, imaging, electrophysiologic)
scd risk markers (e.g., lv apical aneurysm, lge, ef < 50 %)
scd risk reduction via ablation
scd‑heft (sudden cardiac death in heart failure trial)
scientific statement
scientific statement (american heart association)
scientific statement on dilated cardiomyopathy diagnostics and treatment
scientific statements
scimitar syndrome
scimitar syndrome (scimitar vein repair)
scimitar vein (variant of apvc)
score (systematic coronary risk evaluation)
scot‑heart trial
screening (for af)
screening (for aneurysm)
screening (genotype‑positive family members)
screening (ultrasound screening)
screening and referral processes
screening aortic imaging (if testing negative or vus)
screening for aaa
screening for abdominal aortic aneurysm
screening for abdominal aortic aneurysm (aaa)
screening for all risk factors (e.g., head 2 toes)
screening for aneurysms
screening for asymptomatic first‑degree relatives
screening for congenital aortic valve abnormalities
screening for coronary artery anomalies
screening for heart failure (stop‑hf)
screening for intracranial aneurysms in coarctation of the aorta
screening for mental health disorders
screening for new‑onset atrial fibrillation
screening for pad
screening for serum and urine monoclonal light chains
screening intervals:
screening of first‑degree relatives
screening recommendations for aaa
screening stratification risk prediction
screening tte in first‑degree relatives
seamless transitions from pediatric to achd
seattle angina questionnaire
seattle angina questionnaire (patient‑reported health status measure)
seattle angina questionnaire (saq)
seattle heart failure model
second trimester
secondary (functional) mr
secondary cardiovascular prevention
secondary coronary prevention
secondary erythrocytosis
secondary hyperaldosteronism
secondary mitral regurgitation
secondary mitral regurgitation (mr)
secondary mitral regurgitation (secondary mr)
secondary mr
secondary mr (chronic secondary mr)
secondary mr (lv‑remodeling‑related)
secondary patency
secondary prevention
secondary prevention (post‑discharge care)
secondary prevention (rheumatic fever, endocarditis)
secondary prevention after acs
secondary prevention in atherosclerotic disease
secondary prevention of arrhythmias
secondary prevention of ascvd
secondary prevention of atherosclerotic vascular disease
secondary prevention of cad
secondary prevention of cardiovascular disease
secondary prevention of cardiovascular disease (cvd)
secondary prevention of coronary disease
secondary prevention of coronary ischemic events
secondary prevention of cvd
secondary prevention of heart failure
secondary prevention of mi
secondary prevention of rheumatic fever
secondary prevention strategies
secondary tr
secondary tricuspid regurgitation
secondary‑prevention icd
secondhand smoke
secondhand smoke exposure
second‑ or third‑degree heart block (without pacemaker)
second‑degree atrioventricular block, mobitz type ii
second‑degree av block (mobitz i & ii)
second‑generation des
second‑generation dihydropyridine calcium channel blockers
second‑hand smoke
second‑hand smoke (passive smoking)
second‑hand smoke exposure
secundum asd
secundum atrial septal defect
sedation / patient tolerance
sedation for cardioversion
sedentary behavior
sedentary behaviour
sedentary lifestyle
sedentary time
segmental leg pressures
segmental limb pressure measurements
segmental pressures
segmental systolic pressures
selective invasive approach
selective invasive strategy
selective serotonin reuptake inhibitors (ssris)
selective treatment indications
selexipag (oral prostacyclin receptor agonist)
selexipag therapy
selexipag therapy for pulmonary hypertension
self‑care
self‑care education / self‑care
self‑care education and adherence
self‑care support for heart failure
self‑care support in heart failure
self‑expandable valve (e.g., evolut r)
self‑expanding prosthesis
self‑expanding pulmonary valve
self‑expanding tavi device
self‑expanding valve
self‑expanding valve technologies
self‑management
self‑management in heart failure patients
self‑reported health status
sellar’s criteria
semaglutide
semilunar valve interventions
semi‑supine bicycle exercise testing
seniors
seniors trial
sensory or motor dysfunction in an extremity
sensory polyneuropathy
sepsis
sepsis (from limb ischemia)
sepsis (systemic infection with cardiovascular implications)
sepsis / septic shock management
sepsis / severe sepsis (hospitalized patients)
sepsis‑associated atrial fibrillation
septal alcohol ablation
septal defects
septal e′ velocity
septal hypertrophy
septal myectomy
septal myectomy (surgical)
septal perforator injection
septal radiofrequency therapy (srt)
septal reduction therapy
septal reduction therapy (srt)
septic emboli to the lungs
septic embolism
septic pulmonary infarct
septic pulmonary infarcts
sequelae of avr on mr (improvement vs. persistence)
sequencing gdmt
sequential intervention
sequential pneumatic compression
sequential studies
sequential therapy (heparin then warfarin)
serca2 function / enhancer
serial cardiac imaging
serial clinical assessment
serial doubling of loop diuretics
serial ecg monitoring
serial echocardiograms
serial echocardiographic surveillance intervals (3–5 y, 1–2 y, 6–12 mo, 1 yr)
serial follow‑up echocardiography (every 1–2 years)
serial imaging
serial imaging studies
serial lvef monitoring
serial measurement of natriuretic peptides
serial troponin testing (0, 1–2 h)
serious cardiac complications during transplantation
serological evidence of active infection
serum biomarkers
serum brain natriuretic peptide (bnp)
serum creatinine
serum creatinine (scr)
serum digoxin concentration
serum digoxin level / concentration
serum electrolytes
serum free light chains (flc)
serum magnesium
serum monoclonal light chains
serum nt‑probnp concentrations
serum potassium
serum potassium (hyper‑kalaemia)
serum sodium
serum uric acid in eisenmenger syndrome
severe aortic regurgitation
severe aortic regurgitation (native or bioprosthetic)
severe aortic stenosis
severe aortic stenosis (as)
severe ar
severe ar (stage c1, c2, d)
severe as
severe as (asymptomatic or symptomatic)
severe asymptomatic vhd
severe bradycardia
severe burns (cardiovascular impact)
severe coronary artery disease
severe coronary artery disease (cad)
severe coronary stenosis (≥70 %)
severe dementia








severe disease
severe heart failure
severe high‑gradient as
severe hypotension (risk with pde5i + nitrates)
severe hypoxemia (spo₂ ≤ 85 %)
severe ischemic mitral regurgitation
severe kidney dysfunction (egfr < 30 ml/min/1.73 m²)
severe left ventricular dysfunction
severe lung disease
severe lung, liver, or renal disease
severe lv dysfunction (lvef ≤ 35 %)
severe mitral annular calcification (late paravalvular leak risk)
severe mitral regurgitation
severe mitral regurgitation (mr)
severe mitral regurgitation (mr) due to annular calcification
severe mitral stenosis
severe mitral valve (mv) regurgitation
severe mr (ero ≥ 40 mm² or ≥ 0.4 cm²; regurgitant volume ≥ 60 ml)
severe ms criteria (≤1.5 cm², >5 mm hg gradient)
severe native coarctation or recoarctation
severe obesity
severe or symptomatic valvular disease
severe pah with shunt reversal
severe pain (abrupt, ripping/tearing)
severe pneumonia (cardiovascular comorbidity)
severe primary mitral regurgitation (mr)
severe primary mr
severe pulmonary arterial hypertension
severe pulmonary hypertension
severe regurgitation
severe respiratory diseases
severe rvot obstruction
severe secondary mr
severe stenosis
severe symptomatic aortic stenosis (as)
severe symptomatic tricuspid regurgitation (e.g., due to device leads)
severe tricuspid regurgitation
severe tricuspid regurgitation (severe tr)
severe tricuspid regurgitation (tr)
severe valve disease
severe valvular dysfunction
severe ventricular dysfunction
severely reduced lvef (<35%)
severity grading of as and ar
severity of presentation (fulminant vs nonfulminant)
severity of vhd
severity thresholds for mr (e.g., “severe primary mr”)
sex (female)
sex category (as part of cha2ds2‑vasc score)
sex differences
sex differences in peripheral artery disease
sex differences in symptom presentation and treatment of mi
sex disparities
sex, gender, and ethnicity disparities in cardiovascular care
sex, race, and ethnicity disparities in aortic disease outcomes
sex/gender differences (female vs. male ischemia, outcomes)
sex/gender differences in af treatment and outcomes
sexual activity (as moderate exercise)
sexual activity–related cardiovascular risk
sexual dysfunction
sexual dysfunction after aortic dissection
sexual health
sex‑modified cha₂ds₂‑vasc score
sex‑specific agaston unit thresholds (1300 women, 2000 men)
sex‑specific cardiovascular risk
sex‑specific criteria for myocardial infarction diagnosis
sglt2 inhibitor
sglt2 inhibitor (sglt2i)
sglt2 inhibitor pharmacodynamics in hf
sglt2 inhibitors
sglt2 inhibitors (dapagliflozin, empagliflozin)
sglt2 inhibitors (sglt2i)
sglt2 inhibitors (sodium‑glucose cotransporter‑2 inhibitors)
sglt‑2 inhibitors
sglt‑2 inhibitors (e.g., dapagliflozin, empagliflozin, canagliflozin)
shared decision making
shared decision making (sdm)
shared decision-making
shared decision‐making process
shared decision‑making
shared decision‑making (among cardiology, primary, and specialty teams)
shared decision‑making (as a key process in risk assessment)
shared decision‑making (clinical decision process for preventive therapy)
shared decision‑making (clinical process)
shared decision‑making (for ccd)
shared decision‑making (for valve intervention)
shared decision‑making (in cardiovascular care)
shared decision‑making (in icd placement)
shared decision‑making (multidisciplinary)
shared decision‑making (sdm)
shared decision‑making (sdm) framework
shared decision‑making (sdm) in sports/physical activity
shared decision‑making for icd placement
shared decision‑making for valve therapy
shared decision‑making in aortic surgery
shared decision‑making in cardiac care
shared decision‑making in cardiovascular prevention
shared decision‑making in hcm care
shared decision‑making in hcm management
shared decision‑making in treatment choices
shared decision‑making process
shared decision‑making strategies in pad management
shared decision‑making with patients
shared‑decision making
shear stress
shfm (seattle heart failure model)
shifamed
shift trial (ivabradine treatment)
shift trial (shift) – a clinical trial on hfref
shock
shock (cardiac related)
shock (cardiogenic)
shock (shock) trial
shock energy (j)
shock index (hr/sbp)
shock index >1.0
shock severity scales (risk‑stratification tools for cardiogenic shock)
shock stage classification
shock team
shock team approach
shock teams
shock trial (cardiogenic shock after mi)
shock trial (should we emergently revascularize occluded coronaries for cardiogenic shock)
shockable rhythm (ventricular fibrillation, ventricular tachycardia)
shockwave medical
shockwave therapy
shone complex
shone complex
short stature (growth-related risk factor)
shorter dapt strategy
shortness of breath
shortness of breath / dyspnea
short‑acting nitrates
short‑acting nitrates (e.g., nitroglycerine)
short‑term and long‑term outcomes in mi
short‑term and long‑term survival
short‑term cardiac toxicity (post‑transplant)
short‑term dapt
short‑term dual antiplatelet therapy
short‑term evolution
short‑term mortality
short‑term outcomes (early results, immediate results)
short‑term survival
shunt (left‑to‑right, qp:qs)
shunt (trivial/small, hemodynamically significant)
shunt assessment
shunt closure
shunt closure complications
shunt lesions
shunt lesions (e.g., asd, vsd, patent ductus)
shunt magnitude
shunt magnitude / size
shunt palliation
shunt pre‑repair
shunt repair / closure
shunt type: secundum, primum, sinus venosus (superior/inferior), unroofed coronary sinus
shunting
sibutramine
sick sinus syndrome
sick sinus syndrome (tachycardia‑bradycardia form)
siemens
siemens healthineers** (cardiac imaging equipment)
signal void in mri (mitral regurgitation)
significant cad (>50% stenosis)
significant heart murmur
significant lv disease (chronically elevated left‑atrial pressure ≥ 15 mm hg)
signs / symptoms of heart failure
sildenafil
sildenafil (example pde5 inhibitor)
sildenafil (pde5 inhibitor)
sildenafil citrate therapy
sildenafil therapy
sildenafil therapy for pulmonary hypertension
silent / subclinical af
silent af
silent cerebral embolism
silent cerebral ischemic events
silent ischemia
silent thromboembolic lesion
silk road medical
silver‑coated graft
silver‑impregnated prosthetic graft
simple carbohydrates (e.g., high‑fructose corn syrup)
simple risk models for surgical mortality in type a dissection
simple, moderate, and complex forms of chd
simulation training for operators
simvastatin
simvastatin (10 mg, 20 mg, 40 mg)
simvastatin (20‑40 mg; 10 mg)
simvastatin (20–40 mg)
single antiplatelet therapy (sapt)
single photon emission computed tomography myocardial perfusion imaging (spect mpi)
single photon emission ct (spect)
single staged versus multistaged pci in multivessel nstemi patients (smile trial)
single ventricle (functional single‑ventricle heart)
single ventricle (univentricular)
single ventricle physiology
single-anticoagulant therapy
single‑call transfer protocol
single‑cell rna sequencing
single‑chamber icd
single‑chamber pacing
single‑coil defibrillator lead
single‑coil icd lead
single‑coil icd leads
single‑nucleus profiling
single‑photon emission computed tomography (spect)
single‑photon emission computed tomography myocardial perfusion imaging (spect mpi)
single‑ventricle
single‑ventricle anatomy (including double‑inlet left ventricle, tricuspid/mitral atresia, hypoplastic left heart)
single‑ventricle congenital heart disease
single‑ventricle palliation
single‑ventricle physiology
single‑ventricle repair
sinoatrial (sa) node
sinoatrial node
sinotubular junction
sinus node dysfunction
sinus of valsalva
sinus of valsalva aneurysm
sinus of valsalva aneurysm / prolapse
sinus rhythm
sinus rhythm (electrophysiological term)
sinus rhythm maintenance
sinus rhythm maintenance and targeted therapy in persistent atrial fibrillation
sinus rhythm restoration
sinus tachycardia
sinus venosus asd
sinus venosus atrial septal defect (svasd)
sinus venosus defect
sinuses of valsalva
sinuses of valsalva (non‑replaced) management
sinus‑based atrial maze procedure
sinus‑to‑commissure (s‑c) measurement
sinus‑to‑sinus (s‑s) measurement
sinus‑to‑sinus measurement
sir
sir (society for interventional radiology)
sir (society of interventional radiology)
sir data registry
sirolimus (rapamycin) therapy
sitagliptin
situs abnormalities, ciliary dysfunction, functional asplenia, conduction abnormalities, biliary atresia, atrioventricular septal defects (balanced/unbalanced), malposed great vessels, interrupted ivc, bilateral svc, atrial isomerism
sit‑up maneuver
six‑minute walk distance
six‑minute walk distance improvement
six‑minute walk test
six‑minute walk test (6mwt)
size threshold for repair (≥ 5.5 cm, < 5.5 cm with risk factors)
size thresholds for repair
skeletal muscle mass
skeletal muscle strength and endurance
skeletal muscle weakness or movement disorder (associated with phenocopies)
skeletal myopathy
skilled nursing facility care
skin perfusion pressure (spp)
skin pigmentation (blue‑gray)
sleep
sleep apnea
sleep apnea severity
sleep disorders
sleep disorders in heart failure
sleep disturbances / sleep deficiency
sleep duration (short sleep)
sleep hygiene (sleep quality)
sleep hygiene / short sleep duration (<6 h)
sleep study (polysomnography)
sleep‑apnea therapy
sleep‑disordered breathing
sleep‑disordered breathing (obstructive sleep apnea)
sleep‑disordered breathing (sdb)
sleep‑disordered breathing interaction with atrial fibrillation
slit‑like orifice
slow flow
slow inward calcium channels
slow pathway ablation
slow‑conducting electroanatomic isthmus
slow‑infusion thrombolysis
smac‑af trial (aggressive bp control in ablation)
smad3
smad3 (gene)
smad3 mutation
smad3 pathogenic variant
smad6 gene mutation
smad6 mutation
small aortic root / patient–prosthesis mismatch
small body size
small for gestational age infant
small left‑ventricular chamber
small prospective trial of inhaled prostacyclin in eisenmenger patients with normal lv function
small saphenous vein
small valve area
small vessel (intramural) coronary disease
small vessel ischemia
small, low‑flow, low‑gradient as
smart choice trial
smart devices
smartphone ecg
smartphone‑based tools leveraging artificial intelligence
smartwatch
smartwatch monitoring
smartwatches
smile trial
smoking
smoking (active tobacco use)
smoking (as a risk factor)
smoking (cigarette smoking)
smoking (current or former)
smoking (current/ongoing smoking)
smoking (risk factor for aaa)
smoking (risk factor)
smoking (tobacco use)
smoking / cigarette use
smoking / tobacco cessation – major cardiovascular risk factor
smoking / tobacco use
smoking / tobacco use (including other forms of tobacco)
smoking / vaping
smoking cessation
smoking cessation (behavioral and pharmacologic)
smoking cessation (cardiovascular risk modification)
smoking cessation (risk factor for heart disease)
smoking cessation (risk factor reduction)
smoking cessation / tobacco use
smoking cessation guidelines
smoking cessation pharmacotherapies
smoking cessation, physical activity, nutrition, weight management, stress reduction
smoking history (≥100 cigarettes)
smoking restrictions in homes and vehicles
smoking/tobacco use
smooth muscle cell apoptosis
smooth muscle dysfunction syndrome
smooth muscle dysfunction syndrome (acta2)
soccer trial (oxygen therapy on myocardial salvage)
social / psychosocial limitations
social determinants of ascvd risk
social determinants of cardiovascular disease
social determinants of health
social determinants of health (contextual factor)
social determinants of health (housing stability, food security, transportation)
social determinants of health (impact on hf management)
social determinants of health (medication access, cr attendance barriers)
social determinants of health (racial/ethnic disparities, socioeconomic status, rural residence)
social determinants of health (sdoh)
social determinants of health (sdoh) in af
social determinants of health (sdoh) interventions
social determinants of health (sdoh) risk factors
social determinants of health influencing cardiac disease
social engagement and chronic disease risk











social isolation
social isolation (as a risk factor for poor self‑care)
social relationships and heart failure survival
social support (individual and group)
social worker
social workers
society for cardiovascular angiography & interventions (scai)
society for cardiovascular angiography and intervention (scai)
society for cardiovascular angiography and interventions (scai)
society for interventional radiology (sir)
society for vascular medicine (svm)
society for vascular medicine (svm) guideline on aortic disease
society for vascular nursing (svn)
society for vascular surgery (svs)
society for vascular surgery abdominal aortic aneurysm guidelines
society of cardiovascular anesthesiologists (sca)
society of cardiovascular echocardiography recommendations
society of interventional radiology (sir)
society of interventional radiology virtex registry
society of thoracic surgeons (sts)
society of thoracic surgeons (sts) database
society of thoracic surgeons (sts) guideline on aortic aneurysm care
society of thoracic surgeons (sts) national database
society of thoracic surgeons (sts) score
society of thoracic surgery (sts)
society of thoracic surgery (sts) reporting
society of vascular medicine (svm)
society of vascular surgery (svs)
socioeconomic and racial disparities
socioeconomic deprivation
socioeconomic deprivation / rurality impact on cvd
socioeconomic deprivation and vascular health
socioeconomic factors
socioeconomic inequities
socioeconomic position / social deprivation status
socioeconomic status
socioeconomic status (income, education, distressed communities index)
socioeconomic status (ses)
socioeconomic status (ses) and health inequities
socioeconomic status (ses) – adverse influence on af risk
socioeconomic status and cardiovascular outcomes
socioeconomic stress (risk factor for loss to care)
socio‑demographic disparities
socio‑economic status / poverty / lack of health‑care access
sodium
sodium glucose cotransporter 2 (sglt2)
sodium intake
sodium intake (≤ 2300 mg/d, optimum 1500 mg/d)
sodium intake / dietary sodium
sodium intake / low‑sodium diet
sodium intake / sodium reduction
sodium nitroprusside
sodium nitroprusside (intravenous)
sodium reduction
sodium restriction
sodium restriction (dietary)
sodium restriction / dietary sodium restriction
sodium retention
sodium zirconium cyclosilicate (szc)
sodium zirconium cyclosilicate (zs‑9)
sodium/calcium exchanger (ncx) dysfunction
sodium‑calcium exchanger (ncx)
sodium‑glucose cotransporter 2 inhibitors (sglt2‑i)
sodium‑glucose cotransporter 2 inhibitors (sglt2i)
sodium‑glucose cotransporter‑1 inhibitors (sglt1i)
sodium‑glucose cotransporter‑2 (sglt2) inhibitor
sodium‑glucose cotransporter‑2 (sglt2) inhibitors
sodium‑glucose cotransporter‑2 (sglt2) inhibitors (empagliflozin, canagliflozin, dapagliflozin, ertugliflozin)
sodium‑glucose cotransporter‑2 (sglt‑2)
sodium‑glucose cotransporter‑2 (sglt‑2) inhibitor
sodium‑glucose cotransporter‑2 (sglt‑2) inhibitors
sodium‑glucose cotransporter‑2 (sglt‑2) inhibitors in achd
sodium‑glucose cotransporter‑2 (sglt‑2) inhibitors – cardiovascular benefit agents
sodium‑glucose cotransporter‑2 inhibitor (sglt2i)
sodium‑glucose cotransporter‑2 inhibitor (sglt2i) – e.g., dapagliflozin, empagliflozin
sodium‑glucose cotransporter‑2 inhibitor (sglt₂‑i) therapy
sodium‑glucose cotransporter‑2 inhibitor benefits in heart failure and mortality
sodium‑glucose cotransporter‑2 inhibitors
sodium‑glucose cotransporter‑2 inhibitors (sglt2i)
sodium‑glucose cotransporter‑2 inhibitors (sglt2i) in hfpef, hfmref, and hfref
sodium‑glucose cotransporter‑2 inhibitors (sglt2‑i) (mentioned in broader guideline context)
sodium‑glucose cotransporter 2 (sglt2) inhibitors (empagliflozin, dapagliflozin, canagliflozin)
sodium‑glucose co‑transporter 2 inhibitors (sglt2i)
sodium‑glucose co‑transporter‑2 (sglt2) inhibitors
sodium‑glucose co‑transporter‑2 (sglt‑2) inhibitors
sodium‑glucose co‑transporter‑2 inhibitors (sglt2i)
sodium‑glucose co‑transport‑2 (sglt2) inhibitors
sodium‑hf trial
sodium‑restricted diet
sodium‑water retention in heart failure
sodium–glucose cotransporter‑2 inhibitors (sglt2i)
soft‑tissue infections
soloist‑whf trial
soloman et al. (paradigm‑hf)
soluble guanylate cyclase (sgc) stimulator
soluble guanylate cyclase stimulator (riociguat)
soluble guanylate cyclase stimulators
soluble guanylyl cyclase stimulator
soluble guanylyl‑cyclase stimulators
soluble interleukin‑1 receptor‑like 1 (st2)
soluble st2 (sst2)
solvd (studies of left ventricular dysfunction)
sos (swedish obese subjects) study
sos (symptom‑management framework)
sotagliflozin
sotalol
sotalol (antiarrhythmic)
sotatercept therapy
south asian ancestry (high‑risk race/ethnicity)
spatial frequency domain imaging
spatial resolution
special populations (e.g., cad with valvular heart disease, hf with preserved or reduced ef)
specialist and support services
specialist care
specialist clinics for heart failure
specialized electrophysiologic care in achd
specialized pah management
specialty clinics
specialty hospitals and academic centers in cardiology:
specific antineoplastic agents highlighted as af risk factors:
specific anti‑arrhythmic agents
specific metabolic assays
speckle‑tracking echocardiography
spect (single‑photon emission computed tomography)
spect perfusion imaging
spin echo dark blood sequence
spinal cord dysfunction
spinal cord injury
spinal cord injury (sci)
spinal cord ischemia
spinal cord ischemia (sci)
spinal cord perfusion pressure
spinal cord perfusion pressure (scpp)
spinal cord protection
spinal cord protection strategies
spinal cord stimulation (scs)
spinal infection or non‑vertebral osteomyelitis
spinal ischemia
spinal ischemia (paraplegia)
spinal surgery
spiral computed tomography
spirometry as a predictive tool
spironolactone
spironolactone (aldosterone antagonist)
spirontolactone (topcat)
splanchnic nerve ablation
splenomegaly
spliced arm vein graft
spondin‑1
spontaneous abortion / miscarriage
spontaneous bleed
spontaneous coronary artery dissection
spontaneous coronary artery dissection (scad)
spontaneous coronary artery dissection (scad)
spontaneous diastolic ca²⁺ leak
spontaneous echocardiographic contrast (sec)
spontaneous mi (type 1)
spontaneous miscarriages
spontaneous myocardial infarction (mi)
sporadic taa
sports
sports cardiology
sports participation
sports participation & lifestyle changes in cardiac patients
sports participation counseling
sports‑related sudden death epidemiology
sprint
sprint (intensive vs standard bp)
sprint (systolic blood pressure intervention trial)
sprint (systolic blood pressure intervention) trial
sprint study
sprint trial
sprint trial (subpopulation)
square‑wave response to the valsalva maneuver
squat‑to‑stand maneuver
srt in pediatric and young adult patients (> 100 mm hg gradient)
srt not recommended in asymptomatic patients
st vincent’s screening to prevent heart failure (stop-hf)
st-elevation myocardial infarction (stemi)
st. vincent hospital
st. john’s wort
stability of chronic coronary syndromes
stabilized heart failure (hf)
stable angina
stable angina pectoris
stable coronary artery disease (cad)
stable coronary artery disease (stable cad)
stable coronary disease
stable ischemic heart disease
stable ischemic heart disease (sihd)
stable symptomatic presentation
stable ischemic heart disease
stage a (at‑risk) heart failure
stage a hf
stage a, b, c, d of as progression
stage a: at risk (risk factors present)
stage a: at risk for hf (risk factors, no symptoms)
stage b (pre‑clinical hf)
stage b / c1 disease (valvular disease stages)
stage b hf (pre‑hf)
stage b: pre‑hf (evidence of structural or functional abnormality without symptoms)
stage b: progressive (mild‑to‑moderate, asymptomatic)
stage c (symptomatic hf)
stage c / stage c1 (severity classification)
stage c, stage d1, d2, d3 (as staging)
stage c1, c2, and d (guideline staging).
stage c: symptomatic hf (symptoms plus structural disease)
stage d heart failure
stage d2 (low lvef)
stage d3 (normal lvef)
stage d: advanced hf (marked symptoms, recurrent hospitalizations)
staged multivessel pci
staged percutaneous coronary intervention (pci)
staged revascularization
stages a–d (valvular disease severity/management stages)
stages a–d of vhd progression
stages c2 and d disease
stages of atrial fibrillation
stages of chronic ar (stage a, b, c, d)
stages of hf (stage a, stage b, stage c, stage d)
stages of valve disease (a, b, c, d)
stages c and d of tricuspid regurgitation
stage b progressive disease definition
stage 1 hypertension (bp 130–139/80–89 mm hg)
stage a hf
stage b (medical therapy to treat or prevent disease progression)
stage b disease (progressive, no therapeutic action)
stage b heart failure
stage b hf
stage b, c, d progression (tricuspid regurgitation stages)
stage c (optimal timing of intervention)
stage c heart failure
stage c1: asymptomatic severe, lv/rv compensated
stage c2: asymptomatic severe, lv/rv decompensation
stage d (better options for intervention)
stage d disease
stage d heart failure
stage d mitral stenosis
stage d: symptomatic severe
staging of secondary mr (stages a, b, c, d)
standard 12‑lead ecg
standard blood pressure control
standard deviation (±2 sd) in regression analysis of mortality risk
standard deviations above the mean
standard guideline‑directed medical therapy (gdmt)
standard guideline‑directed medical therapy (gdmt) for hf
standard heart‑failure therapies (e.g., diuretics, mineralocorticoid antagonists)
standard therapy versus early routine pci after fibrinolysis
standardization of cardiac biomarker assays
standardized outcome measures (symptom burden, quality‑of‑life)
standing body weight
stanford classification
stanford classification (system)
stanford classification of aortic dissections
staphylococcal prosthetic valve endocarditis
staphylococcus aureus
staphylococcus aureus bacteremia
staphylococcus aureus endocarditis
staphylococcus aureus infection
stasis of blood flow
stat6 (signal transducer and activator of transcription 6)
static obstruction
statin
statin benefit
statin class
statin eligibility
statin eligibility / statin therapy
statin eligibility criteria
statin exposure (as a medication affecting cardiovascular risk)
statin initiation / continuation
statin intolerance
statin intolerance (partial/complete)
statin intolerance (requiring ≥2 statins)
statin safety
statin therapy
statin therapy (cholesterol‑lowering therapy)
statin therapy (e.g., for elevated ascvd risk or familial hypercholesterolemia)
statin therapy (e.g., pravastatin)
statin therapy (e.g., simvastatin)
statin therapy (e.g., simvastatin, pravastatin, atorvastatin)
statin therapy (high‑dose; statin‑related adverse effects)
statin therapy (high‑intensity statin)
statin therapy (high‑intensity, moderate‑intensity, low‑intensity)
statin therapy (implicitly referenced in cholesterol management)
statin therapy (moderate/high intensity)
statin therapy (moderate‑ or high‑intensity)
statin therapy (primary prevention)
statin therapy / lipid‑lowering therapy
statin therapy / severe statin‑associated side effects
statin therapy / statin prescribing
statin therapy / statin use
statin therapy / statins
statin therapy in ckd patients
statin treatment
statin use
statin use disparities in post‑mi patients
statin use during pregnancy
statin-associated muscle symptoms
statins
statins (e.g., rosuvastatin)
statins (e.g., rosuvastatin, atorvastatin)
statins (e.g., simvastatin, pravastatin, simvastatin)
statins (high‑dose statins)
statins (high‑intensity statins)
statins (high‑intensity, moderate‑intensity, low‑intensity)
statins (hmg‑coa reductase inhibitors)
statins (hydroxymethylglutaryl‑coenzyme a reductase inhibitors)
statins (incl. high‑intensity statin therapy)
statins (including high‑intensity statin therapy)
statin‑associated muscle symptoms (sams)
statin‑associated side effects
statin‑associated symptoms
statin‑intolerant patient management strategies
stationary bicycle exercise test
stationary bicycle training
steep rise in cardiac biomarkers (ongoing ischemia)
stemi (st‑segment elevation myocardial infarction)
stemi care system (regional stemi system of care)
stemi care system pathway
stemi equivalent (e.g., lbbb‑equivalent ecg)
stemi equivalent conditions
stemi network
stemi networks
stemi performance measures
stemi receiving center (src) networks
stemi recognition and activation protocol
stemi surveillance (e.g., ischemic st‑segment episodes)












stenosis
stenosis (clinical threshold for intervention)
stenosis (severe)
stenosis of fontan connection
stenosis of pulmonary and systemic venous pathways
stenotic lesions
stenotic mitral valve
stenotic murmur
stenotic valve lesions
stent (cheatham‑platinum, covered, bare)
stent (endovascular stenting)
stent creep
stent deployment
stent fracture
stent fracture‑related stenosis
stent graft
stent graft (various brands/models)
stent graft / endograft
stent graft / graft / endograft (vascular device)
stent graft fracture
stent graft migration
stent graft separation
stent implantation
stent implantation (drug‑eluting stent, bare‑metal stent)
stent implantation (pulmonary)
stent length (<15 cm)
stent malapposition
stent migration
stent or closure device (artifact in imaging)
stent patency
stent placement
stent placement (common femoral, iliac)
stent placement (intra‑vascular, baffle)
stent placement (thoracic)
stent placement in fontan pathway
stent revascularization
stent thrombosis
stent thrombosis (definite or probable)
stent trials
stent, drug‑eluting stent (des)
stenting
stenting (endovascular stent)
stenting of fontan pathway
stentless bioprosthesis
stents (pci stents)
stent‑graft collapse
stent‑graft deployment
stent‑graft design
stent‑graft fracture
stent‑graft migration
stent‑graft migration risk
stent‑graft oversizing
stent‑induced intimal hyperplasia
stent‑related mi (type 4b)
step 8 trial
sternal‑sparing surgery (cabg)
steroid therapy during myocardial infarction
steroid therapy for giant cell arteritis
steroids
stich trial
stich trial (surgical treatment for ischemic heart failure)
stiff left atrial syndrome
stiff left atrium
stop af first study (cryoballoon ablation)
stop‑dapt2 trial
straddling atrioventricular valves
strain imaging
strain‑rate imaging
stratified diagnostic tiers (acute evaluation, definitive confirmation, auxiliary diagnostics)
stream study (fdg‑pet/ct vs. mri/emb)
stream trial
stream trial (strategic reperfusion early after myocardial infarction)
strength (long‑term outcomes study to assess statin residual risk with epanova in high cardiovascular risk patients with hypertriglyceridemia)
streptokinase
strep a pharyngitis (group a streptococcus)
stress (psychological stress)
stress cardiac magnetic resonance (cmr)
stress cardiac magnetic resonance imaging (dobutamine or other)
stress cardiomyopathy
stress echocardiography
stress echocardiography (exercise doppler)
stress echocardiography in mitral stenosis
stress electrocardiogram (ecg)
stress myocardial perfusion imaging
stress nuclear/pet imaging
stress perfusion imaging
stress positron emission tomography (pet)
stress test
stress test (exercise test)
stress test (screening study)
stress testing
stress testing (dobutamine)
stress testing (exercise treadmill, stress echo)
stress testing (noninvasive)
stress testing (with or without imaging)
stress testing for lvoto or advanced hf consideration
stress, anxiety, and depressive symptoms
stress‑induced cardiomyopathy (takotsubo)
stress‑induced gradient
stress‑induced ischemia
strict rate control
stroke
stroke (as a cardiovascular event)
stroke (as a complication of aortic dissection)
stroke (as a major cardiovascular comorbidity)
stroke (as a major cardiovascular outcome)
stroke (as a related outcome)
stroke (as a vhd‑related complication)
stroke (as an af complication)
stroke (associated with atrial fibrillation)
stroke (cardioembolic)
stroke (cardio‑embolic)
stroke (carotid/vertebral artery involvement)
stroke (cerebral ischemia)
stroke (cerebral malperfusion)
stroke (cerebrovascular disease)
stroke (cerebrovascular event)
stroke (cerebrovascular, brain infarction, brain‑stem infarction)
stroke (embolic stroke)
stroke (hemorrhagic or ischemic)
stroke (high‑risk for stroke)
stroke (in relation to cardiovascular disease)
stroke (incident, ischemic, hemorrhagic)
stroke (incl. cardioembolic stroke)
stroke (including intracranial hemorrhage)
stroke (ischemic and hemorrhagic)
stroke (ischemic events related to af)
stroke (ischemic stroke)
stroke (ischemic stroke, thromboembolic stroke)
stroke (ischemic)
stroke (ischemic, intracerebral hemorrhage)
stroke (neurologic complications)
stroke (neuro‑vascular complication)
stroke (non‑fatal)
stroke (thromboembolic complication)
stroke (thromboembolic event)
stroke / cerebral hemorrhage
stroke / cerebrovascular disease
stroke / systemic embolism
stroke / systemic embolism prevention
stroke / transient ischemic attack
stroke / transient ischemic attack (tia)
stroke and bleeding risks
stroke and embolic events
stroke and mortality outcomes
stroke and mortality risk in af patients with ich
stroke and mortality risks associated with af/vhd
stroke and transient ischemic attack prevention (as a cardiac risk management strategy)
stroke in heart failure
stroke prevention
stroke prevention after cryptogenic stroke
stroke prevention guidelines
stroke prevention in af
stroke prevention in af/vhd
stroke prevention in atherosclerosis
stroke prevention in atrial arrhythmias
stroke prevention in atrial fibrillation
stroke prevention in cardiovascular disease
stroke prevention in patients with prior stroke or transient ischemic attack
stroke prevention in stroke and transient ischemic attack
stroke prevention measures
stroke prevention strategies
stroke prevention strategies in af with high bleeding risk
stroke prevention therapy
stroke rate
stroke rates (varied by cannulation strategy)
stroke registry data in hf with af
stroke risk
stroke risk (as a cardiac complication)
stroke risk (atrial fibrillation)
stroke risk (cha₂ds₂‑vasc score)
stroke risk (hcm patients)
stroke risk (high)
stroke risk (hr)
stroke risk (ischemic stroke) in the peri‑operative period
stroke risk (neurologic outcome)
stroke risk (via pad as a marker)
stroke risk / systemic embolization
stroke risk / thromboembolic risk
stroke risk / thrombo‑embolic complications
stroke risk assessment
stroke risk in af
stroke risk in atrial fibrillation
stroke risk in cyanotic disease
stroke risk in hcm patients with af
stroke risk in valvular disease
stroke risk linked to atrial fibrillation
stroke risk of antiplatelets vs warfarin
stroke risk of doacs vs warfarin
stroke risk reduction
stroke risk reduction (via bp control, anticoagulation)
stroke risk reduction therapy
stroke risk score
stroke risk score (e.g., cha₂ds₂‑vasc)
stroke risk scores
stroke risk scoring (chads2/cha₂ds₂‑vasc)
stroke risk stratification
stroke risk stratification (e.g., cha₂ds₂‑vasc)
stroke risk threshold
stroke statistics
stroke survivors
stroke volume
stroke volume (ml)
stroke volume index (ml m⁻²)
stroke volume index (svi)
stroke volume reserve (≥20% increase with dobutamine)
stroke volume support by rv
stroke/ischemic cerebrovascular event
stroke/systemic embolism risk in laao patients
stroke/tia history
stroke/tia recurrence
stroke/tia risk
stroke‑prevention therapy thresholds
stroke‑risk assessment
stroke‑risk prevention in af
stroke‑risk reduction therapies
stroke‑risk reduction therapy
stroke‑risk scores
stroke‑risk scores (e.g., cha₂ds₂‑vasc)
stroke‑risk scores (general term)
stroke‑volume index <35 ml/m²
structural abnormalities of cellular connections
structural cardiac abnormalities (mitral valve apparatus, subaortic membrane)
structural deterioration of bioprosthesis
structural deterioration probability (15‑year risk %)
structural exercise (as part of gdmt)
structural heart damage
structural heart disease
structural heart disease (apical aneurysm, mid‑ventricular obstruction)
structural heart disease (scar or fibrosis)
structural heart disease (stage c hf)
structural heart disease (implicit in definitions of lone af)
structural heart interventions
structural heart lesions (tricuspid valve dysplasia, ebstein‑like anomaly, vsd, lvot obstruction)
structural inequities in access to cardiac specialists
structural lesion (lvot stenosis, tricuspid regurgitation)
structural measures
structural measures (sm) for hf
structural racism
structural racism / chronic stress (“weathering”)
structural remodeling
structural remodeling assessment
structural remodeling of the left atrium
structural valve degeneration
structural valve degeneration (svd)
structural valve deterioration
structural valve deterioration (svd)
structural valve deterioration / failure
structured community‑based exercise program
structured community‑based exercise programs
structured community‑based exercise programs (including home‑based)
structured community‑based exercise therapy
structured comprehensive risk‑factor management
structured exercise (comparative treatment option)
structured exercise (set)
structured exercise / community‑based exercise therapy (pm‑7)
structured exercise program
structured exercise program classification
structured exercise programs
structured exercise programs for pad
structured exercise therapy
structured exercise therapy (for pad)
structured exercise training (set)
structured prehospital history and physical examination
structured telephone support
structured telephone support / telemedicine alerts
structured telephone support / telemonitoring
structured transition education
sts (society of thoracic surgeons)
sts (society of thoracic surgeons) database
sts (society of thoracic surgeons) risk calculator
sts (society of thoracic surgeons) risk‑scoring system for cardiac surgery
sts (society of thoracic surgeons) surgical risk score
sts adult cardiac surgery database
sts database
sts risk calculator (sts‑predicted risk of death)
sts/acc transcatheter valve therapies registry
sts/acc tvt registry
study / evidence descriptors
stump blowout
st‑elevation mi
st‑elevation myocardial infarction
st‑elevation myocardial infarction (stemi)
st‑segment abnormalities
st‑segment depression
st‑segment depression ≥0.5 mm in ≥2 contiguous leads
st‑segment deviation
st‑segment elevation
st‑segment elevation (definition criteria)
st‑segment elevation (in ecg)
st‑segment elevation (stemi criteria)
st‑segment elevation (st‑elevation)
st‑segment elevation acs (stemi)
st‑segment elevation myocardial infarction (stemi)
st‑segment elevation resolution criteria
st‑segment elevation ≥1 mm in ≥2 contiguous leads (j‑point)
st‑segment resolution / st‑resolution
st‑segment‑elevation myocardial infarction (stemi)
st‑segment–elevation myocardial infarction (stemi)
st jude medical prosthesis
subacute and chronic aortic dissection management
subacute aortic dissection
subacute bacterial endocarditis
subacute/chronic type b management strategies
subaortic (lv outflow tract) calcification
subaortic membrane
subaortic membrane (sam) of the mitral valve
subaortic obstruction
subaortic stenosis
subaortic stenosis (discrete subaortic stenosis)
subaortic stenosis (including discrete subvalvular aortic stenosis)
subclavian artery coverage
subclavian artery disease
subclavian artery revascularization
subclavian flap aortoplasty
subclavian/axillary access











subclinical af
subclinical af burden/duration
subclinical atrial fibrillation
subclinical atrial fibrillation (scaf)
subclinical cardiac injury
subclinical coronary anatomy complexity
subclinical coronary artery disease
subclinical hypertrophic cardiomyopathy
subclinical leaflet thrombosis
subclinical lv systolic dysfunction
subclinical myocardial damage strategies
subcutaneous enoxaparin injections
subcutaneous heparin
subcutaneous icd
subcutaneous icd (s‑icd)
subcutaneous implantable cardioverter‑defibrillator (icd)
subcutaneous treprostinil
subgroup analyses
subgroup analysis
sublingual nitroglycerin
sublingual nitroglycerin prescribing
suboptimal dose of gdmt
suboptimal valve anatomy
suboptimal valvuloplasty results
subpulmonary ef <40 %
subpulmonary stenosis
subpulmonic left‑ventricular dysfunction
subsequent medical management of aortic dissection
substance abuse
substance abuse (cocaine, amphetamines, opioids, marijuana/cannabis)
substance exposures: cocaine, amphetamines, ethanol, copper, iron, lead, venomous bites
substance use
substance‑abuse–related cardiomyopathy
substance‑use disorders (comorbidity)
substrate for re‑entry
substrate modification during ablation
subtherapeutic inr
subvalvular aortic stenosis
subvalvular apparatus
subvalvular apparatus abnormalities
subvalvular chordal fusion
subvalvular fusion/fibrosis
subvalvular mitral apparatus reconstruction
subvalvular stenosis
sudden cardiac death
sudden cardiac death (associated with coronary anomalies)
sudden cardiac death (scd)
sudden cardiac death (scd) in achd
sudden cardiac death (scd) prevention
sudden cardiac death (scd) related to coronary anomalies
sudden cardiac death (scd) risk assessment
sudden cardiac death (scd) risk stratification
sudden cardiac death in heart failure trial (scd‑heft)
sudden cardiac death prevention
sudden cardiac death risk
sudden cardiac death risk stratification
sudden death
sudden death (primary prevention)
sudden death at age < 50 years
sudden death in young athletes
sudden death risk
sudden death risk prediction
sudden unexplained death (scd)
sudden‑onset pain
sugar and high‑carbohydrate diets
sugar‑sweetened beverages
sugar‑sweetened beverages (soft drinks, energy drinks, fruit drinks)
sulfadiazine (oral)
sulfamethoxazole (dmard)
sulfonamides
superior caval‑pulmonary connections
superior mesenteric artery
superior mesenteric artery (sma)
superior qrs axis in ostium primum asd
superior sinus venosus defect
superior svasd
superior vena cava (svc)
superior vena cava (svc) pathway
superior vena cava (svc) stenosis
superior vena cava isolation
superior vena cava obstruction
superior vena cava syndrome
supervised exercise
supervised exercise therapy
supervised exercise therapy (set)
supervised exercise therapy – set
supervised exercise training
supervised exercise training (set)
supplemental oxygen therapy
supplemental oxygen use during exercise
supportive care in hf
suppressive lifelong therapy
supracristal ventricular septal defect
supratherapeutic inr (>5.0)
supravalvar aortic stenosis
supravalvar aortic stenosis (svas)
supravalvar mitral ring
supravalvar pa stenosis
supravalvar pulmonary artery stenosis
supravalvular aortic stenosis
supraventricular arrhythmia
supraventricular arrhythmias
supraventricular arrhythmias (frequent or complex repetitive forms)
supraventricular arrhythmias in pulmonary hypertension
supraventricular tachyarrhythmia
supraventricular tachyarrhythmia (atrial arrhythmias)
supraventricular tachyarrhythmias
supraventricular tachycardia
supraventricular tachycardia (svt)
supraventricular tachycardia
supra‑annular prosthesis insertion
supra‑valvar aortic stenosis
supra‑valvar mitral stenosis
surgery
surgical & endovascular intervention
surgical ablation
surgical ablation (af)
surgical ablation (atrial)
surgical ablation (cox‑maze, hybrid convergence)
surgical ablation (e.g., maze procedure)
surgical ablation in af
surgical ablation of atrial fibrillation
surgical ablation of ventricular tachycardia
surgical af ablation
surgical and endovascular management of aneurysms
surgical and transcatheter interventional risk evaluation
surgical aortic replacement
surgical aortic root replacement
surgical aortic valve bioprosthesis
surgical aortic valve replacement
surgical aortic valve replacement (savr / avr)
surgical aortic valve replacement (savr)
surgical approach
surgical atrial fibrillation ablation
surgical backup
surgical bioprosthesis
surgical bypass
surgical bypass surgery
surgical candidacy
surgical cannulation strategies (axillary vs. femoral)
surgical closure
surgical closure / repair of congenital lesions
surgical closure of vsd
surgical closure procedures
surgical considerations for cad in vhd
surgical conversion strategies for fontan patients
surgical correction of anomalous coronary artery origins.
surgical correction of aortic regurgitation
surgical correction of interarterial coronary anomaly
surgical correction of left‑to‑right shunts
surgical correction of mr
surgical debridement (for foot infections/gangrene)
surgical delay in acute severe ar
surgical durability
surgical era (pre‑1980 vs. ≥1980)
surgical expertise
surgical indication
surgical indications
surgical indications and guidelines for chronic mitral regurgitation
surgical indications: before lvef falls below 55 %
surgical ineligibility
surgical interruption of accessory pathways
surgical intervention
surgical intervention (reoperative avr, savr)
surgical intervention (repair)
surgical intervention (timing, upfront vs delayed)
surgical intervention (type a vs type b aortic dissection)
surgical intervention for aortic aneurysm
surgical intervention timing
surgical interventions for loeys‑dietz syndrome
surgical laao
surgical left atrial appendage exclusion/excision
surgical left atrial appendage obliteration
surgical left atrial appendage occlusion (s‑laao)
surgical left atrial reduction (with cardiac surgery or af ablation)
surgical ligation of the laa
surgical limb revascularization
surgical management of aortic aneurysm
surgical management of lvot obstruction
surgical management of valve disease
surgical membrane resection
surgical mitral valve repair
surgical mitral valvotomy / valve replacement
surgical mortality
surgical myectomy
surgical myectomy / papillary muscle surgical management
surgical myectomy benefit (e.g., improvement in pulmonary hypertension, exercise tolerance, reverse atrial enlargement)
surgical myectomy with concomitant af ablation
surgical or transcatheter intervention criteria
surgical outcome improvement with high case volume
surgical outcomes
surgical outcomes and repair of dcrv
surgical outcomes for chronic aortic valvular disease
surgical outcomes in aortic disease
surgical outcomes of double‑root translocation for tga with pulmonary stenosis
surgical outcomes of tricuspid valve procedures.
surgical palliation sequelae
surgical procedures for chd
surgical procedures for valve disease
surgical procedure‑specific mortality (e.g., avr, avr+cabg, mitral repair, etc.)
surgical prosthetic valve implantation
surgical pulmonary valvotomy
surgical reconstruction vs. endovascular placement
surgical reintervention
surgical relief therapy (srt) for refractory lvoto
surgical reoperation
surgical repair
surgical repair (aortic or coronary)
surgical repair (aortic root/ascending aorta)
surgical repair (aortic)
surgical repair (coronary ostial stenosis, supravalvar aortic stenosis)
surgical repair (coronary revascularization)
surgical repair (membrane resection, myectomy)
surgical repair (of avsd, shunt, valve, or lvot)
surgical repair (of dcrv)
surgical repair (open)
surgical repair (pulmonary vein repair)
surgical repair (resection of obstructive muscle bundles)
surgical repair / baffle rerouting
surgical repair / closure
surgical repair / primary repair / reoperation
surgical repair and replacement
surgical repair of aortic aneurysm/dissection
surgical repair of aortic dissection
surgical repair of asd
surgical repair of coa
surgical repair of cor triatriatum
surgical repair of coronary anomalies (e.g., translocation to the aortic root)
surgical repair of pulmonary valve atresia with coronary‑pulmonary artery fistula
surgical repair of subaortic stenosis
surgical repair of svas or valve
surgical repair of the ascending aorta
surgical repair of tof (initial surgery)
surgical repair of transposition with vsd and subpulmonary stenosis
surgical repair of tricuspid valve (repair versus replacement)
surgical repair of type a dissection
surgical repair of vascular ring/pa sling
surgical repair of ventricular septal defect
surgical repair strategies for complex transposition (double‑root, rastelli, nikaidoh, rev, etc.)
surgical repair/stent therapy
surgical resection
surgical resection (membrane removal, valve repair)
surgical revascularisation
surgical revascularization
surgical revascularization procedures
surgical risk
surgical risk (e.g., low, high)
surgical risk (high or prohibitive)
surgical risk (high, low, intermediate)
surgical risk (high, prohibitive, low)
surgical risk (low, moderate, high)
surgical risk (sts score)
surgical risk (valve surgery)
surgical risk assessment
surgical risk categories: low, intermediate, high, prohibitive
surgical risk in infective endocarditis
surgical risk models (e.g., society of thoracic surgeons)
surgical risk stratification
surgical risk stratification in young patients
surgical septal myectomy
surgical specialist
surgical superior svasd repair
surgical therapy
surgical therapy (valve replacement/repair)
surgical threshold
surgical threshold (aortic diameter)
surgical threshold (e.g., 5.0 cm, 4.5 cm, 5.5 cm)
surgical threshold (≥4.5 cm, 5.0–5.5 cm, ≥5.5 cm)
surgical threshold for aaa repair
surgical thresholds for aortic surgery
surgical thresholds for prophylactic aortic root and ascending aorta replacement.
surgical thrombectomy / atrial appendage exclusion
surgical thromboembolectomy (e.g., fogarty catheter)
surgical timing
surgical timing (>4 weeks after stroke or hemorrhage)
surgical timing for mixed valve disease
surgical treatment
surgical treatment of endocarditis
surgical treatment of valve disease
surgical valve repair
surgical valve replacement
surgical valve replacement/repair
surgical valvotomy
surgical ventricular remodeling
surgical versus endovascular comparison
surgical volume (expertise)
surgical vs interventional risk
surgical vs. endovascular therapy for chronic limb‑threatening ischemia
surgical vs. interventional risk
surgical vs. transcatheter strategies for valve disease
surmount‑1 trial
surrogate decision maker
surveillance after aortic repair
surveillance after endovascular aneurysm repair
surveillance cmr
surveillance for medical management
surveillance for thoracic aortic disease
surveillance imaging
surveillance imaging (ct, mri, duplex ultrasound)
surveillance imaging (routine aortic imaging)
surveillance imaging / annual imaging
surveillance imaging for aortic monitoring
surveillance imaging intervals
surveillance imaging schedule
surveillance interval
surveillance of small abdominal aortic aneurysms
surveillance protocols
surveillance strategy
surveillance testing
survival
survival (30‑day, 1‑year, 5‑year, 10‑year)
survival (5‑year survival, event‑free survival)
survival (long‑term, post‑ablation)
survival (mid‑, long‑term)
survival (mortality, 1‑ and 2‑year survival)
survival / mortality (surgical vs. medical)
survival advantage
survival advantage (type b vs type a)
survival advantage of cabg over medical therapy in left‑main cad
survival advantage of pci over medical therapy in left‑main cad
survival advantage with mechanical valves
survival after repair
survival after transplantation
survival after veno‑arterial ecmo (save) score
survival analysis
survival and functional results
survival and functional status after surgery
survival benefit
survival benefit (device removal)
survival benefit / cost‑effectiveness ratios (e.g., <$60,000 per year of life added)
survival benefit of elective aortic repair
survival benefit with revascularization
survival impact of stage d tr
survival of patients with congenital vsd
survival outcomes
survival outcomes in achd
survival outcomes in hf/hcm patients
survival rate
survival rate / therapy outcomes
survivors of cardiac arrest











suspected myocarditis
suspected myocarditis diagnostic criteria
sustained arrhythmia
sustained arrhythmia requiring treatment
sustained atrial fibrillation
sustained atrial flutter/fibrillation (>30 s)
sustained monomorphic ventricular tachycardia
sustained monomorphic vt
sustained ventricular tachyarrhythmia
sustained ventricular tachycardia (vt)
sustained ventricular tachycardia/fibrillation
sustained‑release metoprolol succinate
sustain‑6 trial
suture line disruption, annular disruption, endocarditis
sutureless or covered stent closure
sva (society of vascular anesthesiologists) (implicit)
svm
svm (society for vascular medicine)
svm (society of vascular medicine)
svn
svn (society for vascular nursing)
svs
svs (society for vascular surgery)
svs (society of vascular surgeons)
svs (society of vascular surgery)
svs clinical practice guidelines
svs vascular quality initiative
svs/sts 2020 classification
svt (supraventricular tachycardia)
swedeheart registry
swedish health registries
sweetened beverages
sword (survival with oral d‑sotalol)
sympathetic and parasympathetic neuron activity
sympathetic denervation
sympathetic efferent stimulation
sympathetic hyperactivity
sympathetic hyperinnervation
sympathetic nervous system stimulation
sympathetic tone / mechanical stretch interaction
sympathomimetic weight‑loss drugs
symptom assessment
symptom assessment and monitoring in hf
symptom burden
symptom evaluation (e.g., dyspnea, chest pain)
symptom improvement in atrial fibrillation
symptom management
symptom management (dyspnea, fatigue, pain, nausea, depression, anxiety)
symptom management in hf
symptom onset
symptom onset (clinical, exercise‑provoked)
symptom onset in severe as
symptom persistence despite medical therapy
symptom relief
symptom staging (stages b, c, c2, d)
symptom status
symptom status (nyha class)
symptomatic af
symptomatic aneurysm
symptomatic aortic stenosis
symptomatic as
symptomatic atrial arrhythmia (post‑ablation)
symptomatic atrial fibrillation
symptomatic atrial fibrillation (study)
symptomatic atrial fibrillation investigative research on dofetilide (safer‑d)
symptomatic coronary artery disease
symptomatic heart failure
symptomatic hf
symptomatic hypotension
symptomatic improvement
symptomatic improvement (≥1 nyha functional class)
symptomatic ischemia
symptomatic low‑gradient as with preserved lvef.
symptomatic nonsustained ventricular tachycardia
symptomatic non‑ruptured aneurysm
symptomatic pad
symptomatic pad (claudication, ischemia-related exertional symptoms)
symptomatic patient
symptomatic patients
symptomatic patients (with severe ar)
symptomatic pau
symptomatic peripheral arterial disease
symptomatic peripheral artery disease
symptomatic peripheral artery disease (abi < 0.85)
symptomatic recurrence of atrial fibrillation
symptomatic response
symptomatic severe ar
symptomatic severe as
symptomatic severe vhd
symptomatic survival benefit of avr
symptomatic versus asymptomatic aortic stenosis
symptomatic versus asymptomatic status
symptomatic vertebrobasilar insufficiency
symptomatic vs asymptomatic atrial fibrillation
symptomatic vs asymptomatic presentation
symptomatic vs. asymptomatic as
symptomatic vs. asymptomatic pad
symptomatic vs. asymptomatic patient management
symptomatic vs. asymptomatic patients
symptomatic vs. asymptomatic pulmonary stenosis
symptoms
symptoms (angina, dyspnea, fatigue)
symptoms (symptomatic disease)
symptoms and rehospitalizations (mortality)
symptoms of aneurysm expansion
symptoms of heart failure
symptom‑based indications
symptom‑based indications for intervention
symptom‑based monitoring
symptom‑based therapeutic strategy
symptom‑based treatment decisions
symptom‑driven pacing indications (symptomatic bradycardia, heart failure symptoms)
symptom‑free (asymptomatic) pad
symptom‑guided titration
symptom‑relief of lvoto
sync failure / iatrogenic ventricular fibrillation (complications of cardioversion)
synchronized cardioversion
syncope
syncope (carotid artery or cardiac tamponade)
syncope (symptom)
syncope (unexplained, arrhythmia‑related)
syncope / presyncope
syndromic aneurysm (e.g., marfan syndrome)
syndromic features
syntax score
syntax score (age‑dependent impact on mortality post‑pci)
syntax score (≥ 33 cutoff)
syntax trial
syphilitic aortitis
systematic review
systematic review and meta‑analysis
systematic review of atrial fibrillation in hcm
systematic reviews
systematic reviews of cardiac interventions
systemic and pulmonary shunts
systemic anticoagulation treatment
systemic arterial and venous thromboembolic events
systemic blood pressure
systemic blood pressure (sbp)
systemic blood pressure control (tight vs usual) in hypertensive patients
systemic congestion (peripheral edema, ascites)
systemic desaturation
systemic ef <40 %
systemic emboli
systemic embolic event
systemic embolic events
systemic embolism
systemic embolism prevention
systemic embolism risk
systemic embolization
systemic features of syndromic htad
systemic fibrinolysis
systemic hypertension
systemic hypertension (as a risk factor for af)
systemic hypotension
systemic infection
systemic inflammation
systemic inflammatory activation (post‑cardiac surgery)
systemic inflammatory disorders (ibd, sle, ra, gout, psoriatic arthritis, ankylosing spondylitis)
systemic inflammatory responses
systemic left ventricle
systemic left ventricle (lv)
systemic left ventricular (lv) dysfunction
systemic lupus erythematosus (lupus)
systemic lupus erythematosus (sle) and myocardial infarction
systemic or pulmonary venous pathway stenosis
systemic perfusion
systemic postmenopausal hormone therapy
systemic proinflammatory states
systemic resistance
systemic right ventricle
systemic right ventricle (dextro‑tga with atrial switch, cctga)
systemic right ventricle (rv) function
systemic right ventricle (srv)
systemic right ventricle with depressed function
systemic right‑ventricle (rv) dysfunction
systemic syndromes associated with cardiomyopathy (e.g., limb‑girdle dystrophy, duchenne/becker muscular dystrophy, emory‑dreifuss)
systemic thromboembolic event
systemic thromboembolism
systemic tricuspid regurgitation severity (mild vs. severe, progressive disease)
systemic tricuspid valve dysfunction / regurgitation
systemic tricuspid valve function
systemic vascular load
systemic vascular resistance
systemic vascular resistance (svr)
systemic vasodilation
systemic venous congestion
systemic venous hypertension
systemic venous pathway stenosis
systemic ventricular dysfunction
systemic ventricular dysfunction (ef < 30 %)
systemic ventricular dysfunction (post‑pacing, post‑surgery)
systemic ventricular dysfunction (right‑ventricular systolic dysfunction)
systemic ventricular dysfunction / srv failure
systemic ventricular outflow tract obstruction
systemic ventricular overload
systemic ventricular preload
systemic ventricular systolic dysfunction
systemic ventricular volume measurement
systemic ventricular volume overload
systemic/organizational factors
systemic‑to‑pulmonary arterial collaterals
systems of care
systolic (reduced‑ejection‑fraction) heart failure
systolic and diastolic rv function
systolic anterior leaflet motion
systolic anterior motion (sam)
systolic blood pressure
systolic blood pressure (bp)
systolic blood pressure (sbp)
systolic blood pressure (sbp) 60–90 mm hg
systolic blood pressure (sbp) < 120 mm hg
systolic blood pressure control
systolic blood pressure fall during exercise
systolic blood pressure intervention trial (sprint)
systolic blood‑pressure differential
systolic bp (sbp)
systolic dysfunction
systolic dysfunction (ef < 50%)
systolic dysfunction (ef < 50 %)
systolic dysfunction (lvef < 50 %)
systolic ef thresholds (≤35%, 35‑50%, ≤50%)
systolic function
systolic function assessment
systolic heart failure
systolic heart failure (hf)
systolic heart failure (hfref)
systolic heart failure trials
systolic hypertension
systolic impairment
systolic murmur (harsh crescendo‑decrescendo)
systolic pulmonary artery pressure (pa pressure)
systolic/diastolic function














t cell‑mediated inflammation
t1 mapping
t1 mapping (non‑contrast)
t1‑based imaging (t1‑mapping)
t1‑mapping
t2 mapping
t2* mri for myocardial iron overload
t2‑based imaging (t2‑mapping)
tachyarrhythmia
tachyarrhythmia detection algorithms
tachyarrhythmia management
tachyarrhythmias
tachycardia
tachycardia runs (atrial ectopy)
tachycardia‑induced cardiomyopathy
tachycardiomyopathy
tachyphylaxis
tachy‑brady syndromes
tact trial (trial to assess chelation therapy)
tadalafil
tadalafil therapy
tafamidis
tafamidis therapy
tagged white‑blood‑cell scans
tailored therapies
takayasu arteritis
takayasu’s arteritis
takeuchi repair
takotsubo (stress) cardiomyopathy
takotsubo (stress‑induced) cardiomyopathy
takotsubo syndrome
takotsubo syndrome (stress‑cardiomyopathy)
tandemheart
target anti‑xa range (0.8–1.2 u/ml)
target blood‑pressure goal <130/80 mm hg (or <120/80 mm hg in some trials)
target dose vs. lower dose of hfref medications
target doses of beta blockers, acei‑arb, arni, mra
target gdmt dose
target international normalized ratio (inr)
target lesion revascularization
target vessel failure
target vessel myocardial infarction (mi)
target vessel revascularization
targeted anterior septal thickness
targeted pah therapy
targeted pulmonary hypertension therapy
targeted temperature management
targeted therapy arrhythmias
targeted therapy to slow or reverse disease progression
target‑vessel ischemia
task force guideline
taste disturbances
taurine
tavi (transcatheter aortic valve implantation)
tavi (transfemoral)
tavi – alternative access (transthoracic, transapical, subclavian, carotid, caval)
tavr unload trial
tc (technetium) labeling
team‑based approach (for ccd)
team‑based care
team‑based care (in cardiovascular management)
team‑based care / multidisciplinary care (clinical strategy for ascvd prevention)
team‑based care for cardiac comorbidities
team‑based heart‑failure care
tear site
technetium‑99m sestamibi spect
technetium‑pyrophosphate (¹⁰¹⁹tc‑pyp)
technical success rate
tee (transesophageal echocardiogram)
tee (transesophageal echocardiography)
teer (transcatheter edge‑to‑edge repair)
telehealth
telehealth & digital interventions
telehealth (virtual visits for vascular care)
telehealth and remote rehabilitation efficacy
telehealth as a care option
telehealth cardiac rehabilitation
telehealth for pad management
telehealth implementation
telehealth in cardiovascular disease
telehealth in cardiovascular disease management
telehealth interventions
telehealth medication adherence
telehealth programs
telemedicine
telemedicine (remote ie management)
telemedicine / digital health technology
telemedicine/virtual visits for chronic hf management
telemetry capability
telemetry duration in acs management
telemetry monitoring
telemetry unit
telemetry‑based prediction of in‑hospital adverse outcomes
telephone‑delivered health coaching
tele‑health / remote patient monitoring
tele‑health interventions for acute coronary syndrome (acs)
telmisartan
temporal artery tenderness / pulse attenuation
temporal resolution
temporal trends in cardiogenic shock incidence
temporal trends in hf incidence and mortality
temporary circulatory support devices
temporary mcs
temporary mcs (e.g., implantable vascular devices)
temporary mcs / bridge therapy
temporary mcs devices
temporary mechanical circulatory support
temporary mechanical circulatory support (e.g., biventricular support)
temporary mechanical support
temporary mechanical support (e.g., intra‑aortic balloon pump, temporary peripheral ventricular assist device, ecmo)
temporary pacemaker
temporary pacemaker insertion
temporary wearable cardioverter‑defibrillator
temporary/permanent interruption of cardiotoxic agents
tenax
tendyne
tenecteplase
tenecteplase (tnk‑tpa)
teratogenicity
terminal disease/end‑stage hf
terms related to heart disease (from the guideline excerpt)
terms related to heart disease extracted from the guideline text
terms related to heart disease extracted from the text
tertiary‑care center
terumo
testosterone therapy
tetralogy of fallot
tetralogy of fallot (repaired)
tetralogy of fallot (tof)
tetralogy of fallot (tof) – repaired tof
tetralogy of fallot (tof)
tetramer stabilizer therapy (for amyloidosis)
tevar (thoracic endovascular aneurysm repair)
tevar (thoracic endovascular aortic repair)
tevar‑related reintervention rates
text messaging
text‑messaging adherence programs for chd
tgfb2
tgfb2 (gene)
tgfb2 mutation
tgfb2 pathogenic variant
tgfb3
tgfb3 (gene)
tgfb3 mutation
tgfb3 pathogenic variant
tgfbr1
tgfbr1 (gene)
tgfbr1 mutation
tgfbr1 pathogenic variant
tgfbr2
tgfbr2 (gene)
tgfbr2 mutation
tgfbr2 pathogenic variant
tgf‑beta receptor mutation (tgfbr1/tgfbr2)
tgf‑β receptor
tgf‑β receptor mutations (associated with aneurysm syndromes)
tgf‑β signaling pathway in vascular disease
tgf‑β signalling
th17 cells
th17 immune response
th2 cells
th2 immune polarization
the aristotle trial (apixaban)
therapeutic & management terms
therapeutic angiogenesis
therapeutic anticoagulation
therapeutic benefit prediction (for revascularization vs. medical therapy)
therapeutic decision‑making in af
therapeutic footwear – a preventive strategy to reduce cardiovascular‑related foot ulceration risk
therapeutic inr
therapeutic inr range
therapeutic range
therapeutic recommendations
therapeutic value of warfarin
therapy
thermodilution
thermodilution cardiac output
thiamin supplementation
thiamine
thiamine supplementation
thiazide diuretic
thiazide diuretic (add‑on)
thiazide diuretics
thiazide diuretics (chlorthiazide, chlorthalidone, hydrochlorothiazide, indapamide)
thiazide diuretics (metolazone, chlorthalidone, hydrochlorothiazide)
thiazide‑type diuretics
thiazolidinediones
thiazolidinediones (e.g., rosiglitazone, pioglitazone)
thiazolidinediones (pioglitazone, rosiglitazone)
thiazolidinediones (rosiglitazone, pioglitazone, ipratropium‑related agents)
thiazolidinediones (tzds)
thienopyridine
thiocyanate toxicity
third heart sound (s3)
third trimester
third‑degree (complete) av block
third‑degree atrioventricular (av) block
third‑degree atrioventricular block
third‑degree atrioventricular block (infranodal)
thoracic
thoracic (thoracic surgery)
thoracic aorta
thoracic aorta disease
thoracic aorta imaging
thoracic aortic aneurysm
thoracic aortic aneurysm (taa)
thoracic aortic aneurysm (taa) / descending taa
thoracic aortic aneurysm (taaa / taaa)
thoracic aortic aneurysm (taaa)
thoracic aortic aneurysm and dissection
thoracic aortic aneurysm and dissection (taad)
thoracic aortic aneurysmal disease
thoracic aortic dilation
thoracic aortic dilation (tad)
thoracic aortic disease
thoracic aortic disease (tad)
thoracic aortic disease management guidelines
thoracic aortic dissection
thoracic aortic dissection (tad)
thoracic aortic imaging
thoracic aortic injury
thoracic aortic involvement
thoracic aortic pathologies
thoracic aortic repair
thoracic aortic surgery
thoracic arch pathologies
thoracic cardiovascular surgery
thoracic endograft / endovascular repair
thoracic endovascular aneurysm repair (tevar)
thoracic endovascular aortic repair
thoracic endovascular aortic repair (tevar)
thoracic endovascular aortic repair for descending thoracic aortic aneurysms
thoracic endovascular aortic repair for penetrating ulcers
thoracic radiation therapy
thoracic spinal‑cord stimulation
thoracic surgery
thoracic surgery for aortic arch in loeys‑dietz syndrome
thoracic aortic disease
thoracoabdominal aneurysm
thoracoabdominal aorta
thoracoabdominal aorta interventions
thoracoabdominal aortic aneurysm
thoracoabdominal aortic aneurysm (taaa)
thoracoabdominal extent of aneurysm
three‑dimensional dataset
three‑dimensional echocardiography
three‑dimensional echocardiography (3‑d echo)
three‑dimensional echocardiography (3‑de)
three‑dimensional echocardiography of tricuspid/mitral valves
three‑dimensional echodoppler imaging
three‑dimensional tee
three‑dimensional trans‑echocardiographic imaging (3d tee)
three‑vessel disease
threshold gradient (e.g., ≥ 50 mm hg, ≥ 80 mm hg)
thresholds for pulmonary valve replacement (rvedv >80 ml/m², rvedv ≥2× lvedv)
thrombectomy (manual, intracoronary)
thrombin
thrombin generation
thrombin generation / activity
thrombocytopenia
thrombocytopenia (platelet count <50 × 10⁹/l)
thrombocytopenia (platelet < 50 000/µl)
thromboelastography
thromboembolic complications
thromboembolic complications (related to baffle leaks)
thromboembolic disease
thromboembolic event
thromboembolic event rates
thromboembolic event risk
thromboembolic events
thromboembolic events (e.g., stroke)
thromboembolic events / thromboembolism
thromboembolic events / thrombosis
thromboembolic prophylaxis
thromboembolic risk
thromboembolic risk (annual %)
thromboembolic risk / thromboembolism
thromboembolic risk factors
thromboembolic stroke
thromboembolism
thromboembolism (arterial/venous)
thromboembolism (clinical, cardiovascular)
thromboembolism (mechanism and prevention)
thromboembolism / stroke risk
thromboembolism / systemic embolism
thromboembolism / thromboembolic risk
thromboembolism / thrombosis
thromboembolism history
thromboembolism in hcm
thromboembolism incidence in hcm
thromboembolism prevention
thromboembolism risk
thromboembolism risk (in af)
thromboendarterectomy
thrombogenesis & arrhythmogenesis in left atrium
thrombogenesis (virchow’s triad, clot formation)
thrombogenesis / hypercoagulability
thrombogenic endocardial lesions
thrombogenic milieu
thrombolysis
thrombolysis (intra‑arterial, catheter‑directed)
thrombolysis (tissue‑type plasminogen activator, tpa)
thrombolysis / thrombolytic therapy
thrombolysis in myocardial infarction (timi)
thrombolysis in myocardial infarction (timi) risk score
thrombolysis in myocardial infarction (timi) risk score for secondary prevention (trs 2p)
thrombolytic agents (streptokinase, tissue plasminogen activator)
thrombolytic therapy
thrombolytic therapy (intravenous thrombolysis)
thrombolytic therapy for mechanical pulmonic/tricuspid valves
thrombophilia
thromboprophylaxis
thromboprophylaxis (including direct oral anticoagulants)
thromboprophylaxis for atrial arrhythmias
thrombosis
thrombosis (branch false lumen)
thrombosis (post‑repair risk)
thrombosis / atherothrombosis
thrombosis / pro‑thrombotic state
thrombosis events / thromboembolism
thrombosis in congenital heart disease
thrombosis in eisenmenger syndrome
thrombosis prevention
thrombosis prevention in prosthetic valves
thrombosis research institute
thrombosis risk
thrombosis risk (fontan population)
thrombotic biomarkers
thrombotic complications
thrombotic complications (stroke, valve thrombosis)
thrombotic disease
thrombotic events
thrombotic events (stroke, etc.)
thrombotic events / thromboembolism
thrombotic events associated with prosthetic valves.
thrombotic risk
thrombotic/embolic complications (atrial thrombosis, emboli)
thrombo‑embolism
thrombo‑prophylaxis
thrombus
thrombus (aortic)
thrombus (lv)
thrombus (valve thrombus, subclinical bioprosthetic valve thrombosis)
thrombus aspiration
thrombus burden
thrombus detection
thrombus detection before cardioversion
thrombus formation
thrombus formation (subclinical)
thrombus formation risk
thrombus on prosthetic valve
thrombus resolution rates with vka and rivaroxaban
thrombus size criteria (>10 mm) for mechanical valve thrombosis.
thrombus surveillance
thrombus visualization
thrombus vs. pannus differentiation
thyroid disease
thyroid disease (as hf precipitant)
thyroid disease (hyperthyroidism)
thyroid disease / thyroid hormones
thyroid disease – hyperthyroidism
thyroid dysfunction
thyroid dysfunction (amiodarone‑induced)
thyroid dysfunction / thyroid‑stimulating hormone (tsh)
thyroid hormone replacement therapy (levothyroxine t4, triiodothyronine t3)
thyroid hormone therapy
thyroid hormones and cardiovascular disease
thyrotoxicosis (amiodarone‑induced)















th‑17 immune response
tia (transient ischemic attack)
ticagrelor
ticagrelor (p2y12 inhibitor)
ticagrelor monotherapy
tier‑2 diagnosis of definite myocarditis
timacs trial (timing of intervention in acute coronary syndromes)
time factors
time from fmc to device activation (≤120 minutes threshold)
time from symptom onset (≤12 hours window)
time in therapeutic range (ttr)
time to first medical contact (fmc)
time to intervention (hours from onset to surgery)
time to reperfusion
time to treatment (>4 h)
timeliness, safety, effectiveness, efficiency, equity (quality domains)
time‑dependent reduction in mortality and morbidity
time‑to‑device
time‑to‑event analysis in cardiovascular trials
timi (not explicitly mentioned, but related to reperfusion)
timi (thrombolysis in myocardial infarction)
timi 3 epicardial flow grade
timi flow grade
timi frame count
timi risk score
timi study group
timi trial (thrombolysis in myocardial infarction)
timing of angiography (≤24 hours, >24 hours, immediate)
timing of anticoagulation resumption
timing of cabg after myocardial infarction
timing of infection after valve intervention.
timing of intervention
timing of intervention (early vs delayed)
timing of intervention (surgery)
timing of periodic imaging (baseline, 1 yr, 5 yr, 10 yr, annual)
timing of valve intervention
tirofiban
tirzepatide
tirzepatide (ly3298176)
tissue doppler echocardiography
tissue doppler imaging
tissue growth optimization
tissue loss
tissue plasminogen activator (t‑pa)
tissue protrusion
tissue valve (bioprosthetic)
tissue‑based molecular diagnostic system (mmdx)
tissue‑type plasminogen activator
tissue‑type plasminogen activator (tpa)
titin (ttn) gene mutations
titin loss‑of‑function variants
titin truncations
titrated intravenous (iv) nitrates (e.g., nitroglycerin)
titration and uptitration of guideline‑directed therapy
tnf‑superfamily member 12 (tnfs12)
tnni3
tnni3 (troponin i type 3)
tnnt2
tnnt2 (troponin t type 2)
tobacco
tobacco avoidance
tobacco cessation
tobacco cessation (smoking cessation)
tobacco cessation interventions
tobacco cessation treatment
tobacco cessation treatment for cardiovascular risk reduction
tobacco dependence
tobacco product regulation
tobacco products
tobacco smoke pollution
tobacco smoking
tobacco use
tobacco use (risk factor)
tobacco use / cessation
tobacco use / smoking cessation
tobacco use / tobacco treatment
tobacco use disorder
tobacco use screening and counseling
tobacco use screening and counseling (pm‑6)
tobacco use/cessation interventions
tocilizumab
tocilizumab (il‑6 receptor inhibitor)
toe pressure
toe pressure / toe‑brachial index (tbi)
toe pressures
toe‑brachial index (tbi)
toe‑brachial index (tbi) <0.70
tof (tetralogy of fallot)
toll‑like receptors (tlrs)
tomographic imaging
topas study
topcat
topcat (treatment of preserved cardiac function heart failure with an aldosterone antagonist)
topcat trial
toric study (torasemide)
torsade de pointes
torsades de pointes
torsades de pointes (tdp)
torsemide
total arch replacement
total arch replacement (tar)
total bilirubin
total cholesterol
total ischemic time
total mortality
total walking distance
tpm1
tpm1 (tropomyosin 1)
tra 2p‑timi 50 trial
trace, mild, significant, worsening tr
tracheal compression
tracheal deviation
tracheomalacia
tracking of revascularization procedures
tracking of transfer patients (via emr and databases)
traditional cardiovascular risk factors
traditional cardiovascular risk factors (e.g., age, sex, ldl‑c, hdl‑c, systolic bp, smoking)
trandolapril
trans fat
trans fat (to be avoided)
trans fat intake
trans fats
trans fatty acids
trans fatty acids (risk factor for heart disease)
trans-thoracic echocardiography (tte)
transaminase elevation
transannular patch
transaortic approach to septal myectomy
transaortic maximum velocity
transaortic myectomy
transaortic pressure gradient
transaortic pressure gradient (cardiac catheterization)
transaortic septal myectomy / extended septal myectomy (esm)
transaortic volume flow rate
transapical approach
transapical approach to septal myectomy
transapical myectomy
transapical valve implantation
transcarotid access
transcatheter (catheter‑based) closure devices
transcatheter ablation
transcatheter aortic valve (tavr)
transcatheter aortic valve implantation
transcatheter aortic valve implantation (tavi)
transcatheter aortic valve implantation (tavi/tavr)
transcatheter aortic valve implantation (tavr)
transcatheter aortic valve replacement
transcatheter aortic valve replacement (tavr / tavi)
transcatheter aortic valve replacement (tavr)
transcatheter aortic valve replacement (tavr) / implantation (tavi)
transcatheter aortic valve replacement or implantation
transcatheter aortic valve‑in‑valve implantation
transcatheter approach
transcatheter balloon dilatation of cor triatriatum
transcatheter bioprosthetic valves
transcatheter closure
transcatheter closure of asd
transcatheter closure of paravalvular defects
transcatheter coa repair / stent therapy
transcatheter device closure
transcatheter edge‑to‑edge mitral repair (mitraclip)
transcatheter edge‑to‑edge mitral valve repair
transcatheter edge‑to‑edge repair
transcatheter edge‑to‑edge repair (teer / mitraclip)
transcatheter edge‑to‑edge repair (teer)
transcatheter endovascular aortic repair (tevar)
transcatheter fistula closure (management of coronary artery fistula)
transcatheter heart valve (thv)
transcatheter heart valve thrombosis
transcatheter intervention
transcatheter interventions
transcatheter mitral edge‑to‑edge repair (teer)
transcatheter mitral valve edge‑to‑edge repair (teer) – mitraclip
transcatheter mitral valve intervention
transcatheter mitral valve repair (mitraclip)
transcatheter mitral valve replacement
transcatheter mitral‑valve repair (tmvr)
transcatheter or surgical prosthetic valves
transcatheter pacing leads
transcatheter paravalvular leak closure (catheter‑based, percutaneous repair)
transcatheter procedure
transcatheter procedures (e.g., transcatheter aortic valve, transcatheter aortic valve replacement)
transcatheter pulmonary arterial hypertension therapy
transcatheter pulmonary valve (mpv)
transcatheter pulmonary valve implantation
transcatheter pulmonary valve implantation (melody valve)
transcatheter pulmonary valve placement (balloon‑expandable platform)
transcatheter pulmonary valve replacement
transcatheter repair
transcatheter stent therapy
transcatheter therapies
transcatheter tricuspid valve interventions
transcatheter valve implantation
transcatheter valve implantation (tavi)
transcatheter valve migration
transcatheter valve placement
transcatheter valve procedures (tavr, ttvr, etc.)
transcatheter valve repair
transcatheter valve replacement
transcatheter valve‑in‑valve (viv) procedure
transcatheter valve‑in‑valve procedure
transcatheter versus surgical avr choice
transcatheter viv (valve‑in‑valve) procedure
transcatheter viv procedure
transcatheter‑implanted prostheses
transcatheter pulmonary valve replacement
transcoronary ablation of septal hypertrophy (tash)
transcranial computed tomography (ct) imaging
transcutaneous oxygen pressure (tcpo₂)
transcutaneous oxygen tension (tcpo₂)
transcutaneous partial pressure of oxygen (tcpo₂)
transesophageal echocardiogram (tee)
transesophageal echocardiography
transesophageal echocardiography (tee)
transesophageal echocardiography (tee) for valve assessment
transesophageal echocardiography (tte)
transfemoral access
transfemoral access / femoral approach
transfemoral aortic valve replacement
transfemoral approach
transfemoral delivery
transfemoral tavi
transfemoral tavi approach
transfer delays
transfer for ppci (interhospital transfer)
transfer of care from pediatric to achd providers
transfer of care policies and procedures
transfer time to pci‑capable hospital
transfer to pci‑capable center
transfer-of-care protocols
transforming growth factor‑β (tgf‑β) pathway
transfusion thresholds (restrictive vs. liberal)
transient bacteremia
transient dyspnea
transient ischemic attack
transient ischemic attack (tia)
transient ischemic attack / stroke (as a cardiac embolic event)
transient ischemic dilation ratio
transient ischemic electrocardiographic changes
transition (care/education)
transition / transitional care interventions
transition education
transition education policies
transition education procedures
transition education programs (e.g., stepstones, transition‑chd)
transition education success metrics
transition from hospital to home
transition of care
transition readiness & education programs
transition strategy from intravenous to oral p2y12 inhibition
transition study (sacubitril/valsartan initiation)
transition to adulthood (for congenital heart disease)
transition to adulthood for adolescents with congenital heart disease
transition to heart transplantation after vsr
transition trial
transitional avsd (transitional atrioventricular canal)
transitional care / discharge planning
transitional‑care services program
transitions of care
transjugular liver biopsy
translational research in cardiovascular medicine
translucent skin
transluminal septal ablation
transmitral gradient
transmitral mean gradient
transmitral mean pressure gradient
transmural pressure
transmural scar
transmural scar (identified by lge)
transmyocardial laser revascularization
transmyocardial laser revascularization (tlr)
transplant assessment
transplant cardiology
transplant center volume
transplant evaluation
transplant in myocarditis
transplant listing and timing
transplant outcomes in cardiac sarcoidosis
transplant outcomes in congenital heart disease
transplant outcomes in hypertrophic cardiomyopathy
transplant referral
transplant surgery
transplant wait‑list management
transplant wait‑list mortality
transplantation
transplantation (cardiac transplant)
transplantation (cardiac transplantation)
transplantation (cardiac/heart‑lung)
transplantation (heart‑lung, heart).
transplantation referral for thoracic organ disease
transplant‑free survival
transportation / access to care
transportation access
transportation difficulties
transposition of the great arteries
transposition of the great arteries (dextro‑tga)
transposition of the great arteries (tga)
transposition of the great arteries (tga) with systemic right ventricle
transposition of the great vessels
transposition technique
transprosthetic regurgitation severity
transpulmonary gradient
transpulmonary gradient measurement
transradial access
transradial access / radial approach
transradial approach
transradial coronary intervention
transradial or radial artery access for coronary intervention
transradial rescue pci
transseptal mitral balloon valvuloplasty
transseptal puncture
transthoracic echocardiogram
transthoracic echocardiogram (tte)
transthoracic echocardiogram (tte) follow‑up
transthoracic echocardiogram follow‑up
transthoracic echocardiography
transthoracic echocardiography (echo)
transthoracic echocardiography (tte)
transthoracic echocardiography (tte) with doppler
transthoracic echocardiography (tte) – baseline, periodic imaging
transthoracic echocardiography (tte) – imaging modality for valvular assessment
transthoracic impedance
transthyretin (ttr) amyloidosis
transthyretin amyloid (attr) subtype
transthyretin amyloid cardiomyopathy
transthyretin amyloid cardiomyopathy (attr‑cm)
transthyretin amyloidosis
transthyretin amyloidosis (attr)
transthyretin cardiac amyloidosis (attr)
transthyretin tetramer stabilizer
transthyretin‑related amyloidosis (attr)
transvalvular flow rate
transvalvular gradient
transvalvular gradients












transvalvular leak
transvalvular pressure gradient
transvalvular pressure gradients
transvalvular regurgitation (pannus, thrombus, vegetation)
transvalvular velocities
transvalvular velocity
transvenous icd
transvenous lead extraction
transvenous lead placement
transvenous pacemaker
transvenous pacemaker leads
transvenous pacemaker system
transvenous pacing leads
transverse arch repair
transwomen cardiovascular risk
trans‑aortic stroke volume
trans‑aortic velocity
trans‑echocardiographic echocardiography (tee)
trans‑esophageal echocardiography (tee)
trans‑mitral jet velocity curve
trans‑radial access (conventional & distal)
trans‑thoracic echocardiography (tte)
trans‑ulnar access
trap 2p timi 50 trial
trastuzumab
trastuzumab cardiotoxicity
trastuzumab‑associated heart failure
trastuzumab‑related cardiotoxicity
traumatic aortic injury
traumatic aortic rupture
traumatic mitral valve injury (blunt chest trauma)
traumatic thoracic aortic injury
trauma‑related aortic pathology
treadmill exercise abi
treadmill exercise test
treadmill exercise testing
treadmill exercise training
treadmill training
treadmill walking
treadmill walking (low‑intensity vs. moderate/high‑intensity)
treatment adherence
treatment approaches for chronic coronary disease
treatment arms (rescue pci, conservative care, repeat fibrinolytic therapy)
treatment cost per qaly
treatment decision / surgical indication
treatment decisions
treatment eligibility criteria
treatment guidelines for acute coronary syndromes (acs)
treatment guidelines for non‑st‑elevation acute coronary syndromes (nst‑acs)
treatment guidelines for st‑elevation myocardial infarction (stemi)
treatment of asymptomatic left‑ventricular dysfunction
treatment of concomitant coronary artery disease in hcm patients
treatment of diabetes in heart failure
treatment of early post‑myocardial infarction heart failure
treatment of heart failure with mid‑range ejection fraction (hfmref)
treatment of heart failure with preserved ejection fraction (hfpef)
treatment of heart failure, multi‑drug strategies
treatment of metabolic disorders in heart disease
treatment of post‑infarction remodeling
treatment of vascular disease
treatment options for pad
treatment outcome
treatment outcomes
treatment strategies
treatment strategy
treatments
treat‑and‑repair approach (treat‑and‑repair)
treat‑and‑repair strategy
treat‑close‑treat strategy
treat‑to‑close approach
treat‑to‑close strategy
treponema pallidum (syphilitic aortitis)
triage to pci‑capable facility
trial inclusion criteria (lvesd ≤70 mm)
trial names and acronyms:
trial of hypertension prevention (thp)
trials: revived‑bcis2, courage, bari 2d, ischemia.
triangulated, shortened action potentials (pro‑arrhythmic)
tricuspid annular dilatation
tricuspid annular dilation
tricuspid annular plane systolic excursion (tapse)
tricuspid annular systolic velocity
tricuspid annular velocity (s′)
tricuspid annuloplasty
tricuspid annulus
tricuspid annulus dilation > 4.0 cm (40 mm)
tricuspid annulus dilation > 40 mm or > 21 mm/m² indexed to bsa
tricuspid annulus dilation > 70 mm intra‑operatively
tricuspid annulus end‑diastolic diameter
tricuspid annulus end‑diastolic diameter > 4 cm
tricuspid aortic valve
tricuspid aortic valve (tav)
tricuspid aortic valve (tricuspid)
tricuspid aortic valve replacement
tricuspid prosthesis
tricuspid regurgitation
tricuspid regurgitation (tr)
tricuspid regurgitation (tr) velocity
tricuspid regurgitation (tr) – secondary
tricuspid regurgitation velocity
tricuspid repair
tricuspid stenosis
tricuspid surgery
tricuspid valve (systemic av valve)
tricuspid valve (tr)
tricuspid valve closure
tricuspid valve disease
tricuspid valve dysfunction / tricuspid regurgitation
tricuspid valve dysfunction following pacemaker/icd implantation
tricuspid valve grading scheme
tricuspid valve hypoplasia
tricuspid valve imaging
tricuspid valve intervention
tricuspid valve morphology & function
tricuspid valve procedure
tricuspid valve regurgitant gradient
tricuspid valve regurgitation
tricuspid valve regurgitation (tr)
tricuspid valve regurgitation / insufficiency
tricuspid valve repair
tricuspid valve repair (surgical / percutaneous)
tricuspid valve repair / replacement
tricuspid valve repair vs. replacement selection criteria
tricuspid valve repair/annuloplasty
tricuspid valve replacement
tricuspid valve replacement (surgical)
tricuspid valve replacement (systemic right ventricle)
tricuspid valve replacement / tricuspid regurgitation
tricuspid valve surgery
tricuspid valve surgery (repair or replacement)
tricuspid valve/isthmus
tricuspid regurgitation
tricyclic antidepressants
trigger for arrhythmic activity
triglyceride levels ≥ 500 mg/dl (cardiovascular risk)
triglycerides
triglycerides (tg)
trileaflet aortic valve
triple antiplatelet therapy
triple antithrombotic therapy
triple therapy
triple therapy (full‑intensity anticoagulation + dapt)
triple therapy (oac + p2y12 inhibitor + aspirin)
triple therapy (warfarin + aspirin + clopidogrel/ticagrelor)
triple vasodilator therapy
triple‑vessel disease
trireme medical
triton‑timi 38 trial
triton‑timi 38 trial (pragmatic comparison of prasugrel and clopidogrel)
triumph study (treatment‑resistant hypertension)
troponin
troponin (conventional, older generation)
troponin (tn)
troponin (troponin‑negative)
troponin elevation
troponin i
troponin i (cardiac biomarkers)
troponin t
troponin‑based rule‑out of acute cardiac insufficiency (tacit)
troponin‑t
troponin i
troponin t
true lumen
true lumen collapse
true lumen flow
true lumen involvement
true‑lumen flow
truncus arteriosus
trypanosoma cruzi infection
tte (transthoracic echocardiography)
tte screening for bav and aortopathy
ttn (titin) loss‑of‑function variants
ttn (titin) variants
ttr (transthyretin protein)
ttr amyloidosis (transthyretin)
tumor necrosis factor (tnf)
tumor necrosis factor (tnf) inhibitors
tumor necrosis factor inhibitors
tumor necrosis factor inhibitors (tnf)
tumor necrosis factor‑inhibitors (biologic dmards)
tumor necrosis factor‑α (tnf‑α)
turner syndrome
turner syndrome (45,x) – bicuspid aortic valve, coarctation of the aorta, aortopathies, partial anomalous pulmonary venous connection, atherosclerosis risk
turner syndrome (cardiovascular involvement)
turner's syndrome (turner’s syndrome)
twilight trial
two‑dimensional (2d) imaging
two‑dimensional echocardiogram
two‑dimensional echocardiography
type 2 diabetes mellitus
type 2 diabetes mellitus (t2dm)
type a (involves ascending aorta)
type a aortic dissection
type b (does not involve ascending aorta)
type b aortic dissection
type b aortic dissection (acute, subacute, chronic)
type i (ascending to descending aorta)
type i aortic arch
type ii (isolated ascending aorta)
type iii (descending thoracic aorta)
type iiia (isolated descending thoracic aorta)
type iiib (descending thoracic aorta extending below the diaphragm)
type ii‑a aortic arch
type ii‑b aortic arch
type 1 myocardial infarction (type 1 mi)
type 2 myocardial infarction
type 2 myocardial infarction (type 2 mi)
type 3 myocardial infarction (type 3 mi)
type 4a peri‑pci myocardial infarction (pci mi)
type 4b post‑pci myocardial infarction (stent‑related mi)
type 4c post‑pci myocardial infarction (stent restenosis)
type 5 peri‑coronary artery bypass grafting myocardial infarction (cabg mi)
type‑1 myocardial infarction (mi)
type 1 diabetes mellitus
type 2 diabetes
type 2 diabetes (in the context of ccd)
type 2 diabetes mellitus
type 2 diabetes mellitus (diabetes, prediabetes, impaired glucose tolerance)
type 2 diabetes mellitus (t2dm)
type 2 diabetes mellitus (t2dm) – interaction with hf medications
type a aortic dissection
type a aortic dissection (stanford type a)
type a imh
type b aortic dissection
type b aortic dissection (stanford type b)
type b imh
typical atrial flutter
tyrosine kinase inhibitors
tyrosine kinase inhibitor‑associated cardiovascular toxicity
tyrosine‑kinase inhibitors
tyrosine‑kinase inhibitors (ibrutinib, acalabrutinib, zanubrutinib, ponatinib, trametinib, osimertinib, nilotinib, ribociclib)
t‑helper lymphocyte (th)
t‑wave abnormalities
t‑wave inversion >1 mm in ≥2 contiguous leads













uk small aneurysm trial
uksat (uk small aneurysm trial)
ulceration / critical limb‑threatening ischemia (clti)
ulcerative plaques
ulcer‑like projection
ultrafiltration
ultrasonography / ultrasound
ultrasound
ultrasound (duplex, doppler)
ultrasound enhancing agents
ultrasound guidance (for vascular access)
ultrasound imaging
ultrasound mapping
ultrasound screening
ultrasound screening for aaa
ultrasound surveillance
ultrasound‑accelerated thrombolysis
ultrasound‑enhancing agent use (intravenous, intracardiac)
ultrasound‑enhancing agents
ultrasound‑guided femoral access
ultrasound‑guided femoral artery cannulation
ultrasound‑guided percutaneous access
ultrasound‑guided vascular access
umbrella trials
unadjusted cumulative risk of af recurrence
unanticipated conduit dysfunction
uncomplicated aortic dissection
uncomplicated intramural hematoma
uncomplicated myocarditis
uncomplicated type b aortic dissection
unconclusive abi and physiological testing.
uncontrolled arrhythmias
uncontrolled bleeding
uncontrolled cardiac arrhythmias
uncontrolled diabetes
uncontrolled hypertension
underdosing
underexpansion
under‑representation of female patients in vascular trials
under‑utilization of cardiac rehabilitation
unexplained hemolysis
unexplained sudden death
unexplained syncope
unexplored myocarditis
unfractionated heparin
unfractionated heparin (ufh)
unguided de‑escalation of dapt
unhealthy diet
unicuspid aortic valve
unilateral antegrade cerebral perfusion
unilateral cerebral perfusion
uninterrupted anticoagulation
uninterrupted doac therapy
uninterrupted health insurance coverage
uninterrupted warfarin therapy
united network for organ sharing (unos) heart transplant allocation policy
united therapeutics (pulmonary hypertension association)
univentricular hearts
universal definition and classification of heart failure
universal definition of myocardial infarction (2018)
universal trial (routine ultrasound‑guided femoral vascular access)
university of arizona
university of north carolina
university of pennsylvania
unoperated single ventricle
unos (united network for organ sharing)
unplanned heart‑failure hospitalizations
unplanned revascularization
unprotected left‑main stenosis
unrepaired asd
unrepaired coa
unrepaired cor triatriatum sinister
unrepaired cyanotic congenital heart disease
unrepaired cyanotic heart disease
unrepaired or partially palliated cyanotic congenital heart defect
unrepaired pda
unrepaired tetralogy of fallot
unrepaired vsd
unroofed right upper pulmonary vein
unruptured aaa
unsaturated fats (monounsaturated, polyunsaturated)
unsaturated fatty acids
unstable angina
unstable angina (unstable coronary artery disease)
unstable or decompensated ccd
unstructured exercise (self‑directed walking)
upfront combination pah therapy
upper extremity hypertension
upper‑limb aerobic exercise
upper‑lower extremity systolic blood pressure gradient
upper‑to‑lower extremity systolic bp gradient >20 mm hg
upright treadmill exercise testing
upstream administration
upstream therapy
upstream therapy (e.g., anti‑inflammatory approach)
urban heat island
urban heat island effect
urea nitrogen
urgent cabg
urgent coronary artery bypass grafting (cabg)
urgent coronary revascularization
urgent repair (clinical recommendation)
urgent revascularization
urinalysis markers: hemoglobin a1c (hba1c) (used in diabetes control)
urinary sodium
urinary sodium excretion
urinary tract infection
urine output (reduced urine output)
us food and drug administration (fda)
us preventive services task force recommendations (aspirin, statin use)
use of ace inhibitors or arbs for pad (pm‑2)
use of aspiration thrombectomy
use of intracoronary imaging (ivus, oct)
use of smokeless tobacco (e.g., snus, snuff)
use of vasodilators in hypertension and renal protection
use of β‑blockade with vasoconstrictor to reduce heart rate and contractility
utility assistance needs
u‑shaped oxygenation–mortality relationship


















v2–v3 lead criteria (male/female thresholds)
vaccination against respiratory illnesses
vaccine‑associated vascular complications (influenza, sars‑cov‑2)
vacuum‑assisted percutaneous mechanical thrombectomy
vagal nerve stimulation
vaginal delivery
vaginal delivery (low‑risk aortic cases)
vaginal delivery (preferred first‑choice delivery option)
vaginal delivery (when appropriate for aortic diameter <4.0 cm)
vaginal delivery with regional anesthesia
vagus nerve stimulation (vns)
val-heft (valsartan heart failure trial)
valiant study (heart failure post‑mi predictors)
valsalva maneuver
valsalva maneuver (biomarker)
valsalva maneuver (during labor)
valsalva maneuver (echo provocation)
valsalva maneuver (intense isometric exercise)
valsalva maneuver / amyl nitrite provocation
valsartan
valsartan (angiotensin ii receptor blocker) for early hcm
valsartan heart failure trial (vht)
value assessment of drug/device/intervention
valve
valve abscess
valve academic research consortium (varc) criteria
valve academic research consortium (varc) – 5‑class grading for paravalvular leak severity
valve academic research consortium‑2 (varc‑2) criteria
valve anatomy
valve anatomy (favorable/unfavorable)
valve anatomy (leaflets, chordae, annulus)
valve anatomy and hemodynamics assessment
valve anatomy and motion
valve anatomy assessment
valve apparatus
valve area
valve area (cm²)
valve area (effective orifice area)
valve area / projected valve area
valve area determination
valve area index
valve area index (cm² m⁻²)
valve area indexed to body size
valve area measurement
valve area measurement by continuity equation
valve area progression (0.1 cm²/year)
valve areas
valve bioprosthesis
valve calcification
valve calcification/fibrosis
valve center (comprehensive valve center)
valve choice
valve chords
valve clinic organization and structure
valve clip (mitral valve clip)
valve commissures
valve commissurotomy
valve coordinator (dedicated role)
valve degeneration
valve degeneration (early bioprosthetic degeneration)
valve dehiscence
valve design
valve deterioration
valve disease
valve disease / valve lesions
valve disease burden
valve disease guidelines
valve disease imaging (ct, pet/ct, echocardiography)
valve disease management
valve disease prevention (e.g., systolic blood pressure, calcific aortic stenosis)
valve disease prognosis and re‑operation risks
valve disease progression
valve disease severity
valve disease severity assessment
valve disorder
valve durability
valve durability (long‑term, >5 years)
valve durability and degeneration
valve durability data (20‑year, 5‑year)
valve durability data (≥10 years)
valve durability vs age
valve dysfunction
valve dysfunction (mild, moderate, severe)
valve echocardiographer (pre‑ and post‑procedural assessment)
valve enlargement procedures
valve evaluation
valve failure
valve failure (regurgitation of the neoaortic valve)
valve function
valve function assessment
valve function improvement
valve gradient
valve gradient ≥10 mm hg
valve gradients
valve hemodymamics
valve hemodynamics
valve imaging
valve imaging assessment
valve implantation baseline hemodynamics
valve implantation outcomes
valve infection
valve intervention
valve intervention (aortic valve replacement, avr)
valve intervention (replacement, repair)
valve intervention (timing, type, approach)
valve interventions
valve leaflet motion
valve leaflet opening/closing angles
valve leaflet pathology
valve leaflet thrombosis
valve leaflets
valve lesion
valve lesion staging (stages c, d; stage c1)
valve mobility
valve morphology
valve morphology (bicuspid, unicuspid, thickening, perforations, clefts, calcification, stenosis)
valve morphology and function (stenosis, regurgitation)
valve morphology evaluation
valve obstruction
valve outcomes
valve pathology
valve pathology and diagnostics.
valve pathology evaluation
valve perforation
valve performance
valve position (aortic, mitral)
valve position (pulmonic, aortic)
valve pressure half‑time
valve prosthesis
valve prosthesis infection
valve prosthesis maintenance
valve prosthesis mismatch
valve prosthesis selection (bioprosthetic vs mechanical)
valve prosthesis selection (mechanical vs biological)
valve regurgitation
valve regurgitation (general)
valve regurgitation (including paravalvular leak)
valve regurgitation (mitral, aortic, etc.)
valve regurgitation (severe)
valve regurgitation evaluation
valve reintervention
valve remodeling (lv remodeling)
valve reoperation risk
valve repair
valve repair (aortic)
valve repair (mitral)
valve repair criteria (lvef > 64 %, lvesd < 37 mm)
valve repair durability
valve repair freedom from reoperation
valve repair indications (≤½ posterior leaflet)
valve repair outcomes
valve repair rates
valve repair success rate
valve repair thresholds (lvesd ≈ 40 mm, lvef ≈ 60 %)
valve repair versus replacement
valve repair vs. replacement strategy
valve repair with prosthetic material
valve repair/replacement
valve repair/valve prosthesis type
valve reparability
valve replacement
valve replacement (aortic)
valve replacement (mechanical on‑x aortic valve)
valve replacement (mechanical/electronic)
valve replacement (surgical & transcatheter)
valve replacement (surgical)
valve replacement (transcatheter)
valve replacement / repair
valve replacement durability data (5‑year tavi, 20‑year bioprosthetic)
valve replacement freedom from recurrence
valve replacement in high‑risk patients
valve replacement in low‑risk patients
valve replacement indications
valve replacement outcomes
valve replacement recommendations
valve replacement strategy (savr vs. tavi)
valve replacement surgery
valve replacement timing criteria
valve resuspension
valve re‑intervention
valve selection
valve severity
valve stenosis
valve stent (bioprosthetic valve)
valve substitutes
valve surgery
valve surgery (open heart)
valve surgery (repair/replacement)
valve surgery (timing of aortic/mitral valve surgery)
valve surgery / valve replacement
valve surgery for ie
valve surgery volume
valve surgical outcomes
valve surveillance guidelines
valve tethering
valve thickening
valve thrombosis
valve thrombosis (incl. mechanical valve thrombosis)
valve thrombosis (including subclinical leaflet thrombosis)
valve thrombosis (see sections 11.6 & 11.8)
valve thrombosis prevention
valve type (aortic, mitral, bioprosthetic)
valve type and size
valve type selection
valve type selection (mechanical vs. bioprosthetic)
valve vegetation
valve-related bacteremia (e.g., staphylococcus aureus bacteremia)
valved conduit
valved prosthesis (bioprosthetic)
valved prosthesis (mechanical)
valved‐conduit aortic root replacement
valves
valve‑centric hemodynamic metrics (e.g., effective regurgitant orifice area)
valve‑in‑valve (viv)
valve‑in‑valve (viv) procedure
valve‑in‑valve (viv) procedures
valve‑in‑valve catheter intervention
valve‑in‑valve implantation
valve‑in‑valve procedure
valve‑in‑valve procedures
valve‑in‑valve tavi
valve‑in‑valve tavi (viv tavi)
valve‑prosthesis interaction
valve‑related complications
valve‑related morbidity and mortality.
valve‑related sepsis / septic shock
valve‑sparing aortic root procedures
valve‑sparing aortic root repair (david procedure)
valve‑sparing aortic root replacement
valve‑sparing aortic root replacement (vsrr)
valve‑sparing procedure
valve‑sparing procedures / valve‑spare surgery
valve‑sparing root repair
valve‑sparing root replacement
valve‑sparing root replacement (vsrr)
valve‑sparing surgery
valve replacement (surgical / transcatheter)
valvular
valvular af
valvular anatomy
valvular aortic stenosis
valvular atrial fibrillation
valvular atrial fibrillation (non‑valvular)
valvular calcification
valvular degeneration
valvular disease
valvular disease (mitral valve prolapse, pulmonary stenosis)
valvular disease management
valvular dysfunction
valvular dysfunction (e.g., mitral regurgitation)
valvular dysplasia
valvular function
valvular function evaluation
valvular heart disease
valvular heart disease (management)
valvular heart disease (mitral, aortic)
valvular heart disease (vhd)
valvular heart disease (vhd) – mild, moderate, severe
valvular heart disease in pregnancy
valvular heart disease with atrial fibrillation
valvular heart disease – valve replacement or repair for significant stenosis or regurgitation
valvular heart disease, severe aortic stenosis
valvular heart surgery
valvular insufficiency
valvular involvement
valvular lesions/valve dysfunction
valvular perforation
valvular pulmonary stenosis
valvular pulmonary stenosis (ps)
valvular regurgitant lesion
valvular regurgitation
valvular regurgitation evaluation
valvular replacement
valvular stenosis
valvular thickening.
valvular thrombosis risk (~5 %)
valvular pulmonary stenosis (moderate/severe)
valvuloplasty (general)
val‑heft trial
vaping / electronic nicotine‑delivery devices
vaping products
vardenafil
varenicline
varenicline (nicotine replacement)
varenicline (partial nicotine agonist)
varenicline (treatment)
varenicline therapy
variable early follow‑up
variable penetrance
varian medical systems
variant aortic arch anatomy
variant interpretation
variant of uncertain significance
variant of uncertain significance (vus)
variant of unknown significance (vus)
variant pathogenicity
variant reclassification
variant transthyretin (attrv)
variant transthyretin amyloidosis (attrv)
variants of unknown significance (vus)
varices
variosa‑af study (sleep apnea variability)
vasa vasorum
vascular
vascular (as a related medical specialty)
vascular (cardiovascular) disease
vascular abnormalities (extracoronary)
vascular access
vascular access (femoral artery)
vascular access approach for pci (radial vs femoral)
vascular access complications
vascular access constraints
vascular anatomy compatibility
vascular and endovascular surgery society (vess)
vascular anomalies (magnetic resonance angiographic features)
vascular assessment
vascular assessment (photoplethysmography, laser doppler flowmetry, duplex ultrasonography, ct angiography, mr angiography, angiography)
vascular bruit (epigastric, periumbilical, groin)
vascular care
vascular cause (of death or embolism)
vascular cell adhesion molecule‑1 (vcam‑1)
vascular center
vascular complications
vascular complications (access‑related)
vascular complications (access‑site, systemic)
vascular complications (wall injury, remodeling)
vascular complications from device insertion
vascular complications of cancer treatments (vascular‑related heart disease)
vascular conduit
vascular death
vascular death after ami
vascular dilator reserve impairment
vascular disease
vascular disease (general)
vascular disease (risk factor for hf)
vascular dissection
vascular dysfunction
vascular dysfunction (von willebrand factor activity)
vascular ehlers‑danlos syndrome
vascular ehlers‑danlos syndrome (veds)
vascular emboli / embolization (including stroke, septic pulmonary infarcts, mycotic aneurysm)
vascular endothelial cytoprotection
vascular event
vascular events
vascular events (general)
vascular events (including mi and stroke)
vascular examination of legs and feet
vascular follow‑up guidelines (surgery & endovascular)
vascular function














vascular graft
vascular graft infection
vascular graft infection epidemiology
vascular graft infections
vascular guidelines
vascular guidelines for chronic limb‑threatening ischemia
vascular health institute (vascular‑medicine focus)
vascular health outcomes (e.g., limb‑related events, mortality)
vascular imaging
vascular imaging (duplex ultrasound, duplex surveillance)
vascular imaging modalities
vascular imaging specialist
vascular imaging technology
vascular inspection of lower extremities
vascular instrumentation
vascular intervention
vascular interventional radiology
vascular involvement
vascular laboratory
vascular laboratory assessment
vascular laboratory setting
vascular laboratory‑based duplex ultrasound
vascular load
vascular medicine
vascular medicine in aortic disease follow‑up
vascular medicine outcomes program (vamos)
vascular morbidity
vascular mortality
vascular nursing
vascular occlusion
vascular operations
vascular outcomes study (voyager pad)
vascular outcomes study of asa (voyager pad)
vascular pathogenesis
vascular pathology
vascular quality initiative (clinical outcomes database)
vascular quality initiative (vqi)
vascular quality initiative (vqi) database
vascular quality‑of‑life questionnaire
vascular remodeling
vascular resistances
vascular revascularization
vascular review of systems (for pad)
vascular review of systems (vascular review)
vascular review of systems for lower extremity pad
vascular review of systems for lower‑extremity pad (qm‑1)
vascular ring
vascular ring anatomical classifications (complete, incomplete, double aortic arch, etc.)
vascular ring or sling
vascular ring repair
vascular rings
vascular risk
vascular risk factors
vascular risk factors (e.g., smoking, secondhand smoke)
vascular risk factors in heart disease
vascular risk levels
vascular screening
vascular screening programs
vascular specialists
vascular stiffness
vascular surgeon
vascular surgery
vascular surgery (open reconstruction)
vascular surgery (procedural specialty)
vascular surgery (svs) and thoracic surgery (sts) guidelines
vascular surgery / endovascular intervention
vascular surgery fellowship
vascular surgery follow‑up
vascular surgery outcomes studies
vascular surgery residency
vascular surgery support
vascular surveillance protocols (duplex)
vascular testing interventions
vascular tolerance (nitrate tolerance)
vascular toxicities of cancer treatments
vascular toxicity
vascular ultrasound screening (for pad)
vascular/heart‑related biotech: cytokinetics, cvrx, cyclerion, etc.
vascular‑related adverse events
vasculature
vasculitides
vasculitis (as a cause of lower‑extremity arterial disease)
vasculopathy screening
vasoactive agents
vasoactive medications
vasoactive peptides
vasoconstriction
vasoconstrictors
vasoconstrictors (non‑inotropic)
vasodilation
vasodilator stress cardiac magnetic resonance
vasodilator stress cmr
vasodilator therapy
vasodilator therapy (e.g., verapamil)
vasodilator therapy (for mr)
vasodilator therapy (hydralazine)
vasodilator therapy, nitrates
vasodilators
vasodilators (nesiritide, nitroglycerin, nitroprusside, clevidipine)
vasopressin antagonists
vasopressors
vasospastic angina
vasospastic angina (vsa)
vaughan williams class ic antiarrhythmic agents
ve/vco₂ slope
vegetables, fruits, legumes, nuts, whole grains, fish
vegetarian/vegan diet
vegetation
vegetation mobility
vegetation size
vegetation size >10 mm
vegetations
vegetations (mobile >10 mm)
vegf inhibitors (sorafenib)
vein bypass graft
vein conduit suitability
vein graft failure
vein graft vs. ptfe graft (bypass)
vein mapping
velocity pressure gradient (vpg)
velocity‑encoded cine mr imaging
vena contracta
vena contracta (cm)
vena contracta (vc)
vena contracta analysis
vena contracta width (≥0.7 cm)
venoarterial extracorporeal membrane oxygenation (va‑ecmo)
venous arterialization
venous autograft
venous hypertension (elevated fontan pressure)
venous return pathways
venous stasis
venous stenosis
venous thromboembolic disease
venous thromboembolism
venous thromboembolism (vte)
venous thromboembolism (vte) prophylaxis
venous thromboembolism (vte) prophylaxis in cancer patients
veno‑arterial extracorporeal membrane oxygenation (va‑ecmo)
veno‑venous collaterals
ventilation
ventilation strategies in achd surgery
ventilation to co₂ output slope
ventilator strategies
ventilatory anaerobic threshold
ventilatory efficiency
ventilatory efficiency (ve/vco₂ slope)
ventilatory gas exchange measurements
ventricular activation pattern
ventricular anatomy and function
ventricular and vascular function impact
ventricular and vascular interactions
ventricular arrhythmia
ventricular arrhythmia (va)
ventricular arrhythmia (va) ablation
ventricular arrhythmia / tachyarrhythmia
ventricular arrhythmia burden
ventricular arrhythmia monitoring
ventricular arrhythmia risk score
ventricular arrhythmias
ventricular arrhythmias (5.8% prevalence)
ventricular arrhythmias (aaoca presentation)
ventricular arrhythmias (atrial and ventricular)
ventricular arrhythmias (frequent or complex repetitive forms)
ventricular arrhythmias (sudden cardiac death risk)
ventricular arrhythmias (tachyarrhythmias)
ventricular arrhythmias (va)
ventricular arrhythmias (vas)
ventricular arrhythmias (vt)
ventricular arrhythmias / icd shocks
ventricular arrhythmias / malignant arrhythmias
ventricular arrhythmias in achd
ventricular arrhythmias occurring >48 hours post‑reperfusion
ventricular arrhythmias related to antiarrhythmic therapy
ventricular assist device (vad)
ventricular assist device (vad) / durable vad
ventricular assist device as a bridge to transplant
ventricular assist device therapy versus intensive medical therapy
ventricular assist devices (vads) – specifically left ventricular assist devices (lvads)
ventricular deformation imaging
ventricular depolarization pattern
ventricular diastolic function
ventricular diastolic volume
ventricular dilation
ventricular dilation / dysfunction
ventricular dimensions
ventricular dysfunction
ventricular dysfunction (general)
ventricular dysfunction (left‑ventricular systolic dysfunction)
ventricular dysfunction (mentioned in related contexts)
ventricular dysfunction (mild, moderate, severe)
ventricular dysfunction (right or left)
ventricular dysfunction (subpulmonary & systemic)
ventricular dysfunction, systolic and diastolic
ventricular dyssynchrony
ventricular end‑diastolic pressure
ventricular end‑diastolic volume
ventricular end‑systolic volume
ventricular enlargement
ventricular enlargement (mild)
ventricular enlargement after myocardial infarction
ventricular fibrillation
ventricular fibrillation (implied)
ventricular fibrillation (vf)
ventricular fibrosis
ventricular flutter
ventricular free‑wall rupture
ventricular function
ventricular function (general)
ventricular function (systemic and subpulmonary)
ventricular function assessment
ventricular function monitoring
ventricular hypertrophy
ventricular hypertrophy (rv or lv)
ventricular inflow obstruction (pulmonary venous & systemic)
ventricular involvement
ventricular outflow obstruction
ventricular outflow‑tract obstruction (left ventricular outflow‑tract obstruction)
ventricular overload
ventricular pacing
ventricular pacing burden
ventricular pacing burden (>40 %)
ventricular pacing percentage
ventricular pacing reduction
ventricular physiology after fontan
ventricular preexcitation
ventricular preload
ventricular preload, afterload, contractility
ventricular pressures
ventricular pre‑excitation
ventricular rate
ventricular rate control
ventricular rate control guidelines
ventricular rates
ventricular relaxation
ventricular remodeling
ventricular remodeling acceleration (due to exercise)
ventricular remodeling, left and right
ventricular response
ventricular response reduction
ventricular scar / fibrosis
ventricular scar detection
ventricular septal defect
ventricular septal defect (vsd)
ventricular septal defect (vsd) as a common comorbidity
ventricular septal defect closure strategy
ventricular septal defect repair techniques (patch, valve‑patch, double‑patch)
ventricular septal defects
ventricular septal geometry
ventricular septal myectomy
ventricular septal rupture
ventricular septal rupture (vsr)
ventricular septal thickness
ventricular size
ventricular size and function (subpulmonary left ventricle)
ventricular size and systolic function
ventricular synchrony
ventricular systolic dysfunction
ventricular systolic dysfunction (moderate vs. severe, residual dysfunction post‑repair)
ventricular systolic function
ventricular systolic function assessment
ventricular tachyarrhythmia
ventricular tachyarrhythmias
ventricular tachyarrhythmias (vt/vf)
ventricular tachycardia
ventricular tachycardia (monomorphic)
ventricular tachycardia (nonsustained)
ventricular tachycardia (vt)
ventricular tachycardia (vt) – monomorphic, sustained, reentrant
ventricular tachycardia / non‑sustained ventricular tachycardia
ventricular tachycardia inducibility
ventricular tachycardia isthmus
ventricular tachycardia outcomes
ventricular tachycardia risk
ventricular tachycardia substrate
ventricular tachycardia substrate characteristics
ventricular tachycardia substrate characterization
ventricular tachycardia suppression
ventricular tachycardia triggers
ventricular tachycardia/fibrillation (vt/vf)
ventricular tachycardia‑related anatomical isthmuses
ventricular volume and function
ventricular volumes
ventricular wall motion abnormalities
ventricular‑ventricular interaction
ventricular–atrial coupling
ventricular preexcitation
ventricular size
ventriculography
ventriculotomy
ventri­cular tachycardia (vt)
verapamil
verapamil (av‑nodal blocker)
verapamil (nondihydropyridine calcium channel blocker)
verapamil (nondihydropyridine calcium‑channel blocker)
verapamil therapy
verbal artery tortuosity index (vascular complication indicator)
verdict trial (very early vs deferred invasive evaluation)
vericiguat
vericiguat (soluble guanylate cyclase stimulator)
vericiguat for hfref with high natriuretic peptides
vericiguat trial (vericiguat in hfref)
vertebral arterial tortuosity
vertebral artery
vertebrobasilar insufficiency
verve therapeutics
very high‑risk ascvd (table 10)
very high‑risk definition for future ascvd events (history of multiple events or one major event plus ≥ 2 high‑risk conditions)
very severe aortic stenosis
very‑low ldl‑c
vess
vess (vascular & endovascular surgery society)
vess (vascular and endovascular surgery society)
vess (venous and vascular surgery society)
vessel patency
vessel wall inflammation in aneurysm formation
vessel wall layers (intima, media, adventitia)
vest trial (vest prevention of early sudden death)
veterans administration cooperative study (vacs)
vf (ventricular fibrillation)
vhd (valvular heart disease)
viability imaging
viable myocardium
victoria trial
vigorous exercise
vigorous‑intensity aerobic activity
vigorous‑intensity aerobic physical activity
vigorous‑intensity exercise
vigorous‑intensity physical activity
viral myocarditis
viral myocarditis (coxsackievirus b3‑induced, viral myocarditis)
viral serology: hcv, hiv, lyme borreliosis, influenza
viral titers
viral tropism
virchow’s triad
viridans streptococci endocarditis
viridans streptococci, streptococcus bovis, staphylococcus aureus, enterococci
virtex registry
virtual coaching
virtual or home‑based care delivery.
virtual surgical planning / 3‑d modelling of intracardiac baffles (dorv)
visceral adiposity
visceral artery stenting
visceral ischemia
visceral malperfusion
visceral organ protection
visceral vessel avulsion
visual disturbances
vital signs














vital‑heart failure trial (vitamin d supplementation)
vitamin b‑complex supplementation
vitamin c & e supplementation (antioxidants)
vitamin c supplementation
vitamin d deficiency / hypovitaminosis d
vitamin d supplementation
vitamin e supplementation
vitamin k antagonist
vitamin k antagonist (e.g., warfarin)
vitamin k antagonist (vka)
vitamin k antagonist (vka) therapy
vitamin k antagonist (warfarin)
vitamin k antagonists
vitamin k antagonists (anticoagulation)
vitamin k antagonists (e.g., warfarin)
vitamin k antagonists (e.g., warfarin, phenprocoumon)
vitamin k antagonists (vka)
vitamin k antagonists (vkas)
vitamin k antagonists (vkas) – warfarin
vitamin k antagonists (warfarin)
vitamin k1
vitamins (as supplements)
vitamins and nutritional supplements
vitamins c, d, e, beta‑carotene
vitamin d supplementation
vitamin‑k antagonist (vka)
vitamin‑k antagonist (vka) anticoagulation
vitamin‑k antagonist (vka) therapy
vitamin‑k guided anticoagulation strategy
vitamin c
vitamin d
vitamin d supplementation
vitamin d supplementation (serum 25‑hydroxyvitamin d)
vitamin e
vitamin e supplementation
vitamin k
vitamin k antagonist
vitamin k antagonist (vka)
vitamin k antagonists
vitamin k antagonists (e.g., warfarin)
vitamin k antagonists (vkas)
vitamin k intake
vivid registry (valve‑in‑valve international data)
vka (vitamin k antagonist) anticoagulation
vka (vitamin k antagonist)
vka (warfarin) vs doac comparison
vka anticoagulation
vka therapy
voltage mapping (bipolar endocardial voltage mapping)
volume depletion
volume overload
volume overload from valve regurgitation
volume overload impact on pulmonary circulation during pregnancy
volume resuscitation
volume status
volume status optimization
volume‑outcomes relationship for open repair
volume–outcome relationship
von willebrand factor (vwf)
vorapaxar
vorapaxar (par‑1 antagonist)
vorapaxar (thrombin receptor antagonist)
voyager pad trial
voyager trial (anticoagulation with aspirin)
vo₂ max (maximal oxygen consumption)
vo₂ max / maximal metabolic equivalent (mets)
vsd (ventricular septal defect)
vsd closure
vsd closure (surgical or percutaneous)
vt (ventricular tachycardia)
vte prophylaxis
vulnerable atherosclerotic plaques
v‑heft i (vasodilator heart failure trial)
v‑wave ltd.** (cardiac imaging/diagnostic firm)














w.l. gore (surgical/medical devices)
waist circumference
waist circumference (obesity marker)
waist‑hip ratio
waitlist mortality
waitlist outcomes
walking capacity / walking distance
walking distance
walking distance / maximal walking distance – functional capacity metric
walking distance and speed progression
walking exercise therapy
walking impairment
walking impairment / claudication
walking performance
walking performance (functional outcome)
walking performance / functional status
walking performance metrics (time to onset of symptoms, maximal walking time)
walking test (provocative maneuver)
wall motion abnormalities
wall shear stress
wall strength vs. wall stress dynamics
wall stress (saccular vs fusiform aneurysm)
wall stress and ventricular geometry
wall stress in the aorta
wall thickening / aortitis
wall thickness measurement
wall thickness ≥15 mm
wall‑motion abnormalities
wall‑motion abnormality
wall‑stress reduction strategies
warden procedure
warden procedure (repair method)
warfarin
warfarin (vitamin k antagonist, vka)
warfarin (vitamin k antagonist)
warfarin embryopathy
warfarin embryopathy / teratogenicity
warfarin therapeutic window (inr > 1.9)
warfarin therapy (in the context of graft patency)
warfarin therapy (therapeutic range)
warfarin‑associated bleeding
warfarin‑associated intracranial hemorrhage
watch trial (warfarin & antiplatelet therapy)
watchful waiting
watchful waiting (conservative management)
watchman device
watchman device (including watchman flx)
watchman device (left atrial appendage closure device)
water‑pipe (hookah) smoking
wave (warfarin antiplatelet vascular evaluation) trial
wave trial
weaning of mechanical support
wearable and remote monitoring technologies
wearable cardiac device
wearable cardioverter‑defibrillator
wearable cardioverter‑defibrillator (wcd)
wearable devices
wearable devices (e.g., smart watches)
wearable ecg monitoring
wearable heart‑monitoring devices
wearable sensors for pad‑related physiologic changes
wearable technology
wearables (remote monitoring devices)
wearables, telemonitoring, device monitoring
weight assessment
weight loss
weight loss (as a benefit)
weight loss (as prevention strategy)
weight loss (primary and secondary prevention of af)
weight loss / obesity
weight loss / weight maintenance
weight loss / weight management
weight loss / weight reduction
weight loss, sodium reduction, dietary patterns (dash)
weight loss/obesity management
weight management
weight management (obesity, bmi reduction)
weight management (pharmacologic and non‑pharmacologic therapies for cardiovascular risk)
weight management / obesity
weight management / weight loss
weight management/weight reduction
weight monitoring
weight/fluid overload
weight‑loss drugs
weight‑loss interventions
wheelchair confinement
whf (world heart federation)
white blood cell (wbc) count with differential
who cardiovascular risk classification (modified iii/iv)
who guidelines on body‑mass index for asian populations
who pulmonary hypertension groups 1, 3, 4
whole genome sequencing
whole grains
whole‑grain diet
wifi (wound‑ischemia‑foot‑infection) classification tool
wifi classification (wound, ischemia, foot infection)
wildfire smoke
wildfire smoke exposure
wild‑type transthyretin (attrwt)
wild‑type transthyretin amyloidosis (attrwt)
wild‑type transthyretin cardiac amyloidosis
wild‑type/transthyretin‑derived amyloidosis
wilkins morphology score
wilkins score (echocardiographic scoring system for mitral stenosis)
williams syndrome
williams syndrome (7q11.23 deletion) – supravalvar aortic stenosis, branch pulmonary artery stenosis, supravalvar pulmonary stenosis, coronary ostial stenosis, qtc prolongation, mid‑aortic narrowing syndrome
williams syndrome (elastin‑associated arteriopathy)
williams‑beuren syndrome
woest
wolff‑parkinson‑white (wpw) syndrome
wolff‑parkinson‑white pattern
wolff‑parkinson‑white syndrome
wolff–parkinson–white syndrome (wpw)
women (gender representation)
women‑specific ischemia risk
women’s heart clinic
women’s heart failure presentation and outcomes
wood units
wood units (measure of pulmonary vascular resistance)
wood units (unit of pvr measurement)
wood units (wu)
work and career disruptions
world health organization (who) class iv
world health organization (who) functional class
world health organization (who) risk score for pregnancy and cardiac disease
world heart federation (whf)
worsening heart failure
worsening heart failure symptoms
worsening heart‑failure symptoms (increased oxygen requirement, inotropic support)
worsening renal function
wound care
wound care, infection management, and pressure off‑loading as adjuncts
wound complications, vascular fragility, bleeding complications
wound healing
wound healing (vascular component)
wound healing / amputation‑free survival in clti
wound healing / complete wound healing
wound healing and limb salvage strategies for clti
wound healing in pad/clti
wound healing in peripheral artery disease
wound infection
wound, ischemia, and foot infection (wifi) classification
wound, ischemia, foot infection (wifi) classification
wound‑care specialist
wound‑healing therapies
wpw (wolff‑parkinson‑white)
wpw (wolff–parkinson–white) syndrome



xenograft
yale university
young adulthood (18‑26 years) chd care
zahara (zwangerschap bij aangeboren hartafwijking – pregnancy in women with congenital heart disease) study
zanchetti et al. (hypertension bp lowering)
zic3, shroom3, grk5, anks3, nodal, cfc1, lefty2, gdf1, smad2, acvr2b
zinc deficiency
zinc supplementation
zoll
zone 0–11 aortic landing zones
zone 0 thoracic endovascular aortic repair (landing zone classification)
zone 1/2 landing for thoracic stent graft
zwolle score
z‑score
z‑score for aortic diameter (turner‑specific)
α‑methyldopa
β‑1 receptor blockade
β‑adrenergic blockade
β‑adrenergic blocking drugs
β‑adrenergic receptor activation
β‑adrenoceptor antagonists
β‑blocker
β‑blocker (beta‑blocker)
β‑blocker (beta‑blocker) therapy
β‑blocker dosing, sequencing, and uptitration
β‑blocker effects (used in sotalol)
β‑blocker therapy
β‑blocker therapy / β‑blockade
β‑blockers
β‑blockers (beta blockers)
β‑blockers (cardioselective and non‑selective)
β‑blockers (e.g., bisoprolol)
β‑blockers (e.g., metoprolol, carvedilol, bisoprolol)
β‑blockers (e.g., nebivolol, bisoprolol, digoxin‑related β‑blockade)
β‑blockers (pre‑operative, postoperative)
‘no‑touch’ technique
“at risk” for hf (stage a)
“dyspnea paroxysmal”
“edema cardiac”
“pill‑in‑the‑pocket” approach
• 2021 aha/acc chest pain guideline
• aha/acc/accp/aspc/nla/pcna chronic coronary disease guideline
• bari‑2d
• courage
• ischemia
• stich
≥10 % lvef decline to <50 %
